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Abstract 
Antiepileptic drugs (AEDs) are prescription only medications which were firstly 
introduced in the 1880s to treat epilepsy. However, the rapid growth in the drug discovery 
market led to a new generation of AEDs with multiple mechanisms of action. These new 
drugs represent a promising treatment for many diseases in addition to epilepsy such as 
neurological disorders, psychological disorders and substance and alcohol abuse treatment 
as substitutes for benzodiazepines and methadone. However, their multiple roles triggered 
their misuse potential and concern on their abuse potential was raised in the literature, the 
media, and by many addiction organizations. Hence, this research highlights some of the 
AEDs which have raised concern and discusses their therapeutic effects, mechanism of 
action as well as their overdose and abuse probability from a forensic toxicology point of 
view.  
Some AEDs have a narrow therapeutic index and require therapeutic drug monitoring in 
order to attain the optimum response. The majority of published analytical methods 
focuses on their analysis in serum and plasma within therapeutic ranges and includes a 
maximum of 11 AEDs in one analytical step. Therefore, a robust and accurate method was 
developed for the simultaneous analysis of 15 common AEDs and two of their major 
metabolites in whole blood using LC/MS/MS. The method was validated according to the 
standard practices for method validation in forensic toxicology (SWGTOX, May 2013) 
over a wide concentration range to include AED therapeutic and toxic concentrations 
which make it suitable for both clinical and forensic analysis. 
Stability studies are of great importance in forensic cases where it takes up to a few weeks 
for autopsy, sampling, drug screening and finally confirmation analysis. However, reports 
specifically addressing the stability of antiepileptic drugs in whole blood are relatively 
scarce compared with those for drugs of abuse. Thus, using the previous method, the 
stability of AEDs in whole blood was investigated under different storage conditions. 
The LC/MS/MS method developed for AEDs analysis in whole blood was successfully 
transferred to another laboratory and extended to include 18 AEDs and 4 metabolites. It 
was revalidated for AEDs analysis in serum and plasma in addition to whole blood.  Before 
any new method can be adapted to routine forensic analysis, it has to be validated using 
authentic samples. A total of 467 previously processed samples were reanalysed using the 
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transferred method. The results were compared to the reference laboratory's values and 
these showed a very good correlation. 
The prevalence of AED abuse, namely gabapentin and pregabalin, was investigated among 
prisoners. 904 urine samples were collected from 8 prisons in Scotland over a one month 
period.  Firstly, a simple and accurate method was developed and qualitatively validated 
for 21 AEDs in urine to screen the urine samples. Secondly, the method was quantitatively 
validated for the positive AEDs.  
Drug analysis in hair has multiple applications in clinical laboratories and forensic 
toxicology. However, only a few papers have considered conventional AEDs analysis in 
hair for therapeutic drug monitoring purposes. As part of this research, AED extraction 
from hair samples was investigated. Six different digestion methods and 4 clean-up 
procedures were compared for 16 AEDs. An LC/MS/MS method was qualitatively 
validated using the extraction procedure that attained the highest recovery with all AEDs. 
Subsequently, two authentic hair samples were tested and the method was quantitatively 
validated for the positive AEDs in these samples.   
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1  Antiepileptic Drugs 
1.1 Introduction 
In recent years, there has been a growth in reports of drug facilitated-crime following 
ingestion of drugs that depress the central nervous system (CNS) such as hypnotic and 
anti-anxiety drugs. In some reports, combinations of drugs or intoxicants containing legal 
as well as illegal substances have been reported to have been used. In other reports, 
unforeseen legal drugs have been found to have been misused. These cases make the list of 
drugs associated with forensic cases unlimited on the grounds that perpetrators may use 
any drug to help them to commit their offences either for self-harm or for harming others.  
Furthermore, any person working within the health sector should be aware of any drug 
with CNS effects (either depressant or stimulant) which is widely used and has the 
potential to be misused.  
One group of legal medications which have increased awareness recently is the new 
generation of antiepileptic drugs (AEDs). This group has a wide range of effects on the 
central nervous system. Many of these show mood stabilizing effects, work as sedative and 
depressive agents and they are prescribed extensively for their effects on chronic 
neuropathic pain, anxiety and other psychotic disorders, although most of these indications 
are still unlicensed. Due to the rapid raise in their off-label indications, the prevalence of 
these drugs has significantly amplified during the last decade which increases their 
potential for abuse. 
Debates in the press and scientific literature regarding these drugs and their probability to 
be misused were the reason they were chosen as a topic for this research. 
1.2 History 
Epilepsy is a neurological disorder that affects brain activity leading to abnormal firing of 
nerve cells, which manifests by seizures. Seizures are defined as a disturbance in the 
electrical activity of the brain that causes temporary changes in movement, awareness, 
feelings, behaviour, or other bodily functions. Their severity varies widely from one 
individual to another and depends on the type and size of the affected area of the brain (1, 
2).  
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Epilepsy has been recognized since ancient times. The first known document to describe 
epilepsy, the Edwin Smith papyrus, goes back to ~3000 BC. Epilepsy at this time was 
considered a scary and unclean disease that was of demonic cause and its patients were 
treated by magic and religion. Magicians imposed a very strict diet in addition to the use of 
blood, bones and other human organs as a drink to cast out the devils. Religious treatment 
relied on sending the patients to sleep in temples until God appeared in their dreams and 
advised them about their cure (1, 2).  
By the second century AD, the anatomy of the nervous system was beginning to be 
studied, and epilepsy was thought to arise either in the brain or from peripheral nerve 
stimulation. Therapies prescribed at this time were changing the diet and life style such as 
living in a warm dry climate, avoiding loud noises, sleeping and exercising regularly. More 
aggressive therapies included bleeding, skull  cautery and trephination which was one of 
the more frequently used and widespread early surgeries (2). More simple regimens 
included herbals such as cardamom, plantain and tree fungi. 
In the renaissance age, important modifications of the older theories were developed. It 
was believed that seizures resulted from an irritation of the brain and its membrane. This 
idea sets the stage for the advances in the modern era. Despite the rapid increase in 
understanding of physiological mechanisms of seizures in the 19
th
 century, primitive 
treatments were still in use like mistletoe, turpentine, trephining, castration and 
circumcision. 
Bromides salts first appeared in 1857 and were the first successful pharmacological 
treatment for epilepsy. Potassium salts to treat hysterical epilepsy among young women 
were introduced by Charles Locock. Potassium bromide is a sedative compound that was 
used to counteract the excessive activity in the brain. However, it had toxic effects and 
diminished the mental function in addition to its sexual dysfunction effect. This successful 
treatment, besides its severe side effects, led to the introduction of another sedative drug, 
phenobarbital, in 1912, by Alfred Huaptmann (2, 3). In 2004, phenobarbital was one of the 
most widely prescribed AEDs because of its reasonable cost (4). Active investigation into 
other chemical compounds yielded hundreds of barbiturate derivatives, but most of these 
were toxic and not suitable for daily treatment.   
In 1938, a new compound that shared similar properties to barbiturates but with fewer 
sedative effects, phenytoin, proved its high efficacy and came into use. Phenytoin is still 
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the most used AED in the United States (3). The next major drugs to be licensed were 
ethosuximide in 1958, carbamazepine licenced in the UK in 1965 and sodium valproate, 
first marketed as an AED in France. In the 1960s, benzodiazepines were introduced as an 
effective treatment for epilepsy specifically diazepam, lorazepam and clobazam. 
Since the 1990s, there has been a noticeable increase in the number of antiepileptic drugs 
(AEDs) on the market. These include lamotrigine, topiramate, gabapentin, tiagabine, 
levetiracetam, eslicarbazepine acetate. Most of these have multiple mechanisms of action 
that facilitate their use in the treatment of a wide variety of CNS disorders (migraine, 
neuropathic pain, chronic pain conditions, psychiatric disorders, anxiety and panic 
disorders) in addition to their major indication as anti-seizure medication (5, 6).  
Nowadays, epilepsy is considered the fourth most common disease after migraine, stroke 
and Alzheimer's disease. Epilepsy affects 50 million people worldwide, of which 80% live 
in the developing world (7, 8). In the United Kingdom, it was represented in 0.5-1% in 
2002 of the adult population, increased to 0.95-1.11% in 2011 and the prevalence is still 
increasing (9, 10). The prevalence of new AED prescriptions has shown a 5-fold increase 
in children and adolescents in UK primary care between 1993 and 2005 even although the 
long-term safety surveillance data of these drugs is limited (11). New AED prescribing was 
highest among those aged between 20-50 years (12). A study of 21,551 nursing home 
residents found that 12% were taking an old generation AEDs such as valproic acid (13). 
In another study, 7.7% of nursing home residents were taking new AEDs with nearly half 
(42%) using the drugs for non-seizure conditions (14). The uptake of lamotrigine, 
topiramate and levetiracetam rose rapidly within the same period with domination for  
lamotrigine  which accounted for  65% of all newer AED prescriptions (11).  
Between 2001 and 2005, a comparison study on AED prescribing patterns was conducted 
in three different countries (United Kingdom, Netherlands and Italy). This research found a 
steady increase in the prevalence of all AEDs over these 5 years with a significant change 
in the United Kingdom but not in the Netherlands. Simultaneously, the prevalence of 
conventional AEDs decreased in the Netherlands and Italy, but not in the United Kingdom. 
The prevalence of newer AEDs showed a slight increase in all three countries. In 2005, 
lamotrigine use was highest in the Netherlands and the United Kingdom, whereas 
topiramate was dominating in Italy. The most significant increase was for vigabatrin which 
increased  from 13% to 31% over this period  whereas topiramate and levetiracetam had 
the highest number of prescriptions for younger people aged under 18 years (15). A 
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recently published study in 2014 assessed prevalence of AEDs over a nine year period 
(from 2001 to 2009) in five European countries; Denmark, Germany, Italy, Spain, the 
Netherlands and the United Kingdom. The study showed a steady linear increase in the use 
of AEDs between 6-15% each year. This increase was entirely attributed to the new 
generation of AEDs; particularly gabapentin, pregabalin, lamotrigine, levetiracetam and 
topiramate. The increase was majorly due to their off label use or being prescribed for 
indications other than epilepsy. On the other hand, the use of conventional AEDs was 
stable and did not show any significant change. The study also showed a slightly higher 
use of AEDs among female patients compared to male patients and their use increased with 
age (16). 
1.3 AEDs Classification 
AEDs‎ are‎ classified‎ into‎ new‎ and‎ conventional‎ “old”‎ AEDs‎ depending‎ when‎ they‎ first‎
appeared on the market. All AEDs found and used before the 1990s are considered old 
AEDs. These include phenobarbital, phenytoin, ethosuximide, carbamazepine and sodium 
valproate whereas all AEDs appearing on the market after 1990 are considered new AEDs 
such as eslicarbazepine acetate, gabapentin, lamotrigine, lacosamide, levetiracetam, 
oxcarbazepine, pregabalin, retigabine, rufinamide, tiagabine, topiramate, vigabatrin and 
zonisamide (16).   
1.4 AEDs and Their Potential Role in Forensic Cases  
1.4.1 Off Label Use of AEDs in Non-Epileptic Medications 
The‎ term‎ “off-label‎ prescribing”‎ refers‎ to‎ the‎ use‎ of‎ a‎ drug‎ outside‎ the‎ terms‎ of‎ its‎
marketing authorization or its product licence as known previously, including prescribing 
for unlicensed or unapproved indications. Generally, doctors have the right to prescribe a 
drug off-label but this will increase their professional responsibility (17). The off-label 
prescription of drugs affecting the central nervous system (CNS) such as mood stabilizers 
is well-known in the health care sector, especially by the psychiatric professions (18). 
However, the use of medication outside their approved indications may increase the risk of 
the side effects that could outweigh the potential benefits in addition to the ethical and 
legal issues related to the commercial promotion of the off label indications that have been 
raised recently (19-21). 
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In recent years, antiepileptic drugs have been associated with increased likelihood of off-
label prescription in the non-epilepsy disorders even though most of these indications are 
still under investigation (22). The disorders in which AEDs have been noted as being 
effective include neurological disorders such as essential tremor, neuropathic pain and 
migraine and psychiatric disorders including anxiety, schizophrenia and bipolar disorders. 
This expected efficacy is mainly related to their mechanism of action which interferes with 
the disease process. For instance, topiramate and valproate are probably effective in 
treating migraine because of their ability to enhance GABAergic and reduce glutamatergic 
neurotransmission. Other drugs such as pregabalin, gabapentin, tiagabine, and 
levetiracetam are possibly effective in psychiatric disorders due to their enhancing effect of  
GABAergic transmission, whereas drugs that have blocking effects on voltage-gated 
sodium or calcium channels may be useful in treating neuropathic pain (such as 
gabapentin, pregabalin, carbamazepine, oxcarbazepine, lamotrigine and valproate). 
Another   possible disorder where AEDs may be of clinical importance includes substance 
(23, 24) and alcohol abuse (25, 26).  
In a study of data from the 2001 IMS Health National Disease and Therapeutic Index 
(NDTI) defining the prescribing patterns in the United States, Radley et al found an overall 
off-label use of 21% of which an estimated 15% lacked scientific evidence of therapeutic 
efficacy. Forty six per cent of these medications came from antiepileptic drugs. Gabapentin 
alone accounted for 83%.  The problem was that only 17% of its prescriptions had 
scientific support compared with 66% without any support (27). Another study conducted 
in the St Andrew`s hospital, the largest psychiatric hospital in the United Kingdom, found 
that 28.5% of patients were treated with off-label mood stabilizers and 94% of these 
prescriptions were for unlicensed indications. The mood stabilizers most frequently 
prescribed off-label were: valproic acid (34%), carbamazepine (27%), lamotrigine 
(15.5%), topiramate (14%) and gabapentin (1.4%) while lithium, the licensed drug for 
psychiatric disorders, accounted for only 4% of all prescriptions owing to its side effects, 
toxicity, contraindications in other illnesses and compliance problems with blood 
monitoring (18).  
Of all AEDs dispensed between 2004 and 2007, 71% was in epilepsy, 15% in psychiatry, 
13% in neuropathic pain and <1% in migraine. Over these 4 years, the use of newer 
antiepileptic drugs increased from 40% to 49% in epilepsy, whereas it rose from 5% to 
64% in psychiatry; mainly due to the increase in using lamotrigine, and increased from 
79% to 95% in neuropathic pain as a result of the large increase in pregabalin prescriptions 
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(Figure ‎1-1). For migraines, the percentage increased from 72% to 96% due to topiramate 
and gabapentin while new AEDs use in trigeminal neuralgia increased from 3% to 16% 
where pregabalin and gabapentin dominated (28). 
 
Figure  1-1: The Percentage of Increase in AEDs Use For Off-Label Indications Between 2004 
and 2007.  
The AED prescriptions have been increasing even though the proof for their indications is 
still unavailable. For instance, more than 83% of gabapentin sales came from off –label 
prescriptions (22, 27, 29). The main concern is that for most patients, gabapentin was not 
the optimal treatment (30). Off-label sales of zonisamide, topiramate, lamotrigine, and 
oxcarbazepine as well represented 66%, 53%, 52% and 50% respectively while tiagabine 
and levetiracetam had most of their prescriptions for authorised indications with 34% and 
28% for off-label use (22). Compared with other practitioners, psychiatrists accounted for 
greater than 50% of the AED off-label expenditure (22). More than two thirds of them did 
not inform their patients about their off label medications because they considered  that 
most of their patients did not have the mental capacity to understand the off-label concept 
and this  information could adversely affect them (18).  
A recent study published in 2012 showed that off label prescription in primary care was 
highest among CNS drugs including AEDs (66.6%) which represented the highest 
proportion followed by antipsychotics (43.8%) and antidepressants (33.4%). Specific 
AEDs with the highest off label use included gabapentin (99.2%). Indications that were 
most likely to be treated with off label AEDs were neurogenic pain (gabapentin and 
topiramate) and bipolar disorder (gabapentin and lamotrigine), chronic pain, fibromyalgia, 
and diabetic neuropathy (gabapentin) (19).  
Table ‎1-1 summarises the most common off label indications of antiepileptic drugs and 
shows whether these indications are scientifically supported or not. 
Analgesia
(PGR&GBP) Epilepsy
Psychiatry
(LTG) Neuropathic
pain(PGR) Migraine
(TPR&GBP)
3% 
40% 
5% 
79% 
72% 
16% 
49% 
64% 
95% 96% 
2004 2007
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Table  1-1: AEDs Scientifically Supported and Non-Supported Off–Label Indications (5, 6, 25, 26, 31). 
Drug Anxiety Insomnia 
Essential 
tremor 
Schizophrenia 
Bipolar 
disorder 
Neuropathic pain 
Migraine 
Substance 
abuse 
withdrawal 
Diabetic 
neuropathy 
Trigeminal 
neuralgia 
Carbamazepine    o    o     o  
Oxcarbazepine    o    o      
Gabapentin  * o  o       o    
Pregabalin   o            
Phenytoin      o       
Lamotrigine        o  o    
Levetiracetam   o   o    o   
Tiagabine o * o  o      o   
Topiramate o    o  o        
Valproic acid o        o  o      
Zonisamide   o      o   
*‎●:‎Scientifically‎recommended,‎○:‎No‎strong‎scientific‎support. 
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1.4.2 AEDs Accidental Overdose, Self-Poisoning Cases and 
Suicidality  
The widespread use of the new generation of AEDs particularly in patients with psychiatric 
disorders, often as an unlicensed indication, increases the risk of self-poisoning (12). The 
frequency of AED intoxication in different studies was between 1.7% and 8% of drug 
related-poisoning (32). A study conducted between 2000 and 2007 in Edinburgh estimated 
the occurrence rate of AED overdose especially after increased used of these drugs in 
patients with psychiatric disorders who were at high risk of self-harm by drug overdose.  
There were 613 patients who ingested at least one AED. Carbamazepine, valproate, 
lamotrigine and phenytoin accounted for most of these cases (carbamazepine: 306, valproic 
acid: 163, phenytoin: 68 and lamotrigine: 63). The rest of the cases were 21 poisoning 
cases of gabapentin, 6 of  topiramate, 6 of levetiracetam and 3 of pregabalin (12).  
Another study was conducted over a period of 10 years (from 2002 to 2011) to evaluate the 
clinical effect of new AEDs in overdose. After excluding poly drug overdose and children 
under 15, they found that 347 cases met their inclusion criteria. The majority of these cases 
were gabapentin (116 cases), lamotrigine (67 cases), topiramate (56 cases), oxcarbazepine 
(55 cases), levetiracetam and tiagabine (15 cases each) and pregabalin (23 cases). Most of 
these cases resulted in mental status. Seizures were observed in cases of lamotrigine, 
oxcarbazepine and tiagabine. Lamotrigine was ranked the highest in terms of toxicity 
followed by topiramate, oxcarbazepine, gabapentin, pregabalin, tiagabine and 
levetiracetam was the lowest (33). 
Many cases of individual self-poisoning by AEDs have been reported separately. 
Lamotrigine (34, 35), carbamazepine (36) and valproic acid (12, 37) poisoning reports 
were the most common in literature before the newer AEDs appeared. Topiramate comes 
after those drugs (38). Recently, poisoning cases of newer drugs seem to be reported more 
frequently. For instance, a deliberate overdose case of pregabalin (11.5 g) and lamotrigine 
(32 g) with a depressed level of consciousness was reported for a 29-year-old male in 
2007. The plasma concentration of lamotrigine in this case was 45 mg/L. This 
concentration was the highest concentration ever recorded in the literature, while the  
plasma concentration of pregabalin was about 60 mg/L (39). Cases of suicide and 
intoxication by gabapentin have also been reported. Its effects varied from non-serious side 
effects (40) to coma (41) and death (42).  The blood concentration in one of these cases 
was within the therapeutic range (42). In another suicidality case, gabapentin  was ingested 
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with valproic acid and alcohol (37). Reports of acute tiagabine overdose have been 
published as well (43-45).  In spite of their recent availability on the market and their wide 
range of safety, zonisamide (2005), lacosamide (2008) and levetiracetam (2014) have been 
reported in poisoning and attempted suicide cases (46-48), one of which ended in death 
(49).    
As a result of these increased poison reports, a cross-sectional study was carried out to 
evaluate the risk factors associated with non-benzodiazepine AED intoxication. Deliberate 
self-poisoning accounted for the majority of AED intoxications. Different risk factors were 
found responsible for these cases such as psychological and physiological disorders and 
loneliness whereas higher education played a positive role in reducing the likelihood of 
self-poisoning (32). 
Suicide is considered to be one of the most significant reasons for increased mortality 
among patients with epilepsy (5-7% of death cases) (50), bipolar disorder (one third of 
patients admitted to at least one suicide attempt) (51), and chronic pain conditions (52). 
Interestingly, 50% of currently available reports on suicide in epilepsy have been published 
in the last 10 years (53). Regarding their effect on mood, a meta-analysis study applied by 
the FDA in 2008 showed that suicidality occurred in 4.3 per 1000 patients treated with 
AEDs. As a  result, they raised concerns that all prescriptions should be accompanied with 
a patient medication guide describing this risk on the grounds that all current AEDs pose 
an increased risk of suicidal thoughts and behaviour, regardless of their classification or 
mechanism of action (54). After the FDA alert, many researchers started to investigate 
suicidality in AEDs (50, 55-58).  
A cohort study (2010) conducted by a team of researchers in Boston hospital over a five-
year-period between 2001 and 2006 looked at prescription data for 15 AEDs used by 15 
year-old patients and older. Among 297620 patients who used these drugs, there were 801 
suicide attempts, 26 suicides and 41 violent deaths. They compared 13 out of the 15 drugs 
with two other AEDs (topiramate and carbamazepine). Topiramate is prescribed widely for 
different indications but not as a first line therapeutic approach whereas carbamazepine is 
usually prescribed for initial treatment of epilepsy. In this study, AEDs were compared 
with carbamazepine to investigate the risk of suicidal events in patients starting to use 
AEDs and they were compared with topiramate in cases of chronic AEDs treatment. As a 
result, five of these 13 drugs were found to increase the risk of suicide more than 
topiramate and carbamazepine (gabapentin, tiagabine, oxcarbazepine, lamotrigine and 
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valproic acid). Furthermore, this study found an increased menace in suicidal acts 
beginning within the first 14 days of treatment initiation, which means that AEDs may 
provoke behavioural effects prior to attaining their full therapeutic level (55).  
However, few studies suggested that FDA concerns might be excessive and that the risk of 
not prescribing AEDs is far greater than their potential suicidal act (57, 59). They claimed 
that the major limitation of the FDA meta-analysis was the lack of a systematic data 
collection and that all these trials were not designed to evaluate the relation between AEDs 
and suicide, as a consequence, data gathering was not reliable. These studies suggested that 
the increased number of suicidality to be related to epilepsy itself. Available data is, 
however, not methodologically strong enough to support or reject the claimed increased 
risk of suicidality with AEDs. Hence, proper epidemiological studies investigating this 
phenomenon are prerequisites to understand whether AEDs are a precipitating factor in 
vulnerable individuals like epileptic patients. Moreover, clinicians need to pay attention 
not only to seizure patterns when choosing the appropriate AED but also to a number of 
different parameters, not least the mental state of the individual patient (59, 60). 
1.4.3 AED Related Deaths  
AEDs have been associated with many fatality reports and hepatotoxicity in younger 
people (<18) between 1964 and 2000. The new AEDs (vigabatrin, lamotrigine, topiramate, 
and gabapentin) were associated with 20 (30%) of 65 antiepileptic-treated death cases. 
Valproic acid had the highest percentage with 31 cases  (48%) while carbamazepine, 
vigabatrin, lamotrigine  and phenytoin were found in 11 (16%), 8 (12%), 7 (11%)  and 3 
cases (5%), respectively (61).  
In Scotland, the number of AED related deaths increased from 1% in 2007 to 10% in 2012 
resulting mainly from gabapentin cases (62).  44% of these cases were accidental 
poisoning, 14% mental disorder resulting from substance abuse, 16% intentional self-harm 
poisoning and 26% undetermined intent (Figure ‎1-2). Generally, death among epileptic 
patients results from epilepsy conditions including sudden unexplained death in epilepsy 
(SUDEP), status epilepticus, accidents and suicide.  
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Figure  1-2: AED-Related Deaths in Scotland Between 2007 and 2012. 
 
SUDEP accounts for approximately 17% of all epilepsy related deaths (63). It is defined as 
a sudden unexpected death in an epileptic patient in a reasonable state of health. The death 
occurs during normal activities without any obvious medical cause or evidence of seizures 
near the time of death (64). Different risk factors account for this phenomenon. The second 
most important factor after seizures frequency is the number of AEDs taken concomitantly. 
The risk is almost 10 times higher in patients taking more than two drugs compared to 
those who are on monotherapy (65, 66). Other factors contributing to SUDEP incidence 
are correlated to the variability of AED ingestion over time (67),  alcohol abuse (68, 69) 
and to the usage of antipsychotic drugs (66). On the other hand, there are a number of 
studies which did not find any correlation between SUDEP and these factors (70). 
1.4.4 AEDs and Online Pharmacies  
As a consequence of both the ease and rapidity of access, the Internet offers a flood of 
drug-related data. The emergence of the internet as an unregulated source of controlled 
substances is an important development that may have significant public health 
implications (71).  Advertising prescription drugs to patients directly is illegal in the 
United Kingdom and a high level of public awareness of this illegal trade of prescription 
drugs has been made. However, owing to the universal nature of the Internet, governments' 
bodies are incapable of controlling all of them. Moreover, most Internet drug vendors 
selling drugs without prescription usually do so to overseas customers to keep away from 
authorities in their countries (72, 73).  
Psychonaut is a European Union, multi-site research project to investigate the developing 
relationship between the Internet and drugs with abuse potential. It involves 15 research 
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centres from eleven European countries. This project described the findings of the Scotland 
research site, which investigated the online availability of prescription drugs (74). An 
increased number of online pharmacies have been found to offer all kind of prescription 
drugs without prescription (74-76). Considering the issues of literacy, Internet access, and 
credit card ownership, it concluded that the increase access to Internet- sourced drugs may 
increase the role of the Internet in drug abuse in both higher and lower socioeconomic 
groups (74). 
AEDs are available online in different sites. Examples of online pharmacies supplying 
AEDs online without prescription and forum sites of AEDs attended by AED misusers are 
shown in Table ‎1-2. 
Table  1-2: Sites Attended by AED Misusers and Online Pharmacies Supplying AEDs. 
Examples of Online Forum Sites Attended by AED Misusers (Websites Last  Accessed 23 
August 2015) 
- Erwoid, 2011. Available from: https://www.erowid.org/experiences/exp.php?ID=85863. 
- Stever, 2010. Available from: http://aciddata.com/experiences/exp.php?ID=60394 
- Valhallen, 2003. Available from: http://www.erowid.org/experiences/exp.php?ID=28984 
- BluelightForum (2005-2009).  Available from: http://www.bluelight.ru 
- Opiophile (2009). Lyrica recreational dosage/IV use. Available from: 
http://forum.opiophile.org 
- Drugs-forum (2007-2009). Available from: http://www.drugs-forum.com/index.php 
Examples of Online Pharmacies Supplying AEDs Inside and Outside the UK (Websites Last  
Accessed 23 August 2015): 
- http://uk.popularpillsonline.net/. 
- http://auragenerics.com/index.php. 
- http://www.drugshoponline.com (pregabalin and gabapentin are advertised under the 
antidepressant drugs). 
- http://www.ipharmacylist.com. 
- http://www.eurodrugstore.eu. 
- http://www.77canadapharmacy.com/gabapentin.php. 
- http://www.omfgg.com/profiles/blogs/order-gabapentin-online-order. 
- http://firsthealthstore.net/products/neurontin.htm. 
- http://cheapest-shop24h.com/group.php?group_id=52 (levetiracetam is advertised as 
antianxiety and antidepressant). 
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Since the newer AEDs are not controlled drugs and the reports of their abuse uncommon, 
most of them are still available for sale online without any control over them, namely 
pregabalin, gabapentin and levetiracetam (77). Despite the lack of scientific reports 
regarding AED abuse in published literature, the situation is completely different on the 
World Wide Web (www), where information about drugs is just a click away. Tracking the 
www, it is clear that some AEDs, namely pregabalin and gabapentin, are increasingly 
misused by young people who are interested in using legal high and illicit drugs and 
sharing their experience with other users by posting on online forums. Another concern 
about online pharmacies is that some of these sites advertise for AEDs as antianxiety drugs 
without prescription.  
1.4.5 AED Abuse Cases 
Drug misuse is a deeply rooted social problem with serious consequences for public health 
and criminal fairness. Today drug selections are made from a variety of substances and, 
perhaps most importantly, the mix of drugs or intoxicants used contains legal as well as 
illegal substances (78).‎ ”Problematic‎ use‎ refers‎ to‎ anyone‎ who‎ experiences‎ social,‎
psychological, physical or legal problems related to intoxication and/or regular 
consumption and/or dependence as a consequence of his/her own use of drugs or other 
chemical‎substances”‎as‎defined‎by‎The‎Scottish‎Consortium‎on‎Crime‎&‎Criminal‎Justice‎
(78).  
AEDs are a group of these legal prescription drugs which are found in abuse cases either 
alone or with alcohol (37, 79) and/or other common drugs of abuse in order to enhance 
their effects (37, 77, 79). These cases included carbamazepine, pregabalin, gabapentin, 
topiramate, phenytoin and lacosamide.  
Unexpected abuse of few unscheduled sedating medications has raised concern over the 
liability of prescription drugs to be misused even though their preclinical abuse potential 
assessment studies implied that they would not be expected to produce any physical 
dependence of the CNS depressant type (80, 81).  Programs for assessing the abuse 
potential of new chemical entities in humans were largely developed to be used in studies 
of the known drugs of abuse and a good correlation has been recognized between the 
signals detected in these methods and the actual abuse of substances in classes such as the 
opiates (82) and hypnotic drugs (83).  A similar study has been conducted to investigate 
the reinforcing effects of levetiracetam (4000 mg), valproic acid (1500 mg), diazepam (30 
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mg) and diphenhydramine (400 mg). As a result, for the doses studied, the statistical 
findings of abuse potential were diazepam (9/10 measures significant) > levetiracetam 
(6/10) > diphenhydramine (5/10) > valproic acid (2/10) (81). Levetiracetam met the criteria 
for displaying abuse potential in this laboratory study even though no reports of actual 
abuse have been reported in the marketplace which make this finding difficult to elucidate 
(81). Maybe, the 4000 mg dose of levetiracetam used in the study is high enough (8-fold 
than the usual stated single dose) to consider the low liability of abuse. However, another 
explanation of these findings is that there is a significant risk of actual abuse of 
levetiracetam that has not been realized owing to its recent availability in the market (since 
2000 in USA and Europe), the willingness of drug abusers to experiment with new drugs 
and as mentioned before, the ease with which information of drug effects can be shared on 
the Internet (81). Diphenhydramine is an example of an unexpected sedating drug. Pre-
clinical studies carried out on diphenhydramine to investigate its liability of abuse did not 
recognize this effect and suggested that it had a low potential of abuse. The statistical 
findings of this study showed that the abuse potential of diphenhydramine is lower than 
that of levetiracetam, even though reports of actual abuse and fatalities from 
diphenhydramine have been recently reported  (84, 85).  The major drawback of such 
studies is that they do not assess the factors involved in the actual abuse of drugs (81), for 
example, the availability of other misused drugs, the cost or difficulty of getting them and 
the social circumstances of the abusers (86). 
In the world of crime, lamotrigine, carbamazepine, phenytoin and valproic acid have been 
reported in drug-facilitated sexual assault cases (87-91). Actual abuse reports have been 
found in the press and scientific literature regarding a number of AEDs. Drugs mentioned 
are carbamazepine, valproic acid, phenytoin, gabapentin, pregabalin, topiramate and 
lacosamide. 
1.4.5.1 Carbamazepine and Valproic Acid Misuse 
The first report of AED misuse is for carbamazepine published in 1993 which describes 
two of several carbamazepine abuse cases. Both subjects were prescribed carbamazepine 
for alcohol withdrawal but they continued consuming the drug with alcohol after leaving 
hospital owing to their feeling of euphoria comparable to that of consuming alcohol with 
benzodiazepines (92).  Another recreational misuse case report was in 1997 for a 20-year-
old female who also abused carbamazepine with alcohol. She claimed that she had learned 
to‎abuse‎it‎“on‎the‎street”‎(93). Valproic acid has also been associated with alcohol abuse 
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(37). By the end of 1990s, both drugs had been mentioned in forensic literature as potential 
drugs of misuse (88, 90, 91). 
1.4.5.2 Gabapentin Misuse  
Gabapentin has been reported to be misused orally and intramuscularly in combination 
with other illicit substances such as: baclofen, cannabis, alcohol, SSRIs antidepressants 
(selective serotonin reuptake inhibitors), amphetamine, gamma-hydroxy butyric acid 
(GHB) (77) and  lysergic acid diethylamide (LSD). People who misuse this drug say that 
their feelings are comparable to MDMA (methylenedioxymethamphetamine - known as 
ecstasy), amphetamine, fully–sedated opiate, dextromethorphan, and cannabis abuse. It 
causes euphoria but its tolerance level is very high (77). The first reported case of 
gabapentin abuse in the literature appeared in 1997 (94). This case involved a 41-year-old 
woman, who had been consuming crack cocaine for at least twelve months. During her 
rehabilitation from cocaine abuse, she had started using her husband`s prescribed 
gabapentin voluntarily to substitute her cocaine dependence. She said that it was useful in 
diminishing her cravings, but after three months she had resorted to drug-seeking behavior. 
Another case was a 67-year-old women who had a history of alcohol abuse leading to 
polyneuritis; a simultaneous impairment of function of many peripheral nerves such as the 
cranial nerves (95). She was prescribed gabapentin as a pain relief, but she developed 
tolerance toward the drug which resulted in doubling her dose to 4800 mg/day, but she 
actually increased the dose to 7200 mg/day by herself to get an acceptable analgesic 
effects. When she ran out of her drug, withdrawal symptoms appeared and she was 
hospitalized.  
Secondary to the wide spread use of gabapentin in correctional facilities, reports of 
gabapentin abuse have been published describing inmates who snort gabapentin powder 
from capsules during their incarceration (96, 97). Most of them were cocaine abusers who 
intended to misuse gabapentin as a way to get high, feeling similar to that following 
cocaine use. These concerns about the potential abuse of gabapentin started to arise in 
2001 when the medical staff at several correctional institutions in Florida noticed that 
inmates were requesting refills of gabapentin capsules sooner than scheduled and often 
making allegations that their medication had been stolen by others. They were prescribed 
gabapentin for assorted medical and psychiatric conditions (neuropathic pain, epilepsy, 
anxiety and mood disorders) and they were allowed to keep their prescription bottles 
themselves. After investigation, the medical staff discovered that only 19 out of 96 
Chapter 1   16 
 
prescription bottles were found to be in the possession of the appropriate patients (96). As 
a result of these findings, gabapentin was removed from the department of correction 
formulary in August 2001, because it was noted that gabapentin was not abused for its 
sedating properties but for its effects of getting high, especially after intranasal ingestion, 
as admitted by the inmates themselves (96).  
Individual cases of gabapentin abuse have been increasingly reported in different places 
(98-100). In some cases, it has been abused with heroin (100), alcohol (98) and other 
substances of abuse (77). In most cases reported, abuse of gabapentin occurred during the 
recovery program of alcohol abuse (95) or cocaine abuse (94). Furthermore, there are cases 
in which gabapentin abuse was by epileptic patients themselves who described having 
euphoric feelings after using it as a treatment (99).  More details about these cases can be 
found in Appendix 1-1. In‎ all‎ these‎ cases‎ euphoria‎ and‎ “substance‎ abuse”‎ like‎ feelings 
were reported. Symptoms of withdrawal syndrome were associated with gabapentin 
discontinuation, (confusion, agitation, nervousness, anxious, headache), even when it was 
used within the therapeutic dose (1600-4800 mg/day)(101). This syndrome was found to 
be similar to that of benzodiazepines and alcohol (102).  
1.4.5.3 Pregabalin Misuse  
Pregabalin use has rapidly increased from 4.6 million Defined Daily Doses (DDDs) in 
2007 to 9.3 million in 2009 (103). A controlled clinical study carried out on over 5500 
patients showed that self-reporting rates of euphoria ranged between 1-12% (104) and the 
effects seemed to be dose-related (77). These effects are summarized in Table ‎1-3. 
Table  1-3: Pregabalin Effects–Related Dose as Described by its Misusers (77). 
Dose Reported Symptoms 
600 mg  
Disorientation, increased physical and psychological awareness, 
difficulty to drive, slurred speech, hallucinations. 
900 mg Strong feelings of drunkenness, difficulty to walk, little euphoria. 
1200 mg Drowsiness, euphoria. 
>1500 mg 
Uncontrolled drowsiness, frequent hallucinations, great euphoria, 
Dextromethorphan-like dissociative effects.  
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Another study reported 16 cases of pregabalin abuse between 2007 and 2009 (103). Most 
of these were for patients with a median age of 29 years who were prescribed pregabalin 
for treatment of generalized anxiety disorder (GAD). Six out of these 16 cases were 
intentional abuse with maximum daily doses ranging from 300 to 4200 mg, mostly taken 
as a single dose. As a result, this study suggested that pregabalin is likely to be associated 
with an abuse potential (103).  
Pregabalin was reported to be misused in combination with alcohol, prescription drugs 
(zopiclone, benzodiazepines, and gabapentin), Illicit/recreational drugs (marijuana, 
heroin/opiates,‎ amphetamines‎ and‎ LSD)‎ and‎ with‎ the‎ “Legal‎ High”‎ drugs‎ such‎ as‎
mephedrone and salvia divinorum. Its tablets have been taken by different routes: orally 
(parachuting), intravenous after dissolving the tablets in water, rectal (plugging) and by 
inhalation. Users state that dose for dose, pregabalin outshines gabapentin, however 
tolerance is gained more quickly (77, 103). 
Pregabalin withdrawal symptoms have been also reported in many cases. One of them was 
for a 47-year-old man who was consuming pregabalin with alcohol and cannabis at 
irregular intervals. He developed vegetative withdrawal syndrome when he attempted to 
wean himself off pregabalin (105).    
Since 2012, several articles have been published questioning the potential of gabapentin 
and pregabalin;‎ which‎ are‎ known‎ as‎ “gabapentinoids”,‎ to‎ be‎ abused‎ (24, 106-108). A 
questionnaire-based survey was carried out in six substance misuse clinics in Edinburgh. 
The results showed that 22% of respondents admitted to abusing gabapentinoids, and of 
these, 38% abused them in order to potentiate methadone-like effects (109). Most 
gabapentinoid abusers were individuals with a history of recreational poly-drug misuse, 
who self-administered these drugs with excessive dosages up to 3–20 times of clinical 
dose. Hence, it has been advised that physicians considering prescribing gabapentinoids for 
neurological/psychiatric disorders should carefully evaluate for a possible previous history 
of drug abuse (108). 
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1.4.5.4 Phenytoin Abuse  
Reports of phenytoin misused with marijuana and cocaine by inhalation have been reported 
since 1993 (79, 110, 111)
 
. In two of these reports, phenytoin was abused with crack 
cocaine. Abusers tended to mix phenytoin with crack before the drug was smoked (110). 
Recently, a case was found of a 19-year-old man who combined phenytoin, marijuana and 
alcohol recreationally based on a rap song  (79).  Phenytoin has also been detected in 
sexual assault cases (88). 
1.4.5.5 Topiramate Abuse 
Topiramate has also been misused by a bipolar patient with an eating disorder in order to 
lose more weight. She refused to use valproic acid and lithium because of their side effect 
of weight gain. Due to this decision, she was prescribed topiramate. Two weeks later, she 
had decreased cognition, dulled thinking, moderate sleepiness, and a gastrointestinal 
disorder. After her examination, it was obvious that she had increased her dose voluntarily 
when she noticed that she started to lose weight. This positive advantage of topiramate  
over other anti-manic agents, may result in its abuse by those patients with obesity body-
image disorder (112). Another case was reported of topiramate abuse by a 17-year-old 
female. She ingested 800 mg topiramate intentionally in order to get high. She fell down 
nonresponsive and became combative and confused with  significant speech impairment 
(113).  
1.4.5.6 Lacosamide Abuse 
No actual reports have been found for lacosamide abuse, but clinical studies conducted on 
this drug indicate that it has the potential for abuse, especially by recreational abusers who 
described its effect as similar to alprazolam. It produces a kind of sedation with high 
euphoric drunk and drug like effects. Healthy subjects in these studies reported a high rate 
of euphoria-type response but no liability to produce physical dependence has been 
recorded (114).  
An overview of relevant data from the reports mentioned above can be found in Appendix 
1-1. 
Chapter 1   19 
 
1.4.1 AEDs, Alcohol and Substance Abuse Treatment 
Carbamazepine, phenytoin and valproic acid are AEDs used in the treatment of alcohol 
withdrawal (26). As a result of perceived low abuse potential, many studies have 
investigated the role of AEDs in the rehabilitation of substance (23, 115-117) and alcohol 
abuse as alternatives to benzodiazepines (25, 31). However, reports of AED abuse with 
alcohol and other substances of abuse have recently increased and awareness of this 
problematic issue has been raised in the press and scientific literature (24, 37, 77, 79, 103, 
106-108). This indicates that the potential for abuse may have been underestimated. 
1.4.2 AEDs and Driving Cases 
Driving under the influence of drugs (DUID) whether prescribed medication or illegal 
substances is an issue of growing concern in industrialized countries, as it is a risk factor 
for and a cause of road accidents and is considered as dangerous as driving under the 
influence of alcohol (118). Drugs may lead, alone or in combination with alcohol or other 
CNS influencing compounds, to slower reaction times, sleepiness, poor concentration, 
distorted‎perception,‎overestimation‎of‎one’s‎abilities‎(leading‎to‎unnecessary‎risk-taking), 
aggression until panic attacks, or blurred vision due to widened pupils. As a consequence, 
the number of accidents attributed to the consumption of psychoactive substances is still 
increasing. For these reasons, many countries consider driving whilst controlled substances 
are present in the blood to be an executive offence and, in the case of additional signs of 
impairment or an accident caused by any intoxicant, a criminal offence (119). In the UK, it 
is an offence under the Road Traffic Act of 1988 to drive under the influence of drugs or 
medicine and in most cases this offence would be considered in the same way as a drink 
driving conviction and carry similar penalties (120).  
AEDs are considered to have the potential to  impair a driver and should be tested in cases 
of suspected impaired driving (121). A study conducted between 2003 and 2007 in the 
USA to evaluate the prevalence of gabapentin in impaired driving cases found 137 positive 
gabapentin cases. Seven per cent of these accident cases were positive for gabapentin alone 
with the remaining 93% showing multiple drug use (122). 
Nowadays, scientists are calling for a new way of highlighting the dangers of driving after 
using drugs. They want a "traffic light" system, with red, amber or green markings 
indicating whether it is safe to drive after taking a medicine or not. The red mark means 
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that the drug should not be used by drivers, the amber one means that the driver should 
take advice, whereas the green mark means that the drug should not affect driving 
performance. They claimed that there is a widespread confusion among the population 
about what is safe for driving and what is not (123). This system is still under investigation 
and has not been applied yet in most countries.  
1.5 AEDs and Legislations  
AEDs are not controlled by either the Misuse of Drugs Act 1971 of the UK, the Misuse of 
Drugs Registrations 2001, or the Poison Act 1972 (124, 125). AEDs are classified as 
prescription only medicines (POM) under the Medicine Act 1968 (126). Recently, 
pregabalin has been added to the list of new recreational psychoactive substances and 
officially notified to the relevant EU agencies (127). With regards to the US Controlled 
Substances Act (CSA), pregabalin and lacosamide are classified in schedule V (114, 128). 
Recently, new guidance on prescribing responsibilities for selected medications has been 
applied.  It aims to provide a clear understanding of where clinical and prescribing 
responsibility‎ rests‎ between‎ specialists‎ and‎ GPs.‎ It‎ is‎ called‎ The‎ “Traffic‎ Light‎ System‎
(TLS)”.‎This‎system‎divides‎drugs‎in‎categories‎depending‎on‎the‎patient safety, ensuring 
appropriate usage and the presence of a shared care protocol. These categories are red, 
amber, green and grey. The red group includes drugs majorly prescribed by consultant or 
other physician within a secondary care service, drugs with new prescribed indication, new 
drugs in the markets and drugs not listed in the NHS references. The amber group includes 
drugs that are usually initiated by a specialist but for which GPs may agree to continue 
ongoing prescribing, drugs that have shared protocols or treatment guidelines. The green 
group includes drugs for which GPs take full responsibility for initiating and ongoing 
prescribing whereas the grey category includes drugs that lack evidence of clinical 
effectiveness, cost prioritization or drugs that have concerns over their safety. With regards 
to the Traffic Light Drugs List published in 28 June 2011, AEDs are classified under the 
amber category except gabapentin and pregabalin which are classified under the green 
category in case these drugs are prescribed for neuropathic pain (129). 
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1.6 AED Chemistry and Pharmacology 
1.6.1 AED Chemical Structures 
AEDs are acidic, basic and amphoteric compounds with a wide range of pKa and different 
polarities as indicated in Figure ‎1-3.  
 
Figure  1-3: Chemical Structures of 18 Commonly Used AEDs and 4 of Their Main 
Metabolites.  
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Old AEDs represent the core structures for the development of subsequent second and 
third generation of new AEDs. For instance,  
a. Phenobarbital was the first successful AED derivative of barbituric acid and it was 
used subsequently in primidone and phenytoin synthesis. These are second 
generation AEDs. Fosphenytoin is a derivative of phenytoin and therefore a third 
generation AED to phenobarbital. 
b. Carbamazepine is an iminostilbene chemically related to the tricyclic 
antidepressant; imipramine. Its structure is the base for oxcarbazepine, a second 
generation AED which in turn represents the core for eslicarbazepine acetate 
synthesis, a third generation AED to carbamazepine.  
c. Valproic acid is an achiral short branched fatty acid with 8 carbons without any 
nitrogen atom or cyclic ring and represents the core for a few derivatives such as 
valpromide and valnoctamide. 
AEDs produced after 1990s have a wide variety of new chemical structures and are not 
considered as a second generation to existing AEDs. Some new AEDs contain the 
GABA moiety in their structure such as vigabatrin, tiagabine, gabapentin and its 
second generation pregabalin. Lacosamide is an N-benzyl-N-acetamide derivative of 
serine. Lamotrigine is a triazine and rufinamide is a triazole but they are not chemically 
similar. Levetiracetam is a heterocyclic amide related to piracetam which is a cognitive 
enhancer. Retigabine is a carbamic acid ethyl ester derivative. Topiramate is a sugar 
derivative from D-fructose and acetone and finally zonisamide is a benzisoxazole 
derivative (130, 131). 
1.6.2 AED Pharmacokinetics  
A summary of AED pharmacokinetics are presented in Table ‎1-4 (130, 132-137). 
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Table  1-4: A Summary of AED Pharmacokinetics. 
Drug 
Half Life (Hrs) Blood concentration 
Vd 
(L/kg) 
Blood/ 
plasma 
Protein 
Binding 
(%) 
Chronic 
therapy 
Single 
dose 
Chronic therapy 
(mg/L) 
Single dose 
(mg/L) 
Time to Peak 
Concentration 
(Hrs) 
Carbamazepine 18-65 5-26 1.7-15 4-8 3.2-5.7 0.8-1.8 0.6 75 
Eslicarbazepine acetate 10-16 13-21 8.8-25 7.8-16 2.1-3.3 0.7 1.2-1.4 40 
Lacosamide 13 - 2.5-13.5 - 1-5 0.5-4 n/a 15 
Lamotrigine 12-62 29 2.3-5.6 0.4-1.6 1.9-2.1 1.9-1.3 n/a 55 
Levetiracetam 6-10 7.8 29-31 14-51 1-4 0.4-0.7 0.8-0.9 <10 
Oxcarbazepine 1-3 - 0.05-1.2 1 1.3 3-15 0.5 40 
Gabapentin 5-9 - 1.9-2.6 2.2-6.1 4-8 0.8-1.3 1.0 <3 
Phenobarbital 48-144 - 10-48 0.7-18 1.9 0.5-0.6 0.8-0.9 50 
Phenytoin 8-60 17 7.8-20 1.6-14 2-5.2 0.5-0.8 0.5-0.6 87-93 
Pregabalin 5-11 9.1 1.3-4.9 1.9 1 0.5-0.6 n/a 0 
Rufinamide 5-11 8.8 2.6-4.7 2.2-4.3 5.4 0.8-1.2 1 26-35 
Retigabine 7-11 7.4-9.2 0.49-0.98 0.41-0.11 1.4-1.8 2-3 0.6-0.7 60-80 
Stiripentol 4.5-13 - 4-22 - 1.5 1.03 n/a 99 
Tiagabine 4-9 - 0.03-0.16 0.06-0.13 1-2.2 0.8-2.1 n/a 96 
Topiramate 19-23 - 2.4-27 1.7-7.7 1.4-3.5 0.5-0.8 1.3-7.1 15 
Valproic acid 8-12 9 50-100 32-90 1.5-3 0.1-0.4 0.5-0.6 90-95 
Vigabatrin 6-8 - 75 18-77 0.8-0.9 0.8 0.6-0.9 0 
Zonisamide 53-75 63 21-28 2.9-6.4 2-5.3 0.7-1.8 4-5 40 
Chapter 1   24 
 
1.6.3 Metabolism and Excretion 
1.6.3.1 Carbamazepine  
Carbamazepine is a type of tricyclic antidepressant. It is extensively metabolized to 10, 11-
dihydroxycarbamazepine via 10, 11-epoxide formation with subsequent hydrolysis with 
only 1% excreted unchanged in urine (Figure ‎1-4). Another minor pathway results in 
iminostilbene formation. Its three major metabolites are 10,11-dihydroxycarbamazepine 
(10-20%), carbamazepine-10-11-epoxide (2%) which has an anticonvulsant activity similar 
to that of the parent drug and iminostilbene (0.5%) (137). 
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Figure  1-4: Carbamazepine Metabolic Pathway. 
1.6.3.2 Eslicarbazepine Acetate and Oxcarbazepine 
Eslicarbazepine acetate is a second generation AED to oxcarbazepine and third generation 
to carbamazepine. It is a prodrug of S-licarbazepine which is a mono hydroxyl metabolite 
(S-MHD) of oxcarbazepine and the main active metabolite responsible for the antiepileptic 
effect of both oxcarbazepine and eslicarbazepine acetate. As the MHD could not be 
patented, the favourable pharmacokinetic profile of S-licarbazepine was one of the 
incentives for the development of ESL as a new AED. Eslicarbazepine acetate is rapidly 
hydrolysed to S-licarbazepine only which in turn oxidises to oxcarbazepine and reduces to 
trans-diol carbazepine, whereas oxcarbazepine as a drug is metabolized to both S-
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licarbazepine (80%) and R-licarbazepine (20%) (Figure ‎1-5). All their metabolites are 
subject to conjugation with glucuronic acid prior to their urinary excretion; conjugated S- 
and R-licarbazepine and trans-diol carbazepine (137, 138). 
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Figure  1-5: Eslicarbazepine Acetate and Oxcarbazepine Metabolic Pathway. 
1.6.3.3 Gabapentin 
Gabapentin is a gamma amino butyric acid (GABA) analogue. It is not metabolized, not 
bonded to plasma protein and is eliminated unchanged by the kidneys (76-81%) and by 
faeces (10-32%) (137). 
1.6.3.4 Lacosamide 
Lacosamide (SPM 927, Harkoseride: as known previously) is a functionalized amino acid 
molecule. Its urinary excretion profile shows 40% as unchanged parent drug, 30% 
corresponding to its main metabolite desmethyl lacosamide and 17% to unknown polar 
fractions (Figure ‎1-6). Minor fractions were biotransformed to hydroxyl lacosamide and 
descarbonyl lacosamide (132, 139)
 
. 
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Figure  1-6: Lacosamide Metabolic Pathway. 
1.6.3.5 Lamotrigine 
Lamotrigine is a dichlorophenyltirazine derivative that is extensively metabolized by 
hepatic enzymes, mainly by conjugation with glucuronic acid (Figure ‎1-7). It is eliminated 
in the urine (8% as a parent drug and 62% as metabolites). Its major metabolites that have 
been detected in urine are lamotrigine-N-2-glucuronide and N-5-glucoronide (137, 140). 
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Figure  1-7: Lamotrigine Metabolic Pathway. 
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1.6.3.6 Levetiracetam 
Levetiracetam is a pyrrolidine derivative from piracetam. Sixty six per cent of the drug is 
eliminated unchanged by kidney, 24% is metabolised to a carboxylic acid derivative 
known as L057, 2% to a pyrrolidine ring hydroxylation product and 1% to a ring fission 
product (Figure ‎1-8) (137). 
N O
CONH 2H5C2
Levetiracetam
N O
COOHH5C2
L057
Ring hydroxylation  
 
Figure  1-8: Levetiracetam Metabolism Pathway. 
1.6.3.7 Phenobarbital 
Phenobarbital is a barbituric acid derivative that is mainly metabolized by N-glucoside 
formation and by oxidation to p-hydroxy phenobarbital which in turn conjugates with 
glucuronide acid (Figure ‎1-9). The drug is excreted in urine as free drug (25-33%), N-
glucosyl phenobarbital (24-30%) and free or conjugated p-hydroxy phenobarbital (18-
19%)(137) . 
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Figure  1-9: Phenobarbital Metabolic Pathway. 
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1.6.3.8 Phenytoin 
Phenytoin is a diphenyl hydantoin analogue metabolized by p-hydroxylation of the phenyl 
ring and formulates the known metabolite, HPPH (p-hydroxyphenytoin) which 
accumulates in the plasma in concentration as high as 37 mg/l. Other products of oxidation 
are m-hydroxylated and 3,4-dihydroxyphenyl derivatives which appear as minor 
metabolites (Figure ‎1-10). The urinary excretion profile shows > 4% as unchanged drug 
while the p-hydroxy phenytoin as a conjugate metabolite accounts for 23-67% (137). 
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Figure  1-10: Phenytoin Metabolic Pathway. 
1.6.3.9 Pregabalin 
Pregabalin is a gamma amino butyric acid (GABA) and gabapentin analogue. Ninety two 
per cent of the drug is eliminated unchanged in urine, 0.9% is eliminated as N-methyl 
pregabalin and 0.4 % as unidentified metabolite (Figure ‎1-11) (137).  
Pregabalin
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Figure  1-11: Pregabalin Metabolic Pathway. 
Chapter 1   29 
 
1.6.3.10 Rufinamide 
Rufinamide is a triazole derivative that is extensively hydrolysed to inactive metabolites; 
CGP 47292 that undergoes glucuronidation and a carboxylic derivative. Only 2% of the 
drug is eliminated unchanged in urine whereas 66% is eliminated as free or conjugated 
CGP47292 (Figure ‎1-12) (137). 
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Figure  1-12: Rufinamide Metabolic Pathway. 
1.6.3.11 Retigabine 
Retigabine is predominantly metabolized via N-glucuronidation and N-acetylation that 
results in the formation of two distinct inactive N-glucuronides and an N-acetyl metabolite 
that demonstrates minimal pharmacologic activity. The majority of drug and metabolite are 
renally excreted. Retigabine is not metabolized via CYP isoenzymes (Figure ‎1-13) (130). 
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Figure  1-13: Retigabine Metabolic Pathway. 
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1.6.3.12 Stiripentol 
Stiripentol is metabolized by O-dealkylation of the methylenedioxy moiety, resulting in the 
corresponding di-hydroxy analog (Figure ‎1-14). This dihydroxy intermediate is then 
methylated at either hydroxy position by the catechol 0-methyl transferase system giving 
p- and m-hydroxy metabolites which are urinary eliminated by conjugation (141). 
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Figure  1-14: Stiripentol Metabolic Pathway. 
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1.6.3.13 Tiagabine 
Tiagabine is a GABA-reuptake inhibitor metabolized extensively by thiophene ring 
oxidation and glucuronidation (Figure ‎1-15). It is eliminated by urine (25%) and faeces 
(63%) and only 2% is eliminated unchanged (137) . 
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Figure  1-15: Tiagabine Metabolic Pathway. 
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1.6.3.14 Topiramate 
Topiramate is a sulfamate-substituted monosaccharide. This drug is eliminated mainly in 
urine (81%). Forty per cent of the drug is eliminated unchanged. The rest is metabolized to 
formulate six metabolites which result from C-oxidation and their glucuronide or sulphate 
conjugates (Figure ‎1-16). The major two metabolites are 2, 3-di-OH-topiramate and 10-
OH- topiramate (137). 
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Figure  1-16: Topiramate Metabolic Pathway. 
1.6.3.15 Valproic acid 
Valproic acid is a carboxylic acid derivative, 59% of the parent drug is eliminated as a 
glucuronide conjugate and 23% as 3-ketovalproic acid in addition to other minor 
metabolites and products of valproic acid desaturation which are found in plasma 
(Figure ‎1-17) (137). 
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Figure  1-17: Valproic acid Metabolic Pathway. 
1.6.3.16 Vigabatrin 
Vigabatrin is a structural analogue of GABA that is eliminated mainly unchanged (82%). 
Two urinary metabolites have been detected but they have been found to represent less 
than 5% of a single dose (137). 
1.6.3.17 Zonisamide 
Zonisamide is a sulphonamide derivative with nonlinear plasma kinetics when the dose 
exceeds 400 mg. It is slowly eliminated in the urine (63%). Twenty two per cent of the 
drug is eliminated unchanged, 9.3% as N-acetylzonisamide and 3% as a glucuronide ring 
fission product known as M1 (Figure ‎1-18) (137). 
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Figure  1-18: Zonisamide Metabolic Pathway. 
 
1.6.4 Antiepileptic Drug Interactions 
Pharmacokinetic interactions result from any alteration in the drug absorption, protein 
binding, and metabolism and excretion pathway. The most common interactions are due to 
hepatic enzyme induction or inhibition, mainly Cytochrome P450 enzyme (CYP). This 
enzyme has a number of isoenzymes that has its unique gene code and characteristic 
substrate specificity. Knowledge of the isoenzymes involved in the metabolism of 
established AEDs allows a prediction of interactions with new drugs in development. CYP 
isoenzymes involved in AEDs interactions are CYP1A2, CYP2C9/10, CYP2C19, and 
CYP3A3/4. Another key enzyme is uridine glucuronyl transferases (UGTs) which catalyse 
glucuronidation via two enzyme families, UGT1 and UGT2. UGTs are in general less 
substrate specific compared to CYP. As for the CYPs, UGTs are susceptible to induction 
or inhibition but their role in AED metabolism is still under investigation. 
Antiepileptic drugs (AEDs) are a group of drugs that are highly susceptible to drug 
interactions because of their effect on CYP and UGT enzymes or for being a substrate for 
these two enzymes. For instance, some of the older AEDs (such as carbamazepine, 
phenobarbital, phenytoin and primidone) cause CYP and/or UGT induction resulting in a 
decrease in the serum concentration of other prescribed drugs. On the other hand, other 
AEDs cause CYP and/or UGT inhibition (valproic acid) resulting in an increase in the 
serum concentration of other medications (e.g. oral contraceptives, antidepressants, 
antipsychotics, anticoagulants, antimicrobal drugs, antineoplastic drugs, and 
immunosuppressants). Newer AEDs involved in pharmacokinetic interactions include 
felbamate, rufinamide, and stiripentol as enzyme inhibitors and oxcarbazepine and 
topiramate as enzyme inducers. Conversely, the serum concentrations of AEDs may be 
increased by enzyme inhibitors among antidepressants and antipsychotics, antimicrobal 
drugs (as macrolides or isoniazid) and decreased by other mechanisms as enzyme 
induction, reduced absorption or excretion such as oral contraceptives, cimetidine, 
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probenicid and antacides (130, 142). Table ‎1-5 summarise the effect of AEDs on CYP and 
UGT isoenzymes and the AEDs that play as a substrate for these enzymes. 
Table  1-5: AEDs Mechanisms of Elimination and Susceptibility to Pharmacokinetic 
Interactions. 
AED 
Main Route of 
Elimination 
CYP* 
Metabolism 
Pathway 
AED Effect(s) 
on CYP 
UGT* 
Metabolism 
Pathway 
AED 
Effect on 
UGT 
Carbamazepine Oxidation Yes Inducer No Inducer 
Eslicarbazepin
e acetate 
Oxidation No CYP3A4 inducer Yes None 
Gabapentin Renal excretion No None No None 
Lacosamide Demethylation No None No None 
Lamotrigine Conjugation No None Yes None 
Levetiracetam 
Hydrolysis, renal 
excretion 
No None No Unknown 
Oxcarbazepine 
Conjugation, renal 
excretion 
No 
CYP3A4 inducer 
& CYP2C19 
inhibitor 
Yes Inducer 
Phenobarbital 
Conjugation, renal 
excretion 
Yes Inducer Yes None 
Phenytoin Oxidation Yes 
CYP3A4 inducer 
& CYP2C19 
inhibitor 
No Inducer 
Pregabalin Renal excretion No None No None 
Rufinamide 
Hydrolysis, 
glucuronidation 
No CYP3A4 inducer Yes None 
Retigabine 
Glucuronidation, 
acetylation 
No None No None 
Stiripentol 
Oxidation, 
glucuronidation 
No Inhibitor No None 
Tiagabine Oxidation Yes None No None 
Topiramate 
Oxidation, renal 
excretion 
Yes 
CYP3A4 inducer 
& CYP2C19 
inhibitor 
No None 
Valproic acid 
Oxidation, 
conjugation 
Yes 
CYP2C19 
inhibitor 
Yes Inhibitor 
Vigabatrin Renal excretion No None No None 
Zonisamide 
Oxidation, renal 
excretion 
Yes None No None 
*CYP: Cytochrome P450 enzyme, UGT: Uridine diphosphate glucuronosyltransferase enzymes. 
 
1.6.5 AED Mechanism of Action  
Epilepsy is a neurological disorder represented by different types of seizures. The 
development of these seizures includes many structures and neurological pathways such as 
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neurons, ion channels, receptors, ganglia, and inhibitory and excitatory synapses. 
Generally, these seizures are induced as a result of imbalance between factors that 
manipulate the excitatory postsynaptic potential (EPSP) such as depolarization, sodium 
and calcium channels and those which manipulate the inhibitory postsynaptic potential 
(IPSP) such as potassium and chlorine channels (143). AEDs are developed to modify 
these factors by favouring inhibition over excitation in order to stop the seizure activity. 
Mechanisms of action of the most commonly used AEDs are illustrated in Figure ‎1-19.  
Regarding their major mechanisms of action, AEDs can be classified into (5, 6, 144, 145): 
A. Sodium channel blockers: carbamazepine, eslicarbazepine acetate, oxcarbazepine, 
lacosamide, lamotrigine, phenytoin, rufinamide and zonisamide. 
B. Calcium channel blockers: gabapentin, pregabalin and ethosuximide. 
C. Potassium channel activators: retigabine. 
D. GABA enhancers: benzodiazepines, barbiturates, tiagabine and vigabatrin.  
E. SV2A modulators: levetiracetam. 
F. Drugs with multiple mechanisms of action: felbamate, topiramate and valproic 
acid. 
All these drugs, chiefly the new generation drugs, have more than one mechanism of action 
which gives them a wide range of neurological effects that lead to their off-label use in 
many disorders. Table ‎1-6 demonstrates the different mechanisms of action related to these 
drugs. It is noticeable that most of these drugs have an effect on the GABA 
neurotransmitter, its receptor or its re-uptake mechanism. GABA is the major 
neurotransmitter in the CNS inhibition process which is affected by benzodiazepines, 
common drugs of misuse in forensic toxicology (5). 
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Figure  1-19: Main Mechanisms of Action of Most Commonly Prescribed AEDs (145). 
"Permission Obtained From Dr. Wolfgang Loscher" (AMPA:‎α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid, GABA: γ-aminobutyric acid, GAT-1: sodium- and chloride-dependent 
GABA transporter 1, SV2A: synaptic vesicle glycoprotein 2A. All these factors are involved in 
synaptic vesicle cycling and neurotransmitter release in normal and pathological conditions). 
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Table  1-6 : AED Mechanism of Action (5, 6, 130, 132, 146, 147). 
Drug 
Na
+ 
channel 
inhibitors 
Ca
+2 
channels 
inhibitors 
K
+ 
channel 
activators 
GABA 
enhancers 
Glutamate 
inhibitors 
SV2A 
modulators 
Carbamazepine   
  
    
 
Eslicarbazepine         
 
Gabapentin 
 
     
  
Lacosamide 
  
     
 
Lamotrigine      
   
Levetiracetam 
 
         
Oxcarbazepine   
 
     
 
Pregabalin 
 
     
  
Phenobarbital  
 
     
 
Phenytoin   
 
 
   
Retigabine 
  
   
  
Rufinamide   
 
  
  
Stiripentol 
  
   
  
Tiagabine 
  
   
  
Topiramate   
 
     
 
Valproic acid          
 
Vigabatrin      
  
Zonisamide         
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1.7 AEDs Indications  
The major indication for which AEDs are manufactured is epilepsy disorder. 
Carbamazepine and valproate are licensed for use in all type of epilepsy seizures. 
Stiripentol is the drug of choice in children with epilepsy. Due to the side effects of 
retigabine; blue-grey discoloration of ocular tissue, nails, lips and skin, it is only 
recommended for use in cases of drug-resistant seizures.  Most AEDs are licensed for 
mono or adjunctive therapy for the treatment of focal seizures with or without secondary 
generalised seizures. Focal seizures are those which start in one part of the brain. When 
they spread to the rest of the brain causing generalised seizures this is known as secondary 
generalisation. Phenobarbital and phenytoin are largely used intravenously in status 
epilepsy where seizures last for more than 30 minutes and become life threatening that 
emergency treatment is needed. Levetiracetam is licensed for use in juvenile myoclonic 
epilepsy; a type that experiences seizures associated with muscle twitching or jerking. 
Finally rufinamide followed by lamotrigine are drugs of choice in cases of Lennox-Gastaut 
syndrome (148). Lennox-Gastaut syndrome is an uncommon and difficult to treat type of 
childhood epilepsy that occurs in between one to five in every 100 children with epilepsy. 
Usually, it starts between three and five years of age and is associated with learning 
difficulties. 
Generally, 18% of epileptic patients are using a polytherapy of AEDs to get an acceptable 
control of their seizures. The most frequently combinations of AEDs are lamotrigine with 
valproate (42%), phenobarbital with phenytoin (20%), and carbamazepine with 
levetiracetam (19%) (149). As a result of their multiple targets of action, many preclinical 
studies suggest that these drugs could be effective in other CNS disorders beside their use 
in epilepsy. The extensive use of AEDs to treat non-epilepsy disorders, both in neurology 
and psychiatry was discussed earlier (see ‎1.4.1). In the UK, carbamazepine is licensed for 
use in manic psychosis and trigeminal neuralgia. Gabapentin is approved for neuropathic 
pain and migraine but is being prescribed off label for migraine prophylaxis. Pregabalin is 
also licensed to treat neuropathic pain in addition to generalized anxiety disorder. 
Lamotrigine and valproate are being used in depression associated with bipolar disorder 
and finally topiramate is approved for migraine prophylaxis (Table 1-7). 
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Table  1-7: AED Trade Name, Daily Dose and Licensed Indications in the UK and Their Label Prescription in Epilepsy and Non-epilepsy Disorders (148). 
Generic name Trade name 
UK 
licence 
Licensed indication in epilepsy Licensed  in other indications  
Maintenance dose 
(mg/day) 
Carbamazepine Tegretol 1965 All forms of epilepsy 
Prophylaxis of manic depressive-
psychosis in patient unresponsive to 
lithium therapy, trigeminal neuralgia 
400-1600 
Eslicarbazepine 
acetate 
Zebinix 2009 
Adjunctive treatment in adults with focal seizures with 
or without secondary generalisation 
None 400-800  
Gabapentin Neurontin 1993 
Monotherapy and adjunctive treatment of focal 
seizures with or without secondary generalisation 
Neuropathic pain, migraine 
prophylaxis (unlicensed) 
100-4800  
 
Lacosamide Vimpat 2008 
Adjunctive treatment of focal seizures with or without 
secondary generalisation 
None 100-800  
Lamotrigine Lamictal 1991 
Monotherapy and adjunctive treatment of focal 
seizures and generalised seizures, Lennox-Gastaut 
syndrome 
Prevention of depressive episodes 
associated with bipolar disorder 
100-700  
Levetiracetam Keppra 2000 
Monotherapy and adjunctive treatment of focal 
seizures with or without secondary generalisation, 
juvenile myoclonic epilepsy 
None 1000-3000 
Oxcarbazepine Trileptol 2000 
Monotherapy or adjunctive therapy of focal seizures 
with or without secondary generalised seizures 
None 1200-1400 
Phenobarbital Phenobarbital 1912 Status epilepticus None  10 mg/kg  
Phenytoin Epanutin 1938 
Status epilepticus; acute symptomatic seizures 
associated with head trauma or neurosurgery 
None 300-400 
Pregabalin Lyrica 2004 
Adjunctive therapy for focal seizures with or without 
secondary generalisation 
Neuropathic pain, generalized anxiety 
disorder 
50-200 
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Table 1-7: AED Trade Name, Daily Dose and Licensed Indications in the UK and Their Label Prescription in Epilepsy and Non-epilepsy Disorders 
(Continued…). 
Generic 
name 
Trade name 
UK 
licence 
Licensed indication in epilepsy Licensed  in other indications  
Maintenance dose 
(mg/day) 
Retigabine Trobalt 2011 Drug-resistant focal seizures None  600-1200 
Rufinamide Inovelon 2007 
Adjunctive treatment of seizures in Lennox-Gastaut 
syndrome 
None 200-1600 
Stiripentol Diacomit 2006 
Orphan drug for severe myoclonic epilepsy of 
infancy 
None 10-50 mg/kg 
Tiagabine Gabitril 1998 
Adjunctive treatment for focal seizures with or 
without secondary generalisation 
None 4-32 
Topiramate Topamax 1995 
Monotherapy or adjunctive in generalised or focal 
seizures with or without secondary generalisation 
Prophylaxis of migraine  200-1600 
Sodium 
valproate 
Epilim 1973 All forms of epilepsy 
Semi-sodium valproate for acute 
manic episode associated with 
bipolar disorder 
250-2500 
Valproic acid 
Depakote, 
Convulex 
1993 All forms of epilepsy 
Acute mania associated with 
bipolar disorder  
250-2500 
Vigabatrin Sabril 1973 
Monotherapy or adjunctive treatment in focal 
epilepsy with or without secondary generalisation 
None 1000-4000 
Zonisamide Zonergan 2005 
Adjunctive treatment in focal seizures with or 
without secondary generalisation 
None 100-400  
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1.8 AEDs Side Effects and Overdose Symptoms 
With respect to their multiple mechanisms of action, AEDs are reported to have 
undesirable side effects on the central nervous system. Somnolence, dizziness and ataxia 
are common side effects of all AEDs (150) in addition to the increased risk of imbalance 
within the therapeutic dose (151). All AEDs in all dose-analysis studies demonstrated that 
they increase the risk of imbalance and ataxia compared with placebo suggesting an overall 
dose-response effect in both old and new generation drugs (151). The major adverse effects 
of concern are related to action on the mental functions which present as cognitive 
impairment and psychological and behavioural disturbances (152) The most frequent 
cognitive effects seem to be sedation, amnesia, confusion, blurred speech, abnormal 
thinking, and depression (153). Some drugs also cause euphoria (93, 99, 105, 153). A 
summary of these effects is demonstrated in Table 1-8. 
Cognitive impairments include delirium, memory disturbances (amnesia, fugue) as well as 
effects on intellect and behaviour. AEDs are classified among drugs that induce cognitive 
impairment owing to their effects on reducing neural irritability which leads to an increase 
in memory deficits and psychomotor slowing. Most of them potentiate the effect of 
GABA, the major inhibitory neurotransmitter. In turn, GABA impairs the function of the 
subcortical structures which play an important role in the consolidation of newly learned 
information. Thus, AEDs which affect GABA receptors may impair potentiation and cause 
deficits both in the acquisition and the retention of information. This effect is dose related 
and reversible after reducing the dose of the AED (154). Frequency and severity of 
cognitive impairment resulting from the use of AEDs has been correlated with the 
pharmacokinetics and pharmacodynamics (such as elimination half-life and receptor 
binding affinity) in addition to the duration of the drug administration (154, 155). 
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Table  1-8: AED Mental and Neurological Side Effects and Overdose Symptoms. 
Drug name Mental side effects Overdose effects References 
Carbamazepine 
Amnesia, ataxia, unsteadiness, psychotic symptoms, 
phobias, mania 
Coma, convulsions, respiratory depression and 
death 
(148, 153) 
Eslicarbazepine 
acetate 
Drowsiness, headache, impaired coordination, confusion, 
mood changes, psychosis, impaired memory, suicidal 
ideation 
No cases have been reported (148) 
Gabapentin Sedation, amnesia, ataxia, paraesthesia Sedation, tachycardia, hypotension 
(153, 156, 
157) 
Lacosamide 
Memory and cognition impairment, somnolence, blurred 
vision 
Coma, respiratory depression, status epilepticus (46) 
Lamotrigine 
Memory loss, sedation, cognitive impairment, ataxia, 
confusion 
Convulsions, respiratory depression 
(35, 153, 
157) 
Levetiracetam Sedation, amnesia,  agitation, irritability, psychosis Hallucination,  respiratory depression 
(153, 156, 
157) 
Oxcarbazepine Ataxia, tremor, vertigo,  somnolence Sedation, ataxia, nystagmus 
(153, 156, 
157) 
Phenobarbital 
Drowsiness, lethargy, depression, ataxia, paradoxical 
excitement, hallucinations, impaired memory and 
cognition 
Coma, hypotension, respiratory depression (153, 158) 
Phenytoin Slurred speech, ataxia, confusion Respiratory depression (153) 
Pregabalin 
Sedation, disturbed attention and memory loss, 
confusion, paraesthesia, euphoria 
Sedation, tachycardia, hypotension. (153, 157) 
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Table1-8: AED Mental and Neurological Side Effects and Overdose Symptoms (Continued…). 
Drug name Mental side effects Overdose effects References 
Retigabine 
vertigo, amnesia, paraesthesia, impaired coordination, 
speech and attention, confusion, psychosis, anxiety, 
suicidal ideation 
Discoloration of ocular tissue, nails, lips and 
skin, cardiac arrhythmia (cardiac arrest) 
(148, 159) 
Rufinamide 
Drowsiness, insomnia, anxiety, impaired coordination, 
depression, agitation, and activation of suicidal ideation 
No cases have been reported (148, 160) 
Stiripentol Aggression, anorexia, ataxia, drowsiness, sleep disorders No cases have been reported (148) 
Tiagabine 
Somnolence, sedation, confusion, psychosis, impaired 
concentration 
Coma, respiratory depression, status epilepticus 
(44, 153, 
157) 
Topiramate 
Sedation, amnesia, drowsiness, confusion, somnolence, 
psychomotor retardation 
Memory loss, sedation, coma and death. It cause 
the greatest impairment of neuro-cognitive 
impairment 
(153, 156, 
157, 161)
 
Valproic acid Sedation,  lethargy, confusion, reversible dementia Encephalopathy, coma (153) 
Vigabatrin 
Ataxia, paraesthesia, impaired concentration, confusion, 
depression 
Visual defects (153, 161) 
Zonisamide Psychiatric changes, somnolence, reduced concentration 
Memory loss, coma, speech difficulties, 
respiratory depression and death 
(49, 153, 
157) 
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Over 50% of reported AED overdoses are considered as a consequence of the new 
generation drugs. In most cases of AED overdose, the drugs produce some degree of CNS 
impairment at low toxic doses, while at higher toxic doses; coma, seizures and death have 
been reported as a result of respiratory depression or cardiac disturbances. In addition, each 
drug has other specific poisoning effects related to its mechanism of action (156). Some 
AEDs (carbamazepine, lacosamide, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, 
primidone, and rufinamide) cause what is so-called AED hypersensitivity syndrome which 
is a fatal syndrome. The symptoms usually start between 1 and 8 weeks of exposure 
including fever, rash, and lymphadenopathy. Other systemic signs are liver dysfunction, 
haematological, renal, and pulmonary abnormalities, vasculitis, and multi-organ failure 
(148). 
1.9 AEDs Analysis- A Review of Previous Work  
1.9.1 AEDs and Biological Matrices 
Multiple analytical methodologies have been reported for the measurement of all AEDs in 
plasma and serum for therapeutic drug monitoring (TDM) but less information has been 
found on the detection of the new generation of AEDs in whole blood and urine (162-164). 
Few articles have mentioned the analysis of conventional AEDs in hair (67, 165-169). 
However, no studies were found regarding the analysis of the newer AEDs in hair. Only 
one paper published in 2014 analysed pregabalin in hair (170). All these studies used hair 
for TDM purposes. AEDs analysed were carbamazepine, phenytoin, lamotrigine, valproic 
acid and pregabalin in human hair in addition to phenobarbital in rat hair (169-174). 
Blood and urine are the conventional specimens used to document drug facilitated crime 
(DFC). Blood, plasma and serum are the samples of choice for detecting drugs in general 
owing to the best correlation between the effects of drugs and their concentrations in these 
biological fluids, if equilibrium distribution between all tissues has been reached  (175). 
The next favorable sample is urine. Collection of urine samples does not require medical 
supervision but it should be collected at the earliest opportunity especially if a rapidly 
eliminated drug is suspected to have been used. Urine is the most useful sample to be taken 
in DFC cases as it gives a much greater chance of drugs being detected. It is also essential 
if the full range of relevant toxicology tests are to be carried out (88).  
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However, when blood and urine samples are not available (not sampled, degraded, lost, 
crime not reported at the time of DFC), hair as a sample represents the best alternative 
choice for analysis (176). Hair has been considered as a valuable specimen in situations 
such as DFC for many reasons. Firstly, in DFC, there is often a delay in reporting the 
crime, so the natural processes have had enough time to eliminate the drug from typical 
biological specimens (blood, urine). Hair samples are found to have a large surveillance 
window (weeks to months depending on the length of the hair shaft) compared to 2-4 days 
for most drugs in urine and blood (91). Secondly, hair samples are easier to collect from 
the victim and the embarrassment associated with urine collection especially in case of 
sexual assault can be greatly mitigated (177). Thirdly, hair analysis has the ability to 
distinguish between chronic use and single dose exposure, while urine and blood analysis 
is unable to make this distinction (91, 176). This unique property of hair testing is very 
important both in the interpretation of results in cases of taking hypnotic drugs 
concomitantly for therapeutic reasons and in the discrimination of false assault reports such 
as revenge cases where little evidence is available. The victim could claim that the 
defendant has spiked his/her drink with a drug (177) whereas in reality the victim 
him/herself has abused this drug for a long time. In such cases, hair testing only can 
discriminate between chronic use and single dose.  
Generally, for practical purposes, the two tests are applied as they are complementary to 
each other. Urine and‎ blood‎ analysis‎ provides‎ short‎ term‎ information‎ of‎ an‎ individual’s‎
drug use, whereas long term histories are accessible through hair analysis (91, 176).  
Another concern in forensic work is in relation to the stability of substances in human 
samples. Samples should be stable and preserve the analytes as long as possible. For this 
reason, analyzing human hair has become an important tool next to blood and urine 
analysis on the grounds that the hair samples are stable for a long time and the majority of 
drugs and their metabolites can be analyzed years after drug incorporation into the hair. 
Taking into account these assets, this research will evaluate different types of human 
samples including blood, urine and hair and establish a method to detect the drugs of 
interest which have the highest incidence of abuse such as gabapentin and pregabalin. 
1.9.2 Sample Extraction Techniques of AEDs 
The separation process of most AEDs from biological samples relies on protein 
precipitation with acetonitrile or methanol (178). Liquid-liquid extraction (LLE) is 
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sometimes required after the deproteinization step (179). LLE has been the method of 
choice for years however the technique suffers from several disadvantages (180). These 
include problems of environmental concern due to high levels of solvent usage, difficult 
automation and poor extraction recoveries for some drugs. Solid phase extraction (SPE) 
has been used to overcome the disadvantages of LLE (181).  
SPE allows the use of lower sample volumes and lower solvent volumes with shorter 
sample extraction times. Biological samples are notoriously dirty; injecting them with 
minimum clean up onto very sensitive and expensive instruments makes very little sense. 
SPE has been shown to significantly increase gas (GC) and liquid chromatography (LC) 
column life while reducing the downtime on equipment for source cleaning compared to 
LLE and protein precipitation. LLE often requires several extraction steps to achieve 
sample clean up.  However, the more extractions required, the more drug that will be lost. 
LLE often has trouble achieving high recoveries on a reliable, reproducible level. SPE, on 
the other hand, concentrates the sample on the column and allows for reproducible results 
at very low concentrations of analytes. LLE and protein precipitation are general 
techniques that extract many compounds, whereas SPE gives the analyst the ability to 
extract a broad range of compounds with increased selectivity (182). 
1.9.3 AEDs and Analytical Instrumentation 
With respect to the analytical method used, various analytical tools have been developed 
for therapeutic drug monitoring of AEDs. Automated immunoassay methods have been the 
most appropriate methods for the determination of anticonvulsants during TDM since the 
1980s (183, 184). Since immunoassays are not available for most of the newer AEDs 
(pregabalin, vigabatrin, tiagabine, lacosamide) with only one paper for gabapentin 
immunoassay analysis published recently (185), several chromatographic techniques are 
used, including HPLC and GC methods. Simple chromatographic applications such as 
Thin Layer Chromatography (TLC) have been developed in the past (186). 
A number of simultaneous chromatographic assays for AEDs have been developed using 
GC (187-189) and HPLC alone, (190, 191) or coupled to an ultraviolet detector (192, 193) 
or an evaporative light-scattering detector, (194) in addition to fluorescence polarization 
immunoassay (183). The early initial simultaneous assays, from the 1980s, concentrated on 
separating the older AEDs such as ethosuximide, primidone, carbamazepine, 
carbamazepine-epoxide, phenytoin, and phenobarbital with the inclusion or removal of one 
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or more additional drugs or metabolites such as ethyl-phenacemide, 5-para-hydroxyphenyl-
5-phenylhydantoin (p-HPPH), N-des-methyl-methsuximide, phenyl-2-ethyl-malonamide 
and lamotrigine (191, 195, 196). However, these methods required time-consuming and 
difficult extraction procedures or relatively large sample volumes (~1mL) as well as 
lengthy chromatographic run times that limited their throughput capacity and sensitivity 
(178). All methods which employed ultraviolet detection have the risk of matrix, 
metabolite or other co-medication interferences (197). Furthermore, a number of these 
previous analytical techniques are not applicable to some AEDs due to lack of volatility 
and chromophores for some of these such as pregabalin, gabapentin, vigabatrin, topiramate 
and valproic acid (198, 199).  
Over the past twenty years, developed assays have focused more on separating the newer 
AEDs such as levetiracetam, lamotrigine, oxcarbazepine, topiramate, and zonisamide
 
(178, 
200-202). More recently, LC/MS/MS analysis has been applied to these drugs as well (179, 
192, 197). These techniques have allowed for improved selectivity during separation and 
detection. A simultaneous LC/MS/(MS) assay would be faster and more reliable than 
multiple analytical assays when quantification of multiple AEDs is needed for samples of 
patients with poly AED therapy (197). However, few papers have been published for the 
simultaneous analysis of 10 or more AEDs. A simultaneous analysis of 22 AEDs by 
UPLC/MS/MS was reported recently, however it was for TDM purposes and samples had 
to undergo 3 different dilutions with 3 different calibration curves to obtain the desired 
results. Furthermore, it did not use any internal standard to eliminate the matrix effect 
associated with LC/MS/(MS) analysis (203). Another two simultaneous methods to 
determine 9 and 10 AEDs have also been reported. The first paper used LC/MS and it was 
quantitatively validated for only 6 of these drugs with their metabolites and tested the 
others by screening (178, 197). Few studies have been published regarding AEDs analysis 
in postmortem blood (171, 204, 205). The first of these included 9 AEDs and two 
metabolites; carbamazepine, carbamazepine-10, 11-epoxide, gabapentin, lamotrigine, 
levetiracetam, oxcarbazepine, 10-OH-carbazepine, phenobarbital, phenytoin, pregabalin 
and topiramate whereas the second one had lamotrigine, carbamazepine, 10-OH-
carbazepine, phenytoin and phenobarbital only and did not cover any newer AEDs. No 
simultaneous studies until now have been found to include eslicarbazepine acetate, 
retigabine and lacosamide although individual LC/MS/MS methods on human plasma do 
exist for measuring these (133, 206, 207). A brief overview of simultaneous quantitative 
analysis methods of AEDs is presented in Table 1-9. 
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Table  1-9: An Overview of Studies Published for Simultaneous AED Analysis. 
RF AEDs Sample 
Sample 
Preparation  
Instrumentation 
C
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Others 
(203), 2012 16 Plasma PP UPLC/MS/MS +  +  + +  + +     + + + + + 
CBZ-E, ETM, FBM, PRM, 
6 Benzodiazepines 
(178), 2010 10 Plasma PP LC/MS/MS +  +  + + + +       +  + + CBZ-E 
(208), 2010 10 Plasma PP HPLC +     +  + +         + FBM, MHD, CBZ-E, PRM  
(179), 2009 11 Serum PP, LLE LC/MS/MS   +  + + +   +  + + + +   + FBM 
(197), 2008 9 Plasma SPE LC/MS +  +  + + + + + +    + +  + + CBZ-E, MHD, CBZ-Diol 
(200), 2007 7 Serum SPE LC/UV +     + + + +         + CBZ-E, CBZ-Diol, PRM 
(201), 2002 6 Plasma PP + SPE LC/UV +     + + + +          PRM,CBZ-E, CBZ-Diol 
(181), 1990 6 Serum SPE GC/FID +       + +        +  PRM, ETM 
(202), 1999 6 Plasma LLE LC/DAD +     +  + +          
CBZ-E,CBZ-Diol, ESM, 
PRM 
(209), 2003 6 Plasma - MECC/DAD +     +  + +          PRM, CBZ-E 
(210), 1994 5 Plasma PP LC/UV +       + +          HPPH,CBZ-E, PRM, FBM 
(211), 2002 5 Plasma SPME GC/TSD +     +  +           PRM, CBZ-E 
(193), 2010 5 Plasma PP LC/UV      + +  +         + FBM, MHD 
CBZ-E: carbamazepine-10, 11 epoxide, CBZ-Diol: carbamazepine -10-11-Diol, HPPH: 5-(4-hydroxyphenyl)-5-phenylhydantoin, MHD: 10-hydroxycarbamazepine, FBM: 
felbamate, PRM: primidone, ESM: ethosuximide, PP: protein precipitation, LLE: liquid-liquid extraction, FID: flame ionization detector, DAD: dual array detector, NPD: 
nitrogen phosphorus detector, MECC: micellar electrokinetic capillary chromatography, SPME: solid-phase microextraction,  GC/TSD: gas chromatography with 
thermionic specific detection, CE: capillary electrophoresis, CED: coulometric electrochemical detection. 
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Table 1-9: An Overview of Studies Published for Simultaneous AED Analysis (Continued...). 
RF 
AED
s 
Sample 
Sample 
Preparation  
Instrumentation 
C
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Others 
(180), 2011 5 Blood LLE LC/MS/MS 
+
     
+
  
+
 
+
          MHD, 12 non-AEDs 
(212), 1993 4 Blood, Saliva, Urine PP + SPE LC/DAD 
+
       
+
 
+
          PRM 
(213), 2002 4 Serum - Immunoassay 
+
       
+
 
+
        
+
   
(214), 2002 4 Serum PP LC/UV 
+
      
+
 
+
 
+
          CBZ-E, CBZ-Diol 
(215), 2002 4 Plasma PP LC/UV 
+
      
+
 
+
 
+
          CBZ-E, MHD, 
(192), 2005 4 Plasma PP LC/UV      
+
 
+
            MHD, FBM 
(216), 2005 4 Serum PP LC/UV 
+
     
+
  
+
 
+
           
(217), 1997 3 Serum SPE HPLC 
+
     
+
  
+
           CBZ-E 
(218), 2004 3 Serum PP LC/F   
+
       
+
      
+
   - 
(219), 2007 3 Serum - Immunoassay 
+
       
+
         
+
  - 
(220), 2007 3 Plasma PP LC/UV      
+
 
+
           
+
 MHD 
(221), 2008 3 Plasma LLE LC/UV 
+
       
+
 
+
          CBZ-E 
(198), 2008 3 Serum PP LC/MS   
+
       
+
      
+
   - 
CBZ-E:carbamazepine-10,11 epoxide, CBZ-Diol: carbamazepine-10-11-Diol, HPPH: 5-(4-hydroxyphenyl)-5-phenylhydantoin, FBM: felbamate, MHD: 10-
hydroxycarbamazepine, PRM: primidone, ESM: ethosuximide, P.P: protein precipitation, LLE: liquid-liquid extraction, FID: flame ionization detector, DAD: dual array 
detector, NPD: nitrogen phosphorus detector, MECC: micellar electrokinetic capillary chromatography, SPME: solid-phase microextraction,  GC/TSD: gas chromatography 
with thermionic specific detection, CE: capillary electrophoresis, CED: coulometric electrochemical detection. 
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Table 1-9: An Overview of Studies Published for Simultaneous AED Analysis (Continued...). 
RF AEDs Sample 
Sample 
Preparation  
Instrumentation 
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Others 
(222), 2010 3 Plasma SPE LC/F   +            + +   
- 
(223), 1990 2 Serum LLE LC/UV +       +           
-
 
(224), 1994 2 Serum - Immunoassay +       +           
- 
(225), 1995 2 Serum LLE LC/UV +      +            6 metabolites 
(226), 1996 2 Serum PP HPLC   +             +   - 
(227), 1997 2 Serum PP GC/MS +     +             CBZ-E 
(228), 1998 2 Plasma PP LC/UV +       +           CBZ-E 
(229), 1998 2 Urine/Serum PP LC/F   +             +   - 
(230), 2003 2 Plasma PP LC/F   +             +   - 
(231), 2005 2 Serum PP GC/MS   +             +   - 
(232), 2005 2 Plasma PP LC/MS/MS +      +            8 metabolites 
(233), 2006 2 Serum PP LC/UV +                 + CBZ-E 
(234), 2011 2 Plasma PP LC/MS/MS   +  +              - 
CBZ-E: carbamazepine-10, 11 epoxide, CBZ-Diol: carbamazepine -10-11-Diol, HPPH: 5-(4-hydroxyphenyl)-5-phenylhydantoin, MHD: 10-hydroxycarbamazepine, FBM: 
felbamate, PRM: primidone, ESM: ethosuximide, P.P: protein precipitation, LLE: liquid-liquid extraction, FID: flame ionization detector, DAD: dual array detector, NPD: 
nitrogen phosphorus detector, MECC: micellar electrokinetic capillary chromatography, SPME: solid-phase microextraction,  GC/TSD: gas chromatography with thermionic 
specific detection, CE: capillary electrophoresis, CED: coulometric electrochemical detection. 
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Finally, all of these studies were applied to investigate the pharmacokinetics of these drugs 
or to monitor their concentrations in the therapeutic regimens of epilepsy but no studies 
have been found for their potential misuse in DFC either as a single dose or multiple doses. 
In other words, all these methods analyzed the drugs within the therapeutic range in serum 
and plasma with some including overdose concentrations. No studies were found about the 
stability of the newer AEDs in postmortem human samples. Such studies are very 
important in forensic cases where a delay in obtaining and analyzing the samples is not 
unusual.  
1.10 LC/MS/(MS) Role in Forensic Toxicology 
As the compounds of interest are usually unknown, the first step before quantification 
should be the screening and identification of these compounds. Due to serious clinical or 
forensic consequences, high selectivity and reliable methods are required. Gas 
chromatography-mass spectrometry is still the most widely used method in all 
toxicological applications. Recently, liquid chromatography coupled with single or tandem 
mass spectrometry has become significantly more important in routine toxicological 
analysis. LC/MS is complementary to GC/MS, specifically for the quantification of 
thermo-labile, low-dose, high molecular mass and polar compounds (175).  
The high sensitivity of LC/MS/(MS) appears to be a prerequisite in DFC especially when 
samples are collected many days after ingestion of the last therapeutic dose. It seems to be 
the best instrumentation to increase the likelihood of detection of drugs in biological 
samples (176). Furthermore, this technique needs less special conditions than other 
procedures such as immunoassay analysis. Immunoassay methods which are applied in the 
routine laboratory to screen for AEDs are very expensive and time consuming. Moreover, 
some AEDs (pregabalin, vigabatrin, tiagabine and lacosamide) have no immunoassay 
method available (198). 
With respect to sample preparation, LC/MS/(MS) methods are more effective, productive 
and less time consuming compared to gas chromatography. GC/MS methods require a 
sample that is volatile or thermally stable with or without derivatization whereas 
LC/MS/(MS) has the advantage of being able to directly separate and analyze almost 
anything that is soluble in the mobile phase. This feature allows a wide range of drugs to 
be detected using LC/MS/(MS) since most drugs administered through ingestion, 
inhalation or injection are water soluble (235).  
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1.10.1 LC/MS/MS principle 
LC/MS/(MS) is a high performance liquid chromatography instrument (HPLC) coupled 
with a tandem quadruple mass spectrometer. A mass spectrometer consists of two main 
components; the ion source which is responsible for ionizing the molecules and the mass 
analyser that sorts the ions according to their mass to charge ratios (m/z). There are 
different types of ion source and mass analyser that suit different classes of compounds.  
1.10.1.1 Ion Sources 
The primary focus on LC/MS research over the last decade has been to improve the 
separation of the analyte of interest from the mobile phase and enhance its ionization. The 
introduction of atmospheric pressure ionization (API) was a milestone in chromatography 
history because it greatly expanded the number of chemicals that could be analysed by 
LC/MS. Using API, the molecule is ionized first at atmospheric pressure before it is 
mechanically and electrostatically separated from the neutral solvent particles. The three 
most common API techniques are (236, 237) : 
a) Electrospray Ionization (ESI):  
This source generates analyte ions in solution before the analyte reaches the mass 
spectrometer. The LC eluent is sprayed into a chamber at atmospheric pressure in the 
presence of a strong electrostatic field which causes further dissociation of the analyte 
molecules and is heated using a drying gas that evaporates the solvent in the droplets 
(Figure ‎1-20).  
 
Figure  1-20: ESI Source. 
“Reproduced‎with‎Permission‎From‎Agilent‎Technologies”‎(236). 
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As the droplets shrink, the charge concentration in the droplets increases. Eventually, the 
repulsive force between ions with like charges exceeds the cohesive forces and ions are 
desorbed into the gas phase. These ions pass through a capillary sampling orifice into the 
mass analyzer. Electrospray is especially useful for analyzing large and small molecules. 
b) Atmospheric Pressure Chemical Ionization (APCI) 
In this source, the LC eluent is sprayed through a heated vaporizer (250°C– 400°C) at 
atmospheric pressure which turns the liquid to gas phase. The resulting gas-phase solvent 
molecules are ionized by electrons discharged from a corona needle. The solvent ions then 
transfer charge to the analyte molecules through chemical ionization. The analyte ions pass 
through a capillary sampling orifice into the mass analyzer (Figure ‎1-21). APCI is 
applicable to a wide range of polar and nonpolar molecules; however, APCI is less well-
suited than electrospray for analysis of thermally unstable large molecules because it 
involves high temperatures.  
 
Figure  1-21: APCI Source. 
“Reproduced‎with‎Permission‎From‎Agilent‎Technologies”‎(236). 
 
c) Atmospheric Pressure Photo Ionization (APPI) 
This is a relatively new technique. As in APCI, a vaporizer converts the LC eluent to the 
gas phase. A discharge lamp generates photons in a narrow range of ionization energies 
(Figure ‎1-22). The range of energies is carefully chosen to ionize as many analyte 
molecules as possible while minimizing the ionization of solvent molecules. The resulting 
ions pass through a capillary sampling orifice into the mass analyzer. APPI, similar to 
APCI is applicable to a wide range of polar and nonpolar molecules, however, it has also 
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showed promising results for highly nonpolar compounds when a very low flow rate was 
required (< 100µL/min) whereas APCI showed a low sensitivity. 
 
Figure  1-22: APPI Source. 
“Reproduced‎with‎Permission‎From‎Agilent‎Technologies”‎(236). 
1.10.1.2 Mass Analyzers 
There are three types of mass analyzers that are used most often with LC/MS (236-241): 
a) Tandem Quadrupole 
Quadrupole Mass Analyzers were first described by Paul and Steinwegen from the 
University of Bonn in 1953. Quadrupole mass analyzers consist of four rods arranged in a 
square. The analyte ions are directed down the center of the square. Voltages applied to the 
rods generate electromagnetic fields. These fields determine which mass-to-charge ratio of 
ions can pass through the filter at a given time.  
Quadrupoles lend themselves to being coupled to one another. Often incorrectly referred to 
as‎ ‘Triple‎ Quadrupole’‎ instruments,‎ they‎ are‎ actually‎ “Tandem‎ Quadrupole”‎ mass‎
analyzers. The two quadrupole mass analyzers are referred to as Q1 and Q3, with the Q2 
being a collision cell only (Figure ‎1-23). Ions are accelerated into the collision cell, filled 
with an inert gas (Argon, Nitrogen or Helium), with sufficient velocity that collisions with 
the gas molecules cause the analyte to break apart to form fragments. This process is called 
Collision Induced Dissociation (CID). The main advantage of these tandem quadruple 
mass analyzers is greater structural information and enhanced selectivity and sensitivity. 
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Figure  1-23: Tandem Quadrupole Mass Analyser. 
 
b) Time-of-Flight 
A uniform electromagnetic force is applied to all ions at the same time, causing them to 
accelerate down a flight tube. Lighter ions travel faster and arrive at the detector first, so 
the mass-to-charge ratios of the ions are determined by their arrival times (Figure ‎1-24). 
Time-of-flight mass analysers have a wide mass range and can be very accurate in their 
mass measurements. 
 
Figure  1-24: TOF Mass Analyser. 
 
c) Ion Trap 
An ion trap mass analyzer consists of a circular ring electrode plus two end caps that 
together‎form‎a‎chamber.‎Ions‎entering‎the‎chamber‎are‎“trapped”‎there‎by‎electromagnetic‎
fields. Ion traps have the advantage of being able to perform multiple stages of mass 
spectrometry without additional mass analyzers (Figure ‎1-25). 
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Figure  1-25: Ion Trap Analyser. 
 
1.11 Conclusion 
To sum up, the newer generation of antiepileptic drugs has clear sedative and depressive 
effects that allow them to be potential misused drugs in DFC. Some of them have already 
been abused (pregabalin, gabapentin) and awareness reports about their use have started to 
increase.  
Numerous methods have been developed to analyze these drugs for TDM purposes in 
plasma and serum but few studies have been reported analyzing these drugs in post mortem 
blood, urine and hair. A wide range of analytical techniques either immunoassay or 
chromatographic analysis (GC and LC) with various kinds of detection applications (UV, 
DAD,‎ FID…)‎ have‎ also‎ been‎ applied.‎ The‎ use‎ of‎ LC/MS/(MS) is considered as a 
prerequisite in forensic toxicology due to its ability to detect the low levels of drugs and 
their metabolites in the biological fluids at least six days after the ingestion of one 
therapeutic dose. This fact is very important in DFC cases where there is a delay in sample 
collection owing to late reporting of the offence by the victim. LC/MS/(MS) has been 
shown to be an ideal supplement to GC/MS/(MS). It may become the premium standard 
for quantification in clinical and forensic toxicology if the cost of the equipment can be 
reduced. 
A number of simultaneous methods have been developed but none of these analyzed more 
than 11 drugs in a single run. Only one paper included 22 drugs but these drugs were 
divided into 3 groups with 3 different calibration curves depending on the abundance. 
None of these included lacosamide, eslicarbazepine acetate and retigabine.  
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Furthermore, all of these investigations were applied to study the pharmacokinetics of 
these drugs or to monitor their concentrations in the therapeutic regimens of epilepsy. 
Some of these included overdose concentrations as a result of studying the adverse effects 
of these drugs but few studies were found regarding concentrations of the newer AEDs in 
human postmortem blood or concentrations found in the days following the last dose 
where the concentration becomes very low. Such studies are very important in forensic 
cases where a delay in sampling is very common.  
Hence, regarding the debate over these drugs and their ability to be misused in the press 
and scientific literature, this research highlights some of the AEDs which have concern and 
will evaluate their prevalence and abuse probability. Ultimately, a simultaneous analytical 
method was developed to analyze these drugs and their metabolites in human samples 
(postmortem blood, serum, plasma, urine and hair as an alternative sample) using liquid 
chromatography tandem mass spectrometry (LC/MS/MS). The method was validated 
according to the standard practices for method validation in forensic toxicology 
(SWGTOX, May 2013) and applied to authentic samples (242). It was used to study AED 
stability in blood, optimize the best extraction method with higher recovery to extract all 
AEDs in one analytical step in different matrices (protein precipitation, liquid-liquid 
extraction and solid phase extraction) and finally evaluate their prevalence and abuse 
potential among drug abusers and prisoners. 
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2  Method Development and Extraction 
Optimization of 17 AEDs in Whole Blood     
Using LC/MS/MS 
2.1 Introduction 
Various analytical tools have been developed for therapeutic drug monitoring (TDM) of 
AEDs (162, 163). Automated immunoassay methods have been the most widely used 
methods for the determination of anticonvulsants for TDM since the 1980s (183). 
A number of simultaneous chromatographic assays for AEDs have been developed using 
GC (187), and HPLC coupled to an ultraviolet detection (190) or an evaporative light-
scattering detector (194) in addition to fluorescence polarization immunoassay (183). The 
initial simultaneous assays, from the 1980s, concentrated on separating the older AEDs 
such as ethosuximide, primidone, phenytoin, phenobarbital, carbamazepine and 
carbamazepine-epoxide, with the inclusion or removal of one or more drug(s) or 
metabolite(s) such as lamotrigine, 5-para-hydroxyphenyl-5-phenylhydantoin (p-HPPH), 
ethyl-phenacemide, N-des-methyl-methsuximide and phenyl-2-ethyl-malonamide (178, 
191, 196). However, these methods required time-consuming and difficult extraction 
procedures or relatively large sample volumes (about 1mL) as well as lengthy 
chromatographic run times that limited their throughput capacity and sensitivity (178). In 
addition, all methods which employ ultraviolet detection have the risk of interferences due 
to matrix, metabolites or other co-medications (197) and they are not applicable to some 
AEDs  such as pregabalin, gabapentin, vigabatrin, topiramate and valproic acid due to a 
lack of a chromophore in their structures (199, 208). 
Several methods have been described for the simultaneous LC/MS/(MS) analysis of a 
selection of AEDs (see 1.9.3). All of these methods were designed for TDM in 
plasma/serum over the therapeutic ranges. None of these methods were validated for 
postmortem blood over a wide concentration range including those associated with toxic 
levels. 
The aim of this project was to develop a quantitive method for the analysis of the most 
commonly encountered AEDs in post mortem whole blood to include carbamazepine and 
its metabolite carbamazepine-10,11-epoxide, eslicarbazepine acetate, gabapentin, 
Chapter 2  60 
 
lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, phenytoin and its 
metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin, retigabine (ezogabine in the US), 
topiramate, tiagabine, valproic acid, vigabatrin,  and zonisamide, which would be suitable 
for routine forensic toxicological analysis. 
2.2 Materials and Methods 
2.2.1 Materials 
Carbamazepine (CBZ), carbamazepine 10,11-epoxide (CBZO), gabapentin (GBP), 
lamotrigine (LTG) levetiracetam (LEV), oxcarbazepine (OXC), phenytoin (PHT), 5-(3-
Hydroxyphenyl)-5-phenylhydantoin (p-HPPH), topiramate (TPR), vigabatrin (VIG), 
valproic acid (VPA) and zonisamide (ZNS) were purchased from Sigma Aldrich 
(Basingstoke, UK). Eslicarbazepine acetate (ESL), lacosamide (LAC), pregabalin (PGR), 
retigabine (RTG) and tiagabine (TIG) were obtained from LGC standards (Teddington, 
UK). All these drugs were purchased as powders. 
Deuterated standards; gabapentin-D10 (GBP-D10), pregabalin-D6 (PGR-D6) and topiramate-
D12 (TPR-D12), were obtained from LGC standards (Teddington, UK). Analog internal 
standards; 10, 11- dihydrocarbamazepine (CBZ-DiOH) and tolbutamide (TUB) were 
purchased from Sigma Aldrich (Basingstoke, UK). 
Ammonium acetate and acetic acid were purchased from Sigma Aldrich (Basingstoke, 
UK). Acetonitrile (ACN), isopropanol (IPA) and methanol (MeOH) were supplied by 
VWR International Ltd (Lutterworth, UK). Double distilled water was obtained from the 
in-house Millipore® system. 
2.2.2 Solutions Preparation 
2.2.2.1 Preparation of Standard Solutions for Method Development 
In order to optimize the fragmentor voltage and the collision energy required to analyse the 
drugs on LC/MS/MS, an individual stock solution for each drug was prepared at 
concentration of 1 g/L in methanol. These were prepared by adding 5 mg of the drug 
powder to a 5 mL volumetric flask and made up to volume with methanol. The stock 
solutions were further diluted 1:100 to obtain one working solution for each drug at 10 
mg/L. These were achieved by adding 100 µL of the stock solution to a 10 mL volumetric 
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flask and made up to volume with mobile phase mixture (10 mM ammonium Acetate/ 
ACN: 50/50). These working solutions were used for method development. 
2.2.2.2 Preparation of Calibrators and Quality Controls 
AEDs were divided into 3 groups according to their proposed calibration curve ranges as 
explained in Table ‎2-1. 
Table  2-1: AEDs Groups According to Their Proposed Calibration Curve Ranges. 
Group 1 (0.5-50 mg/L) Group 2 (0.05-10 mg/L) Group 3 (5-300 mg/L) 
Drug Abbrev. Drug Abbrev. Drug Abbrev. 
Carbamazepine CBZ Oxcarbazepine OXC Levetiracetam LEV 
Carbamazepine epoxide CBZO Tiagabine TIG Vigabatrin VIG 
Eslicarbazepine acetate ESL Retigabine RTG Valproic acid VPA 
Gabapentin GBP 
    
Lacosamide LAC 
    
Lamotrigine LTG 
    
Phenytoin PHT 
    
5-(3-Hydroxyphenyl)-5-
phenylhydantoin 
p-HPPH 
    
Pregabalin PGR 
    
Topiramate TPR 
    
Zonisamide ZNS 
    
 
Two separate stock solutions were prepared in methanol for each drug individually. One 
stock was used to prepare the calibration curve and the other was used to prepare the 
quality control samples (QCs). For LEV, VIG, VPA, CBZ and GBP, stocks were prepared 
at 10 g/L by dissolving 10 mg drug powder in 1 mL methanol. For all other drugs, stock 
solutions were prepared at 1 g/L by adding 5 mg drug powder to a 5 mL volumetric flask 
and made up to volume with methanol.  
Three working solutions at concentrations of 100 mg/L for group 1 and 2 and 1 g/L for 
group 3 were prepared by combining certain volumes of the stock solutions and made up to 
volume with methanol as detailed in Table ‎2-2.  
Eight calibration standard solutions were prepared in methanol by combining certain 
volumes of the three working solutions in 5 mL volumetric flasks and made up to volume 
with methanol to achieve the target concentrations as detailed in Table ‎2-3. 
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Table  2-2: Preparation of Calibrators and QCs Working Solutions. 
Working Solution 1  (10 mL volumetric flask) 
Analyte Stock Concentration Amount Added Final Concentration 
CBZ 10 g/L 100 µL 100 mg/L 
CBZO 1 g/L 1000 µL 100 mg/L 
ESL 1 g/L 1000 µL 100 mg/L 
GBP 10 g/L 100 µL 100 mg/L 
LAC 1 g/L 1000 µL 100 mg/L 
TPR 1 g/L 1000 µL 100 mg/L 
LTG 1 g/L 1000 µL 100 mg/L 
PGR 1 g/L 1000 µL 100 mg/L 
PHT 1 g/L 1000 µL 100 mg/L 
p-HPPH 1 g/L 1000 µL 100 mg/L 
ZNS 1 g/L 1000 µL 100 mg/L 
Working Solution 2  (10 mL volumetric flask) 
Analyte Stock Concentration Amount Added Final Concentration 
OXC 1 g/L 1000 µL 100 mg/L 
TIG 1 g/L 1000 µL 100 mg/L 
RTG 1 g/L 1000 µL 100 mg/L 
Working Solution 3 (10 mL volumetric flask) 
Analyte Stock Concentration Amount Added Final Concentration 
LEV 10 g/L 1000 µL 1 g/L 
VIG 10 g/L 1000 µL 1 g/L 
VPA 10 g/L 1000 µL 1 g/L 
  
Table  2-3: Preparation of the Calibration Curve Standards. 
Volumetric 
Flask 
(5 mL) 
No. 
Calibrator 
No. 
Amount Added (µL) Final Concentration (mg/L) 
Working 
Solution 1 
Working 
Solution 2 
Working 
Solution 3 
Group 1 Group 2 Group 3 
1 Cal 1 25 2.5 25 0.5 0.05 5 
2 Cal 2 50 5 50 1 0.1 10 
3 Cal 3 125 12.5 125 2.5 0.25 25 
4 Cal 4 250 25 250 5 0.5 50 
5 Cal 5 500 50 375 10 1 75 
6 Cal 6 1000 125 500 20 2.5 100 
7 Cal 7 1750 250 1000 35 5 200 
8 Cal 8 2500 500 1500 50 10 300 
 
Three QC samples (low, medium and high) were directly made in whole blood. Using the 
second set of stock solutions, three working solutions were prepared as detailed earlier in 
Table ‎2-2. Three QCs were prepared in whole blood by combining certain volumes of the 
three working solutions in 10 mL volumetric flasks. Then, the methanol solvent was 
evaporated under nitrogen at 25ºC to avoid blood precipitation. The residue was finally 
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reconstituted with 10 mL whole blood to achieve the target concentrations as detailed in 
Table ‎2-4. QC concentrations were 3, 20 and 40 mg/L for group 1; 1, 4 and 8 mg/L for 
group 2; and 20, 120 and 200 mg/L for group 3. For each QC, 0.5 mL aliquots were placed 
into labelled 1.5 mL polystyrene screw cap tubes. All QCs and stock solutions were stored 
at -20°C, and working solutions were stored at 4°C. 
Table  2-4: Preparation of QCs in Whole Blood. 
Volumetric 
Flask 
(10 mL) 
No. 
QC No. 
Amount Added (µL) Final Concentration (mg/L) 
Working 
Solution 1 
Working 
Solution 2 
Working 
Solution 3 
Group 1 Group 2 Group 3 
1 QC 1 300 100 200 3 1 20 
2 QC 2 2000 400 1250 20 4 120 
3 QC 3 4000 800 2250 40 8 200 
 
2.2.2.3 Preparation of Internal Standards 
Five internal standards, GBP-D10, PGR-D6, TPR-D12, TUB and CBZ-DiOH were used. 
GBP-D10, PGR-D6, TPR-D12 were readily purchased in methanol at concentration of 100 
mg/L. TUB and CBZ-DiOH were purchased as a powder. An amount of 1 mg was 
dissolved in 10 mL methanol to obtain a 100 mg/L solution of TUB and CBZ-DiOH. 
Using a 100 mL volumetric flask, a combined internal standard solution was prepared at 10 
mg/L and made up to volume with methanol as outlined in Table ‎2-5 below. 
Table  2-5: Internal Standard Solution Preparation. 
Internal Standard Abbrev. 
Stock Solution 
(mg/L) 
Amount Added 
(mL) 
Final 
Concentration 
(mg/L) 
Gabapentin-D10 GBP-D10 100 1 10 
Pregabalin-D6 PGR-D6 100 1 10 
Topiramate-D12 TPR-D12 100 1 10 
Tolbutamide TUB 100 1 10 
10,11 Dihydro carbamazepine CBZ-DiOH 100 1 10 
 
2.2.2.4 Preparation of Blank Blood  
Whole blood was prepared using packed red cell pouches which were obtained from the 
Blood Bank at the Western Infirmary Hospital (Glasgow, UK) and were frozen on receipt 
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within Forensic Medicine and Science (FMS). The packed red blood cells was fully 
defrosted and then measured and diluted 1:1 with 1% saline solution. Saline solution was 
prepared by adding 9.5g sodium chloride into a 1L volumetric flask and dissolving it in 
deionised water by making up to the mark. The blank whole blood was used to prepare 
quality control samples. 
2.2.2.5 Preparation of Formic Acid 0.1% (pH=2.8) 
1 mL of concentrated formic acid was placed in a 1L volumetric flask and made up to 
volume with deionised water. 
2.2.2.6 Preparation of 10 mM Ammonium Formate (pH =3) 
Ammonium formate (0.631g) was added to a 1L volumetric flask and made up to volume 
with deionised water. 
2.2.2.7 Preparation of 10 mM Ammonium Acetate (pH = 5) 
Ammonium acetate (0.77g) and 200 µL of concentrated acetic acid were added to a 1L 
volumetric flask and made up to volume with deionised water.  
2.2.2.8 Preparation of 10 mM Ammonium Carbonate (pH = 9.3) 
Ammonium carbonate (0.785g) was added to a 500 mL volumetric flask and made up to 
volume with deionised water. 
2.2.2.9 Preparation of 2 M Ammonium Acetate 
Ammonium acetate (15.42 g) was added to a 100 mL volumetric flask and made up to 
volume with deionised water. 
2.2.2.10 Preparation of 2 mM Ammonium Acetate in Methanol 
A 1 mL aliquot of 2 M ammonium acetate was added to a 1L volumetric flask and made up 
to volume with methanol. 
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2.2.2.11 Preparation of 2 mM Ammonium Acetate (pH = 6.8) 
A 1 mL aliquot of 2 M ammonium acetate was added to a 1L volumetric flask and made up 
to volume with deionised water. 
2.2.2.12 Preparation of Wash Solution 
Wash solution was prepared using 25% isopropanol, 25% ACN, 25% MeOH and 25% 
2mM ammonium acetate in 0.1% formic acid. 
2.2.3 Instrumentation 
An Agilent LC/MS/MS triple quadruple G6420A mass spectrometer equipped with an 
electrospray ionization (ESI) source, Agilent 1200 Series Auto sampler SL, Agilent 1200 
Series Binary Pump SL with degasser and Agilent 1200 Series Thermostatted Column 
Compartment SL was used.  The turbo ion-spray interface was operated in both positive- 
and negative-ion modes with nitrogen as the collision gas. The Agilent Mass-Hunter 
Workstation software (version: B.01.05) was used for system control and data acquisition. 
Optimizer software was used to optimize the product ions and their fragmentor voltages 
and collision energies. 
2.2.4 Optimisation of the Fragmentor Voltage and Collision 
Energy 
An evaluation of the different tuning techniques available was carried out in order to 
determine the mass spectrometry characterization of the 15 antiepileptic drugs and 2 of 
their metabolites. All compounds of interest and internal standards were individually tuned 
using sample injection program and Optimizer software to detect the precursor ions and 
optimize their product ions, fragmentor voltage and collision energy.  
Optimizer is an automated MS method development Software installed with Agilent Mass-
Hunter Acquisition software. It automatically optimizes the data acquisition parameters for 
multiple-reaction monitoring mode (MRM) for each compound analysed. Specifically, it 
automates the selection of the best precursor ions and their fragmentor voltage, the 
selection of the best product ions and the collision energy values for each transition. A 
mixture of 17 AEDs and 5 internal standards was dissolved in mobile phase and transferred 
to a LC vial. 20 µL was injected through the autosampler. At the end of the analysis, the 
software generated a report with all required details (see Appendix 2-1). 
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For the sample injection program, analytes were prepared individually in the mobile phase 
at concentration of 10 mg/L and a 20 µL volume was injected through the autosampler. 
The tuning was carried out in 4 steps for each analyte as follows: 
Step 1: MS1 scan method to determine the precursor ion of each analyte.  
Step 2: Fragmentor voltage optimization for each precursor ion at 20, 50, 80, 110, 140, 170 
and 240 eV. This was achieved by building up 7 individual methods with different 
fragmentor values. 
Step 3: Product ion mode method to determine the product ions profile using the results 
from step 1 and 2. 
Step 4: Optimize the collision energy of each transition over a range between 0 and 40 V 
by building up different methods and increasing the collision energy value by 5 each time. 
The results of this method were saved as data files and processed using Mass-Hunter 
Qualitative program by overlapping analyte chromatograms to compare their peaks height 
and area.  
LC/MS/MS operation conditions and mobile phase gradient used at this stage are detailed 
in Table ‎2-6 and Figure ‎2-1. 
Table  2-6: Summary of LC and Ion Source Parameters Used During Method Development. 
LC Parameters 
Column 
Gemini‎C18‎column‎(150‎x‎2.1‎mm,‎5‎μm) with guard 
column of the same packing material 
Mobile phase 10 mM ammonium acetate in water/ACN (80:20). 
Column temperature 25 ºC 
Flow rate 300 µL/min 
Mass Spectrometry Parameters 
Operating mode ESI-in positive and negative mode 
Gas temperature 300 ºC 
Gas flow 11 L/min 
Nebulizer pressure 15 PSI 
Capillary voltage 4000 V 
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Figure  2-1: Mobile Phase Gradient System Applied at Method Development Stage. 
 
2.2.5 Optimisation of Nebulizer Gas Pressure 
The nebulizer gas (N2 in this study) pressure (Neb) is an essential component to disperse 
the emerging solution of the sample into small droplets and to direct the droplets on the 
trajectory chosen for optimal sampling. Nebulizer gas pressure was optimized at 15, 25 and 
35 PSI in order to obtain the highest sensitivity. 
2.2.6 Optimization of Mobile Phase  
A suitable eluent for electrospray ionisation should contain an organic modifier (methanol 
or acetonitrile) and a volatile buffer, the concentration of which can be critical; 
concentrations that are too high may result in the suppression of the analyte signal, while 
concentrations that are too low may lead to poor peak shape and efficiency. In order to 
determine the most suitable mobile phase composition for AEDs of interest, an 
investigation into its aqueous and organic components was carried out. 
2.2.6.1  Aqueous Phase Additives 
When developing a robust method, it is desirable to select a mobile phase with a final pH 
that is  at least two units away from the pKa. However, this rule was a bit challenging to 
apply due to the wide range of AEDs of interest. This experiment was carried out for each 
drug separately to investigate the effect of various buffers on the AEDs with the aim of 
choosing the buffer which produced good chromatograms and high abundances for all the 
analytes.  
Four buffers with different additives were tested to achieve the highest response of the 
drugs under the same operating conditions (Table ‎2-7). Four separate non-extracted 
standards of each analyte were prepared using 200 µL aliquot of the 10 mg/L working 
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solution, dried under nitrogen. Each sample was reconstituted with 100 µL of one selected 
mobile phase (buffer/organic, 80:20). A 10 µL volume was injected in triplicate for each 
mobile phase. This experiment was not carried out for CBZO, CBZ-DiOH, p-HPPH, RTG 
and ESL which were added to the method at a later stage. 
Table  2-7: A List of Buffers Tested for Mobile Phase Optimisation.  
pH Buffer Organic phase MP percentages 
2.8 0.1% Formic acid Acetonitrile (80:20) 
3.0 10 mM  Ammonium formate Acetonitrile (80:20) 
5.0 10 mM Ammonium acetate Acetonitrile (80:20) 
9.3 10 mM Ammonium carbonate Acetonitrile (80:20) 
 
2.2.6.2  Mobile Phase pH 
Volatile, low molecular weight organic acids (eg. formic and acetic acid) are commonly 
used as additives in LC/MS to improve ionization and resolution. The addition of acid was 
evaluated by adding glacial acetic acid to the mobile phase of choice, 10 mM ammonium 
acetate (pH= 6.8), to achieve a pH of 4.0, 4.5 and 5.5. Non-extracted standards of each 
analyte were prepared in duplicate using 200 µL aliquot of the 10 mg/L working solution, 
dried under nitrogen. Each sample was reconstituted with 100µL of one selected mobile 
phase (buffer/organic, 80:20). Acetonitrile was used for the organic phase. A 10 µL 
volume was injected in triplicate for each mobile phase. The average peak area was 
calculated for each analyte. 
2.2.6.3 Aqueous Phase Molarity 
The mobile phase additive concentration (molarity) has a significant effect on the analyte 
electro-spray response. It has been reported that increasing the additive concentration leads 
to a dramatic decrease in analyte sensitivity due to its suppressive effect on electro spray 
ionization (243). In order to investigate the effect of the mobile phase additive on AEDs 
ionization, two mobile phases were compared using low and high molarity; 2 and 10 mM 
ammonium acetate. Non-extracted samples were prepared and injected as before in 2.2.6.2.  
2.2.6.4  Organic Phase  
Substitution of methanol for acetonitrile in the HPLC mobile phase has been shown to 
produce a significant difference in the electrospray ionization of a variety of compounds. 
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(244). A comparison was carried out between methanol and acetonitrile to investigate their 
effects on the chromatograms of the analytes, their ion abundances and peak shape. 
2.2.7  Optimization of LC Column Stationary Phase and 
Temperature  
AEDs of interest are a group of acidic, basic and amphoteric compounds with a wide range 
of pKa and different polarities; hence, a simple and general column which can tolerate a 
wide range of pH was required in order to elute all the compounds.  A typical C18 column 
was used as a starting point (Table ‎2-6). In order to achieve better separation and cleaner 
chromatograms, three different columns were compared with the previous Gemini C18 
column (Table ‎2-8). Agilent C18 XDB column and Agilent C8 XDB column were used to 
compare the effect of column dimensions on resolution and analyte elution. Obelisc R 
column has reversed phase (C18) characteristics in addition to the presence of ionic groups 
and a long hydrophobic chain which offer multiple separation modes (ion exchange, 
reverse and normal phase). The column offers additional retention and different 
mechanisms of reaction that should help to resolve the target compounds depending on 
their structure and chemical groups. 
Table  2-8: Chromatographic Column Properties. 
Column 
Length 
(mm) 
Internal Diameter 
(mm) 
Particle Size 
(µm) 
Gemini C18 Pheomenex 150 2.0 5 
Agilent C18 XDB 50 4.6 1.8 
Agilent C8 XDB 150 4.6 5 
Obelisc R (mixed mode) 150 4.6 5 
 
After choosing the best mobile phase and column system for analysing all AEDs 
simultaneously, the column temperature was optimized at 25, 40 and 50°C. 
2.2.8 Optimization of Chromatographic Separation  
A separation issue appeared during the method development stage for 4 of the 
drugs/metabolites. These drugs are carbamazepine and eslicarbazepine acetate, 
oxcarbazepine and carbamazepine 10, 11-epoxide, which are all derivatives of 
carbamazepine having similar structures. In order to separate these drugs and get a good 
resolution, several experiments were carried out by changing the mobile phase gradient 
system and the flow rate. 
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The flow rate was changed using three different rates; 0.1, 0.2 and 0.3 mL/min. Different 
gradient systems were applied by modifying the aqueous/organic phase percentage of the 
mobile phase in order to achieve the best separation for all the compounds in one analysis 
as illustrated in Table ‎2-9. 
Table  2-9: Mobile Phase Gradient Systems Experiments in Order to Achieve the Required 
Chromatographic Separation. 
Time 
(mins) 
System 1 System 2 System 3 System 4 System 5 
  A%* B%* A% B% A% B% A% B% A% B% 
0 80 20 80 20 80 20 90 10 90 10 
2 80 20 60 40 50 50 90 10 50 50 
10 10 90 40 60 50 50 10 90 50 50 
10.5 10 90 10 90 10 90 10 90 10 90 
11.5 10 90 10 90 10 90 10 90 10 90 
12 80 20 80 20 80 20 90 10 90 10 
20 80 20 80 20 80 20 90 10 90 10 
*A: 10 mM ammonium acetate, B: ACN. 
 
2.2.9 Optimization of LC/MS/MS Operation Mode, MRM vs DMRM 
Presently, many reports on the quantitative analysis of AEDs using LC/MS/MS are based 
on multiple reaction monitoring (MRM), which has been widely applied to biomarker 
validation and other target quantification because of its well-known selectivity and 
sensitivity. This method, however, has critical limitations especially when targeting drugs 
with very low LOD and LOQ. Since transitions are monitored in the whole time period of 
a standard MRM time segment, the rate of false positive detection (i.e. peak 
misidentification) increases. With improved sensitivity and better LOD and LOQ, dynamic 
multiple reaction monitoring (DMRM) could offer a good solution to this issue. This 
technique monitors the analytes only around the expected retention time, and thus 
decreases the number of concurrent MRM transitions, allowing both the cycle time and the 
dwell time to be automatically optimized for the highest sensitivity, accuracy and 
reproducibility which in turn decrease limit of detection and quantification. Moreover, 
DMRM allows the monitoring of more MRM transitions in a single run without 
compromising data quality. Hence, it was decided to apply DMRM mode for MS analysis 
of AEDs (245). 
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2.2.10 Extraction Optimization - Solid Phase Extraction vs 
Protein Precipitation 
Before introducing any samples to LC/MS/MS, the analytes first need to be extracted from 
the matrix and concentrated. The method needs to be able to wash enough interfering 
compounds away without diminishing the recovery of the analytes. 
Following development of the instrument method, extraction experiments were carried out 
to optimize the best conditions to extract the 17 AEDs as a mixture with highest recovery 
and minimum matrix effect. Additionally, peak shape, reproducibility, time of extraction, 
linearity range and the cleanliness of the extracts were evaluated when optimizing 
extraction methods. 
It was decided to evaluate two extraction methods modified from the literature; solid phase 
extraction (SPE) using Strata-X 33-mg (Phenomenex) cartridges (30 mg/1mL) and protein 
precipitation.  
a) Solid Phase Extraction: Strata-X 33-mg (Phenomenex) cartridges are made of reversed 
phase polymeric sorbent that gives strong retention of neutral, acidic, or basic compounds 
(246). This sorbent relies on 3 mechanisms of retention: pi-pi bonding, hydrogen bonding 
(dipole-dipole interactions) and hydrophobic interaction. 
A volume of 100µL spiked blood was diluted with 400 µL 0.1% formic acid/MeOH 
(80:20) mixture. The cartridges were conditioned with 1 mL MeOH then equilibrated with 
1 mL deionised water. After loading the diluted sample, it was allowed to drip through 
with no vacuum applied, then the cartridges were washed with 1 mL 20% MeOH and left 
to dry with full vacuum applied for 2 minutes. Elution was achieved using 1 mL MeOH. A 
100 µL internal standards mix solution (TUB, CBZ-DiOH and GBP-D10) at a 
concentration of 10 mg/L was added to the eluted sample which was then evaporated under 
a stream of  nitrogen at 25 °C, reconstituted with 200 µL mobile phase (80/20: A/B) and 
transferred to a LC vial. A 10 µL volume was injected into the LC/MS/MS. 
b) Protein Precipitation with MeOH: A 100 µL aliquot of blood was transferred to a 2-mL 
snap top polypropylene micro-centrifuge tube followed by 100 µL of mixed working 
standard solution at 10 mg/L and 300 µL of MeOH. This was vortex mixed for 10 seconds 
and centrifuged for 10 minutes at 5000 rpm. A 100 µL internal standard mix solution 
(TUB, CBZ-DiOH and GBP-D10) at a concentration of 10 mg/L was added to the 
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supernatant which was then evaporated under a nitrogen stream at 25 °C, reconstituted 
with 200 µL mobile phase (80/20: A/B) and transferred to a LC vial. A 10 µL volume was 
injected into LC/MS/MS. 
For both extractions, standards were prepared in triplicate and injected in duplicate at a 
concentration of 10 mg/L. In order to calculate the recovery, a non-extracted standard at 
the same concentration was also prepared at the same time in triplicate. Internal standards 
mix solution was added after the extraction to all extracted and non-extracted standards in 
order to eliminate the matrix effect on the internal standard and evaluate the absolute 
recovery of the analytes. The peak area ratios for the analyte and its respective internal 
standard were calculated. The absolute recovery was determined for each analyte by 
dividing the extracted STD/IS ratio by that of the non-extracted STD/IS ratio at the same 
concentration and multiplying by 100. 
2.2.11 Sample Reconstitution Optimization 
Due to the different chemical structures of the AEDs of interest, the analytes exhibited 
different intensities which required different reconstitution volumes in order to attain good 
linearity. Hence, the effect of the reconstitution solution composition and its volume on 
linearity and lower limit of quantification had been optimized. 
The use of different reconstitution volumes for the same extracted sample in order to get 
the desirable results was previously reported in the literature. A method published recently 
had to divide the AEDs into 3 groups with 3 different dilution volumes in order to achieve 
good sensitivity and acceptable linearity (203). In other words, three different sets of 
calibrations had to be prepared which increased the time spent on the analysis and 
increased the cost on consumables.  
In order to achieve one dilution step for all the AEDs with good linearity, the following 
parameters were investigated; sample reconstitution solution volume and reconstitution 
solution composition effect on drug solubility. 
2.2.11.1 Sample Reconstitution Volume  
A series of dilution volumes were evaluated starting at 1.0, 2.0, 3.0 and 4.0 mL. The 
mobile phase (80/20: A/B) was used as a reconstitution solution at this stage. 
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Samples were prepared in triplicate as follows; a 100µL aliquot of blood was transferred to 
a 2-mL micro-centrifuge tube, 100 µL of standard mix solution at 10 mg/L, 100 µL of 
internal standard and 200 µL MeOH were added, vortex mixed for 10 seconds and 
centrifuged for 10 minutes at 5000 rpm. The supernatant was then evaporated under a 
nitrogen stream at 25°C and reconstituted with mobile phase (80/20: A/B) to achieve the 
volumes mentioned earlier. 1 mL was transferred to a LC vial and 10 µL injected into the 
LC/MS/MS. The lower limit of detection and linearity for each analyte were compared. 
2.2.11.2 AED Solubility in Reconstitution Solution 
Seven different reconstitution solution mixtures including the mobile phase were 
evaluated. Non-extracted standards were used for this experiment in order to eliminate the 
effect of the matrix on the drug responses. Non-extracted analytes were spiked directly into 
the reconstitution solutions to obtain a final concentration of 2, 0.2 and 20 mg/L for group 
1, 2 and 3 respectively as detailed in Table ‎2-10 (See Table ‎2-2 for working solution 
preparation). A volume of 1 mL was transferred to a LC vial and 10 µL was injected. 
Analyte response and peak shape were compared by overlapping the chromatograms of 
each analyte and the highest abundance was recorded. 
Table  2-10: Preparation of AEDs Samples to Evaluate Their Solubility in Different 
Reconstitution Solutions 
Amount Added (µL) to 10 mL 
Volumetric Flask Reconstitution 
Solution 
Volume 
(µL) 
Final Concentration (mg/L) 
Working 
Solution 1 
(100 mg/L) 
Working 
Solution 2 
(100 mg/L) 
Working 
Solution 3 
(1 g/L) 
Group 1 Group 2 Group 3 
200 20 200 9580 2 0.2 20 
 
The following reconstitution solution mixtures were used: 
1. 2 mM ammonium acetate/MeOH (80:20) 
2. 10% MeOH in water 
3. 10% MeOH/0.1% formic acid in water 
4. 5% ACN in water 
5. 5% ACN/0.1% formic acid in water 
6. 0.1% formic acid  
7. Water 
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2.2.12 Investigation into Protein Precipitation Extraction 
Conditions 
The aim of this study was to optimize the effect of sample preparation steps on the protein 
precipitation extraction of 15 AEDs and 2 metabolites to create an efficient routine 
forensic toxicological method. Steps evaluated in the study are the solvents used for 
extraction, the centrifuge duration and speed and finally the effect of blood haemolysis 
with water before extraction on recovery.  
For this study two standards were prepared; non-extracted and spiked whole blood at the 
same concentrations; 10 mg/L for group 1, 2.5 mg/L for group 2 and 100 mg/L for group 3, 
as outlined in Table ‎2-11.  
Table  2-11: Preparation of AEDs Standards in Whole Blood for Extraction Optimization 
Experiments. 
AEDs 
Standard 
Amount Added to 10 mL 
Volumetric Flask  (µL) Whole  
Blood 
(µL) 
MeOH 
(µL) 
Final Concentration 
(mg/L) 
Working 
Solution 1 
Working 
Solution 2 
Working 
Solution 3 
Group 
1 
Group 
2 
Group 
3 
Whole blood 
Standard 
1000 25 100 8875 - 10 2.5 10 
Non-extracted 
standard 
1000 25 100 - 8875 10 2.5 10 
 
Two internal standards were used at concentration of 10 mg/L; 10, 11 dihydro-
carbamazepine (CBZ-DiOH) for CBZ, CBZO, ESL and OXC and tulbotamide for the 
other drugs (See Table ‎2-2 and Table ‎2-5 for working and internal standards solutions 
preparation). 
2.2.12.1 Effects of Extraction Solvent  
The effects of seven different solvent mixtures were evaluated for the protein precipitation 
extraction of 17 AEDs. 
Seven sets; 3 samples each, of spiked whole blood samples were prepared. Each set was 
extracted with one of the 7 solvent mixtures shown in Table ‎2-12 as follows; 100 µL of 
spiked blood was transferred to a 2-mL micro-centrifuge tube, 400 µL of solvent mixture 
were added, vortex mixed for 10 seconds and centrifuged for 10 minutes at 5000 rpm. A 
200‎ μL‎ aliquot‎ of‎ the‎ supernatant‎ was‎ transferred‎ to‎ a‎ LC‎ vial,‎ spiked‎ with‎ 20‎ μL‎ of‎
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internal standard (10 mg/L) and diluted to 1.5 mL with deionized water. 10 µL were 
injected into the LC/MS/MS.  
In order to calculate the recovery, seven sets of non-extracted samples at the same 
concentration (see Table ‎2-11) were also prepared at the same time in triplicate as 
following;‎100‎μL‎of‎the‎standard‎solution‎was‎diluted‎with‎400 µL of one solvent mixture. 
A‎200‎μL‎aliquot‎of‎the‎diluted‎standard‎was‎transferred‎to‎a‎LC‎vial,‎spiked‎with‎20‎μL‎of‎
internal standard (10 mg/L) and diluted to 1.5 mL with deionized water. 
Internal standard was added after the extraction to all extracted and non-extracted samples. 
The ratios between the analyte mean peak area and its respective deuterated standard were 
calculated. The absolute recovery was determined for each analyte by dividing the 
extracted STD/IS ratio by that of the non-extracted STD/IS ratio at the same concentration 
and multiplying by 100. 
Table  2-12: Solvent Combinations Tested. 
Set No. Solvent Mixture   Total Volume (µL) 
Set 1 Methanol 400  
Set 2 Ethanol 400 
Set 3 Acetonitrile 400  
Set 4 Acetone  400  
Set 5 MeOH/ACN/EtOH  200:100:100 
Set 6 MeOH/ACN/Acetone  200:100:100 
Set 7 MeOH/EtOH/Acetone  200:100:100 
2.2.12.2 Effect of Centrifuge Speed and Duration  
The effect of centrifuge duration on extraction yield was evaluated at 10, 15 and 20 
minutes and its speed was assessed at 3000, 5000 and 10000 rpm. 
Six sets of spiked whole blood samples were prepared in triplicate. Three sets were 
centrifuged at 5000 rpm for 10, 15 and 20 minutes, and the other three sets were 
centrifuged for 10 minutes at 3000, 5000 and 10000 rpm. All sets were extracted as 
in ‎2.2.12.1. One set of non-extracted standards at the same concentration was also prepared 
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at the same time in triplicate and absolute recovery was calculated as mentioned earlier 
in ‎2.2.12.1. 
2.2.12.3 Effects of Water Haemolysis  
Water haemolysis of blood was reported to improve the extraction yield of some drugs by 
uniformly dissolving blood components and providing a desirable consistency after vortex-
mixing (247).  In order to assess the effect of water haemolysis on AEDs extraction, a set 
of 3 spiked whole blood samples were extracted with MeOH. Before the extraction, 100 
μL‎deionized‎water‎was‎added‎to‎100‎µL‎of‎spiked‎blood‎(1:1‎v/v)‎and‎vortex‎mixed‎for‎10‎
seconds.‎ A‎ 100‎ μL‎ of‎ haemolysed‎ blood‎ was‎ extracted‎ with‎ 400‎ µL‎ MeOH‎ and‎
centrifuged for 10 minutes at 5000 rpm. Three non-extracted samples were prepared at the 
same time. Both sets were spiked with 20 µL internal standard after extraction. Recovery 
was calculated as mentioned earlier in ‎2.2.12.1. 
2.2.12.4 Matrix Effect Evaluation 
Finally, the matrix effect was evaluated for two selected extraction methods (methanol and 
acetonitrile) using the post-extraction addition approach to assess ionization 
suppression/enhancement. 
Recovery and matrix effect in this experiment were assessed using the Matuszewski 
strategy (248).  Three sets of QCs at a concentration of 10 mg/L for group 1 and 3 and 2.5 
mg/L for group 2 (Table ‎2-11) were prepared as follows: 
Set 1 (Non-extracted QCs): 6 QCs were prepared using non-extracted standards and 
internal standards. A 100 µL aliquot of the QC solution with 100 µL of the internal 
standard solution was added to a micro centrifuge tube. A 200 µL aliquot of methanol was 
added (total volume 400 µL) and mixed, then 200 µL of the sample was transferred to a 
LC vial and diluted to 1.5 mL with water. 
Set 2 (Post extraction QCs): Blank blood was extracted as mentioned in ‎2.2.12.1 using 6 
different sources (donors) of blood. QC solutions and internal standards were added after 
extraction. 
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Set 3 (Pre extraction QCs): Blank blood was spiked with QC solutions and internal 
standards before extraction and extracted as mentioned in ‎2.2.12.1 using the same 6 
sources of blood.  
After analysing the samples, the peak area was used to calculate the recovery, matrix effect 
and process efficiency using the following equation: 
Recovery RE (%) = Pre (3) / Post (2) x 100 
Process Efficiency PE (%) = Pre (C) / Non-extracted (A) x 100 
Matrix Factor (MF) = Post (2) / Non-extracted (1) 
MF is acceptable if the value is within 1±0.25.  
If MF = 1, there is no matrix effects.  
If MF <1, there is an ionisation suppression effect.  
If MF >1, there is ionisation enhancement and/or analyte loss in the absence of matrix.  
Finally, recoveries using both approaches, peak area/IS ratio and Matuszewski strategy 
were compared. 
2.3 Results and Discussion 
2.3.1 Optimisation of the Fragmentor Voltage and Collision 
Energy 
Optimizer Software was used initially to investigate AEDs precursor and product ions, 
fragmentor voltage, collision energy and the ionization mode.  
Using the automated software saved time and effort required for method development. 
However, the program did not predict the parameters needed for most AEDs of interest. 
For instance, in the case of CBZ and its derivatives; CBZO and OXC and their internal 
standard CBZ-DiOH, the program did not give any results in either negative or positive 
mode. On the other hand, Optimizer predicted a fragmentation pattern for p-HPPH in 
positive mode (Appendix 2-1) but the abundance was very low.  This occurred also with 
Chapter 2  78 
 
CBZO but in negative mode. As a result, the values were not sufficiently reliable to be 
used as a reference to build the acquisition method.  
The sample injection program was used as an alternative procedure to tune the compounds 
of interest. All the analytes investigated in this study generated the prominent protonated 
molecular ion ([M+H]+) in positive-ion mode and the deprotonated molecular ion ([M-
H]−)‎ in‎ negative‎ ion‎ mode.‎ Based‎ on‎ signal‎ intensity‎ and‎ fragmentation‎ pattern,‎ the‎
analytes were divided into two ionization groups; positive ionisation mode including all 
AEDs except PHT, p-HPPH, TPR, TPR-D12, TUB, VPA and ZNS which showed a 
negative ionisation mode.   
The fragmentor voltage was in the range of 50–140 V for all AEDs and their internal 
standards. The optimum abundance of the precursor ions is illustrated in Figure ‎2-2. 
Collision energy was optimized to get the most abundant product ions using nitrogen gas 
for collision. Most analytes had optimum collision energy of less than 20 eV as illustrated 
in Figure ‎2-3. Although a qualitative ion and a quantitive ion is required for LC/MS/MS 
quantitive analysis, however, no fragment ions were observed in MS/MS spectra for 
valproic acid, so quantitative analysis was applied using the non-reactive transition m/z 
143 for this drug and its retention time. These were the only criteria used to confirm 
valproic acid analysis.  Table ‎2-13 summarizes the optimization data.  
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Figure  2-2: Fragmentor Voltage Optimization of 17 AEDs and 5 Internal Standards. 
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Figure  2-3: Collision Energy Optimization of 17 AEDs and 5 Internal Standards. 
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Table  2-13: Optimization Parameters Using 2 Different Tuning Methods. 
AEDs 
Ionization 
Mode 
Precursor  
(m/z) 
Optimizer Software Sample Injection System 
Quantifier (m/z) 
Qualifier 
(m/z) 
Frag
a
 
(V) 
CE
b
 
(eV) 
Quantifier (m/z) Qualifier (m/z) 
Frag
a
 
(V) 
CE
b
 
(eV) 
CBZ + 237.3 99.1 n/a 100 20 194 179.1 140 20 
CBZO + 253.1 59.2 n/a 45 8 236.1 180 110 10 
ESL + 297.2 237.2 194.2 85 4 237.2 194.2 80 5 
GBP + 172.2 154.2 137.1 70 12 154.2 137.1 80 10 
LAC + 251.1 59.2 n/a 75 12 108.1 91.1 80 10 
LEV + 171.1 126.1 154.1 90 12 126.1 154.1 80 10 
LTG + 256.1 153.7 n/a 80 20 165.7 211 110 20 
OXC + 253.2 59.2 n/a 100 12 208 180 110 10 
PGR + 160.2 142.2 55.2 80 8 142.2 97.2 80 10 
PHT - 251.2 n/a n/a n/a n/a 180 208.2 110 15 
p-HPPH - 267.2 n/a n/a n/a n/a 118.1 224.1 80 20 
RTG + 304.2 n/a n/a n/a n/a 230.1 258.1 110 20 
TIG + 376.1 263 n/a 110 12 149 278.2 140 20 
TPR - 338.1 n/a n/a n/a n/a 78 96 140 20 
VIG + 130.1 71 113.1 70 12 113.1 71 50 10 
VPA - 143.1 143.1 n/a 100 0 143.1 n/a 80 0 
ZNS - 211.2 n/a n/a n/a n/a 118.1 147.1 80 10 
Internal Standards 
CBZ-DiOH + 239.1 n/a n/a n/a n/a 179 n/a 140 20 
GBP-D10 + 182.1 164.3 n/a 70 12 164.2 n/a 110 15 
PGR-D6 + 166.1 148.2 n/a 145 8 148.2 n/a 110 20 
TPR-D12 - 350.1 n/a n/a n/a n/a 96 n/a 140 20 
TUB - 269.2 170 n/a 120 10 170 n/a 110 5 
a: Fragmentor voltage, b: Collision energy. 
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2.3.2 Optimization of Nebulizer Gas Pressure  
Figure ‎2-4 shows an increase in AEDs response when increasing the nebulizer pressure 
from 15 to 25 except for RTG which showed a decrease in its sensitivity. Increasing the 
pressure to 35 PSI decreased the abundance of all AEDs and internal standards.  
 
Figure  2-4: Nebulizer Gas Pressure Optimization of 15 AEDs. 
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TPR-D12 showed very low sensitivity under all conditions. TPR-D12 gave similar product 
ions and retention time to TPR but it did not mimic TPR abundance at the same 
concentration (Figure ‎2-5). 
 
Figure  2-5: TPR and TPR-D12 Chromatograms at Concentration 10 mg/L and Neb 15 PSI. 
 
 A pressure of 25 PSI was used during the method development period. However, at a later 
stage, the gas pressure was decreased to 15 PSI in order to obtain good sensitivity for all 
drugs including RTG. Furthermore, decreasing the nebulizer pressure decreased the 
sensitivity slightly which helped to prevent the MS source saturating due to high calibrator 
concentrations. On the other hand, TPR-D12 was excluded from this project due to its poor 
abundance under the used conditions.  Also, PGR-D6 and GBP-D10 have similar structure 
and same retention time. As a result, it was decided to use GBP-D10 instead of PGR-D6 due 
to its cheaper cost.  
2.3.3 Optimization of Mobile Phase  
2.3.3.1 Aqueous Phase Additives 
Four buffers with different pH ranging from 2.8 to 9.3 were optimized using the same 
gradient system which is illustrated in Figure ‎2-1. ACN was used as an organic phase in all 
of these. Taking into account the sensitivity, relative abundance, precursor ion 
fragmentation and enhancing product ion formation, 10 mM Ammonium acetate (pH= 5) 
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was the mobile phase which gave the optimum result for most of the AEDs under the same 
analysis conditions (Figure ‎2-6, Figure ‎2-7 and Figure ‎2-8).  
It was obvious that highly acidic mobile phase such as 0.1% formic acid  (pH=2.8) had a 
strong suppression effect on product ion formation of PHT, TPR, VPA and ZNS which are 
analysed in negative ionization mode (Figure 2-7) whereas it enhanced the sensitivity of 
other drugs analysed  in positive mode such as gabapentin, pregabalin and lacosamide. 
Similar results were observed with 10mM ammonium formate (pH= 3). Although 
ammonium formate and ammonium acetate have the same concentration of 10 mM, 
ammonium acetate exhibited higher responses with all AEDs and their internal standards. 
That may be due to the difference in pH of the mobile phase from 7 (ammonium formate) 
to 5 (ammonium acetate) which improves the ionization and increases the analyte 
sensitivity. Regarding 10mM ammonium carbonate, its high pH exhibited suppressive 
effects with most AEDs except OXC, LEV and LTG which showed considerable responses 
but still lower than 10mM ammonium acetate. However, amphoteric drugs and their 
deuterated internal standards; GBP, PGR and VIG showed good sensitivity with either 
acidic or basic mobile phases. PGR and its internal standard PGR-D6 gave slightly higher 
responses with 0.1% formic acid compared to 10 mM ammonium acetate. Results were 
presented using the average peak area. 
 
Figure  2-6: Effect of Mobile Phase Additives on Analyte Abundance in Positive Ionization 
Mode. 
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Figure  2-7: Effect of Mobile Phase Additives on Analyte abundance in Negative Ionization 
Mode.  
 
Figure  2-8: Effect of Mobile Phase Additives on Amphoteric Analyte Abundance in Positive 
Ionization Mode. 
 
As a result, 10 mM ammonium acetate is considered the mobile phase of choice that 
showed acceptable sensitivity for 13 AEDs and 4 internal standards.  
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2.3.3.2 Mobile Phase pH 
Adjustment of pH of 10 mM ammonium acetate from 6.8 to 5.5, 4.5 and 4 showed no 
improvement effect on resolution or ionization. On the other hand, using mobile phase 
with low salt and acid concentration gave higher responses and improved the sensitivity of 
the analytes except TPR-D12 which did not show a good response with any of the 
conditions tested above (Figure ‎2-9). As a result, a mobile phase with a pH of 6.8 was 
used. 
 
Figure  2-9: Effect of Acetic Acid as an Additive in Aqueous Mobile Phase on AEDs 
Response. 
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2.3.3.3 Aqueous Phase Molarity  
It was clear that decreasing the concentration of the additive salt from 10 mM to 2 mM 
resulted in a higher response and better sensitivity for all the analytes especially for those 
tested in negative mode such as PHT and TPR. Thus, it was decided to use 2mM 
ammonium acetate as an aqueous mobile phase  (Figure ‎2-10). Data is not available for 
PGR-D6 and TPR-D12 because they were excluded from the project at this stage (see 2.3.2). 
 
 Figure  2-10: Effect of Ammonium Acetate Concentration on AED Responses. 
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2.3.3.4 Organic Phase  
Methanol was shown to give higher responses with all AEDs compared with acetonitrile 
with the exception of RTG which exhibited a slightly higher response using acetonitrile 
(Figure ‎2-11). Although acetonitrile gave a better peak shape it also exhibited a 
suppressive effect on product ion formation which in turn affected the lower limit of 
detection (LOQ) for some drugs such as PHT, p-HPPH, LTG, OXC and ZNS. Methanol 
and acetonitrile effects on the LOQ for all AEDs and internal standards are illustrated in 
Figure ‎2-12, Figure ‎2-13 and Figure ‎2-14.  
 
Figure  2-11: Comparison of Response of AEDs and Internal Standards Using MeOH and 
ACN in Mobile Phase. 
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Figure  2-12: Effects of MeOH and ACN as an Organic Mobile Phase on LOQ. 
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Figure  2-13: Effects of MeOH and ACN as an Organic Mobile Phase on LOQ.  
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Figure  2-14: Effects of MeOH and ACN as an Organic Mobile Phase on Internal Standards. 
Finally, 2 mM ammonium acetate in water (pH not adjusted) and 2 mM ammonium acetate 
in methanol were used as the mobile phase of choice for all AEDs of interest and their 
internal standards.  
2.3.4 Optimization of LC Column Stationary Phase and 
Temperature  
2.3.4.1 Stationary Phase  
Figure ‎2-15 to Figure ‎2-17 show the response of the analytes using 4 different columns. It 
was clear that using the Gemini C18 column (150 mm x 2.0 mm, 5 µm) gave a greater 
response and better peak shape for every analyte except PHT and its metabolite p-HPPH 
which showed higher abundance using the Agilent C8 XDB column (150 mmx 4.6 mm x 
5µm).  
Although the Agilent C8 showed a higher abundance with some drugs, the peak shape was 
unacceptable. They exhibited wide and tailing peaks for most drugs. On the other hand, 
due to its wide diameter, the flow rate had to be increased from 0.3 µL/min to 0.6 µL/min 
in order to shorten the analysis time from 40 to 17 minutes. This flow rate caused a quick 
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build up on the front of the source which decreased the sensitivity of the analysis and 
increased the frequency of the MS source maintenance. Moreover, it did not give good 
separation results with CBZ, OXC, ESL and CBZO. The same issue was seen when using 
Obelisc R (150 mm x 4.6 mm, 5 µm) due to its wide diameter as well. However, Obelisc R 
showed good separation with CBZ and ESL but not OXC and CBZO. On the other hand, 
Obelisc R did not give the expected results with most drugs such as VPA, LTG and, CBZ-
DiOH.  
The Agilent C18 XDB (50 mm x 4.6 mm, 1.8 µm) gave very sharp peaks and good 
responses with all the drugs due to its small particle size. However, CBZ derivatives 
separation was not successful. Furthermore, the very small particle size imposed a high 
pressure on the LC pump which can shorten the pump life time on a longer term basis. 
Additionally, columns with small particle size are not preferable for postmortem blood 
analysis due to the complicated and clotted sample nature which can cause a quick build up 
in the column if the extraction procedure is not sufficiently clean. As a result, Gemini C18 
column (150 mm x 2.0 mm, 5 µm) was chosen as column of choice to develop this 
method. 
 
Figure  2-15: Column Diameter and Stationary Phase Effect on Analyte Peak Shape and 
Resolution. 
Chapter 2  93 
 
 
Figure  2-16: Column Diameter and Stationary Phase Effect on Analyte Peak Shape and 
Resolution. 
 
 
Figure  2-17: Column Diameter and Stationary Phase Effect on Analyte Peak Shape and 
Resolution. 
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2.3.4.2 LC Column Temperature  
After‎choosing‎ the‎Gemini‎C18‎column‎(150‎x‎2.1‎mm,‎5‎μm)‎ from‎Phenomenex‎and‎2 
mM ammonium acetate in water/2 mM ammonium acetate in methanol as the most 
suitable mobile phase the column temperature was optimized. It was found that increasing 
the column temperature from 25 to 40°C showed a slight increase in the method sensitivity 
by increasing the AEDs intensities (Figure ‎2-18) 
 
 
 
 
Figure  2-18: Effect of Chromatographic Column Temperature on AEDs and Internal 
Standards Sensitivity. 
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Furthermore, it improved the instrument performance by decreasing the turbo pump 
pressure as a result of decreasing the mobile phase viscosity. However, at 50°C, the 
sensitivity of all the drugs and internal standards were significant reduced. The column 
temperature was therefore set at 40°C. 
2.3.5 Optimization of Chromatographic Separation  
OXC and ESL are new AEDs derived from CBZ whereas CBZO is the metabolite of CBZ. 
All these compounds are structurally similar (Figure ‎2-19). OXC and CBZO have identical 
fragmentation patterns. Their product ions are 236, 210, 208 and 180 m/z. 
 
Figure  2-19: CBZ, CBZO, OXC and ESL Chemical Structure. 
 
Although the Gemini C18 column gave good separation of these 4 drugs, the separation 
was very sensitive to any change in the mobile phase composition or flow which led the 
peaks to be merged again. 
Slowing the flow rate from 0.3 mL/min to 0.2 mL/min to 0.1 mL/min gave a partial 
separation for OXC and CBZO but there was no improvement to CBZ and ESL separation 
(Figure ‎2-20). On the other hand, reducing the flow rate increased the method run time 
from 17 to 32 minutes in order that all the drugs could be eluted. 
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Figure  2-20: Flow Rate Effect on CBZ Derivatives Separation. 
 
The change of the gradient showed a significant change in the separation and retention 
time of these 4 drugs as illustrated in Figure ‎2-21. Five different systems were used as 
detailed in Table ‎2-9. Best results were obtained with system 2 and 5. Tthe gradient mobile 
phase system implied finally started at 80:20 A/B and was increased to 50:50 A/B within 2 
minutes. This percentage was maintained for 6 minutes before it was increased to 10:90 
A/B for 2 minutes. The percentage decreased finally to 80:20 A/B for 7 minutes in order to 
condition the column before the next injection. 
 
Figure  2-21: Gradient System Used to Improve the Separation of 4 AEDs. 
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The change in the aqueous/organic phase percentage affects the polarity of the mobile 
phase and greatly improves the drugs separation as showed in Figure  2-22. 
 
Figure  2-22: Carbamazepine (CBZ) and Eslicarbazepine (ESL), Oxcarbazepine (OXC) and 
Carbamazepine Epoxide (CBZO) Separation Using Different Mobile Phase Gradient 
Systems.  
 
Finally, Figure ‎2-23 shows the chromatogram of all analytes of interest obtained by 
dynamic multiple reaction monitoring mode and using non-extracted standards mixture at a 
concentration of 10 mg/L. 
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Figure  2-23: The Chromatogram of 17 AEDs and 3 Internal Standards Using a Standard 
Mixture at 10mg/L. 
Chapter 2  99 
 
2.3.6 Extraction Optimization - Solid Phase Extraction vs Protein 
Precipitation  
Solid phase extraction did not achieve the optimum results for all analytes although the 
used cartridges are designed for the extraction of basic and acidic drugs mixtures. Peak 
shape and sample purity were not as good as protein precipitation and blood samples 
following SPE extraction were brownish in colour (Figure ‎2-24).  
 
Figure  2-24: Chromatogram of Extracted Analytes Using SPE and Protein Precipitation at a 
Concentration of 10 mg/L. 
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Amphoteric drugs (GBP, PGR and VIG) showed poor recovery using the SPE method 
(43.4%, 4.3% and 4.6% respectively) and RTG could not be extracted at all. Protein 
precipitation attained recoveries higher than 70% for all the analytes and their internal 
standards except RTG which was less than 50% (Table ‎2-14). Regarding linearity, the R
2
 
values were not acceptable for some drugs using SPE due to their poor recoveries 
(amphoteric drugs). For other drugs such ESL, LEV, LTG and ZNS, the upper limit of 
quantification (ULOQ) was not high enough compared to protein precipitation. This would 
therefore require reanalysis and dilution of real case samples in order to achieve accurate 
quantitative results within the linear range. Furthermore, SPE was found to be time 
consuming due to the number of steps involved with sample preparation. 
Table  2-14: Recoveries, Calibration Ranges and Linearity Values for SPE and Protein 
Precipitation. 
AEDs 
Recovery (%) Calibration Range (mg/L) Calibration Model R² 
P.P SPE P.P SPE P.P SPE P.P SPE 
CBZ 103.3 110.5 0.5-50 0.5-50 Quadratic Quadratic 0.999 0.996 
CBZO 116.0 85.0 0.5-50 0.5-50 Quadratic Quadratic 0.999 0.997 
ESL 94.2 118.0 0.5-50 0.5-25.0 Quadratic Linear 0.999 0.991 
GBP 89.3 43.4 0.5-50 N/A Quadratic N/A 0.998 N/A 
LAC 100.9 77.7 0.5-50 0.5-50 Quadratic Quadratic 0.999 0.998 
LEV 100.4 38.2 5.0-300 5.0-200.0 Quadratic Quadratic 0.999 0.999 
LTG 110.3 61.3 1.0-50 1.0-25.0 Quadratic Linear 0.9995 0.995 
OXC 104.3 77.0 0.05-10 0.05-10 Linear Linear 0.999 0.997 
PGR 104.6 4.3 0.5-50 N/A Quadratic N/A 0.997 N/A 
PHT 100.0 85.9 0.5-50 1.0-50.0 Linear Linear 0.9997 0.998 
p-HPPH 75.2 82.4 0.5-50 0.5-50 Linear Linear 0.998 0.994 
RTG 50.0 0.3 0.5-10 N/A Quadratic N/A 0.991 N/A 
TIG 85.4 100.2 0.05-10 0.05-10 Quadratic Linear 0.998 0.997 
TPR 90.0 105.0 0.5-50 0.5-50 Linear Linear 0.997 0.997 
VIG 70.9 4.6 5.0-300 N/A Quadratic N/A 0.999 N/A 
VPA 97.4 67.1 5.0-300 5.0-100 Linear Linear 0.997 0.988 
ZNS 100.0 55.0 0.5-50 1.0-25.0 Linear Linear 0.996 0.995 
 
The protein precipitation method compared with the SPE method for blood was more 
robust and used less solvent. Linearity criteria were acceptable for all analytes (R
2
 > 0.996) 
using high ULOQ concentrations, except for RTG. In spite of its adequate recovery, the 
methods were not sufficiently robust to give acceptable linearity for RTG. Sample 
preparation was fast using protein precipitation due to the fact that it contained fewer and 
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shorter steps. Thus, it was decided to use protein precipitation as the method of choice to 
extract all the analytes simultaneously. 
2.3.7 Sample Reconstitution Optimization  
Due to the wide range of analytes used in this method and the high abundance of the 
analytes, the quadratic model had to be used with most of these and a carryover issue was 
observed. Although the quadratic model was reported to have been used in literature, a 
series of dilutions were applied to the extraction supernatant in order to improve the 
linearity, and decrease the carryover issue while maintaining an acceptable LOQ for all the 
drugs. The linearity values (R
2
) were > 0.99 for all dilutions. The only factors affected by 
dilution were LOQ and calibration model. Table ‎2-15 shows LOQ and calibration models 
resulted from applied dilutions. It was clear that increasing the dilution helps to improve 
the linearity by preventing the MS source from saturating due to high concentrations used. 
Although a 4 mL dilution gave linear ranges with all the analytes (except RTG), it also 
increased the LOQ for some drugs, such as LTG, PHT, p-HPPH, TPR and ZNS, due to the 
variance in their intensities. A 3 mL dilution gave acceptable LOQ and linear range for all 
drugs except LTG and solved the issue of carryover at high ULOQ concentrations, thus, it 
was used as the reconstitution volume. 
The protein precipitation‎method‎used‎a‎total‎of‎400‎μL‎of‎methanol‎ to‎100‎μL‎of‎blood.‎
After centrifuging the sample, the supernatant volume was approximately 390 to 430 mL 
depending on the water volume in the blood sample. In order to simplify the extraction 
method and obtain accurate results, it was decided to use half of the supernatant volume, 
200‎μL‎and‎dilute this to 1.5 mL with mobile phase (half of the chosen dilution volume). 
This adjustment meant that the evaporation step could be avoided, saving time and giving 
better accuracy. 
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Table  2-15: LOQ and Calibration Models Resulting From Series of Dilutions. 
1 mL 2mL 3mL 4mL 1 mL 2mL 3mL 4mL
CBZ 0.50 0.50 0.50 0.50 Quadratic Linear Linear Linear
CBZO 0.50 0.50 0.50 0.50 Quadratic Quadratic Linear Linear
ESL 0.50 0.50 0.50 0.50 Quadratic Linear Linear Linear
GBP 0.50 0.50 0.50 0.50 Quadratic Linear Linear Linear
LAC 0.50 0.50 0.50 0.50 Quadratic Quadratic Linear Linear
LEV 5.00 5.00 5.00 5.00 Quadratic Linear Linear Linear
LTG 0.50 1.00 1.00 2.50 Quadratic Quadratic Quadratic Linear
OXC 0.05 0.05 0.05 1.00 Linear Linear Linear Linear
PGR 0.50 0.50 0.50 0.50 Quadratic Linear Linear Linear
PHT 0.50 1.00 2.50 10.00 Linear Linear Linear Linear
p-HPPH 0.50 1.00 2.50 10.00 Linear Linear Linear Linear
RTG 0.05 0.50 0.50 1.00 Quadratic Linear Linear N/A
TIG 0.05 0.05 0.25 0.50 Quadratic Linear Linear Linear
TPR 0.50 0.50 0.50 2.50 Linear Linear Linear Linear
VIG 5.00 5.00 5.00 5.00 Quadratic Linear Linear Linear
VPA 5.00 5.00 5.00 5.00 Linear Linear Linear Linear
ZNS 0.50 1.00 2.50 5.00 Linear Linear Linear Linear
Calibration Model
AEDs
LOQ (mg/L)
   
Often, the mobile phase or a similar solution are used for reconstitution when using 
LC/MS/(MS)
n
. This may not always be applicable in practice where drugs may not be 
soluble enough in the percentage of organic/aqueous phase used which can exhibit 
suppressing or enhancing effects on the analyte response (249). Interestingly, this study 
showed that mobile phase may not always be the most appropriate reconstitution solution. 
In the case of AEDs, responses were significantly higher when the supernatant was diluted 
with only water or 0.1% formic acid in water compared to the dilution with mobile phase 
for both basic and acidic drugs (Figure ‎2-25). Again, this study proved the fact the less salt 
or additives present in the mobile phase, the better the response (see ‎2.3.3.3).  Furthermore, 
dilution with water or 0.1% formic acid in water improved the LOQ for some drugs like 
ZNS, PHT and its metabolite p-HPPH from 2.5 to 1 mg/L.  Responses attained from using 
either water or 0.1% formic acid in water were almost comparable, hence, water was used 
as the reconstitution solution of choice. 
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Figure  2-25: Effect of 7 Different Reconstitution Solution Compositions on AED Response. 
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2.3.8 Investigation Into Protein Precipitation Extraction 
Conditions 
2.3.8.1 Effect of Extraction Solvent  
A total of 7 different solvents combinations were assessed in triplicate. Figure ‎2-26 shows 
graphic representations of the recovery results for the 7 extraction methods. All solvent 
combinations used provided a recovery higher than 80% for all the AEDs except VIG 
(70%) and RTG (less than 50%). Although extraction yields were good with all solvents 
used, the methanol and acetonitrile extractions were much cleaner. 
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Figure  2-26: Comparison of AEDs Recoveries with 7 Different Solvent Combinations. 
 
2.3.8.2  Effect of Centrifuge Duration and Speed 
Centrifuge duration was assessed at 10, 15 and 20 minutes. Figure ‎2-27 shows that 
centrifuge duration does not have a significant effect on the extraction yield of these drugs, 
although CBZ and its derivatives (OXC, ESL and CBZO) showed a higher recovery by 
10% after 10 minutes centrifuge.  
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Figure  2-27: The Effect of Centrifuge Duration on Extraction Yield. 
 
 Figure ‎2-28 shows that increasing the centrifuge speed improved the extraction yield by 
10-20% for all drugs. Although LTG and TIG showed a higher recovery (>100%) with 
5000 rpm centrifuge speed which may be due to increased matrix effects,  the standard 
deviation was lower and results were more robust when 10000 rpm used. Hence, a 
centrifuge time of 10 minutes at 10000 rpm was chosen for protein precipitation extraction 
of AEDs. 
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Figure  2-28: The Effect of Centrifuge Speed on Extraction Yield. 
2.3.8.3  Effects of Water Haemolysis 
For AEDs, water haemolysis (1:1 v/v) does not improve the extraction yield and the 
recovery was lower by 5-20% compared with non-haemolysed blood samples Figure ‎2-29. 
As a result, protein precipitation was applied without water haemolysis. 
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Figure  2-29: The Effect of Water Haemolysis Step of Blood Sample on Extraction Yield.  
(100 µL Blood Sample was Diluted with 100 µL Water Before the Sample Undergo Protein 
Precipitation Extraction) 
2.3.8.4  Matrix Effect Evaluation   
Since methanol and acetonitrile extractions were found to provide higher recoveries with 
cleaner supernatants, the matrix effect was assessed for these two extraction methods. 
Figure ‎2-30 shows an acceptable matrix effect with both extractions (within ± 25%) except 
for RTG which shows a poor recovery and an unacceptable matrix effect. The matrix effect 
is slightly lower using ACN extraction but it exceeded the acceptable range with TIG 
(29%), while all AEDs showed acceptable values with MeOH extraction. 
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Figure  2-30: Comparison of the Matrix Effect and Recovery Yields for Two Different Protein 
Precipitation Methods Used Methanol and Acetonitrile as Solvents and Post Extraction 
Approach (Matuszewski Strategy).  
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Extraction recovery in Figure ‎2-30 was calculated using the Matuszewski strategy which 
uses the mean of the analyte peak area only whereas the recovery mentioned previously 
was calculated using analyte/internal standard peak area ratios. A comparison between 
recovery values obtained using both of these methods is illustrated in Figure ‎2-31.  Both 
methods gave comparable results, although recovery calculation of vigabatrin was about 
20% higher using the Matuszewski strategy which may due to eliminating the matrix effect 
in case of post extraction approach.. 
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Figure  2-31: Comparison of Recovery Values Calculated Using Matuszewski Strategy Which 
Uses Peak Area Only and Recovery Values Calculated Using Analyte/IS Peak Area Ratio. 
2.4 Conclusion 
The separation of 15 AEDs, 2 metabolites and 3 internal standards was achieved using an 
Agilent LC/MS/MS triple quadruple coupled with a Gemini C18 column (150 mm x 2.0 
mm, 5µm) and a C18 guard column (4.0 mm x 2.0 mm) maintained at 40 °C. Electrospray 
ionization was used and the MS operated in dynamic multiple reaction monitoring mode 
(DMRM) with ion mode switching.  The optimal MS conditions were achieved using a 
nebulizer pressure of 15 psi, a capillary voltage of 4,000 V, nitrogen gas heated to 300 °C 
and delivered at 10 mL/min.  
Gradient elution was employed using a mobile phase consisting of A: 2 mM ammonium 
acetate in water and‎B:‎2‎mM‎ammonium‎acetate‎in‎methanol‎at‎a‎ﬂow‎rate‎of 0.3 mL/min. 
The total run time was 17 min. The gradient mobile phase system started at 80:20 A/B 
increasing to 50:50 A/B within 2 min. This percentage was maintained for 6 min before 
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being increased‎to‎10:90‎A/B‎for‎2‎min.‎The‎percentage‎was‎ﬁnally‎decreased to 80:20 A/B 
for 7 min in order to condition the column before the next injection.  
The complex mixture of AEDs used in this method required a very general method in order 
to attain high recoveries with all drugs of interest. Although Strata X cartridges are 
recommended for general SPE extraction they did not achieve the optimum results in the 
case of AEDs. 
Protein precipitation gave higher recoveries with all AEDs (>70%) except RTG (<50%). 
Although, it is not a highly clean method, the purity of the samples was sufficient to be 
injected into LC/MS/MS. On the other hand, it was simple, fast, time saving and little 
solvent was required. 
It is important as part of any method development to evaluate the effect of reconstitution 
volume and composition due to its significant effect on linearity, LOQ and calibration 
model. This study showed that reconstitution with mobile phase may not give the optimum 
results and sensitivity can be improved by investigation of different solution compositions. 
Although most of the solutions used were similar to the mobile phase composition, a slight 
modification on the percentage of the reconstitution composition could result in a 
considerable change in the analyte response which in turn improved the sensitivity of the 
analysis. 
Hence, it was decided to use protein precipitation as the extraction of choice for the 
analysis of the 17 AEDs and a further investigation into the factors that might affect 
protein precipitation extraction was carried out.  
The two precipitants found to yield highest recoveries with lowest standard variations were 
methanol and acetonitrile. Extraction with methanol centrifuged at 10000 rpm for 10 
minutes without water haemolysis was considered as the method of choice because it was 
cheaper and simpler. 
To sum up, the extraction of 15 AEDs and 2 metabolites was carried out using protein 
precipitation extraction as follows; a 100 µL of spiked blood was transferred to a 2-mL 
micro-centrifuge‎ tube,‎ 100‎ μL‎ of‎ internal‎ standard‎ solution‎ and‎ 300‎ µL‎ of‎MeOH‎were‎
added, vortex mixed for 10 seconds and centrifuged for 10 minutes at 10000 rpm. A 200 
μL‎ aliquot‎ of‎ the‎ supernatant‎ was‎ transferred to a LC vial and diluted to 1.5 mL with 
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deionized water.  10 µL were injected into the LC/MS/MS. This extraction procedure was 
used to validate the method quantitively in the following chapter. 
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3 Method Validation of 17 AEDs in Whole Blood 
Using LC/MS/MS 
3.1 Introduction 
Before a new analytical method can be employed for the quantitative determination of 
drugs and their metabolites in biological samples, it has to be validated to fit the purpose of 
use. Method validation is a prerequisite to prove that an accurate, precise and rugged 
method has been developed to yield reliable results which can be satisfactorily interpreted 
(250). 
Many protocols regarding method validation process have been published in the literature 
by different organisations to ensure high quality and reliable data such as FDA Guidance 
for industry-bioanalytical method validation (2001) (251), SOFT/AAFS forensic 
toxicology laboratory guidelines (2006) (252), the United Kingdom and Ireland association 
of forensic toxicologists forensic toxicology laboratory guidelines (UKIAFT 2010) (253) 
and the standard practices for method validation in forensic toxicology which was 
published by the Scientific Working Group for Forensic Toxicology (SWGTOX) in May 
2013 (242). All these protocols and many others aim to improve method development and 
validation procedure, to implement good laboratory practice which in turn gives the most 
reliable results. 
Method validation criteria vary depending on whether the method will be used for 
qualitative or quantitative analysis. In case of qualitative method, only few parameters 
need to be investigated; the limit of detection, specificity/selectivity, carryover and 
stability of analyte in given matrices. More parameters are required in case of quantitive 
analysis as drug concentration needs to be reported. These parameters include linearity, 
accuracy in addition to limit of detection, limit of quantification, specificity/selectivity, 
carryover and stability. Furthermore, a matrix effect assessment should be carried out in 
case of LC/MS/MS analysis. 
The aim of this project was to quantitively validate the method developed in chapter 2 
according to the standard practices for method validation in forensic toxicology 
(SWGTOX, May 2013) for whole blood as most up to date guidance available at the time 
of this project (242). 
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3.2 Materials and Methods 
3.2.1 Materials 
These were the same as those described in 2.2.1 
3.2.2 Calibrators, Internal Standards and QCs Preparation 
See 2.2.2.2 and 2.2.2.3 for calibrators, QCs and internal standards solutions preparation. 
All QCs and stock solutions were stored at -20°C and working solutions were stored at 
4°C. Calibration curves were extracted in duplicate and quality controls in triplicate by 
adding the following volumes to 2 mL Eppendorf tube: 
Calibrator: 100µL of whole blood, 100µL of calibration standard, 100 µL of internal 
standard solution and 200 µL of methanol (methanol total volume 400 µL).  
QC: 100 µL of internal standard solution and 300 µL of methanol (methanol total volume 
400 µL). 
The calibrators and QCs were vortex mixed for 30 seconds and centrifuged for 10 minutes 
at 10000 rpm. An aliquot of 200 µL of the supernatant was transferred to an LC vial and 
diluted to 1.5 mL with deionized water. A 5 µL aliquot of the diluted supernatant was 
injected and analysed by LC/MS/MS. 
3.2.3 Instrumentation  
An Agilent LC/MS/MS triple quadruple G620A mass spectrometer equipped with Agilent 
1200 series auto sampler, quaternary pump SL with degasser and thermostatted column 
compartment was used. Electrospray ionization (ESI) was used and the MS operated in 
dynamic multiple reaction monitoring mode (DMRM) with ion mode switching. The 
optimal conditions were achieved using a nebulizer pressure at 15 psi, a capillary voltage 
of 4000 V, nitrogen gas heated to 300 °C and delivered at 10 mL/min. The column used 
was a Phenomenex Gemini C18 (150 mm x 2.0 mm,‎ 5μm)‎ coupled‎ with‎ a‎ C18‎ guard‎
column (4 x 2.1 mm).  The column temperature was maintained at 40 °C. Gradient elution 
was employed using a mobile phase consisting of A: 2 mM ammonium acetate in water 
and B: 2mM ammonium acetate in methanol at a flow rate of 0.3 mL/min. The total run 
time was 17 minutes. The gradient mobile phase system started at 80:20 A/B increasing to 
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50:50 A/B within 2 minutes. This percentage was maintained for 6 minutes before being 
increased to 10:90 A/B for 2 minutes. The percentage was finally decreased to 80:20 A/B 
for 17 minutes in order to condition the column before the next injection. Data analysis 
was performed using Agilent Mass-Hunter Workstation (version: B.01.05). 
3.2.4 Selectivity and Specificity  
Selectivity represents the extent to which an analytical method can be used to distinguish 
the target analyte in a complex matrix without any interference from other components of 
similar behaviour (such as metabolites, impurities, degradation) whereas specificity is 
defined as the ultimate selectivity where interference possibility is 0 %. Due to the 
confusion‎of‎using‎both‎terms,‎it‎has‎been‎recommended‎to‎use‎the‎term‎“Selectivity”‎and‎
discourage‎the‎term‎“Specificity”‎‎because‎a‎method‎can‎be‎either‎specific‎or‎not‎and‎it‎is‎
rare to have a very specific method for an analyte without any  interference (254, 255).  
Hence, a selectivity study was carried out to determine if there were any potential 
interferences from matrix components (endogenous) by comparing the chromatograms of 
11 different blank sources (donors) with those of corresponding standards spiked with 17 
AEDs at a concentration of 10 mg/L. Specificity was assessed by spiking drug-free matrix 
with each AED and internal standard individually at a concentration of 10 mg/L to evaluate 
the extent to which the method is selective for each AED and whether there is any 
interference among the AEDs of interest or their internal standards (exogenous) which 
might affect the quantitation results at a later stage. 
3.2.5 Limits of Detection and Limits of Quantification 
Instrument Limits of Detection LOD is considered the lowest concentration that gives a 
reproducible instrument response and which also can be distinguished from the matrix 
background noise‎ ‎ with‎ signal‎ to‎ noise‎ ratio‎ (S/N)‎ ≥‎ 3‎ using‎ non-extracted standards. 
Assay LOD is considered the lowest concentration that gives a reproducible instrument 
response‎with‎signal‎to‎noise‎ratio‎(S/N)‎≥‎3‎as‎well‎but‎using‎extracted‎standards,‎in‎other‎
word, assay LOD is in the presence of the matrix effect (242). 
 The lower limit of quantification (LLOQ) is considered the lowest concentration that gives 
a reproducible instrument response with a relative standard deviation (RSD or %CV) less 
than‎20‎%‎and‎S/N‎≥‎10.‎The‎limit‎of‎quantification‎(LOQ)‎was‎determined on the basis of 
the‎clinical‎need‎and‎should‎have‎a‎%CV‎less‎than‎20%‎and‎S/N‎≥‎10. 
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Instrument LOD is determined using decreasing concentrations of non-extracted drugs 
standard solutions within the expected range of the LODs; 0.05, 0.1, 0.5, 1, 2.5, 5 and 10 
mg/L for levetiracetam, vigabatrin and valproic acid (group 3); 0.005, 0.01, 0.05, 0.1, 0.25, 
0.5 and 1 mg/L for other AEDs . The samples were analysed in duplicate for three separate 
runs.  
Assay LODs, LLOQs and LOQs were determined using drug free blood spiked with the 
same decreasing concentrations of AEDs used to determine the instrument LODs and also 
analysed in duplicate for three separate runs using three different sources (donors) of blank 
blood. Mass-Hunter Workstation program was used to calculate the S/N ratio. 
3.2.6 Linearity 
One of the main purposes of developing this method was to evaluate the linearity with a 
wide range covering therapeutic and toxic concentrations. Calibration curves with a wide 
range would be important in toxic cases where laboratories are often required to repeat the 
analysis using a sample dilution procedure to obtain an accurate concentration.  This is 
because the calculated results are higher than the upper limit of quantification (ULOQ) of 
the method. Hence, linearity was assessed by analysing five separate calibration curves 
prepared by spiking blank blood with AEDs working solutions at 8 concentrations ranging 
from 5-300 mg/L for levetiracetam, vigabatrin and valproic acid; 0.05-10 mg/L for 
oxcarbazepine, retigabine and tigabine and; 0.5-50 mg/L for carbamazepine, 
carbamazepine epoxide, eslicarbazepine acetate, gabapentin, pregabalin, lacosamide and 
topiramate; 1-50 mg/L for lamotrigine, phenytoin, p-HPPH and zonisamide. All 
calibrations were prepared freshly in duplicate over 5 different days. Calibration curves 
were generated by plotting the peak area ratio versus the spiked analyte concentrations 
using the simplest least-squares linear regression model and Agilent Mass-Hunter 
Workstation-Quantitive software. A blank blood extract containing internal standard was 
run with each batch but not included in the calibration curve. The correlation coefficient 
(R
2
) was calculated. The R
2
 values should be greater than 0.99.  
3.2.7 Bias and Precision 
Bias (accuracy) describes the closeness of mean concentration obtained by the method to 
the true concentration of the analyte.  Precision is defined as the closeness of agreement 
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(degree of scatter) between a series of measurements obtained from multiple sampling of 
the same homogeneous samples under the prescribed conditions (251). 
Bias (accuracy) and precision were assessed by analysing replicates of spiked controls at 3 
different concentrations (low, medium and high). A calibration curve was prepared with 
each batch of QCs using the optimised method to calculate the concentrations.  Intra-day 
(within) precision and bias were calculated from 6 replicates per QC in one batch. Inter-
day precision and bias were determined over 5 different runs. Their values were calculated 
using the following equations (242):  
𝑀𝑒𝑎𝑛 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛   ?̅? =
∑ 𝑥𝑖
𝑛⁄   
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 (𝑆𝐷) =  √
∑(𝑥 − ?̅?)2
𝑛 − 1⁄  
𝐵𝑖𝑎𝑠 (%) =  
?̅?
𝑋 
× 100  (𝑋: 𝑛𝑜𝑚𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛) 
𝐼𝑛𝑡𝑟𝑎 − 𝑑𝑎𝑦 𝑟𝑢𝑛 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%𝐶𝑉) =  
𝑆𝐷 𝑓𝑜𝑟 𝑠𝑖𝑛𝑔𝑙𝑒 𝑟𝑢𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
?̅? 𝑓𝑜𝑟 𝑠𝑖𝑛𝑔𝑙𝑒 𝑟𝑢𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
 × 100 
𝐼𝑛𝑡𝑒𝑟 − 𝑑𝑎𝑦 𝑟𝑢𝑛 (%𝐶𝑉) =  
𝑆𝐷 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑣𝑒𝑟 5 𝑟𝑢𝑛𝑠 
?̅? 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 × 100 
Bias was expressed as a percentage of the nominal concentration. The mean value should 
not deviate by more than 15% from the true value (±15%). Precision was established by 
the percentage of the co-efficient of variation (%CV). The results are considered 
acceptable if %CV is less than 15%. 
3.2.8 Recoveries and Matrix Effects 
Recoveries and matrix effects were evaluated for all the drugs and the internal standards 
using the post-extraction addition approach (see 2.2.12.4). Eleven different blank blood 
sources (donors) were spiked with either low or high QC and analysed in triplicate. Matrix 
effect was represented by the Matrix Factor (MF). Recovery was calculated by dividing the 
mean peak area of extracted standards (pre-extraction spike) by the mean peak area of the 
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extracted pooled matrix spiked with standards after extraction at the same concentration 
(post-extraction spike). Matrix effect is considered acceptable if the Matrix Factor was 
within a range of 1± 0.25. 
3.2.9 Carryover 
Carryover was tested by injecting three blank controls after two injections of a high 
concentration (QC4) double the upper limit of quantification in the calibration curve (500 
mg/L for levetiracetam, vigabatrin and valproic acid; 20 mg/L for oxcarbazepine, 
retigabine and tigabine and 100 mg/L for the rest of the AEDs). Carryover was evaluated 
by examining the chromatograms visually.  
3.2.10 Stability 
As part of method validation requirements, drug stability has to be investigated under 
preparation and analysis conditions in order to ensure accurate quantitative results. Storage 
conditions evaluated were:  
a) Bench top stability at room temperature (18±2 °C) for 24 hours. 
b) In process (auto sampler) stability (~ 20ºC) for 24 hours. 
c) Stability after 3 freeze-thaw cycles at -20±2 ºC. Samples were left to defrost at 
room temperature and analysed in triplicate after each freeze-thaw cycle. 
Drug-free blood was spiked with the 17 AEDs at 2 concentrations (low and high). Freshly 
spiked samples were initially extracted and analysed in triplicate to establish time zero 
concentrations. For each concentration, 100 µL aliquots were placed into labelled 1.5 mL 
Eppendorf tubes and stored under previous conditions until analysis. Subsequently, 
samples were extracted and processed in triplicate along with freshly spiked calibration 
standards and analysed using the regression equation obtained. The calculated 
concentrations were compared with the average time zero concentrations. Recovery was 
calculated by dividing the calculated concentration after 24 hours by the concentration at 
time zero and multiplied by 100. The analyte was considered stable if the concentration 
was within ± 10% of the time zero concentration.  
Chapter 3  116 
 
3.2.11 Dilution Integration 
Since many forensic cases may involve overdose or lethal concentrations of drugs (higher 
than ULOQ), dilution integrity was evaluated. Dilution integrity was assessed by spiking 
blank whole blood with a concentration (QC4) higher than the ULOQ (500 mg/L for 
levetiracetam, vigabatrin and valproic acid; 20 mg/L for oxcarbazepine, retigabine and 
tigabine; and 100 mg/L for the rest AEDs) and diluting this with blank blood at dilution 
factors of 1:2, 1:5 and 1:10. Four replicates per dilution factor were prepared and processed 
along with freshly spiked calibration standards and analysed by back calculation using the 
calculated regression equation. Dilution of samples should not affect the accuracy and 
precision. The integrity of the samples was considered to be maintained if the mean 
concentration‎obtained‎was‎within ± 15%‎of‎nominal‎values‎and‎%CVs ≤ 15%‎at‎all‎diluted‎
concentrations. 
3.3 Results and Discussion  
3.3.1 Selectivity and Specificity 
It was obvious that there were no endogenous interferences as illustrated in Figure ‎3-1 (a-
e). None of the AEDs or the internal standards showed any interference at the peak area of 
the other drugs included in the method. The method was selective and specific for AEDs of 
interest and their internal standards. The gabapentin chromatogram exhibited a peak at a 
retention time of 2.4 minutes which does not interfere with gabapentin which has a 
retention time of 3.3 minutes and these are completely resolved. The contamination source 
of this peak could not be determined. It may have come from plasticisers and plastic 
materials such as phthalate esters and polypropylene glycols which have been reported as 
interferents in methods using positive ionisation mode in mass spectrometry or it could be 
a matrix component such as phospholipids (256). Plasticisers and other plastic materials 
may be present as a result of using plastic consumables during the sample preparation 
process or may be released from the plastic bank blood used by the hospital (257). 
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Figure  3-1 (a-e): The Chromatograms of 11 Drug Free Whole Blood Sources Compared to AED Standard Mix at 10 mg/L.  
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Figure 3-1(a-e): The Chromatograms of 11 Drug Free Whole Blood Sources Compared to AED Standard Mix at 10 mg/L (Continued…). 
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Figure 3-1(a-e): The Chromatograms of 11 Drug Free Whole Blood Sources Compared to AED Standard Mix at 10 mg/L (Continued…). 
  
C
h
ap
ter 3
 
 
1
2
0
 
 
(d) 
 
Figure 3-1(a-e): The Chromatograms of 11 Drug Free Whole Blood Sources Compared to AED Standard Mix at 10 mg/L (Continued…). 
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Figure 3-1 (a-e): The Chromatograms of 11 Drug Free Whole Blood Sources Compared to AED Standard Mix at 10 mg/L (Continued…).
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3.3.2 LOD and LOQ 
Instrument and Assay LOD, LLOQ and LOQ results of 17 AEDs are presented in Table ‎3-
1. Instrument and assay LOD results were almost identical for most AEDs except valproic 
acid, vigabatrin, eslicarbazepine acetate and carbamazepine which showed lower 
instrument LODs (1 and 0.1 mg/L respectively) compared to their assay LOD (2.5 and 
0.25 mg/L respectively) which may be due to matrix effects. The LOQ in the majority of 
cases was chosen to be the LLOQ.  Only for 6 out of 17 drugs was it chosen to be higher 
than the LLOQ as the level of sensitivity achieved was not required. 
Table  3-1: Instrument and Assay LOD, LLOQ and LOQ of 17 AEDs in Whole Blood. 
AEDs Instrument LOD Assay LOD LLOQ LOQ 
CBZ 0.1 0.25 0.5 0.5 
CBZO 0.05 0.05 0.25 0.5 
ESL 0.1 0.25 0.5 0.5 
GBP 0.1 0.1 0.25 0.5 
LAC 0.05 0.05 0.25 0.5 
LEV 0.1 0.1 0.5 5.0 
LTG 0.25 0.25 0.5 0.5 
OXC 0.025 0.025 0.05 0.05 
PGR 0.25 0.25 0.5 0.5 
PHT 0.5 0.5 1.0 1.0 
p-HPPH 0.5 0.5 1.0 1.0 
RTG 0.025 0.025 0.05 0.05 
TIG 0.01 0.01 0.025 0.05 
TPR 0.25 0.25 0.5 0.5 
VIG 0.1 0.5 1.0 5.0 
VPA 1 2.5 5.0 5.0 
ZNS 0.5 0.5 1.0 1.0 
 
3.3.3 Linearity 
The calibration curves were linear over the wide range of concentrations tested with a R² 
greater than 0.998. Therapeutic levels, calibration model, internal standards, and linearity 
represented by R
2
 are summarized in Table ‎3-2.  
Using a linear regression equation weighted 1/X (X represents concentration); all the 
calibration lines passed all the acceptance criteria except lamotrigine and retigabine. With 
lamotrigine, quadratic regression was used for curve fitting with 1/x as the weighting factor 
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and R
2 
was greater than 0.996 in the 5 validation batches with good accuracy and precision 
results. Although a quadratic curve is not preferred in routine work, it has been reported to 
have been used with lamotrigine in the literature (258, 259) because lamotrigine did not 
show a good linearity at concentrations higher than 10 mg/L. However, the lamotrigine 
therapeutic range can reach 19 mg/L in cases of chronic treatment. This means more 
dilution steps and laboratory work, more consumables and time.  
Table  3-2: Therapeutic Concentrations, Calibration Model and Linearity of 17 AEDs in Whole 
Blood. 
AEDs 
Therapeutic level Calibration Range Calibration Internal 
Standard 
Whole blood 
(mg/L) (mg/L) Model R² (n=5) 
CBZ 1.7-15 0.5-50 Linear CBZ-DiOH 0.9997 
CBZO 0.5-2.0 0.5-50 Linear CBZ-DiOH 0.999 
ESL 10.0-26.0 0.5-50 Linear CBZ-DiOH 0.9995 
GBP 5.0-9.0 0.5-50 Linear GBP-D10 0.999 
LAC 2.5-14.0 0.5-50 Linear GBP-D10 0.998 
LEV 10.0-40.0 5.0-300 Linear GBP-D10 0.998 
LTG 2.3-5.6 1.0-50 Quadratic GBP-D10 0.996 
OXC 0.05-1.2 0.05-10 Linear CBZ-DiOH 0.998 
PGR 1.0-5.0 0.5-50 Linear GBP-D10 0.999 
PHT 7.0-20.0 1.0-50 Linear TUB 0.999 
p-HPPH 1.0-40.0 1.0-50 Linear TUB 0.999 
RTG 0.51-1.85 0.05-10 n/a CBZ-DiOH n/a 
TIG 0.03-1 0.05-10 Linear CBZ-DiOH 0.999 
TPR 2.4-27 0.5-50 Linear TUB 0.9997 
VIG 18-77 5.0-300 Linear GBP-D10 0.998 
VPA 50-100 5.0-300 Linear TUB 0.9995 
ZNS 1.0-50 1.0-50 Linear TUB 0.999 
 
Regarding retigabine, this drug did not give a consistent response during method 
development and validation. It is the last to elute at 15 minutes whereas the method time is 
17 minutes. It was noticeable that any slight change in column conditions or gradient 
program would give poor reproducibility. The reason behind this response fluctuation was 
investigated by checking the gradient system, the mobile phase flow rate and column 
conditions in addition to the LC binary pump. There was a fungi growing issue in the 
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mobile phase due to an unsuitable water source which increased the pump pressure. It was 
thought that this problem affected retigabine elution because it elutes at the end of the run. 
However, after trying to adjust all these parameters, none of them improved the peak 
response or consistency. Hence, the retigabine calibration curve and validation results were 
not acceptable. As a result, retigabine analysis was considered qualitative only in this 
method. Linearity graphs generated using Mass-Hunter quantitative program are illustrated 
in Figure ‎3-2. 
 
Figure  3-2: Linearity Graphs of 17 AEDs Generated Using Mass Hunter Quantitative 
Analysis. 
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Figure 3-2: Linearity Graphs of 17 AEDs Generated Using Mass Hunter Quantitative Analysis 
(Continued…). 
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3.3.4 Bias and Precision 
Accuracy results for 16 AEDs (except retigabine) are presented in Table ‎3-3. The accuracy 
values were within the acceptable range of ± 15% of the nominal concentrations. The intra-
day accuracy was from 92.7 - 103.4%. The inter-day accuracy ranged from 92.7-108.7%. 
Both intra- and inter-day precision values were acceptable and less than 15%. Precision 
results of 16 AEDs (except retigabine) are showed in Table ‎3-4. The intra-day precision 
values were less than 9%. The inter-day precision values were less than 12.1%.  
Table  3-3: Intra- and Inter-Day Accuracy Results of 16 AEDs. 
AEDs 
Accuracy (n=30) 
Intra-day (%) Inter-day (%) 
 
Low Medium High Low Medium High 
CBZ 100.8 99.2 96.8 100.8 99.2 96.8 
CBZO 95.9 101.5 102.5 95.8 101.5 102.5 
ESL 97.5 101.9 98.8 97.5 101.9 98.8 
GBP 99.9 102.7 100.6 102.4 102.7 100.6 
LAC 92.7 102.7 99.7 92.7 102.7 99.7 
LEV 95.1 99.3 101.3 95.1 99.3 101.3 
LTG 101.9 95.9 100.3 101.9 103.3 100.3 
OXC 102.7 97.5 103.1 102.7 97.5 103.1 
PGR 98.3 101.4 102.1 98.3 101.4 102.1 
PHT 101.7 98.2 101.1 101.7 98.2 101.1 
p-HPPH 101.8 99.3 100.7 101.8 99.4 100.7 
TIG 100.6 100.1 97.5 100.6 100.1 97.5 
TPR 98.0 103.4 102.0 98.0 103.4 102.0 
VIG n/a 101.5 102.1 n/a 101.5 102.1 
VPA 100.4 100.5 100.5 100.4 100.5 100.5 
ZNS 94.3 98.2 100.3 94.3 98.2 100.3 
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Table  3-4: Intra- and Inter-Day Precision Results of 16 AEDs. 
AEDs 
Precision (n=30) 
Intra-day (%) Inter-day (%) 
 
Low Medium High Low Medium High 
CBZ 2.6 2.8 1.6 9.2 3.8 4.6 
CBZO 4.9 2.3 1.5 4.3 3.6 4.0 
ESL 2.1 2.6 1.6 3.5 6.9 2.9 
GBP 4.3 2.4 2.9 3.1 4.3 4.1 
LAC 4.4 3.1 3.6 11.0 6.3 5.5 
LEV 3.1 3.5 4.1 12.1 6.9 4.5 
LTG 7.8 4.3 4.8 11.1 9.7 11.6 
OXC 2.6 2.0 2.0 4.4 2.0 3.0 
PGR 4.2 2.3 2.5 5.4 2.6 3.0 
PHT 6.1 1.3 0.7 7.6 2.0 0.3 
p-HPPH 8.4 2.8 2.2 8.1 8.5 4.3 
TIG 5.7 2.4 2.0 6.8 4.8 3.9 
TPR 2.7 1.7 1.7 5.5 4.0 4.7 
VIG n/a 4.3 2.8 n/a 5.8 4.0 
VPA 1.2 0.7 0.4 4.8 0.3 0.4 
ZNS 5.9 3.7 2.7 13.0 3.7 4.0 
 
3.3.5 Matrix Effects and Recoveries 
Table ‎3-5 shows the matrix factor and recovery results of 2 QCs (low and high) using 11 
different sources (donors) of whole blood. Matrix factor values were within the acceptable 
range for all the drugs with standard deviations less than 25% except retigabine. Retigabine 
exhibited unacceptable matrix suppression with matrix factor (MF) of 0.33. Recovery was 
greater than 95% for all other AEDs at low, medium and high concentrations. It was 
unclear whether retigabine MF and recovery values resulted from actual matrix 
suppression or poor analysis response. 
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Table  3-5: Recovery and Matrix Factor Values for 17 AEDs Using Low and High QCs and 11 
Different Whole Blood Sources (n=6 per QC per Matrix). 
AEDs 
QC1 QC2 
Recovery (%) Matrix Factor Recovery (%) Matrix Factor 
CBZ 106±3.0 1.05±0.07 104±3.1 1.00±0.02 
CBZO 105±3.2 1.05±0.05 104±1.6 1.01±0.02 
ESL 107±2.7 1.07±0.05 106±1.9 1.04±0.04 
GBP 109±3.6 0.99±0.08 106±2.6 1.01±0.03 
LAC 108±2.5 1.06±0.07 107±2.3 1.00±0.02 
LEV 109±4.0 1.08±0.06 109±5.9 0.97±0.02 
LTG 101±22.7 1.14±0.22 98±12.6 1.08±0.16 
OXC 110±6.5 1.00±0.07 108±7.3 0.91±0.03 
PGR 100±8.2 1.11±0.08 107±4.8 1.04±0.03 
PHT 95±9.2 1.09±0.08 106±7.1 0.99±0.05 
p-HPPH 96±7.1 1.04±0.09 106±9.7 0.97±0.06 
RTG n/a n/a 33±24.7 0.33±0.08 
TIG 103±18.2 0.93±0.10 101±8.2 1.01±0.02 
TPR 107±5.0 1.10±0.07 108±6.3 1.00±0.03 
VIG 105±3.3 0.75±0.07 111±7.3 0.83±0.02 
VPA 106±8.4 1.05±0.10 108±4.4 1.00±0.04 
ZNS 107±2.5 1.05±0.08 105±4.7 0.99±0.02 
 
3.3.6 Carryover 
No carry over was observed in the blank samples after two consequent injections of the 
highest standard (QC4) as illustrated in Figure ‎3-3 using the total ion chromatogram graph 
and Figure ‎3-4 which shows the detailed chromatograms of 17 AEDs and the blank sample 
injected afterward in DMRM mode. 
 
Figure  3-3: Carryover Results - Total Ion Chromatogram of High Concentration (QC4) Versus 
Blank Mobile Phase.   
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Figure  3-4: Carryover Results- DMRM Chromatogram of High Concentration (QC4) Versus Blank Mobile Phase.
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3.3.7 Stability  
Bench top stability: During the sample preparation process, the stability study showed that 
all the drugs were stable in the whole blood at room temperature (approximately 18ºC) for 
up to 24 hours except eslicarbazepine acetate, oxcarbazepine and retigabine which showed 
a loss of approximately 25 to 46% of their nominal concentration. Retigabine is known to 
be oxygen and light sensitive, as well as acid and heat labile and not stable in methanolic 
solutions as it turns pink as an indication of degradation (260). Oxcarbazepine also was 
described as being a thermo-labile compound (261). Eslicarbazepine acetate was reported 
to degrade significantly in acid, base, neutral hydrolysis conditions as well (262). 
Lamotrigine and levetiracetam stability data indicates a slight increase in the concentration 
of some drugs over 24 hour period. This indicates practically no decomposition of AEDs 
(Table ‎3-6).  
Table  3-6: Benchtop Stability of 17 AEDs for 24 Hours. 
AEDs 
Low (n=3) High (n=3) 
Measured Conc. (mg/L) Recovery Measured Conc. (mg/L) Recovery 
T=0* T=24 % T=0* T=24 % 
CBZ 2.3 2.2 96 20.0 19.1 96 
CBZO 17.0 16.4 96 28.0 28.1 100 
ESL 3.0 0.8 27 21.0 11.3 54 
GBP 2.3 2.3 100 20.0 18.5 93 
LAC 13.0 13.3 102 23.0 23.9 104 
LEV 115.0 132.2 115 185.0 203.0 110 
LTG 1.7 2.0 117 13.0 15.2 117 
OXC 4.3 3.0 70 8.0 5.9 74 
PGR 2.0 1.9 95 16.0 15.5 97 
PHT 2.1 2.1 100 21.0 20.9 100 
p-HPPH 14.5 14.8 102 29.5 29.6 100 
RTG 2.0 1.8 78 9.5 7.3 76 
TIG 1.0 0.9 91 4.0 3.8 95 
TPR 14.0 15.7 112 28.0 30.0 109 
VIG 105.0 105.9 101 181.7 186.3 103 
VPA 92.0 92.3 100 182.0 182.2 100 
ZNS 9.0 9.5 106 17.0 17.5 102 
*T refers to time in Hours. 
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In process stability: The extracted samples were stable in the autosampler (approximately 
20ºC) for up to 24 hours. Although eslicarbazepine acetate, oxcarbazepine and retigabine 
are not stable in whole blood, their stability was acceptable after extraction and 
reconstitution in 13% methanol in water. Summary of the results are presented in Table ‎3-
7. 
Table  3-7: Autosampler Stability of 17 AEDs for 24 Hours. 
AEDs 
Low (n=3) High (n=3) 
Measured Conc. (mg/L) Recovery Measured Conc. (mg/L) Recovery 
T=0
* 
T=24 % T=0 T=24 % 
CBZ 2.0 2.4 102 19.2 18.2 95 
CBZO 15.7 16.0 102 27.4 28.7 105 
ESL 2.9 3.1 108 20.9 20.7 99 
GBP 2.5 2.6 104 21.9 21.8 99 
LAC 13.9 13.8 99 23.2 23.6 101 
LEV 112.9 115.6 102 170.0 187.0 110 
LTG 1.7 1.6 94 12.8 14.0 109 
OXC 4.3 4.1 96 8.0 8.1 101 
PGR 1.6 1.9 116 15.8 16.4 104 
PHT 2.5 2.5 100 19.9 20.5 103 
p-HPPH 1.6 1.4 91 16.2 16.1 99 
RTG n/a n/a n/a n/a n/a n/a 
TIG 1.1 1.0 89 4.5 4.0 88 
TPR 14.3 14.4 100 27.1 28.3 104 
VIG 105.0 126.1 120 181.7 202.5 111 
VPA 92.2 95.0 103 182.8 182.3 100 
ZNS 9.1 9.2 101 16.4 17.3 105 
* T refers to time in Hours. 
 
Freeze-thaw cycles stability: All AEDs including oxcarbazepine and retigabine were stable 
after 3 freeze-thaw cycles at - 20ºC (Table ‎3-8). Eslicarbazepine acetate exhibited better 
stability in whole blood under freezing conditions which increased from 40 % for bench 
top stability to approximately 75 % in case of freeze-thaw stability. 
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Table  3-8: Freeze-Thaw Stability of 17 AEDs.  
AEDs 
Low (n=3) High (n=3) 
Measured Conc. (mg/L) Recovery 
 
% 
Measured Conc. (mg/L) Recovery 
 
% T=0
* 
C1
** 
C2 C3 T=0 C1 C2 C3 
CBZ 2.3 2.3 2.0 2.5 109 20.0 19.5 18.4 20.1 101 
CBZO 17.0 16.2 16.2 17.8 105 28.0 27.1 27.7 27.8 99 
ESL 3.0 3.0 3.0 2.4 80 21.0 22.2 21.4 15.1 72 
GBP 2.3 2.3 2.6 2.3 100 23.0 19.1 21.0 23.2 101 
LAC 13.0 13.6 13.8 15.1 116 23.0 24.6 24.1 23.6 103 
LEV 115.0 131.0 112.1 139.3 121 185.0 204.7 190.7 199.8 108 
LTG 1.7 2.1 1.8 1.6 94 13.0 16.1 13.6 16.2 125 
OXC 4.3 4.4 4.1 4.7 108 8.0 8.8 8.2 7.7 96 
PGR 1.9 2.0 1.8 1.7 89 16.0 15.8 15.9 17.1 107 
PHT 2.1 2.2 2.5 1.9 90 21.0 20.6 20.5 21.5 102 
p-HPPH 1.2 1.1 1.4 1.3 108 14.5 14.6 16.9 14.1 97 
RTG n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
TIG 1.0 1.0 1.1 1.0 98 4.0 4.1 4.0 4.2 106 
TPR 14.0 15.4 14.3 14.7 105 28.0 30.2 29.2 26.5 95 
VIG 120.0 108.6 114.5 127.0 106 195.0 179.7 192.7 190.6 98 
VPA 92.0 93.2 93.1 100.3 109 182.0 181.7 184.0 180.5 99 
ZNS 9.0 9.4 8.8 10.6 118 17.0 18.2 17.9 17.5 103 
* T=0: concentration measured at time zero.  ** C refers to Freeze-thaw cycle number. 
 
3.3.8 Dilution Integrity 
The dilution integrity study showed the accuracy of two, four and ten times diluted 
samples to be within ± 15% of the nominal concentration and the precision was less than 
11% (Table ‎3-9).  These results conclude that the dilution of the concentrated whole blood 
sample up to ten times maintains integrity of AEDs. 
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Table  3-9: Dilution Integrity at 1:2, 1:5 and 1:10 Dilution Factors. 
AEDs 
Actual 
Conc. 
(mg/L) 
QC4 (1in2 dilution, n=4) QC4 (1in5 dilution, n=4) QC4 (1in10 dilution, n=4) 
Mean Measured 
Conc. (mg/L) 
Accuracy 
(%) 
Precision 
(%CV) 
Mean Measured 
Conc. (mg/L) 
Accuracy 
(%) 
Precision 
(%CV) 
Mean Measured 
Conc. (mg/L) 
Accuracy 
(%) 
Precision 
(%CV) 
CBZ 100 82.1±3.4 82 4.1 98.1±2.4 98 2.4 117.6±0.8 115 0.7 
CBZO 100 109.2±0.5 109 0.4 103.3±3.2 103 3.1 93.0±2.8 93 3.0 
ESL 100 82.8±0.4 83 0.4 98.6±1.4 99 1.4 112.1±0.9 112 0.8 
GBP 100 99.1±2.8 99 2.8 108±0.2 108 0.2 110.0±0.0 110 0.0 
LAC 100 114.1±1.2 114 1.1 90.8±7.4 91 8.2 97.1±2.0 97 2.1 
LEV 500 423.2±9.5 85 2.2 497.0±4.8 99 1.0 587.5±309 115 0.7 
LTG 100 82.6±6.4 83 7.8 114.6±3.2 115 2.8 113.0±1.4 113 1.3 
OXC 20 18.2±0.1 91 0.4 18.7±0.5 93 2.7 19.0±0.6 95 3.4 
PGR 100 85±7.1 85 8.3 97.5±3.5 98 3.6 95.3±0.2 95 0.2 
PHT 100 92.7±3.5 93 3.8 108.0±2.8 108 2.6 100.3±0.5 100 0.5 
p-HPPH 100 88.2±0.1 88 0.1 88.6±0.4 89 0.4 95.3±1.2 95 1.2 
RTG 20 n/a n/a n/a n/a n/a n/a n/a n/a n/a 
TIG 20 19.4±0.3 97 1.7 22.8±0.3 114 1.2 19.2±2.1 96 11.0 
TPR 100 91.9±1 92 1.1 97.7±2.1 98 2.1 112.5±3.5 113 3.1 
VIG 500 434.3±0.5 88 0.1 510.0±21.2 102 4.2 575±35.4 35 6.1 
VPA 500 488.3±7.1 98 1.5 551.9±19.9 110 3.6 558.3±58.9 112 10.6 
ZNS 100 114±1.4 114 1.2 81.9±2.7 82 3.3 90.7±4.0 91 4.4 
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3.4 Conclusion  
A simple, accurate and simultaneous analysis of 15 AEDs and 2 metabolites using 
LC/MS/MS triple quadruple was successfully developed and validated according to 
standard practices for method validation in forensic toxicology (SWGTOX) (242). The 
method is quantitative for 16 AEDs and qualitative for retigabine which did not pass the 
quantitative validation criteria for undetermined reasons. 
The method developed for a small sample volume (100µL) used simple protein 
precipitation with methanol and achieved recoveries greater than 95% for all drugs (except 
retigabine, 33%) with acceptable matrix effect (within ± 25%). Good linearity, precision 
and accuracy were obtained for all drugs with R
2 
> 0.99. Lamotrigine was successfully 
validated using quadratic curve. 
In spite of the high cost of this method at the development stage, on a long-term basis the 
method would save on analyst time, cost of consumables and effort as it only requires a 
standard mix for the analysis of the 17 compounds. Rather than using many different 
methods to test for these substances individually, the same procedure can be used. It may 
also reveal the presence of drugs that have not been mentioned in the medical history either 
prescribed or misused. 
Simultaneous methods can be a great advantage for routine laboratory work where 
consumables, time and effort saving are critical and a prerequisite to achieve targets and 
meet deadlines. 
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4 Short Term Stability Study of AEDs in Whole 
Blood  
4.1 Introduction 
Following method validation for the analysis of 15 most encountered antiepileptic drugs 
and two major metabolites (detailed in Chapter 3), the method was used to investigate the 
stability of these drugs (except retigabine) in whole blood under different storage 
conditions.  
Stability studies are of great importance in forensic cases where it takes up to a few weeks 
between autopsy, sampling, drug screening and finally confirmation analysis. In some 
cases, quantitation analysis may not be requested until the case goes to court and is hence 
performed many weeks or months after the sample has been collected. Drug stability may 
lead to false negative results if the drug is not stable for example olanzapine where a loss 
of almost 100% at all storage temperatures was observed (263) or false positive results for 
example for GHB where higher concentration were reported in postmortem blood 
compared to freshly collected ones due to the in-vitro production of GHB during the 
storage time (264). Thus, knowledge of in-vitro drug stability in biological samples under 
different conditions is a prerequisite for the interpretation of the toxicological findings and 
to explain any discrepancies found between the initial quantitative results and those 
obtained in a second requested analysis (265). 
A number of antiepileptic drug stability studies in serum/plasma, pharmaceutical bulk or 
blood collection devices have also been published (262, 266, 267). However, reports 
specifically addressing the stability of antiepileptic drugs in whole blood are relatively 
scarce compared with those for drugs of abuse, and if there are any published studies, they 
discuss the old generation of antiepileptic drugs such as carbamazepine, phenytoin and 
valproic acid (268, 269). Stability experiments for these drugs are often carried out as part 
of the bioanalytical method development and validation, and such data is very difficult to 
retrieve by a systematic literature search, unless the stability experiments are mentioned in 
the title or the abstract (270-273). 
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This would appear to be the first study to specifically address the stability for the new 
generation of antiepileptic drugs of interest in whole blood under different storage 
conditions.  
4.2 Methodology 
A short- term stability study was conducted using 100 mL drug free blood spiked with 16 
AEDs at 3 different concentrations; 3, 20 and 40 mg/L for group 1; 1, 4 and 8 mg/L for 
group 2; and 20, 120 and 200 mg/L for group 3 (see 2.2.2.2 and 2.2.2.3 for QCs and 
solution preparation). Retigabine was excluded from this stability study due to its 
inconsistent response during method development and validation. 
Freshly spiked QCs were initially extracted and analysed in triplicate and injected in 
duplicate using the validated method to establish time zero concentrations (detailed in 
3.2.10). For each concentration, 100 µL aliquots were placed into labelled 1.5 mL 
Eppendorf tubes. The aliquots were stored under three different conditions; at room 
temperature (RT)  about 18 ± 2 ºC, in the fridge at 4 ± 2 ºC, and in the freezer at -20 ± 2 
ºC. In addition, an autosampler stability study was carried out over a 168 hour period. 
Autosampler stability (~ 20 ºC) was evaluated by re-injecting extracted QCs at low and 
high concentrations; 3 and 40 mg/L for group 1; 1 and 8 mg/L for group 2; and 20 and 200 
mg/L for group 3,  after 24, 48, 72, 120 and 168 hours. Samples were stored on the 
autosampler over the study duration. In general, autosampler or in process stability was 
evaluated over the period of time required to analyse the samples on the instrument which 
is 20 minutes per sample in this case and can go up to 10 hours per batch. However, the 
stability study was extended up to 168 hours (7 days) in order to assess the stability of the 
processed samples. This is particularly significant when there is instrument down time and 
samples cannot be analysed directly after preparation or when there is a very long batch 
running. Assuming this study shows that the drugs are stable, then this would save the time 
needed to re-prepare the samples, save on consumables and solvents, and allow the same 
samples to be reinjected if needed with high accuracy. 
Bench top stability at room temperature (18 ± 2) was investigated for 4 weeks. QCs were 
extracted in triplicate and injected in duplicate (n=6) on day 0, 1, 3, 7, 13, 23 and 30. 
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Fridge stability was evaluated for 10 weeks and freezer stability for 12 weeks. Samples 
were analysed in triplicate and injected in duplicate at 3 different concentrations on the 
first, third and seventh day during the first week, then once a week. 
The concentrations of the analytes were calculated using freshly prepared calibration 
curves included in each batch. The values obtained were compared with the average time 
zero concentrations and the recovery of the remaining concentrations was calculated by 
dividing the final concentration obtained at the end of the stability study by the 
concentration at time zero and multiplying by 100.  
4.3 Results and Discussion 
As mentioned previously in 3.3.4, all drugs included in this study were proven to fulfil the 
accuracy acceptance criteria of being within 10 % of the target value during method 
validation with the exception of eslicarbazepine acetate and oxcarbazepine which exhibited 
a loss of about 40 % after 24 hours at room temperature. The stability results obtained in 
this study for AEDs in whole blood were comparable to their stability in serum/plasma and 
agreed with what has been published in the literature (262, 266-273). 
4.3.1 Autosampler Stability 
All AEDs exhibited good stability on the autosampler at 20ºC ± 2 with a recovery higher 
than 93% except tigabine and eslicarbazepine acetate which had recoveries of 85% and 
87% respectively at the low concentration (Table ‎4-1). A slight increase in the 
concentration for some AEDs was observed such as carbamazepine epoxide (116% at low 
concentration and 124% at high concentration), carbamazepine (117% at high 
concentration), vigabatrin (123% at high concentration), lamotrigine (131% at low 
concentration and 111% at high concentration) and phenytoin (116% at low concentration). 
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Table  4-1: Stability Results of 16 AEDs in Whole Blood on The Autosampler Over 168 Hours at 2 Different Concentrations; 3 and 40 mg/L for Group 1; 4 and 8 
mg/L for Group 2; and 20 and 200 mg/L for Group 3. 
AED 
QC1 (mg/L) QC2 (mg/L) 
T*=0 T=24 T=72 T=120 T=168 R%** T=0 T=24 T=72 T=120 T=168 R% 
CBZ 19.2 18.2 22.6 21.9 20.9 109 33.3 33.4 36.1 35.4 38.9 117 
CBZO 15.7 16.0 20.1 19.3 18.2 116 27.4 28.7 30.6 29.9 33.9 124 
ESL 20.9 20.7 24.2 23.2 18.1 87 37.0 37.9 37.3 37.4 37.4 101 
GBP 22.0 21.8 22.1 22.0 21.4 98 41.0 41.0 43.0 40.6 40.7 99 
LAC 13.9 13.8 17.4 15.3 14.1 101 23.2 23.6 22.9 25.5 24.7 106 
LEV 112.9 115.6 139.7 125.8 115.0 102 170.1 186.6 208.2 196.2 185.5 109 
LTG 12.8 14.0 17.3 13.6 16.7 131 19.1 21.0 18.2 20.6 21.2 111 
OXC 4.3 4.1 5.3 4.2 4.0 91 8.0 8.1 8.0 8.6 7.9 99 
PGR 15.8 16.4 15.9 17.5 17.0 108 30.1 30.9 31.8 32.2 32.3 107 
PHT 20.0 20.5 26.9 21.2 23.3 116 40.4 40.5 42.9 44.3 42.0 104 
HPPH 16.2 16.1 16.1 13.9 15.8 97 33.0 31.6 30.4 30.2 33.2 101 
TIG 4.5 3.9 4.0 4.8 3.8 85 8.3 7.4 7.6 8.9 7.7 93 
TPR 14.3 14.4 16.8 15.1 14.0 98 27.1 28.2 30.2 29.9 27.3 101 
VIG 115.0 126.6 115.0 129.6 125.0 109 181.7 202.5 195.4 223.3 223.0 123 
VPA 92.2 94.9 103.0 93.4 97.6 106 182.8 182.3 185.3 183.3 191.3 105 
ZNS 9.1 9.2 9.1 9.2 8.9 98 16.4 17.3 18.0 16.2 16.9 103 
* T represents time in hours. 
** R%= Recovery or Remaining concentration after 168 hours. 
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4.3.2 Bench Top, Fridge and Freezer Stability 
All AEDs exhibited good stability under various storage conditions during the investigated 
time frame. The recoveries of the remaining concentrations were within 20% accuracy of 
nominated concentrations for most drugs except eslicarbazepine acetate and 
oxcarbazepine. 
Eslicarbazepine acetate instability at room temperature was reported earlier in the literature 
(207, 262). It is a prodrug which rapidly metabolises in the body to eslicarbazepine, R-
licarbazepine and oxcarbazepine (Figure ‎4-1).  
 
Figure  4-1: Eslicarbazepine Acetate and its Metabolites Structures. 
 
Licarbazepine was tested for in this study as a racemic mix and the data is presented in 
Figure ‎4-2. By the end of the first week at room temperature eslicarbazepine acetate 
completely degraded (decreased from 8 mg/L to 0 mg/L) while the licarbazepine 
concentration increased from 0 to 5.6 mg/L at the end of the 4 week study duration. 
Although eslicarbazepine is metabolised to oxcarbazepine as well, no formation of 
oxcarbazepine was detected over the 4 week period.  
 
Figure  4-2: Eslicarbazepine Acetate and Licarbazepine Concentration Changes Over 4 
Weeks at Room Temperature. 
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Similarly, oxcarbazepine results exhibited a quick degradation and the results were 
negative after 3 days storage at room temperature (Figure ‎4-3). Although, oxcarbazepine is 
metabolized to licarbazepine, this metabolite was not investigated in this study. By the end 
of the 10 week study duration, both eslicarbazepine acetate and oxcarbazepine exhibited a 
loss of more than 90 % of their nominated concentrations when stored at 4 
o
C. 
Nevertheless, they were stable at -20 °C (freezer stability) for 12 weeks. 
Valproic acid, vigabatrin and zonisamide also lost about 30 - 40 % of their nominal 
concentrations after 4 week bench top stability at room temperature but they were stable in 
the fridge for 10 weeks and in freezer for 12 weeks. 
Finally, results of calculated concentrations in each batch and the remaining concentrations 
presented as percentages at low, medium and high concentrations for bench top, fridge and 
freezer stabilities are detailed in Table ‎4-2 to Table ‎4-9. 
4.1 Conclusion 
This is the first stability study to specifically address the stability of 16 AEDs in whole 
blood. This study showed a good stability for antiepileptic drugs on the auto sampler for 
168 hours, on the bench top at ~20 ºC for 4 weeks, in the fridge at ~4 ºC for 10 weeks and 
in the freezer at -20 ± 2 ºC for 12 weeks except for eslicarbazepine acetate and 
oxcarbazepine which both lost almost 100 % of their concentrations after 3 days bench top 
stability and 7 days fridge stability although they were stable in the freezer over the study 
duration. 
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Figure  4-3: Bench Top, Fridge and Freezer Stability of AEDs in Whole Blood at 3 Different Concentrations; 3, 20 and 40 mg/L for Group 1; 1, 4 and 8 mg/L for 
Group 2; and 20, 120 and 200 mg/L for Group 3. 
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Figure 4-3: Bench Top, Fridge and Freezer Stability of AEDs in Whole Blood at 3 Different Concentrations; 3, 20 and 40 mg/L for Group 1; 1, 4 and 8 mg/L for 
Group 2; and 20, 120 and 200 mg/L for Group 3 (Continued…). 
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Figure 4-3: Bench Top, Fridge and Freezer Stability of AEDs in Whole Blood at 3 Different Concentrations; 3, 20 and 40 mg/L for Group 1; 1, 4 and 8 mg/L for 
Group 2; and 20, 120 and 200 mg/L for Group 3 (Continued…). 
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Figure 4-3: Bench Top, Fridge and Freezer Stability of AEDs in Whole Blood at 3 Different Concentrations; 3, 20 and 40 mg/L for Group 1; 1, 4 and 8 mg/L for 
Group 2; and 20, 120 and 200 mg/L for Group 3 (Continued…). 
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Table  4-2: Bench Top Stability Results of AEDs in Whole Blood at Low Concentrations (3 mg/L for Group 1; 1 mg/L for Group 2; and 20 mg/L for Group 3) Over 
4 Week Period. 
AED T=0 T=24 T=48 T=72 T=7d T=13 T=17 T=23 T=30 R% 
M
ea
n
 Q
C
1
 (
m
g
/L
, 
n
 =
6
) 
CBZ 10.0 ± 0.1 10.1 ± 0.3 11.9 ± 3.0 9.5 ± 0.8 11.1 ± 0.4 11.8 ± 1.1 13.8 ± 1.1 14.2 ± 0.6 12.0 ± 1.0 120 
CBZO 20.0 ± 0.3 20.2 ± 0.5 23.6 ± 4.5 19.5 ± 1.5 28.2 ± 0.6 22.2 ± 2.0 24.8 ± 1.7 24.5 ± 0.7 24.1 ± 1.3 121 
ESL 2.0 ± 0.0 1.5 ± 0.1 0.4 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0 
GBP 5.0 ± 0.1 4.7 ± 0.2 5.8 ± 1.5 5.5 ± 1.4 4.4 ± 0.3 4.3 ± 1.1 4.6 ± 0.7 4.0 ± 0.3 5.3 ± 0.5 106 
LAC 15.0 ± 0.2 13.7 ± 0.4 16.0 ± 3.9 13.0 ± 1.2 19.4 ± 0.6 13.3 ± 1.9 14.0 ± 1.1 13.8 ± 0.4 16.2 ± 0.6 108 
LEV 50.0 ± 0.7 45.4 ± 1.1 55.0 ± 12.8 49.0 ± 8.7 68.1 ± 2.4 50.8 ± 7.5 51.0 ± 3.7 43.8 ± 1.9 50.3 ± 1.6 101 
LTG 10.0 ± 0.2 9.2 ± 0.3 10.8 ± 2.9 8.8 ± 1.1 13.0 ± 0.1 10.5 ± 1.8 11.6 ± 1.1 10.4 ± 0.2 11.6 ± 0.2 116 
OXC 2.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.3 ± 0.1 0.3 ± 0.0 0.0 ± 0.0 0.3 ± 0.0 0.1 ± 0.1 7 
PGR 5.0 ± 0.1 4.7 ± 0.2 5.6 ± 1.4 5.2 ± 1.2 4.3 ± 0.3 3.3 ± 0.9 4.1 ± 0.6 3.9 ± 0.3 3.6 ± 1.6 72 
PHT 12.0 ± 0.5 10.9 ± 0.4 12.8 ± 2.4 11.3 ± 1.9 14.0 ± 0.4 10.9 ± 0.9 12.6 ± 1.4 10.5 ± 0.6 11.2 ± 0.6 93 
HPPH 12.0 ± 0.4 11.7 ± 0.6 13.7 ± 2.4 12.0 ± 1.1 15.6 ± 0.5 12.2 ± 1.7 13.5 ± 0.9 11.8 ± 1.3 13.0 ± 0.9 108 
TIG 2.0 ± 0.0 2.0 ± 0.1 1.6 ± 0.3 1.7 ± 0.0 2.1 ± 0.0 3.0 ± 0.2 1.7 ± 0.3 2.0 ± 0.1 2.3 ± 0.1 113 
TPR 15.0 ± 0.3 13.4 ± 0.5 15.3 ± 2.9 12.4 ± 0.9 15.1 ± 0.6 11.6 ± 1.1 13.3 ± 1.1 13.7 ± 0.7 14.8 ± 0.8 99 
VIG 115.0 ± 1.0 79.9 ± 1.6 84.8 ± 16.4 74.8 ± 4.3 85.5 ± 0.8 73.5 ± 21.6 50.6 ± 0.5 82.1 ± 2.0 51.5 ± 11.8 45 
VPA 70.0 ± 0.0 58.4 ± 0.9 64.6 ± 10.7 55.7 ± 6.5 66.8 ± 1.3 46.6 ± 3.3 56.0 ± 4.4 48.1 ± 1.1 56.1 ± 4.1 80 
ZNS 7.0 ± 0.2 6.2 ± 0.4 6.6 ± 1.5 5.7 ± 0.8 6.7 ± 0.1 4.9 ± 0.6 6.0 ± 0.4 4.6 ± 0.2 5.5 ± 0.5 78 
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Table  4-3: Bench Top Stability Results of AEDs in Whole Blood at High Concentrations (40 mg/L for Group 1; 8 mg/L for Group 2; and 200 mg/L for Group 3) 
Over 4 Week Period 
AED T=0 T=24 T=48 T=72 T=7d T=13 T=17 T=23 T=30 R% 
M
ea
n
 Q
C
2
 (
m
g
/L
, 
n
 =
6
) 
CBZ 40.0 ± 0.8 30.2 ± 0.7 35.7 ± 1.0 30.3 ± 1.0 45.9 ± 3.8 36.2 ± 1.4 42.1 ± 2.1 42.5 ± 1.5 47.3 ± 1.5 118 
CBZO 50.2 ± 0.9 45.6 ± 0.8 50.8 ± 0.8 44.8 ± 1.3 57.1 ± 2.3 49.4 ± 1.1 54.1 ± 2.5 51.0 ± 1.1 49.9 ± 3.3 99 
ESL 8.0 ± 0.3 6.1 ± 0.2 2.9 ± 0.1 0.9 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0 
GBP 20.0 ± 0.2 19.8 ± 0.2 17.8 ± 0.4 19.2 ± 0.7 23.6 ± 1.0 21.4 ± 0.9 22.9 ± 0.7 19.9 ± 0.7 25.3 ± 0.6 127 
LAC 50.0 ± 3.4 40.6 ± 1.5 57.1 ± 1.6 40.7 ± 3.1 48.2 ± 3.7 44.5 ± 4.3 54.4 ± 2.5 49.0 ± 1.6 49.4 ± 0.8 99 
LEV 150.0 ± 2.3 136.3 ± 7.2 169.6 ± 4.2 146.1 ± 9.3 195.2 ± 13.3 146.4 ± 5.9 177.1 ± 10.1 128.8 ± 5.3 153.7 ± 5.4 102 
LTG 30.0 ± 1.6 26.6 ± 0.9 25.5 ± 1.0 25.5 ± 2.0 28.4 ± 2.6 26.7 ± 2.8 29.0 ± 2.4 25.6 ± 0.9 30.0 ± 2.2 100 
OXC 8.0 ± 0.7 0.6 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.4 ± 0.2 0.7 ± 0.6 8 
PGR 20.0 ± 0.2 19.4 ± 0.5 16.7 ± 0.3 14.8 ± 0.6 20.8 ± 1.1 18.4 ± 0.9 20.8 ± 0.5 16.5 ± 0.5 19.7 ± 0.4 98 
PHT 40.0 ± 1.3 38.9 ± 1.0 39.9 ± 1.6 36.4 ± 1.4 42.7 ± 3.7 38.1 ± 0.3 41.9 ± 1.1 34.9 ± 0.8 34.9 ± 1.3 87 
HPPH 40.0 ± 1.0 40.1 ± 1.7 42.2 ± 0.6 37.0 ± 1.5 44.8 ± 2.5 37.4 ± 1.7 44.4 ± 0.9 38.3 ± 2.4 37.7 ± 0.7 94 
TIG 8.0 ± 0.1 7.5 ± 0.1 8.4 ± 0.2 8.0 ± 0.1 6.2 ± 0.5 5.3 ± 0.2 5.9 ± 0.4 6.0 ± 0.4 6.6 ± 0.2 82 
TPR 40.0 ± 1.3 43.8 ± 1.0 44.6 ± 1.0 40.3 ± 1.8 44.8 ± 2.0 38.9 ± 1.1 43.1 ± 1.3 42.9 ± 2.0 43.5 ± 0.4 109 
VIG 190.0 ± 5.0 194.0 ± 9.8 218.3 ± 3.6 188.6 ± 5.5 196.6 ± 1.8 151.6 ± 7.6 158.0 ± 0.6 164.3 ± 5.3 158.1 ± 11.5 83 
VPA 215.0 ± 3.8 197.0 ± 6.9 198.4 ± 3.4 180.5 ± 7.4 196.5 ± 2.4 160.8 ± 4.8 179.2 ± 5.1 145.1 ± 8.2 150.9 ± 5.1 70 
ZNS 20.0 ± 0.8 19.2 ± 1.2 20.0 ± 0.7 18.9 ± 1.6 19.8 ± 1.1 17.3 ± 0.9 19.4 ± 0.5 16.8 ± 0.6 14.2 ± 0.3 71 
  
C
h
ap
ter 4
 
 
1
4
7
 
Table  4-4: Fridge Stability Results of AEDs in Whole Blood at Low Concentrations (3 mg/L for Group 1; 1 mg/L for Group 2; and 20 mg/L for Group 3) Over 10 
Week Period. 
AED Time=0 3 days 1 week 3 weeks 4 weeks 6 weeks 10 weeks R % 
M
ea
n
 Q
C
1
 (
m
g
/L
, 
n
 =
6
 )
 
CBZ 3.0 ± 0.1 2.0 ± 0.1 2.5 ± 0.2 3.2 ± 0.1 1.4 ± 0.1 2.3 ± 0.2 2.5 ± 0.0 83 
CBZO 2.0 ± 0.0 1.5 ± 0.1 1.7 ± 0.2 2.1 ± 0.0 2.5 ± 0.1 2.0 ± 0.2 2.3 ± 0.2 114 
ESL 3.0 ± 0.1 2.2 ± 0.0 1.3 ± 0.2 0.3 ± 0.1 0.5 ± 0.0 0.4 ± 0.2 0.0 ± 0.0 0 
GBP 2.0 ± 0.1 2.5 ± 0.0 2.3 ± 0.0 2.8 ± 0.1 2.7 ± 0.0 2.9 ± 0.0 2.3 ± 0.1 115 
LAC 2.0 ± 0.0 1.3 ± 0.1 1.1 ± 0.0 2.2 ± 0.0 1.2 ± 0.1 1.2 ± 0.0 2.5 ± 0.0 125 
LEV 20.0 ± 0.2 15.6 ± 0.2 15.3 ± 0.1 21.2 ± 0.2 15.6 ± 0.2 15.3 ± 0.1 12.7 ± 0.2 64 
LTG 2.0 ± 0.1 1.6 ± 0.3 1.5 ± 0.1 3.1 ± 0.1 3.0 ± 0.3 3.6 ± 0.1 2.3 ± 0.2 116 
OXC 2.0 ± 0.0 1.0 ± 0.0 0.7 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 8 
PGR 2.0 ± 0.0 1.7 ± 0.0 1.8 ± 0.0 2.3 ± 0.0 2.3 ± 0.0 2.3 ± 0.0 2.3 ± 0.0 115 
PHT 5.0 ± 0.2 4.5 ± 0.4 4.1 ± 0.1 4.2 ± 0.2 5.0 ± 0.4 4.3 ± 0.1 4.0 ± 0.7 80 
HPPH 2.0 ± 0.1 1.3 ± 0.1 1.4 ± 0.0 2.6 ± 0.1 3.0 ± 0.1 1.7 ± 0.0 2.3 ± 0.2 115 
TIG 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.2 1.5 ± 0.1 1.3 ± 0.0 1.2 ± 0.2 0.9 ± 0.0 90 
TPR 3.0 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 2.5 ± 0.1 2.5 ± 0.1 2.1 ± 0.1 2.7 ± 0.1 89 
VIG n/a n/a n/a n/a n/a n/a n/a n/a 
VPA 25.0 ± 0.2 17.8 ± 0.4 16.8 ± 0.2 13.9 ± 0.2 18.8 ± 0.4 16.6 ± 0.2 21.0 ± 0.2 84 
ZNS 2.0 ± 0.1 1.4 ± 0.2 1.9 ± 0.3 1.8 ± 0.1 2.4 ± 0.2 2.7 ± 0.3 2.3 ± 0.1 117 
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Table  4-5: Fridge Stability Results of AEDs in Whole Blood at Medium Concentrations (20 mg/L for Group 1; 4 mg/L for Group 2; and 120 mg/L for Group 3)  
Over 10 Week Period. 
AED Time=0 3 days 1 week 3 weeks 4 weeks 6 weeks 10 weeks R % 
M
ea
n
 Q
C
2
 (
m
g
/L
, 
n
 =
6
) 
CBZ 20.0 ± 0.4 18.6 ± 0.7 19.9 ± 0.8 20.8 ± 0.4 18.9 ± 0.7 18.5 ± 0.8 18.1 ± 0.1 90 
CBZO 20.0 ± 0.4 16.4 ± 0.6 16.5 ± 0.6 14.1 ± 0.4 19.2 ± 0.6 13.3 ± 0.6 20.7 ± 0.4 103 
ESL 20.0 ± 0.2 16.7 ± 0.1 10.0 ± 0.2 3.9 ± 0.2 1.2 ± 0.1 0.7 ± 0.2 1.5 ± 0.0 8 
GBP 20.0 ± 0.2 21.3 ± 0.6 22.1 ± 0.2 22.1 ± 0.2 23.2 ± 0.6 20.1 ± 0.2 20.0 ± 0.4 100 
LAC 15.0 ± 0.6 13.8 ± 0.2 13.4 ± 0.5 15.2 ± 0.6 11.6 ± 0.2 10.3 ± 0.5 11.8 ± 0.3 79 
LEV 115.0 ± 4.4 110.5 ± 0.3 109.3 ± 0.8 131.8 ± 4.4 110.5 ± 0.3 109.3 ± 0.8 78.7 ± 1.7 68 
LTG 15.0 ± 0.8 13.0 ± 0.2 12.1 ± 0.6 22.4 ± 0.8 22.2 ± 0.2 14.1 ± 0.6 19.4 ± 0.9 129 
OXC 4.0 ± 0.1 3.6 ± 0.1 2.8 ± 0.1 1.7 ± 0.1 0.9 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 14 
PGR 15.0 ± 0.2 16.0 ± 0.4 16.4 ± 0.2 16.9 ± 0.2 17.5 ± 0.4 15.6 ± 0.2 14.3 ± 0.3 95 
PHT 20.0 ± 1.7 20.2 ± 0.8 20.6 ± 1.6 23.2 ± 1.7 18.2 ± 0.8 16.6 ± 1.6 16.5 ± 1.2 83 
HPPH 15.0 ± 0.5 16.5 ± 0.3 13.7 ± 0.9 15.6 ± 0.5 16.8 ± 0.3 14.1 ± 0.9 12.2 ± 0.3 82 
TIG 4.0 ± 0.2 4.1 ± 0.1 4.1 ± 0.5 4.9 ± 0.2 4.7 ± 0.1 3.7 ± 0.5 2.5 ± 0.1 64 
TPR 15.0 ± 0.6 14.4 ± 0.4 14.5 ± 0.8 17.6 ± 0.6 17.1 ± 0.4 16.0 ± 0.8 13.2 ± 0.4 88 
VIG 115.0 ± 1.6 118.6 ± 3.8 115.6 ± 3.0 96.4 ± 1.6 136.1 ± 3.8 115.8 ± 3.0 129.0 ± 5.9 112 
VPA 115.0 ± 2.6 94.0 ± 1.0 93.1 ± 3.7 91.3 ± 2.6 103.7 ± 1.0 85.1 ± 3.7 63.9 ± 1.2 56 
ZNS 8.0 ± 0.2 8.8 ± 0.2 9.2 ± 0.4 9.4 ± 0.2 10.4 ± 0.2 10.4 ± 0.4 8.3 ± 0.4 104 
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Table  4-6: Fridge Stability Results of AEDs in Whole Blood at High Concentrations (40 mg/L for Group 1; 8 mg/L for Group 2; and 200 mg/L for Group 3) Over 
10 Week Period. 
AED Time=0 3 days 1 week 3 weeks 4 weeks 6 weeks 10 weeks R % 
M
ea
n
 Q
C
3
 (
m
g
/L
, 
n
 =
6
) 
CBZ 30.0 ± 0.8 31.6 ± 1.3 33.1 ± 0.4 35.7 ± 0.8 31.7 ± 1.3 31.8 ± 0.4 30.0 ± 0.4 100 
CBZO 30.0 ± 0.7 25.0 ± 1.1 28.4 ± 0.5 24.5 ± 0.7 29.3 ± 1.1 23.4 ± 0.5 33.5 ± 0.8 112 
ESL 30.0 ± 0.3 31.3 ± 0.2 20.4 ± 0.3 10.1 ± 0.3 4.0 ± 0.2 2.6 ± 0.3 2.3 ± 0.0 8 
GBP 40.0 ± 0.4 39.6 ± 0.6 41.5 ± 0.3 39.5 ± 0.4 41.8 ± 0.6 36.7 ± 0.3 35.3 ± 0.4 88 
LAC 20.0 ± 0.2 22.8 ± 0.4 22.5 ± 0.2 28.6 ± 0.2 20.1 ± 0.4 17.8 ± 0.2 18.3 ± 0.4 91 
LEV 190.0 ± 3.6 179.4 ± 0.8 176.7 ± 0.5 215.8 ± 3.6 179.4 ± 0.8 176.7 ± 0.5 135.9 ± 2.8 72 
LTG 30.0 ± 0.6 20.1 ± 1.2 19.0 ± 0.6 34.3 ± 0.6 31.6 ± 1.2 20.3 ± 0.6 28.1 ± 1.5 94 
OXC 8.0 ± 0.2 6.8 ± 0.1 5.2 ± 0.1 3.6 ± 0.2 1.8 ± 0.1 0.9 ± 0.1 0.4 ± 0.0 5 
PGR 30.0 ± 0.3 30.4 ± 0.5 30.8 ± 0.2 30.2 ± 0.3 31.1 ± 0.5 28.1 ± 0.2 27.5 ± 0.2 92 
PHT 40.0 ± 2.0 40.1 ± 1.7 40.2 ± 0.6 44.7 ± 2.0 30.0 ± 1.7 28.2 ± 0.6 26.4 ± 1.0 66 
HPPH 30.0 ± 1.0 32.2 ± 0.6 27.6 ± 0.4 30.9 ± 1.0 29.4 ± 0.6 27.8 ± 0.4 21.6 ± 0.6 72 
TIG 8.0 ± 0.3 7.7 ± 0.1 7.9 ± 0.1 9.0 ± 0.3 8.0 ± 0.1 8.1 ± 0.1 3.9 ± 0.2 49 
TPR 30.0 ± 0.5 28.3 ± 0.5 27.5 ± 0.2 33.9 ± 0.5 31.9 ± 0.5 30.0 ± 0.2 23.7 ± 0.4 79 
VIG 190.0 ± 3.7 194.5 ± 9.7 191.3 ± 4.0 174.4 ± 3.7 220.3 ± 9.7 199.4 ± 4.0 223.2 ± 3.0 117 
VPA 190.0 ± 1.6 182.3 ± 2.1 180.8 ± 2.6 174.2 ± 1.6 189.0 ± 2.1 157.1 ± 2.6 109.3 ± 2.0 58 
ZNS 15.0 ± 0.2 17.2 ± 0.2 16.8 ± 0.3 17.9 ± 0.2 18.5 ± 0.2 18.2 ± 0.3 13.9 ± 0.2 93 
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Table  4-7:  Freezer Stability Results of AEDs in Whole Blood at Low Concentrations (3 mg/L for Group 1; 1 mg/L for Group 2; and 20 mg/L for Group 3)  Over 12 
Week Period. 
AED Time=0 1day 3days 1 week 2 weeks 3 weeks 4 weeks 6 weeks 10 weeks 12 weeks R% 
M
ea
n
 Q
C
1
 (
m
g
/L
, 
n
 =
6
 )
 
CBZ 3.0 ± 0.0 2.3 ± 0.2 2.0 ± 0.1 2.5 ± 0.1 2.3 ± 0.0 3.4 ± 0.2 1.7 ± 0.1 2.5 ± 0.1 4.6 ± 0.0 3.3 ± 0.1 110 
CBZO 2.0 ± 0.1 1.6 ± 0.1 1.5 ± 0.1 1.2 ± 0.1 1.7 ± 0.1 2.2 ± 0.1 2.8 ± 0.1 2.1 ± 0.1 3.3 ± 0.1 1.5 ± 0.1 74 
ESL 4.0 ± 0.1 3.0 ± 0.2 3.0 ± 0.3 2.4 ± 0.1 2.9 ± 0.1 3.6 ± 0.2 2.9 ± 0.3 5.1 ± 0.1 4.1 ± 0.1 3.9 ± 0.2 98 
GBP 3.0 ± 0.1 2.3 ± 0.2 2.6 ± 0.1 2.3 ± 0.1 2.4 ± 0.1 3.0 ± 0.2 2.8 ± 0.1 2.9 ± 0.1 4.2 ± 0.1 2.9 ± 0.1 98 
LAC 2.0 ± 0.0 1.3 ± 0.2 1.4 ± 0.0 1.1 ± 0.0 1.2 ± 0.0 2.4 ± 0.2 1.2 ± 0.0 1.4 ± 0.0 3.0 ± 0.0 2.0 ± 0.1 101 
LEV 20.0 ± 0.3 23.7 ± 1.8 17.4 ± 0.1 17.6 ± 0.1 15.2 ± 0.3 25.4 ± 1.8 17.6 ± 0.1 15.2 ± 0.1 17.6 ± 0.3 17.6 ± 0.1 88 
LTG 2.0 ± 0.1 2.1 ± 0.3 1.8 ± 0.3 1.6 ± 0.2 1.8 ± 0.1 1.8 ± 1.8 3.5 ± 0.3 1.8 ± 0.2 1.4 ± 0.1 2.1 ± 0.2 105 
OXC 2.0 ± 0.1 1.9 ± 0.1 2.4 ± 0.1 2.2 ± 0.0 2.2 ± 0.1 2.0 ± 0.1 1.9 ± 0.1 2.0 ± 0.0 2.1 ± 0.1 2.3 ± 0.1 115 
PGR 2.0 ± 0.0 2.0 ± 0.1 1.8 ± 0.1 1.7 ± 0.0 1.8 ± 0.0 2.5 ± 0.1 2.4 ± 0.1 2.4 ± 0.0 3.9 ± 0.0 2.3 ± 0.0 115 
PHT 4.0 ± 1.4 4.2 ± 0.3 4.5 ± 0.2 3.9 ± 1.3 4.0 ± 1.4 4.4 ± 0.3 4.9 ± 0.2 4.9 ± 1.3 5.6 ± 1.4 4.9 ± 1.0 122 
HPPH 3.0 ± 0.1 3.2 ± 0.2 3.4 ± 0.2 3.2 ± 0.3 2.5 ± 0.1 2.8 ± 0.2 3.3 ± 0.2 1.8 ± 0.3 3.2 ± 0.1 3.6 ± 0.3 120 
TIG 1.0 ± 0.0 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.0 0.9 ± 0.0 1.5 ± 0.1 1.1 ± 0.1 1.4 ± 0.0 1.2 ± 0.0 1.2 ± 0.0 116 
TPR 2.0 ± 0.0 1.3 ± 0.1 1.8 ± 0.1 1.7 ± 0.1 1.6 ± 0.0 2.7 ± 0.1 2.4 ± 0.1 2.2 ± 0.1 3.9 ± 0.0 2.4 ± 0.0 118 
VIG n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
VPA 20.0 ± 0.2 17.4 ± 0.8 17.8 ± 0.4 16.7 ± 0.2 16.1 ± 0.2 15.0 ± 0.8 18.4 ± 0.4 17.3 ± 0.2 21.0 ± 0.2 17.9 ± 0.5 90 
ZNS 2.0 ± 0.0 1.2 ± 0.1 1.4 ± 0.1 1.1 ± 0.3 1.5 ± 0.0 1.8 ± 0.1 2.3 ± 0.1 2.9 ± 0.3 2.7 ± 0.0 2.7 ± 0.1 137 
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Table  4-8: Freezer Stability Results of AEDs in Whole Blood at Medium Concentrations (20 mg/L for Group 1; 4 mg/L for Group 2; and 120 mg/L for Group 3) 
Over 12 Week Period. 
AED Time=0 1day 3days 1 week 2 weeks 3 weeks 4 weeks 6 weeks 10 weeks 12 weeks R% 
M
ea
n
 Q
C
2
 (
m
g
/L
, 
n
 =
6
) 
CBZ 20.0 ± 0.3 19.5 ± 3.0 18.4 ± 0.7 20.1 ± 0.5 20.3 ± 0.3 25.1 ± 3.0 20.4 ± 0.7 19.8 ± 0.5 20.4 ± 0.3 22.4 ± 0.8 112 
CBZO 15.0 ± 0.4 16.2 ± 2.3 16.2 ± 0.6 17.8 ± 0.4 18.1 ± 0.4 17.8 ± 2.3 21.4 ± 0.6 14.5 ± 0.4 20.9 ± 0.4 13.8 ± 0.5 92 
ESL 20.0 ± 0.3 22.2 ± 3.4 21.4 ± 0.9 15.1 ± 0.9 21.9 ± 0.3 26.9 ± 3.4 17.9 ± 0.9 28.2 ± 0.9 20.1 ± 0.3 22.1 ± 0.7 111 
GBP 20.0 ± 0.4 19.1 ± 3.9 21.0 ± 0.3 23.2 ± 0.4 21.0 ± 0.4 27.1 ± 3.9 24.7 ± 0.3 21.5 ± 0.4 21.7 ± 0.4 21.7 ± 0.3 109 
LAC 20.0 ± 0.3 13.6 ± 2.5 13.8 ± 0.3 15.1 ± 0.4 13.7 ± 0.3 20.9 ± 2.5 12.4 ± 0.3 10.8 ± 0.4 13.2 ± 0.3 21.2 ± 0.3 106 
LEV 115.0 ± 1.7 131.0 ± 17.6 112.1 ± 0.7 139.3 ± 0.6 110.1 ± 1.7 163.0 ± 17.6 139.3 ± 0.7 110.1 ± 0.6 92.8 ± 1.7 92.8 ± 0.4 81 
LTG 15.0 ± 1.0 16.1 ± 2.3 13.6 ± 0.6 16.2 ± 0.6 14.4 ± 1.0 13.2 ± 2.3 12.5 ± 0.6 14.7 ± 0.6 12.2 ± 1.0 13.8 ± 0.9 92 
OXC 4.0 ± 0.1 4.4 ± 1.4 4.1 ± 0.2 4.7 ± 0.2 4.2 ± 0.1 4.5 ± 1.4 3.5 ± 0.2 3.9 ± 0.2 4.0 ± 0.1 4.5 ± 0.4 113 
PGR 15.0 ± 0.1 15.8 ± 2.9 15.9 ± 0.3 17.1 ± 0.4 16.6 ± 0.1 21.0 ± 2.9 18.8 ± 0.3 16.8 ± 0.4 14.5 ± 0.1 17.4 ± 0.1 116 
PHT 20.0 ± 0.4 20.6 ± 3.7 20.5 ± 2.1 21.5 ± 2.2 20.1 ± 0.4 28.4 ± 3.7 20.4 ± 2.1 18.3 ± 2.2 16.7 ± 0.4 17.1 ± 1.3 85 
HPPH 14.5 ± 0.5 14.6 ± 3.1 16.9 ± 0.8 14.1 ± 5.8 13.3 ± 0.5 19.9 ± 3.1 18.2 ± 0.8 13.1 ± 5.8 13.9 ± 0.5 17.9 ± 1.0 124 
TIG 4.0 ± 0.2 4.1 ± 0.9 4.0 ± 0.2 4.2 ± 0.1 4.0 ± 0.2 6.3 ± 0.9 4.6 ± 0.2 4.8 ± 0.1 3.6 ± 0.2 4.5 ± 0.1 111 
TPR 15.0 ± 0.3 15.4 ± 3.3 14.3 ± 0.4 14.7 ± 0.4 13.6 ± 0.3 22.3 ± 3.3 18.3 ± 0.4 16.5 ± 0.4 14.4 ± 0.3 16.8 ± 0.3 112 
VIG 120.0 ± 4.0 108.6 ± 13.8 114.5 ± 5.2 127.0 ± 3.9 131.6 ± 4.0 120.4 ± 13.8 144.7 ± 5.2 123.7 ± 3.9 156.8 ± 4.0 139.6 ± 1.3 116 
VPA 115.0 ± 1.0 93.2 ± 17.6 93.1 ± 2.7 100.3 ± 1.6 92.3 ± 1.0 117.6 ± 17.6 110.4 ± 2.7 87.7 ± 1.6 114.2 ± 1.0 131.5 ± 1.1 114 
ZNS 10.0 ± 0.2 9.4 ± 1.8 8.8 ± 0.2 10.6 ± 0.3 8.5 ± 0.2 12.2 ± 1.8 11.0 ± 0.2 10.7 ± 0.3 9.1 ± 0.2 10.7 ± 0.2 107 
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Table  4-9: Freezer Stability Results of AEDs in Whole Blood at High Concentrations (40 mg/L for Group 1; 8 mg/L for Group 2; and 200 mg/L for Group 3) Over 
12 Week Period. 
AED Time=0 1day 3days 1 week 2 weeks 3 weeks 4 weeks 6 weeks 10 weeks 12 weeks R% 
M
ea
n
 Q
C
3
 (
m
g
/L
, 
n
 =
6
) 
CBZ 40.0 ± 0.7 34.8 ± 3.1 31.0 ± 1.1 34.0 ± 0.9 34.4 ± 0.7 34.5 ± 3.1 34.6 ± 1.1 32.9 ± 0.9 33.6 ± 0.7 36.6 ± 0.4 92 
CBZO 30.0 ± 0.9 27.1 ± 2.3 27.7 ± 1.0 27.8 ± 0.8 29.4 ± 0.9 25.0 ± 2.3 33.9 ± 1.0 25.2 ± 0.8 33.8 ± 0.9 24.0 ± 0.4 80 
ESL 40.0 ± 1.2 37.5 ± 3.1 38.2 ± 0.9 23.6 ± 1.4 37.2 ± 1.2 37.3 ± 3.1 29.0 ± 0.9 50.2 ± 1.4 32.9 ± 1.2 35.8 ± 0.9 90 
GBP 40.0 ± 1.3 34.1 ± 3.8 40.6 ± 0.4 38.3 ± 0.7 39.1 ± 1.3 39.8 ± 3.8 44.1 ± 0.4 39.4 ± 0.7 37.8 ± 1.3 39.1 ± 0.5 98 
LAC 30.0 ± 0.4 24.6 ± 2.5 24.1 ± 0.4 23.6 ± 0.4 23.7 ± 0.4 28.6 ± 2.5 21.0 ± 0.4 18.4 ± 0.4 19.6 ± 0.4 32.7 ± 0.7 109 
LEV 190.0 ± 3.0 204.7 ± 15.8 190.7 ± 1.1 199.8 ± 0.7 185.8 ± 3.0 217.4 ± 15.8 199.8 ± 1.1 185.8 ± 0.7 152.6 ± 3.0 152.6 ± 1.4 80 
LTG 30.0 ± 1.4 27.5 ± 2.0 20.7 ± 0.8 24.5 ± 0.7 22.8 ± 1.4 33.8 ± 2.0 31.3 ± 0.8 22.5 ± 0.7 30.4 ± 1.4 35.3 ± 2.4 118 
OXC 8.0 ± 0.7 8.8 ± 1.1 8.2 ± 0.3 7.7 ± 0.3 8.4 ± 0.7 8.0 ± 1.1 8.5 ± 0.3 6.7 ± 0.3 7.5 ± 0.7 8.2 ± 0.3 103 
PGR 30.0 ± 0.7 30.1 ± 3.0 31.2 ± 0.4 28.0 ± 0.7 31.0 ± 0.7 30.7 ± 3.0 33.0 ± 0.4 30.4 ± 0.7 24.4 ± 0.7 31.7 ± 0.4 106 
PHT 40.0 ± 1.1 40.6 ± 3.6 41.1 ± 0.7 37.6 ± 0.7 40.3 ± 1.1 41.0 ± 3.6 31.5 ± 0.7 28.7 ± 0.7 28.5 ± 1.1 28.2 ± 0.4 70 
HPPH 29.5 ± 1.0 30.0 ± 2.8 34.6 ± 0.6 24.7 ± 0.5 29.4 ± 1.0 29.6 ± 2.8 31.5 ± 0.6 28.5 ± 0.5 23.7 ± 1.0 31.7 ± 0.2 107 
TIG 8.0 ± 0.1 7.3 ± 0.8 8.0 ± 0.1 7.5 ± 0.2 8.0 ± 0.1 9.1 ± 0.8 8.3 ± 0.1 8.1 ± 0.2 5.5 ± 0.1 7.8 ± 0.2 98 
TPR 30.0 ± 0.9 30.2 ± 2.8 29.2 ± 0.5 26.5 ± 0.3 27.3 ± 0.9 33.2 ± 2.8 33.1 ± 0.5 30.7 ± 0.3 24.5 ± 0.9 31.5 ± 0.8 105 
VIG 190.0 ± 5.9 179.7 ± 24.3 192.7 ± 9.2 190.6 ± 10.3 207.6 ± 5.9 181.9 ± 24.3 231.8 ± 9.2 215.8 ± 10.3 215.7 ± 5.9 215.7 ± 17.4 114 
VPA 190.0 ± 3.3 181.7 ± 15.2 184.0 ± 0.8 180.5 ± 1.5 182.7 ± 3.3 175.3 ± 15.2 201.4 ± 0.8 162.9 ± 1.5 113.6 ± 3.3 242.2 ± 5.2 127 
ZNS 20.0 ± 0.6 18.2 ± 1.7 17.9 ± 0.3 17.5 ± 0.4 16.1 ± 0.6 17.6 ± 1.7 19.3 ± 0.3 18.3 ± 0.4 15.1 ± 0.6 18.6 ± 0.7 93 
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5  Determination of 22 AEDs in Whole Blood, 
Serum and Plasma Using LC/MS/MS: Analytical 
Method Transfer Challenges and 
Considerations.  
5.1 Introduction 
Method transfer can occur within the same organization or between analytical laboratories 
and the transferred method validation can range from a check for accuracy and precision to 
a full validation depending on the analysis requirements and the purpose of the transferred 
method (250). Unfortunately, very limited information about method transfer protocols or 
challenges is available in the literature (274).  
The aim of this project was to transfer the method developed at Forensic Medicine and 
Science lab (FMS), University of Glasgow, (Glasgow, UK) to NMS lab (PA, USA) and 
investigate the main factors required to be taken into consideration when transferring the 
LC/MS/MS method from one instrument to another or from one lab to another. As part of 
any method transfer, it is advised to test the same quality controls to compare the original 
and transferred methods. However, this was not applicable in this study due to the short 
time of the project which was not sufficient to arrange for QCs to be shipped from FMS 
lab to the NMS lab. Authentic sample transfer from NMS lab to FMS was also not possible 
due to ethical approval required by University of Glasgow and could not be obtained on 
time. 
However, in order to verify the transferred method, 467 samples that had previously been 
tested at NMS lab, were reanalyzed using the method. The obtained results were compared 
with NMS lab values and statistically evaluated using Pearson correlation and Band-
Altman plots. The data is discussed in details in Chapter 6. 
The method was transferred and a re-validation was conducted for 22 AEDs. These 
included the 17 AEDs tested in the first developed method as well as a further 5 AEDs 
added as requested by NMS lab due to their high availability in the US market. These 5 
drugs were phenobarbital, S-licarbazepine (eslicarbazepine acetate and oxcarbazepine 
metabolite), N-acetyl retigabine (retigabine metabolite), rufinamide and stiripentol. 
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Fosphenytoin was also one of the requested drugs but this is a prodrug of phenytoin which 
was already included in the method.  
Due to the high number of therapeutic drug monitoring (TDM) analysis carried out by 
NMS lab using serum and plasma, it was decided to extend the method to include serum 
and plasma which made the method suitable for use in TDM as well as postmortem blood 
in forensic cases. 
5.2 Materials and Methods 
5.2.1 Materials  
Eslicarbazepine acetate (ESL) was purchased from Santa Cruz Biotechnology (Texas, 
USA). S-Licarbazepine (S-LC), retigabine (RTG), N-acetyl retigabine (NA-RTG), 
phenobarbital (PBT), rufinamide (RFM), and gabapentin-D10 (GBP-D10) were purchased 
from Cerilliant (Texas, USA). Lacosamide (LAC), pregabalin (PGR) and tigabine (TIG) 
were obtained from LGC standards (Canada, USA). Gabapentin (GBP), vigabatrin (VIG), 
valproic acid (VPA), levetiracetam (LEV), carbamazepine (CBZ), carbamazepine 10,11-
epoxide (CBZO), oxcarbazepine (OXC), zonisamide (ZNS), topiramate(TPR), phenytoin 
(PHT), 5-(3-Hydroxyphenyl)-5-phenylhydantoin (p-HPPH), stiripentol (STP), lamotrigine 
(LTG), tolbutamide (TUB), 10- 11 dihydrocarbamazepine (CBZ-DiOH) and ammonium 
acetate (HPLC grade) were purchased from Sigma Aldrich (Missouri, USA). Methanol 
(HPLC grade) was supplied by VWR International Ltd (Philadelphia, USA). Double 
distilled water was obtained from the in-house Millipore® system.  
5.2.2 Blank Blood and Biological Samples  
Human blank whole blood, plasma and serum were obtained from Golden West Biological 
Inc® (California, USA). Postmortem blood (n=7), plasma (n=7) and serum samples 
(n=453) were kindly provided by NMS lab (PA, USA) collected over a two month period 
and stored in the fridge at 4-8 ºC. 
5.2.3 Calibrators and Quality Control Preparation 
AEDs were divided into 3 groups according to their proposed calibration curve ranges as 
explained in Table ‎5-1. 
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Table  5-1: AEDs Groups According to Their Proposed Calibration Curve Ranges. 
Group 1 (0.5-50 mg/L) Group 2 (0.05-10 mg/L) Group 3 (5-300 mg/L) 
Drug Abbrev. Drug Abbrev. Drug Abbrev. 
Carbamazepine CBZ Oxcarbazepine OXC Levetiracetam LEV 
Carbamazepine epoxide CBZO Tiagabine TIG Vigabatrin VIG 
Eslicarbazepine acetate ESL Retigabine RTG Valproic acid VPA 
S-Licarbazepine S-LE 
N-acetyl 
retigabine 
NA-RTG   
Gabapentin GBP   
  
Lacosamide LAC 
    
Lamotrigine LTG 
    
Phenobarbital PBT     
Phenytoin PHT 
    
5-(3-Hydroxyphenyl)-5-
phenylhydantoin 
p-HPPH 
    
Pregabalin PGR 
    
Rufinamide RFM     
Stiripentol STP     
Topiramate TPR 
    
Zonisamide ZNS 
    
 
Group 1 and 2 standards were purchased as solutions at concentration of 0.5 mg/mL for 
rufinamide, 0.1 mg/mL for N-acetyl retigabine and 1mg/mL for other AEDs. These 
standards were used as stock solutions.  Levetiracetam, valproic acid and vigabatrin (group 
3), were purchased as powder. A weight of 10 mg of each drug was dissolved in 1 mL 
methanol to obtain a stock concentration of 10 mg/mL.  
Two separate set of working solutions; 4 working solutions each, were prepared at 
concentrations of 100 mg/L for working solutions 1, 2 and 3 and 1 g/L for working 
solution 4 by combining certain volumes of the stock solutions in 5 mL volumetric flask 
and made up to volume with methanol as detailed in Table ‎5-2.  
Eight calibration standard solutions were prepared in methanol by combining certain 
volumes of the four working solutions in 5 mL volumetric flasks and made up to volume 
with methanol to achieve the target concentrations as detailed in Table ‎5-3. 
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Table  5-2: Preparation of Calibrators and QCs Working Solutions. 
Working Solution 1: (5 mL volumetric flask) 
Analyte Stock Concentration Amount to Add Final Concentration 
CBZ 1 mg/mL 500 µL 100 mg/L 
CBZO 1 mg/mL 500 µL 100 mg/L 
ESL 1 mg/mL 500 µL 100 mg/L 
S-LC 1 mg/mL 500 µL 100 mg/L 
GBP 1 mg/mL 500 µL 100 mg/L 
LAC 1 mg/mL 500 µL 100 mg/L 
RFM 0.5 mg/mL 1000 µL 100 mg/L 
TPR 1 mg/mL 500 µL 100 mg/L 
Working Solution 2: (5 mL volumetric flask) 
Analyte Stock Concentration Amount to Add Final Concentration 
LTG 1 mg/mL 500 µL 100 mg/L 
PGR 1 mg/mL 500 µL 100 mg/L 
PHT 1 mg/mL 500 µL 100 mg/L 
p-HPPH 1 mg/mL 500 µL 100 mg/L 
STP 1 mg/mL 500 µL 100 mg/L 
ZNS 1 mg/mL 500 µL 100 mg/L 
PBT 1 mg/mL 500 µL 100 mg/L 
Working Solution 3: (5 mL volumetric flask) 
Analyte Stock Concentration Amount to Add Final Concentration 
OXC 1 mg/mL 500 µL 100 mg/L 
TIG 1 mg/mL 500 µL 100 mg/L 
RTG 1 mg/mL 500 µL 100 mg/L 
NA-RTG 0.1 mg/mL 1000 µL 100 mg/L 
Working Solution 4: (5 mL volumetric flask) 
Analyte Stock Concentration Amount to Add Final Concentration 
LEV 10 mg/mL 500 µL 1 g/L 
VIG 10 mg/mL 500 µL 1 g/L 
VPA 10 mg/mL 500 µL 1 g/L 
 
Table  5-3: Preparation of Calibrators and QCs Working Solutions. 
Volumetric 
Flask 
(5 mL) 
No. 
Calibrator 
No. 
Amount Added (µL) Final Concentration (mg/L) 
Working 
Solution 1 
Working 
Solution 2 
Working 
Solution 3 
Working 
Solution 4 
Group 1 Group 2 Group 3 
1 Cal 1 25 25 2.5 25 0.5 0.05 5 
2 Cal 2 50 50 5 50 1 0.1 10 
3 Cal 3 125 125 12.5 125 2.5 0.25 25 
4 Cal 4 250 250 25 250 5 0.5 50 
5 Cal 5 500 500 50 375 10 1 75 
6 Cal 6 1000 1000 125 500 20 2.5 100 
7 Cal 7 1750 1750 250 1000 35 5 200 
8 Cal 8 2500 2500 500 1500 50 10 300 
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Three QC samples (low, medium and high) were directly made in whole blood, plasma and 
serum using the second set of working solutions by combining certain volumes of the four 
working solutions in 10 mL volumetric flasks. Then, the methanol solvent was evaporated 
under nitrogen at 25ºC to avoid blood precipitation. The residue was finally reconstituted 
with 10 mL whole blood, plasma or serum to achieve the target concentrations as detailed 
in Table ‎5-4. QC concentrations were 3, 20 and 40 mg/L for group 1; 2, 4 and 9 mg/L for 
group 2; and 20, 120 and 200 mg/L for group 3. For each QC, 0.5 mL aliquots were placed 
into labelled 1.5 mL polystyrene screw cap tubes. All QCs and stock solutions were stored 
at -20°C, and working solutions were stored at 4°C. 
Table  5-4: Preparation of QCs in Whole Blood, Plasma and Serum. 
Volumetric 
Flask 
(10 mL) 
No. 
QC No. 
Amount Added (µL) Final Concentration (mg/L) 
Working 
Solution 1 
Working 
Solution 3 
Working 
Solution 4 
Working 
Solution 5 
Group 1 Group 2 Group 3 
1 QC 1 300 300 200 200 3 2 20 
2 QC 2 2000 2000 400 1200 20 4 120 
3 QC 3 4000 4000 900 2000 40 9 200 
 
5.2.3.1 Preparation of Internal Standards 
Although it is advisable to use deuterated internal standards for quantitive analysis, 
however, due to the high cost of the analytes included in this method and their deuterated 
internal standards, it was decided to use analog internal standards as alternatives. CBZ-
DiOH was used for carbamazepine and its derivatives, GBP-D10 was used for GBP, PGR 
and VIG and TUB, an anti-diabetic medication that is rarely used in combination with 
antiepileptic drugs was used for the rest analytes. Three internal standards, GBP-D10, TUB 
and CBZ-DiOH were used. GBP-D10 was readily purchased in methanol at concentration 
of 100 mg/L. TUB and CBZ-DiOH were purchased as a powder. An amount of 1 mg was 
dissolved in 10 mL methanol to obtain a 100 mg/L solution of TUB and CBZ-DiOH. 
Using a 100 mL volumetric flask, a combined internal standard solution was prepared at 5 
mg/L and made up to volume with methanol as outlined in Table ‎5-5 below. 
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Table  5-5: Internal Standard Solution Preparation. 
Internal Standard Abbrev. 
Stock Solution 
(mg/L) 
Amount added 
(mL) 
Final 
Concentration 
(mg/L) 
Gabapentin-D10 GBP-D10 100 0.5 5 
Tolbutamide TUB 100 0.5 5 
10,11 Dihydro carbamazepine CBZ-DiOH 100 0.5 5 
 
5.2.4 Calibration Curve Preparation 
Calibration curves were extracted in duplicate by adding the following volumes to 100 µL 
of blank matrix (whole blood, serum or plasma): 100µL of the standards, 100 µL of the 
internal standard solution and 200 µL of methanol (methanol total volume 400 µL). The 
standards were vortex mixed for 30 seconds and centrifuged for 10 minutes at 10000 rpm. 
An aliquot of 200 µL of the supernatant was transferred to a LC vial and diluted with 1.3 
mL of deionized water. A 5 µL aliquot of the diluted supernatant was injected and 
analysed by LC/MS/MS. 
5.2.5 Sample Preparation  
The same protein precipitation extraction used at FMS was applied. A 100 µL aliquot of 
the sample (blood, plasma or serum) was transferred to a 2-mL snap top polypropylene 
micro-centrifuge tube. To this, 100 µL of combined internal standard solution and 300 µL 
of methanol were added (methanol total volume 400 µL). The standards were vortex mixed 
for 30 seconds and centrifuged for 10 minutes at 10000 rpm. An aliquot of 200 µL of the 
supernatant was transferred to a LC vial and diluted with 1.3 mL of demonized water. A 5 
µL aliquot of the diluted supernatant was injected and analysed by LC/MS/MS. 
5.2.6 Optimisation of Chromatographic Conditions 
In order to optimize the fragmentor voltage and the collision energy required to analyse the 
drugs on LC/MS/MS, the stock solutions were diluted 1:100 to obtain one working 
solution for each drug at 10 mg/L. These were achieved by adding 100 µL of the 1g/L 
stock solution to a 10 mL volumetric flask and made up to volume with mobile phase 
mixture (2 mM ammonium Acetate/ MeOH: 50/50). For LEV, VPA and VIG, a 10 µL of 
the 10g/L stock solution to a 10 mL volumetric flask and made up to volume with mobile 
phase mixture.  
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Post column infusion was carried out using a 500µl syringe (from COSAGE, Australia) 
which operated at a flow rate of 10 µL/min. All the drugs were re-tuned and their precursor 
ion, fragmentor voltage, collision energy, and product ions were recorded in order to attain 
a high sensitivity. The response was monitored visually and results were recorded on an 
excel spreadsheet. 
5.2.7 Instrumentation  
An Agilent LC/MS/MS triple quadruple G6430A mass spectrometer equipped with Agilent 
1200 series auto sampler, quaternary pump SL with degasser and thermostatted column 
compartment was used. This system is very similar to G6420A used in the previous 
project. The only difference is that G6430A has a second turbo pump added to improve the 
vacuum  (237). Otherwise, they both operate in the same way and use the same version of 
Agilent Mass-Hunter Work station (version: B.01.05). Electrospray ionization (ESI) was 
used. 
The optimal conditions were achieved using a nebulizer pressure at 15 psi, a capillary 
voltage of 4000 V, nitrogen gas heated to 300 °C and delivered at 10 mL/min. The column 
used‎was‎a‎Phenomenex‎Gemini‎C18‎(150‎mm‎x‎2.0‎mm,‎5μm)‎coupled‎with‎a‎C18‎guard‎
column (4.0 mm x 2.0 mm).  The column temperature was maintained at 40 °C. Gradient 
elution was employed using a mobile phase consisting of A: 2 mM ammonium acetate in 
water and B: 2 mM ammonium acetate in methanol at a flow rate of 0.3 mL/min. The total 
run time was 17 minutes. The gradient mobile phase system started at 80:20 A/B 
increasing to 50:50 A/B within 2 minutes. This percentage was maintained for 6 minutes 
before being increased to 10:90 A/B for 2 minutes. The percentage was finally decreased 
to 80:20 A/B for 7 minutes in order to condition the column before the next injection. Data 
analysis was performed using Agilent Mass-Hunter Workstation. 
5.2.8 MRM vs DMRM 
The method was initially developed using MRM mode to determine the retention time and 
then DMRM was applied similar to the developed method at FMS.  
The main difference between conventional MRM and DMRM is that conventional MRM 
uses time segments and predefined sets of MRM transitions are monitored for each 
segment, whereas DMRM removes the requirement to create well-defined segments 
because it uses the retention time window for each analyte and MRM transitions are built 
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up dynamically throughout the LC/MS run (Figure ‎5-1). With DMRM, the analyte is only 
monitored when it is eluting from the LC. This approach is of great benefit when analysing 
a large number of drugs as conventional MRM may be unable to cope with this. In case of 
having a large number of transitions per segment, it will be necessary to either decrease the 
amount of time required to analyse a single MRM transition or the so-called‎“Dwell‎time”‎
or increase the cycle time for each MS scan. Reducing the dwell time may cause collision 
cell cross talk while increasing the MS cycle may decrease the number of collected data 
points during the elution. Both factors can affect the data quality (245).  
  
Conventional MRM Dynamic MRM 
Figure  5-1: The Difference Between MRM and DMRM Scan Mode on LC/MS/MS (245). 
 
Another advantage of using DMRM is that it significantly improves the LOD for some 
drugs at very low concentrations due to the improved sampling across the chromatographic 
peak resulting in better peak symmetry and more accurate quantitation.  
5.2.9 Method Validation 
Due to the addition of 5 new drugs, 2 other matrices and the use of an Agilent 6430 mass 
spectrometer instead of an Agilent 6420 mass spectrometer, a re-validation was required. 
The method was re-validated according to the standard practices for method validation in 
forensic toxicology (SWGTOX, May 2013) for whole blood, serum and plasma (7). (See 
Chapter 3 for details).   
Selectivity was assessed only in plasma/serum because it had been evaluated for whole 
blood previously. It was evaluated using negative case samples because free blank matrices 
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were not available at the time of the project. Specificity was assessed by spiking drug-free 
matrix with each AED individually. Interferences were examined visually. 
Limits of Detection (LOD): Instrument LODs were determined using decreasing 
concentrations of non-extracted drug standard solutions and analysing in duplicate for 
three separate runs. Assay LODs were determined for each matrix (blood, plasma and 
serum) using 3 different source of blank matrix samples spiked with decreasing 
concentrations of AEDs.  These were analysed in duplicate for three separate runs.  
Linearity was assessed by analyzing five separate calibration curves per matrix prepared by 
spiking blank blood, plasma or serum with AEDs working solution at 8 concentrations 
ranging from 5-300 mg/L for levetiracetam, valproic acid and vigabatrin; 0.05-10 mg/L for 
retigabine and tigabine; 0.1-10 mg/L for N-acetyl retigabine and oxcarbzepine; 0.5-50 
mg/L for carbamazepine, carbamazepine epoxide, eslicarbazepine acetate, S-licarbazepine, 
gabapentin, lacosamide, rufenamide, stiripentol and topiramate; 1-50 µg/mL lamotrigine, 
phenytoin, p-HPPH, pregabalin and zonisamide; and 2.5-50 µg/mL for phenobarbital. All 
calibration points were freshly prepared in duplicate in each batch over 5 different days (10 
replicates  per each concentrations). Calibration curves were generated by plotting the peak 
area ratio versus the spiked analyte concentrations and applying weighed (1/x) least-
squares linear regression analysis. Blank matrix with internal standard was run with each 
batch but not included in the calibration curve. The correlation coefficient (R
2
) was 
calculated. The R
2
 values should be greater than 0.99.  
Accuracy and precision were assessed by analysing replicates of spiked controls at 3 
different concentrations (low, medium and high) in serum and plasma. In whole blood, 3 
different concentrations were prepared for the new drugs, whereas only two concentrations 
(low and high) were used for the drugs included in the original method because they had 
been fully validated previously. Intra-day precision was calculated from 3 replicates per 
QC per matrix in one batch. Inter-day precision was determined over 5 different runs. 
Accuracy was expressed as a percentage of the nominal concentration and precision was 
established by the percentage of the co-efficient of variation (% CV). 
Recoveries and Matrix Effects were evaluated using the post-extraction addition approach 
for the new drugs in whole blood and for all 22 AEDs in serum and plasma (see 2.2.12.4 
for details) (8). Retigabine matrix effect and recovery were re-evaluated due to the 
validation failure of retigabine in the original method. Its recovery was 33% and it 
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exhibited a high matrix suppression effect with a matrix factor of 0.33 (Chapter 3, Table ‎3-
5). 
Carryover was tested by injecting three blank controls after two injections of the upper 
limit of quantification in the calibration curve. Carryover was evaluated by dividing the 
blank peak area at the expected retention time by the mean peak area of the ULOQ and 
multiplying by 100. No carryover is considered if the value is lower than 10%.  
Stability: drug stability from sample preparation until analysis and processing is essential 
to ensure the accuracy and precision of the forensic analysis and interpretation. A stability 
study was carried out using drug free matrix (whole blood, plasma and serum). Storage 
conditions evaluated were: 
• Room temperature (approximately 25 ºC) for 24 hours. Samples spiked in triplicate 
at two concentrations (low and high).  
• In process stability (auto sampler) at approximately 25ºC was evaluated by re-
injecting QCs at two concentrations after 72 hours. Samples were stored in the 
autosampler during the study duration. 
• Freeze-thaw cycles stability. Samples spiked in triplicate using one concentration. 
 The concentrations obtained were compared with those from freshly spiked controls. The 
results were also compared with those obtained from the validation of the original method 
for whole blood. 
5.3 Results and Discussion 
5.3.1 Optimisation of AED Separation and Chromatographic 
Conditions  
The optimized precursor ions, fragmentor voltages, collision energies, and product ions for 
the AEDs are shown in Table ‎5-6. The chromatograms of the AEDs are shown in 
Figure ‎5-2. 
Eslicarbazepine acetate (ESL) is a chiral pro-drug which is quickly and extensively 
metabolized to S-licarbazepine (S-LC)  (95–98%) and, to a minor extent,  R-licarbazepine 
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(R-LC)  and OXC (275). On the other hand, oxcarbazepine (OXC) is a chiral pro-drug 
which, in humans, is reduced to the active licarbazepine metabolite, appearing in plasma as 
S-LC and R-LC in approximately a 4:1 enantiomer ratio (276). As a result, the method has 
been validated using S-LC as a metabolite of both OXC and ESL. 
Post column infusion has the advantage of giving a more accurate tune compared with the 
tuning (optimizer software and sample injection procedure) used in the original method 
because of the possibility to manually tune the compounds and adjust the peak centre and 
the product ion (see 2.3.1, Chapter 2 for more details). Furthermore, it is faster and more 
reliable for method development.  
Table  5-6: Optimization of MRM transitions, Fragmentor Voltage, Collision Energy, 
Ionization Mode and Retention Time of 22 AEDs. 
AEDs 
Precursor  
(m/z) 
Quantifier 
(m/z) 
Qualifier 
(m/z) 
Fraga
 
 (V) 
CEb
 
 (eV) 
RTc 
(mins) 
Ionization 
mode 
CBZ 237.3 194.2 192.0 140 20 12.0 + 
CBZO 253.1 236.1 210.1 90 2 8.7 + 
ESL 297.2 194.1 237.2 100 20 11.2 + 
GBP 172.2 154.2 137.0 110 10 3.4 + 
LAC 251.1 108.1 91.1 90 5 7.3 + 
LEV 171.1 154.0 69.1 50 5 3.7 + 
LIC/S-LC 255.1 194.1 237.2 80 20 8.6 + 
LTG 256.1 166.0 211.0 180 30 7.8 + 
OXC 253.2 180.1 208.1 170 30 9.4 + 
PBT 231.1 188.2 85.0 100 5 8.3 - 
PGR 160.2 142.2 97.1 140 10 3.4 + 
PHT 251.2 102.0 208.2 110 10 11.0 - 
p-HPPH 267.2 118.1 224.1 125 10 7.9 - 
RFM 239.0 127.0 222.0 90 20 7.3 + 
RTG 304.2 230.1 258.1 140 20 12.9 + 
NA-RTG 274.3 256.0 232.1 115 10 9.3 + 
STP 217.2 159.2 187.2 100 10 14.3 + 
TIG 376.1 247.1 278.2 140 20 13.4 + 
TPR 338.1 78.0 96.0 160 20 8.6 - 
VIG 130.1 113.1 71.0 65 10 1.6 + 
VPA 143.1 143.1 n/a 100 0 11.7 - 
ZNS 211.2 119.1 147.1 115 10 6.5 - 
Internal Standards       
CBZ-DiOH 239.1 194.1 n/a 140 20 12.8 + 
GBP-D10 182.1 164.3 n/a 110 10 3.3 + 
TUB 269.2 170.0 n/a 120 10 11.1 - 
a: Fragmentor voltage,  b: collision energy, c: retention time. 
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Figure  5-2: The Chromatogram of the 22 AEDs Using the Extracted Medium QC (20 mg/L for 
Group 1, 4 mg/L for Group 2 and 200 mg/L for Group 3) from Plasma. 
 
Although Agilent 6420 and 6430 mass spectrometry systems are from the same series, 
there were some variations regarding the product ions and the collision energy for some 
drugs (Chapter 2, Table 2-13). For instance, with Agilent 6430, the eslicarbazepine acetate 
quantifier ion was 194.1 which presented the highest abundance under the same conditions 
and 237.2 was used as a qualifier ion whereas it was the other way round using the Agilent 
6420. This was also noticed for oxcarbazepine and levetiracetam. For other drugs like 
phenytoin, the quantifier ion was completely different; 102 instead of 180. Some drugs had 
the same quantifier ion but different qualifier ion such as carbamazepine and 
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carbamazepine epoxide; 192 instead of 179 and 210.1 instead of 180 respectively. This 
variation is expected with LC/MS/MS due to the mechanism of ionization. ESI collision-
induced fragmentations are often not very peak-rich, so they are often not such good 
"fingerprints" as electron impact ionization (EI) spectra that are used in GC/MS, hence, 
they can vary with instrument and conditions. 
5.3.2 MRM vs DMRM 
DMRM was used successfully with the original method using the Agilent 6420 mass 
spectrometer. However, this was not the case when the method was transferred to the 
Agilent 6430. Two of the internal standards, TUB and CBZ-DiOH exhibited poor 
sensitivity using DMRM in spite of the experiments carried out to adjust the method 
parameters and the gradient system to achieve the same results as the original method. 
Hence, the method was developed using MRM with ion mode switching instead of DMRM 
and the dwell time was adjusted to give good sensitivity and peak shape for all the drugs 
with acceptable LOQs.  
5.3.3 Selectivity and Specificity 
No endogenous or exogenous interference was observed and none of the AEDs or their 
internal standards showed any interference at the retention time of the other drugs included 
in the method. The generated results from plasma and serum were comparable to the whole 
blood selectivity study in the original method (See ‎3.3.1, Chapter 3). The results were 
consistent with those expected as the 3 matrices are from the same origin and the only 
difference being the red cell content and fibrinogen factor. Plasma is produced when whole 
blood is collected in tubes that are treated with an anticoagulant and red cells are removed 
by centrifugation, whereas serum is plasma without clotting agents as the whole blood is 
left to clot first before centrifugation. 
5.3.4 Limits of Detection and Limits of Quantification 
Instrument and assay LOD, LLOQ and LOQ results of 22 AEDs compared to the original 
method LOQ are presented in Table ‎5-7. Assay LODs, LLOQs and LOQs had the same 
values in blood, plasma and serum; whereas the instrument LODs were slightly lower than 
the assay LODs for ESL, S-LC, NA-RTG and VIG. Compared to the original method, the 
LOQs for all drugs were the same except pregabalin and oxcarbazepine which had a 
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slightly higher LOQ using MRM compared to DMRM (1.0 and 0.1 mg/L instead of 0.5 
and 0.05 mg/L respectively) but the calibration range was still fit for purpose.  
Table  5-7: Instrument and Assay LOD, LLOQ and LOQ of 22 AEDs in Whole Blood, Plasma 
and Serum Compared to the Original Method LOQs. 
AED 
Instrument 
LOD (mg/L) 
Assay LOD 
(mg/L) 
LLOQ 
(mg/L) 
LOQ 
(mg/L) 
Original  LOQ 
(mg/L) 
CBZ 0.1 0.25 0.5 0.5 0.5 
CBZO 0.05 0.05 0.25 0.5 0.5 
ESL 0.1 0.25 0.5 0.5 0.5 
GBP 0.1 0.1 0.25 0.5 0.5 
LAC 0.05 0.05 0.25 0.5 0.5 
LEV 0.1 0.1 0.5 5.0 5.0 
S-LC 0.05 0.1 0.25 0.5 n/a 
LTG 0.25 0.25 0.5 0.5 0.5 
OXC 0.05 0.05 0.1 0.1 0.1 
PBT 1.0 1.0 2.5 2.5 n/a 
PGR 0.5 0.5 1.0 1.0 0.5 
PHT 0.5 0.5 1.0 1.0 1 
p-HPPH 0.5 0.5 1.0 1.0 1 
RFM 0.1 0.1 0.25 0.5 n/a 
RTG 0.025 0.025 0.05 0.05 0.05 
NA-RTG 0.01 0.025 0.05 0.1 n/a 
STP 0.25 0.25 0.5 0.5 n/a 
TIG 0.01 0.01 0.025 0.05 0.05 
TPR 0.25 0.25 0.5 0.5 0.5 
VIG 0.1 0.5 1.0 5.0 5.0 
VPA 2.5 2.5 5.0 5.0 5.0 
ZNS 0.5 0.5 1.0 1.0 1.0 
 
5.3.5 Linearity 
The same calibration models were used for whole blood, serum and plasma. They were 
linear over the wide range of concentrations tested with an R² greater than 0.99 using a 
weighting of 1/X for all drugs in whole blood, serum and plasma except for CBZ, CBZO, 
ESL, LAC, LEV, LTG and VIG where quadratic regressions were used with a weighting 
of 1/X (Table ‎5-8).  Seven drugs used quadratic regression in the transferred method 
compared to only lamotrigine in the original method, however, using this model, 
regression did not affect the validation process and the results were reproducible. 
Non-linear calibrations over wide ranges are more common with LC/MS/MS (258, 259, 
277, 278). Quadratic regression may result when the proportionality between the analyte/IS 
response ratio and the analyte concentration is lost due to some phenomena during sample 
preparation, LC analysis or MS analysis. This may lead to a bias of analyte/IS ratio 
resulting in non-linearity of the standard curve. The same was observed when using 
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different instruments or the same instrument but over a long period of time. The curve fit 
appeared to change from linear to quadratic due to the sensitivity variation between 
instruments or with time on the same instrument (279). Another reason for a non-linear 
calibration curve is the use of analog internal standards instead of deuterated ones. 
Deuterated internal standards usually compensate for variability during sample preparation 
and analysis process and minimize the matrix effect.  However, quadratic calibrations 
using deuterated internal standards have also been reported (279). In such cases, non-linear 
ranges are caused by saturation at high concentrations during ionization or by detector 
saturation (280, 281). Nevertheless, using quadratic calibration curves, extends the 
dynamic range of the standard curves and allows a broader concentration range to be used 
that can save time, consumables, and labour by avoiding sample dilution. 
Retigabine passed the validation with the transferred method even although the same 
mobile phase, column and LC/MS conditions used in the original method were applied. 
One reason for this would be the high pump pressure that occurred during the first project 
which may have affected the late elution of retigabine towards the end of the method 
(retention time: 15 minutes).  
Table  5-8: Calibration Model and Linearity Results in Whole Blood, Plasma and Serum. 
AED 
Calibration 
Range (mg/L) 
Internal 
Standard 
Calibration  
Model 
Whole blood 
R² (n=5) 
Plasma 
R² (n=5) 
Serum 
R² (n=5) 
CBZ 0.5-50 CBZ-DiOH Quadratic 0.999 0.999 0.999 
CBZO 0.5-50 CBZ-DiOH Quadratic 0.999 0.998 0.998 
ESL 0.5-50 CBZ-DiOH Quadratic 0.999 0.996 0.999 
GBP 0.5-50 GBP-D10 Linear 0.998 0.998 0.999 
LAC 0.5-50 GBP-D10 Quadratic 0.999 0.997 0.998 
LEV 5.0-300 GBP-D10 Quadratic 0.999 0.999 0.999 
S-LC 0.5-50 CBZ-DiOH Linear 0.9997 0.999 0.998 
LTG 1.0-50 GBP-D10 Quadratic 0.9995 0.997 0.998 
OXC 0.1-10 CBZ-DiOH Linear 0.999 0.999 0.999 
PBT 2.5-50 TUB Linear 0.999 0.995 0.998 
PGR 1.0-50 GBP-D10 Linear 0.997 0.999 0.998 
PHT 1.0-50 TUB Linear 0.9997 0.996 0.998 
p-HPPH 1.0-50 TUB Linear 0.998 0.999 0.999 
RFM 0.5-50 GBP-D10 Linear 0.999 0.996 0.996 
RTG 0.05-10 CBZ-DiOH Linear 0.999 0.998 0.997 
NA-RTG 0.1-10 CBZ-DiOH Linear 0.996 0.996 0.997 
STP 0.5-50 TUB Linear 0.994 0.998 0.998 
TIG 0.05-10 CBZ-DiOH Linear 0.998 0.997 0.997 
TPR 0.5-50 TUB Linear 0.997 0.998 0.999 
VIG 5.0-300 GBP-D10 Quadratic 0.999 0.998 0.999 
VPA 5.0-300 TUB Linear 0.997 0.999 0.999 
ZNS 1.0-50 TUB Linear 0.996 0.999 0.999 
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5.3.6 Accuracy and Precision 
Accuracy and precision results are presented in Table ‎5-9, Table ‎5-10 and Table ‎5-11for 
whole blood, plasma and serum respectively. As mentioned previously, precision and 
accuracy for AEDs included in the original method were assessed using two concentrations 
while serum and plasma were assessed using three concentrations. The intraday precision 
values were < 9.0% for whole blood, < 10% for plasma (except PBT where the medium 
QC was 16.2% in plasma) and < 9.0% for serum. The inter-day precision values were < 
14.4% for whole blood, < 13.1% for plasma and serum. The accuracy values were within 
the acceptable range of ±15% of the nominal concentrations. The intra-day accuracy was 
between 91.4-113% for whole blood, 89.7-110.6% for plasma and between 85.7-113.2% 
for serum. The inter-day accuracy was between 90.9-113% for whole blood, 91.7-110.6% 
for plasma and between 91.8-111.8% for serum. 
Table  5-9: Intra- and Inter-day Precision and Accuracy Results of Whole Blood Using 3 
Different QCs at  Different Concentrations of 3, 20 and 40 mg/L for Group 1; 2, 4 and 9 mg/L 
for Group 2; and 20, 120 and 200 mg/L for Group 3. 
AED 
Precision  Accuracy  
Intra-day (%) 
(n=3) 
Inter-day (%) 
(n=15) 
Intra-day (%) 
(n=3) 
Inter-day (%) 
(n=15) 
 
Low Medium High Low Medium High Low Medium High Low Medium High 
CBZ 5.0 n/a 6.4 9.1 n/a 7.6 100.4 n/a 99.9 100.4 n/a 99.9 
CBZO 2.9 n/a 4.7 6.7 n/a 13.1 103.4 n/a 112.4 103.4 n/a 93.7 
ESL 5.2 n/a 5.8 12.6 n/a 14.4 91.4 n/a 94.5 91.4 n/a 110.2 
GBP 4.0 n/a 5.7 9.1 n/a 4.3 99.9 n/a 102.2 94.9 n/a 102.0 
LAC 3.1 n/a 4.2 7.5 n/a 15.9 109.0 n/a 93.3 109.0 n/a 93.3 
LEV 4.4 n/a 3.6 8.3 n/a 10.4 107.8 n/a 96.0 107.8 n/a 96.0 
LIC/S-LC 2.2 4.8 6.6 5.8 5.4 7.4 105.9 108.4 101.3 105.9 108.4 101.3 
LTG 7.9 n/a 8.2 11.7 n/a 14.2 97.5 n/a 101.8 97.5 n/a 100.3 
OXC 5.5 n/a 7.5 7.1 n/a 11.1 95.4 n/a 112.1 95.4 n/a 112.1 
PBT 4.1 5.9 9.0 2.9 12.9 5.2 98.8 98.3 103.0 94.9 98.3 103.0 
PGR 6.5 n/a 5.9 13.9 n/a 13.6 95.7 n/a 99.5 104.2 n/a 99.5 
PHT 8.1 n/a 8.8 9.7 n/a 3.8 100.1 n/a 103.9 100.1 n/a 90.9 
p-HPPH 7.0 n/a 5.2 8.4 n/a 11.3 97.6 n/a 95.0 97.6 n/a 95.0 
RFM 2.4 4.1 3.2 3.7 9.7 3.5 108.7 106.0 96.4 108.7 106.0 96.4 
RTG 6.4 6.6 6.5 4.7 6.7 8 106.8 106.1 101.8 101.8 106.8 106.1 
NA-RTG 7.8 5.5 5.7 12.7 8.8 7.0 98.5 100.5 101.7 98.5 100.5 101.7 
STP 5.9 6.2 7.1 4.6 9.6 3.5 106.5 98.7 101.4 106.5 98.7 101.5 
TIG 5.2 n/a 2.9 14.0 n/a 9.2 113.0 n/a 97.6 113.0 n/a 97.6 
TPR 4.9 n/a 5.2 6.9 n/a 5.3 102.3 n/a 98.5 102.3 n/a 98.5 
VIG 4.7 n/a 4.1 9.0 n/a 7.8 99.8 n/a 99.6 99.8 n/a 99.6 
VPA 4.5 n/a 5.6 8.4 n/a 5.9 111.1 n/a 101.5 105.8 n/a 101.5 
ZNS 2.9 n/a 5.4 6.7 n/a 4.7 103.4 n/a 94.7 103.4 n/a 94.7 
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Table  5-10: Intra- and Inter-day Precision and Accuracy Results of Plasma Using 3 Different 
QCs at  Different Concentrations of 3, 20 and 40 mg/L for Group 1; 2, 4 and 9 mg/L for Group 
2; and 20, 120 and 200 mg/L for Group 3. 
AED 
Precision  Accuracy  
Intra-day (%) 
(n=3) 
Inter-day (%) 
(n=15) 
Intra-day (%) 
(n=3) 
Inter-day (%) 
(n=15) 
 
Low Medium High Low Medium High Low Medium High Low Medium High 
CBZ 1.1 2.2 1.6 1 0.2 4 97.9 101.3 102.5 97.9 101.3 102.5 
CBZO 3.2 0.9 1.9 4.9 3.3 1.6 101.0 104.6 101.1 101.0 104.6 101.1 
ESL 1.8 4.9 1.8 2.4 4.3 5.4 99.9 93.4 99.5 99.9 106.7 99.5 
GBP 1.4 2.6 0.8 0.8 2.7 3.5 96.2 98.3 104.6 105.8 98.3 104.6 
LAC 1.5 1.7 1.3 1.9 3.6 4.5 99.2 100.1 100.7 99.2 100.1 100.7 
LEV 2.6 1.4 3.6 2.1 4.2 2.9 96.5 96.3 97.3 96.5 96.3 97.3 
LIC 1.4 1.3 4.3 5.4 5.6 0.7 101.1 101.5 91.7 101.1 101.5 91.7 
LTG 2.8 2.6 3.1 6.5 10.3 10.7 110.6 103.3 99.9 110.6 103.3 103.1 
OXC 2.3 4.3 2.7 4.6 1.6 3.7 95.2 107.7 100.2 95.2 107.7 100.2 
PBT 5.0 16.2 6.0 7.9 4.7 3.9 93.7 92.2 105.0 93.7 92.2 91.9 
PHT 10.0 6.1 4.6 2.0 3.9 3.8 96.6 103.8 101.8 106.3 103.8 101.8 
PGR 8.7 3.6 2.0 4.3 12.0 12.0 102.1 98.0 105.0 102.1 98.0 107.0 
HPPH 9.9 7.4 4.5 2.4 10.9 2.8 95.4 100.2 97.9 95.4 100.2 97.9 
RFM 3.3 1.3 0.9 13.1 4.2 0.2 107.1 104.0 102.5 107.1 104.0 102.5 
RTG 2.6 6.9 2.1 0.8 6.5 8.2 89.6 106.5 96.2 99.1 106.5 100 
NA-RTG 2.3 2.6 2.7 2.8 4.7 4.8 107.8 103.4 102.8 107.8 103.4 102.8 
STP 5.0 3.8 3.2 2.8 9.9 6 98.5 108.7 103.8 103.8 100.1 98.5 
TIG 3.2 2.2 1.0 9.1 8 9.2 102.5 108.8 96.1 102.5 102.9 96.6 
TPR 7.6 3.7 3.3 7.6 2.0 1.5 103.9 103.3 103.1 103.9 103.3 103.1 
VIG 2.6 4.9 1.4 5.6 2.6 1.7 98.5 97.3 98.9 98.5 97.3 98.9 
VPA 3.5 3.0 2.7 4.3 3.9 0.7 95.0 101.4 104.0 95.0 101.4 104.0 
ZNS 8.7 7.2 3.1 7.3 8.6 3.9 105.6 98.9 108.5 105.6 98.9 95.0 
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Table  5-11: Intra- and Inter-day Precision and Accuracy Results of Serum Using 3 Different 
QCs at  Different Concentrations of 3, 20 and 40 mg/L for Group 1; 2, 4 and 9 mg/L for Group 
2; and 20, 120 and 200 mg/L for Group 3. 
AED 
Precision  Accuracy  
Intra-day (%) 
(n=3) 
Inter-day (%) 
(n=15) 
Intra-day (%) 
(n=3) 
Inter-day (%) 
(n=15) 
 
Low Medium High Low Medium High Low Medium High Low Medium High 
CBZ 2.4 1.9 1.1 1.0 0.7 2.6 98.2 98.3 99.9 98.2 98.3 99.9 
CBZO 2.8 0.9 2.9 4.8 0.4 0.5 94.1 103.6 95.4 94.1 103.6 95.4 
ESL 2.2 3.6 1.9 5.4 5.0 7.7 93.2 85.7 96.8 93.2 97.9 96.8 
GBP 2.2 2.5 2.0 1.8 3.9 0.6 96.7 96.3 103.3 106.3 96.3 103.3 
LAC 1.9 2.7 3.7 4.2 1.1 2.7 96.2 96.3 100.7 96.2 96.3 100.7 
LEV 1.8 2.2 0.8 0.6 0.9 3.7 94.3 96.7 94.2 94.3 96.7 94.2 
LIC 1.1 1.8 2.3 1.7 2.0 2.1 106.2 107.3 104.8 106.2 107.3 104.8 
LTG 1.2 1.6 2.3 3.7 2.6 4.8 107.9 94.6 92.1 107.9 94.6 92.1 
OXC 2.0 2.7 2.8 4.6 1.0 4.7 95.3 102.9 97.8 95.3 102.9 97.8 
PBT 3.1 8.0 4.3 4.0 10.0 2.8 107.7 102.0 97.4 107.0 101.0 97.4 
PHT 4.6 9.0 3.3 5.5 9.6 4.9 105.9 101.9 97.9 105.9 101.9 97.9 
PGR 5.5 3.1 2.9 2.2 4.3 5.7 94.3 101.5 113.2 94.3 96.9 109.8 
HPPH 1.6 8.7 4.2 7.7 5.7 5.7 101.4 102.8 99.4 101.4 102.8 99.4 
RFM 1.8 3.0 1.7 7.2 1.2 3.4 105.3 107.7 102.1 105.3 107.7 102.1 
RTG 2.1 1.3 2.6 2.2 0.5 7.6 103.0 110.5 97.6 103.0 110.5 97.6 
NA-RTG 1.9 2.5 1.6 4.5 1.6 3.8 107.5 98.8 100.2 107.5 98.8 100.2 
STP 1.2 4.4 2.9 6.8 7.6 2.9 104.1 98.6 106.4 104.1 110.9 106.4 
TIG 1.6 0.7 4.3 7.7 6.2 5.7 111.8 92.3 103.2 111.8 92.3 91.8 
TPR 4.0 4.6 4.7 3.3 4.0 3.3 106.0 102.1 100.8 106.0 102.1 100.8 
VIG 1.2 3.1 1.9 2.0 6.6 7.8 93.0 93.8 96.8 93.0 93.8 96.8 
VPA 4.8 4.6 4.3 0.6 3.2 2.4 94.0 102.7 107.6 94.0 102.7 107.6 
ZNS 3.1 3.6 6.1 2.0 13.1 5.3 101.8 104.2 112.5 101.8 104.2 98.4 
 
5.3.7 Matrix Factor and Recovery  
The matrix factor and recovery results of 2 QCs (low and high) using 6 different sources of 
matrix are detailed in Table ‎5-12 and Table ‎5-13 for the 22AEDs in plasma and serum 
respectively and  
Table ‎5-14 for new drugs added in whole blood. Matrix factor values were within the 
acceptable range for all the drugs (within ± 1.25) with standard deviation less than 20%. 
Recovery was greater than 79% for all the AEDs in the three matrices except RTG and its 
metabolite NA-RTG which were about 70% in whole blood compared to their recoveries 
from serum and plasma which were greater than 93%. The recovery and matrix effect 
results in blood were comparable to the values obtained in the original method except for 
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retigabine (> 71%). Its recovery and matrix factor in the original method were 33% and 
0.33 respectively. Interestingly, retigabine exhibited better recovery and acceptable matrix 
suppression effect (MF = 0.85) in the transferred method.   
Table  5-12: Recovery and Matrix Factor Values for 22 AEDs Using Low and High QCs (3 and 
40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L for Group 3) in Plasma 
(n=6 per QC). 
AEDs 
QC1 QC2 
Recovery (%) Matrix Factor Recovery (%) Matrix Factor 
CBZ 102 1.06±0.01 98 1.10±0.04 
CBZO 101 1.07±0.02 99 1.08±0.04 
ESL 99 1.04±0.02 95 1.06±0.05 
GBP 101 1.04±0.02 98 1.13±0.06 
LAC 104 1.09±0.01 99 1.10±0.03 
LEV 104 1.13±0.03 97 1.06±0.04 
S-LC 105 1.11±0.01 102 1.12±0.03 
LTG 86 1.2±0.04 105 1.14±0.2 
OXC 109 1.03±0.06 96 1.03±0.05 
PBT 79 1.24±0.17 99 1.05±0.07 
PGR 104 1.05±0.08 97 1.15±0.06 
PHT 95 1.10±0.14 98 1.06±0.08 
p-HPPH 109 1.07±0.04 99 1.04±0.08 
RFM 104 1.07±0.04 98 1.09±0.06 
RTG 107 0.88±0.02 93 0.94±0.05 
NA-RTG 103 0.99±0.03 100 1.07±0.05 
STP 100 1.15±0.03 99 1.06±0.05 
TIG 94 0.93±0.17 102 1.09±0.11 
TPR 98 1.18±0.03 98 1.07±0.05 
VIG 100 1.11±0.03 93 1.12±0.06 
VPA 105 1.06±0.07 102 1.04±0.05 
ZNS 104 1.08±0.13 98 1.06±0.05 
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Table  5-13: Recovery and Matrix Factor Values for 22 AEDs Using Low and High QCs (3 and 
40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L for Group 3) in Serum (n=6 
per QC). 
AEDs 
QC1 QC2 
Recovery (%) Matrix Factor Recovery (%) Matrix Factor 
CBZ 104 1.04±0.01 103 1.04±0.08 
CBZO 103 1.04±0.02 102 1.03±0.05 
ESL 104 1.0±0.02 102 0.99±0.06 
GBP 106 0.99±0.02 103 1.03±0.06 
LAC 104 1.07±0.01 103 1.04±0.05 
LEV 105 1.10±0.01 105 0.99±0.08 
S-LC 104 1.09±0.01 105 1.09±0.08 
LTG 102 0.98±0.05 104 1.16±0.09 
OXC 105 1.0±0.06 110 0.91±0.06 
PBT 98 1.07±0.19 108 0.96±0.01 
PGR 109 1.04±0.05 104 1.06±0.06 
PHT 104 1.02±0.07 105 1.01±0.06 
p-HPPH 109 1.06±0.05 102 0.97±0.08 
RFM 104 1.06±0.01 103 1.03±0.07 
RTG 107 0.96±0.03 112 0.89±0.07 
NA-RTG 106 0.98±0.01 103 1.02±0.08 
STP 102 1.15±0.05 105 1.02±0.09 
TIG 108 0.98±0.10 103 1.04±0.05 
TPR 105 1.14±0.04 107 0.98±0.07 
VIG 102 0.77±0.01 101 0.83±0.06 
VPA 103 1.07±0.12 108 0.98±0.08 
ZNS 108 1.08±0.14 107 1.0±0.08 
 
Table  5-14: Recovery and Matrix Factor Values for 7 Added AEDs Using Low and High QCs 
(3 and 40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L for Group 3) in 
Whole Blood (n=6 per QC). 
AEDs 
QC1 QC2 
Recovery (%) Matrix Factor Recovery (%) Matrix Factor 
S-LC 108 1.04±0.06 106 0.99±0.01 
PBT 108 0.93±0.24 107 1±0.10 
RFM 106 1.07±0.06 107 1.0±0.03 
RTG 73 0.85±0.05 71 0.83±0.04 
NA-RTG 66 0.89±0.06 68 0.88±0.02 
STP 109 1.10±0.06 109 1.0±0.03 
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5.3.8 Carryover 
No carry over was observed in the blank samples after two injections of the highest 
standards for all 22 AEDs in whole blood, plasma and serum. Carryover percentage after 
first blank injection was lower than 0.2% for all drugs. Summary of the carryover results is 
detailed in Table ‎5-15. 
Table  5-15: Carryover Results of 22 AEDs After Double Injections of Extracted ULOQ. 
AED 
Peak Area Carryover 
(%)* Mean ULOQ (n=2) Blank 1 Blank 2 Blank 3 
CBZ 926727.8 7.1 0.0 0.0 0.0 
CBZO 126984.6 2.5 0.0 0.0 0.0 
ESL 640708.1 381.1 22.4 133.6 0.1 
GBP 193329.0 53.6 26.6 24.9 0.0 
LAC 344197.0 28.4 32.6 48.5 0.0 
LEV 1119556.1 90.8 0.0 0.5 0.0 
LIC/SLE 283631.2 196.0 26.2 60.5 0.1 
LTG 55358.7 0.0 0.0 0.0 0.0 
OXC 6914.8 0.0 0.0 0.0 0.0 
PBT 4667.8 0.0 0.0 0.0 0.0 
PGR 15696.4 1.9 0.0 0.0 0.0 
PHT 1622.0 0.0 0.0 0.0 0.0 
HPPH 1285.6 0.0 0.0 0.0 0.0 
RTG 39308.8 1.4 0.0 0.0 0.0 
NA-RTG 48539.7 108.8 7.1 0.0 0.2 
RFM 190504.3 122.7 32.2 27.2 0.1 
STP 30858.0 0.0 0.0 0.0 0.0 
TIG 64803.6 0.0 0.1 0.1 0.0 
TPR 7355.7 0.0 0.0 0.0 0.0 
VIG 433236.8 10.6 34.3 32.0 0.0 
VPA 201820.4 0.0 0.0 0.0 0.0 
ZNS 7111.5 0.0 0.0 0.0 0.0 
* Carryover percentage was calculated by dividing blank 1 peak area by ULOQ Mean 
peak area and multiplying by 100. 
 
5.3.9 Stability 
5.3.9.1 Bench Top and Freeze-Thaw Stability  
The stability study showed that all the drugs were stable in whole blood, serum and plasma 
at room temperature (approximately 25ºC) for up to 24 hours (bench top stability) except 
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ESL, OXC , RTG and NA-RTG which showed a loss of about 70%, 20%, 21% and 36% 
respectively of their nominal concentrations in the three matrices. Interestingly, valproic 
acid exhibited instability in this study and it lost about 50% of its nominal concentration in 
the 3 matrices, whereas it showed a good stability in the original method. The variation in 
the results may be due to different room temperatures and the variation between 
geographical areas and lab atmosphere where the tests were carried out. Hence, bench top 
stability should be evaluated as part of any method validation and cannot rely on 
information published in the literature. Regarding, freeze-thaw stability, all AEDs 
including RTG, NA-RTG, ESL and OXC were stable after 3 freeze-thaw cycles at - 20 ºC 
in all three matrices.  
5.3.9.2 In Process Stability 
Autosampler stability was evaluated by re-injecting extracted QCs spiked in plasma in 
triplicate. Samples were stored on the autosampler until the next analysis. All AED 
extracted samples were stable in the autosampler (approximately 25ºC) for up to 72 hours. 
While RTG, NA-RTG, ESL and OXC were not stable in whole blood, their stability was 
acceptable after extraction and reconstitution in 13% methanol in water. 
A summary of all bench top, freeze-thaw and autosampler stability study values for whole 
blood, plasma and serum is detailed in Table ‎5-16, Table ‎5-17, Table ‎5-18 and Table ‎5-19. 
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Table  5-16: Bench Top and Freeze-Thaw Stability Results of 22 AEDs in Whole Blood at 
Concentrations of 3 and 40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L 
for Group 3. 
AED 
Bench Top Stability Freeze-Thaw Stability 
QC1 (mg/L, n=3) QC2 (mg/L, n=3) QC (mg/L, n=3) 
T=0* T=24 R (%) T=0 T=24 R (%) T=0 C3** R (%) 
CBZ 8.1 6.5 80.2 40.5 32.3 79.8 1.8 2.0 111.1 
CBZO 8.3 7.9 95.2 29.7 24.4 82.2 6.5 7.3 112.3 
ESL 7.5 1.6 20.7 33.8 11.8 34.8 1.5 1.2 80.0 
GBP 7.1 6.8 95.8 37.0 37.5 101.4 1.8 2.1 116.7 
LAC 9.3 7.5 80.6 41.6 37.5 90.1 1.9 1.8 94.7 
LEV 46.9 33.1 70.6 153.6 123.6 80.5 175.7 140.1 79.7 
LIC/SLE 9.2 11.2 121.7 33.6 41.4 123.2 2.2 2.4 109.1 
LTG 8.5 7.9 92.9 36.5 34.0 93.2 1.4 1.3 92.9 
OXC 2.2 1.8 81.8 9.3 7.9 84.9 4.6 4.1 89.1 
PBT 8.3 10.1 121.7 38.7 43.3 111.9 2.2 2.1 95.5 
PGR 8.6 10.3 119.8 47.5 45.6 96.0 2.5 2.4 96.0 
PHT 8.3 7.9 95.2 36.6 38.6 105.5 3.6 4.0 111.1 
HPPH 8.6 8.7 101.2 38.6 39.4 102.1 2.7 2.4 88.9 
RTG 2.4 1.9 79.2 9.9 7.9 79.8 2.7 2.1 77.8 
NA-RTG 2.6 1.6 61.5 5.3 3.4 64.2 0.6 0.5 84.7 
RFM 10.3 19.5 189.3 9.4 18.1 192.6 4.4 4.6 104.5 
STP 8.8 6.4 72.7 42.7 38.8 90.9 1.3 1.5 115.4 
TIG 2.4 2.4 100.0 7.7 7.4 96.5 3.9 3.4 87.2 
TPR 8.2 7.1 86.6 35.3 32.6 92.4 1.7 1.9 111.8 
VIG 50.2 37.4 74.5 162.3 135.9 83.7 13.1 15.4 117.6 
VPA 46.9 15.4 32.8 158.7 94.6 59.6 21.8 24.6 112.8 
ZNS 8.9 8.0 89.7 39.0 41.8 107.2 4.3 5.1 118.6 
* T represents time in hours. **C3: concentration values after third freeze-thaw cycle 
 
 
  
Chapter 5  176 
 
C
h
ap
ter 4
 
 
1
7
6
 
Table  5-17: Bench Top and Freeze-Thaw Stability Results of 22 AEDs in Plasma at 
Concentrations of 3 and 40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L 
for Group 3. 
AED 
Bench Top Stability Freeze-Thaw Stability 
QC1 (mg/L, n=3) QC2 (mg/L, n=3) QC 2 (mg/L, n=3) 
T=0* T=24 R (%) T=0 T=24 R (%) T=0 C3** R (%) 
CBZ 8.1 7.5 92.6 43.0 37.2 86.6 3.5 4.1 117.1 
CBZO 7.7 6.9 89.3 30.0 25.6 85.3 13.0 15.2 116.7 
ESL 7.2 5.2 72.2 33.0 26.3 79.6 2.9 3.2 110.7 
GBP 6.9 6.3 91.1 35.2 37.2 105.6 3.6 4.0 111.5 
LAC 8.6 7.9 91.9 42.7 39.1 91.5 4.1 4.8 117.1 
LEV 44.6 39.2 87.9 149.3 129.2 86.6 176.7 182.1 103.1 
LIC/SLE 7.7 8.4 108.2 32.4 28.2 87.1 3.4 3.8 111.5 
LTG 7.3 7.4 101.8 28.1 30.4 108.1 2.6 3.0 115.4 
OXC 2.1 1.7 79.3 9.2 6.5 71.1 5.2 6.1 117.3 
PBT 7.0 6.2 88.6 35.5 30.2 85.1 3.1 3.6 118.7 
PGR 6.1 5.9 96.2 30.6 29.6 96.8 4.4 3.5 79.5 
PHT 8.0 7.6 95.3 38.6 30.9 80.1 5.5 5.4 98.2 
HPPH 7.3 6.3 86.5 39.9 35.9 90.0 3.4 4.0 117.6 
RTG 2.0 1.5 74.6 7.4 5.4 73.0 4.0 4.9 121.6 
NA-RTG 2.2 1.6 73.4 4.3 3.1 72.1 0.9 1.1 122.2 
RFM 8.9 8.3 93.3 18.4 16.6 89.9 4.5 4.4 96.9 
STP 7.8 6.7 85.9 40.4 35.5 88.0 2.9 2.8 96.9 
TIG 1.9 2.1 111.7 6.1 6.8 110.7 4.9 5.4 110.2 
TPR 8.2 7.2 87.8 35.4 30.3 85.6 3.8 4.1 107.9 
VIG 42.7 39.2 91.7 149.5 129.2 86.4 7.5 9.1 121.2 
VPA 46.0 13.7 29.8 157.0 75.1 47.8 19.9 20.2 101.5 
ZNS 7.4 6.7 90.0 37.6 32.3 85.8 5.4 5.8 107.4 
* T represents time in hours. **C3: concentration values after third freeze-thaw cycle   
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Table  5-18: Bench Top and Freeze-Thaw Stability Results of 22 AEDs in Serum at 
Concentration of 3 and 40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L for 
Group 3. 
AED 
Bench Top Stability Freeze-Thaw Stability 
QC1 (mg/L, n=3) QC2 (mg/L, n=3) QC2 (mg/L, n=3) 
T=0* T=24 R (%) T=0 T=24 R (%) T=0 C3** R (%) 
CBZ 7.9 7.5 94.9 41.2 35.0 85.0 5.6 6.5 116.1 
CBZO 8.8 8.9 101.1 28.7 26.3 91.6 21.8 22.7 104.1 
ESL 7.0 5.1 72.9 32.1 21.7 67.6 4.6 5.5 119.6 
GBP 7.0 6.3 90.0 36.3 32.3 89.0 5.5 6.3 114.5 
LAC 8.8 8.1 92.0 43.3 36.2 83.6 5.9 6.7 113.6 
LEV 43.3 34.4 79.4 146.7 135.0 92.0 180.6 150.4 83.3 
LIC/SLE 8.8 9.4 106.8 32.1 29.8 92.8 6.7 7.2 107.5 
LTG 7.8 7.2 92.3 34.0 28.7 84.4 5.5 6.3 114.5 
OXC 2.1 2.4 114.3 9.1 5.8 64.1 4.7 5.4 114.9 
PBT 8.8 7.1 80.7 42.3 37.2 87.9 7.4 7.4 100.0 
PGR 8.1 6.3 77.8 46.1 40.2 87.2 4.3 5.1 118.6 
PHT 9.0 7.6 84.4 41.3 38.4 93.0 4.5 4.8 106.7 
HPPH 8.7 7.5 86.2 42.4 35.5 83.7 5.2 5.4 103.8 
RTG 2.2 1.7 77.3 8.6 6.0 69.8 5.0 5.1 102.4 
NA-RTG 2.0 1.4 69.5 4.2 2.8 67.6 0.9 1.0 111.1 
RFM 9.6 8.9 92.7 19.0 16.7 87.9 5.2 4.9 94.2 
STP 9.6 8.4 87.5 44.4 39.0 87.8 3.8 4.5 117.2 
TIG 2.4 2.1 87.5 8.7 7.4 85.1 4.7 4.3 91.9 
TPR 8.5 7.3 85.9 36.5 32.0 87.7 5.5 6.2 112.7 
VIG 45.4 42.4 93.4 158.1 138.0 87.3 10.7 11.6 108.4 
VPA 45.9 22.4 48.8 166.6 82.7 49.6 20.1 22.4 111.4 
ZNS 9.5 8.1 85.3 41.6 35.2 84.6 5.3 5.9 111.3 
* T represents time in hours. **C3: concentration values after third freeze-thaw cycle   
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Table  5-19: In Process (Autosampler) Stability of 22 AEDs Using Extracted QCs in Plasma at 
Concentration of 3 and 40 mg/L for Group 1; 2, 9 mg/L for Group 2; and 20 and 200 mg/L for 
Group 3. 
AED 
QC1 (mg/L, n=3) QC2 (mg/L, n=3) 
T=0* T=72 R (%) T=0 T=72 R (%) 
CBZ 8.1 7.7 94.8 43.0 38.5 89.6 
CBZO 7.7 7.8 100.9 30.0 30.2 100.7 
ESL 7.2 7.1 98.6 33.0 28.3 85.7 
GBP 6.9 7.1 103.4 35.2 39.0 110.7 
LAC 8.6 8.8 101.9 42.7 42.2 98.7 
LEV 44.6 43.3 97.0 149.3 137.5 92.1 
LIC/SLE 7.7 8.1 104.3 32.4 35.3 109.1 
LTG 7.3 8.4 115.2 28.1 37.7 134.2 
OXC 2.1 2.2 101.9 9.2 8.5 93.2 
PBT 7.0 7.5 106.5 35.5 35.8 101.0 
PGR 6.1 7.9 129.3 30.6 31.8 104.1 
PHT 8.0 8.3 103.8 38.6 44.6 115.6 
HPPH 7.3 8.2 112.8 39.9 40.3 101.0 
RTG 2.0 1.6 80.6 7.4 8.8 118.9 
NA-RTG 2.2 2.0 90.4 4.3 3.9 90.3 
RFM 8.9 9.0 101.1 18.4 17.6 95.4 
STP 7.8 9.2 118.1 40.4 44.2 109.5 
TIG 1.9 2.1 113.3 6.1 6.8 110.7 
TPR 8.2 7.7 93.9 35.4 36.0 101.6 
VIG 42.7 43.4 101.6 149.5 142.9 95.6 
VPA 46.0 44.8 97.5 157.0 159.9 101.9 
ZNS 7.4 8.9 119.6 37.6 42.1 111.8 
* T represents time in hours.         
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5.4 Conclusion 
A simple, accurate and cost-effective LC/MS/MS method was transferred for the 
simultaneous quantification of 15 AEDs and 2 metabolites. The method was extended to 
include another 5 compounds; 3 AEDs and 2 metabolites, so a total of 22 AEDs; 
carbamazepine and its metabolite carbamazepine-10,11-epoxide, eslicarbazepine acetate, 
oxcarbazepine and their metabolite S-licarbazepine, gabapentin, lacosamide, lamotrigine, 
levetiracetam, pregabalin, phenobarbital, phenytoin and its metabolite 5-(p-
hydroxyphenyl)-5-phenylhydantoin, retigabine (ezogabine) and its metabolite N-acetyl 
retigabine, rufinamide, stiripentol, topiramate, tiagabine, valproic acid, vigabatrin and 
zonisamide were detected and quantitated in postmortem whole blood, serum and plasma 
using the transferred method. This method was suitable for routine forensic toxicological 
analysis and therapeutic drug monitoring. All AEDs were detected and quantified within 
17 minutes without endogenous interferences. The correlation coefficient (R
2
) was greater 
than 0.994 for all AEDs with accuracy ranging from 90 to 113% and precision < 14.4% for 
all analytes. The recovery ranged from 70% to 98%. No carryover was observed in a blank 
control injected after the highest standard and the matrix effect was acceptable and ranged 
from 80% to 120%.  
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6 Application of a Validated Method For the 
Analysis of AEDs in Biological Matrices 
6.1 Introduction 
The aim behind any method development and validation is its applicability to authentic 
case samples and to insure the accuracy and precision of any drug quantification. In order 
to prove the applicability of the method developed in Chapter 5, the method was verified 
with an anonymous set of 467 biological samples that had previously been quantified by 
NMS Labs, Pennsylvania, US using a variety of different analytical techniques (GC/MS, 
HPLC and LC/MS/MS) and results were compared with the reference lab.  
6.2 Methodology 
467 previously tested samples which had been collected over a period of 3 months from 4
th
 
of December 2013 to 25
th
 of February 2014 were re-tested using the validated method. 
Biological matrices received were whole blood (7 samples), plasma (7 samples) and 
serum/plasma (453 samples). Samples were separated depending on matrix type and then 
classified into groups according to the AED tested by the reference lab (Table ‎6-1).  
Table  6-1: The Number of AED Samples Sent by the Reference Lab For Each Matrix. 
Drug Blood Plasma Serum/Plasma Total No. of Samples 
GBP 1 0 72 73 
LAC 0 1 49 50 
LTG 1 0 43 44 
CBZ 0 0 42 42 
PGR 0 5 36 41 
RFM 0 0 39 39 
TPR 0 0 38 38 
PBT 0 0 35 35 
ZNS 0 0 29 29 
LEV 1 0 25 26 
PHT 3 0 12 15 
TIG 0 0 10 10 
RTG 0 1 8 9 
VPA 0 0 8 8 
STP 1 0 5 6 
VIG 0 0 2 2 
Total 7 7 453 467 
 
The majority of samples received were labelled serum/plasma indicating that the samples 
could be quantified using calibrators prepared in either serum or plasma. Only 7 samples 
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were requested to be specifically tested in plasma. All serum and plasma samples were 
tested by the reference lab for therapeutic drug monitoring purposes. Only 7 whole blood 
samples were received as forensic cases. All samples were kept in the fridge at a 
temperature between 4-8 ºC until the time of analysis. 
Calibration curves, QCs and samples were extracted using protein precipitation in 
methanol as detailed previously (see 5.2.3, 5.2.4 and 5.2.5). A freshly extracted calibration 
curve in the matched matrix was prepared with each batch of samples with two QCs at a 
low and a high concentration. When a large number of samples were prepared for analysis 
in one batch (40-80 samples per batch) QCs were re-injected every 20 samples to ensure 
that the accuracy and precision of the calibration curve were still within the acceptable 
ranges. 
6.2.1 Method Comparison and Statistical Methods  
AED concentrations measured by the reference lab in blood, plasma and serum were 
compared with AEDs measured by the transferred method.  The comparative data was used 
to evaluate the performance of the transferred LC/MS/MS method. Since the true 
concentrations were not known, concentrations quantitated by the reference lab were taken 
as the best estimate available. For each AED, LC/MS/MS concentrations were plotted 
against their values obtained by the reference lab. Using Minitab® 17 (Minitab LTD, UK), 
Pearson correlation, an estimated 95% confidence interval and a regression equation 
describing the line of best fit between the results of two methods was calculated and the 
standard error of this regression slope determined for each drug. 
However, several authors have agreed that the Pearson correlation and the test of 
significance (95% confidence interval) may be misleading and do not reflect the actual 
agreement between two methods (282-287). In the case of the Pearson correlation, the 
results obtained by the two labs could be highly correlated with a systematic difference 
between them. It has been discussed how a high correlation may be associated with a 
considerable lack of agreement between two instruments (283, 285). Also, the range of the 
results significantly affects the value of the correlation coefficient: the higher the range, the 
higher the value of the correlation coefficient (285, 287). The test of significance is aimed 
at detecting the difference not the equivalence, hence, it is considered irrelevant to the 
question of agreement. Furthermore, this test is not applicable in this study due to the small 
number of samples for some drugs (e.g. vigabatrin: 2 samples, stiripentol: 6 samples) and 
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due to the many variations involved; two different laboratories, many drugs, a variety of 
instruments used by the reference lab for AED analysis, different operators and time 
variation between tests (samples were tested over a 3 month period by the reference lab 
whereas all samples were analysed over 4 weeks using the transferred method).  
Bland and Altman suggested using a plot, with bias and precision statistics, to determine 
agreement between methods. The Bland-Altman plot considers the proportion between the 
magnitude of measurements and the error graphically, but not quantitatively. The plot uses 
the difference between the two methods against their means. This allows investigation of 
any possible relationship between the measurement error and the true value. Since the true 
value is not known, the mean of the two measurements is the best estimate available. 
Consequently, agreement between the two measurements was tested by calculating the 
systemic error (bias), and the 95% limits of agreement as bias ± 2 SD, as described by 
Bland and Altman (283).  
6.2.2 Instrumentation 
Samples provided were initially tested by the reference lab using a variety of analytical 
instrumentation with different calibration ranges and limits of quantification. A summary 
of the information provided regarding AED analysis techniques and method LOQs is given 
in Table ‎6-2.  
Therapeutic concentrations and transferred method LOQs have been included for 
comparison. Although LOQs for most AEDs of interest were higher using the transferred 
method, they were still acceptable and below the lowest TDM concentrations. Some drugs 
such as carbamazepine, levetiracetam, retigabine and its metabolite have more than one 
LOQ.  The LOQ for these depends on the method used by the reference lab. For instance, 
carbamazepine is tested using HPLC for total CBZ and CBZO and using immunoassay 
analysis for free CBZ and CBZO. This depends on the clinicians’‎ requirements.‎ The 
reference lab does not test for oxcarbazepine and eslicarbazepine acetate as parents drugs. 
Instead, they test for their metabolite 10-hydroxycarbazepine (MHD or LIC) which is a 
racemic mixture of S and R-licarbazepine (S-LE and R-LE). Phenytoin is also tested as a 
parent drug or as an active metabolite of fosphenytoin. Fosphenytoin is a phosphate ester 
pro-drug of PHT, which does not have significant pharmacological activity (288). 
Therefore, clinical monitoring is concerned only with the plasma concentrations of the 
derived PHT. p-HPPH is not tested by the reference lab. However, the transferred method 
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tests for p-HPPH and LIC as well as their parent drugs phenytoin, oxcarbazepine and 
eslicarbazepine acetate.  
Table  6-2: A Summary of AED Analysis Techniques Used by the Reference Lab and Methods 
LOQs Compared to the Transferred Method. 
AEDs 
Therapeutic 
Concentration (mg/L) 
Method 
LOQ 
Ref Lab 
LOQ 
Ref Lab 
Method 
CBZ 1.7-15 0.5 2/0.5/0.2 HPLC/IA 
CBZO 0.5-2.0 0.5 0.2 HPLC/IA 
ESL 10.0-26.0 0.5 N/A N/A 
GBP 5.0-9.0 0.5 0.1 LC/MS/MS 
LAC 2.5-14.0 0.5 0.5 HPLC 
LEV 10.0-40.0 5 1/2/5 HPLC 
LIC/S-LC 6.0-25.0 0.5 N/A HPLC 
LTG 2.3-5.6 1 0.2 HPLC 
OXC 0.05-1.2 0.1 N/A N/A 
PBT 10.0-40.0 2.5 0.5 GC/MS 
PGR 1.0-5.0 1.0 0.1 LC/MS/MS 
PHT 7.0-20.0 1.0 0.5 HPLC 
p-HPPH 1.0-40.0 1.0 N/A N/A 
RFM 2-7 0.5 0.5 LC/MS/MS 
RTG 0.51-1.85 0.05 0.04/0.4 LC/MS/MS 
NA-RTG 0.015-0.2 0.1 0.04/0.4 LC/MS/MS 
STP 4-22 0.5 0.1 HPLC 
TIG 0.03-1 0.05 0.004 LC/MS/MS 
TPR 2.4-27 0.5 0.2 LC/MS/MS 
VIG 18-77 5 1 LC/MS/MS 
VPA 50-100 5.0 2 HPLC/IA 
ZNS 20-28 1.0 1 HPLC 
 
6.3 Results and Discussion 
6.3.1 Method Comparison 
The method was verified with a set of 467 samples that had previously been quantitated 
during routine case analysis. Six samples were requested to be tested for 2 AEDs. Another 
18 samples were requested to be tested for metabolites as well as parent drugs; 9 samples 
for carbamazepine epoxide and 9 samples for N acetyl retigabine. Thus, the total number 
of requested AEDs and their metabolites was 491 tests. In Table 6-3, the confirmed AEDs 
column represents the number of tests confirmed by the transferred method. Due to the 
simultaneous analysis of 22 AEDs, the transferred method detected an additional 493 
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AEDs. Hence, the total number of AEDs detected by the transferred method was 970 (482 
confirmed by both methods plus an additional 493).  
 Out of 482 confirmed AEDs, only 412 were compared with the reference laboratory 
values. Comparison of the remaining samples was not possible because some of the drugs 
such as carbamazepine, carbamazepine epoxide and valproic acid were analysed for the 
free drug (not bound to blood proteins) by the ref lab whereas the transferred method tests 
for the total concentration (free and protein bound). For other drugs like phenobarbital, the 
reference laboratory values for 5 samples were not available at the time of the project.  
Table  6-3: The Number of Positive AEDs Tested by the Transferred Method in Blood, Plasma 
and Serum Compared to the Reference Laboratory. 
Drug 
No. of 
Requested AEDs 
Confirmed 
AEDs 
Paired 
Results 
Additionally 
Detected AEDs 
Total AEDs 
CBZ 42 42 10 23 65 
CBZO 9 9 5 34 43 
GBP 73 73 73 15 88 
LAC 51 50 49 11 61 
LEV 26 25 25 88 113 
LTG 45 43 42 44 87 
LIC/SLE 0 0 0 21 21 
OXC 0 0 0 19 19 
PBT 35 35 30 38 68 
PGR 41 38 38 6 44 
PHT 15 15 15 57 72 
RFM 39 38 38 2 40 
RTG 9 9 0 1 10 
NA-RTG 9 9 0 1 10 
STP 6 6 5 0 6 
TIG 10 10 10 0 10 
TPR 41 41 41 34 75 
VIG 2 2 2 6 8 
VPA 8 8 1 67 75 
ZNS 30 29 28 26 55 
Total 491 482 412 493 970 
 
There were 21 positive samples for licarbazepine and 19 positive samples for 
oxcarbazepine but eslicarbazepine acetate analysis gave negative results. As these samples 
were not tested for these drugs by the reference laboratory, it was not possible to determine 
whether the compounds found were oxcarbazepine and its metabolite licarbazepine or if 
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they were eslicarbazepine acetate with its two metabolites oxcarbazepine and S-
licarbazepine. Thus, those samples were also excluded from the method comparison 
statistics. 
Retigabine and N-acetyl retigabine were excluded as well due to a stability issue. N-acetyl 
retigabine concentrations decreased considerably from the time samples were tested by the 
ref lab to the time tested by the transferred method (around one month) whereas retigabine 
increased. In order to investigate whether the variation was due to stability of the drugs or 
an analysis performance issue, the samples were retested by the reference laboratory. The 
concentrations were found to decrease further for N-acetyl retigabine and increased for 
retigabine, probably due to the degradation of N-acetyl retigabine to its parent drug. This 
supports the stability results conducted as part of the validation (see 5.3.9). Retigabine 
increase was not been detected during the stability study, however, this may be due to the 
short study period (24 hours) (Table ‎6-4). 
Table  6-4: RTG and NA-RTG Fridge Stability Over a Two Month Period. 
Sample No. 
  
RTG Results* (mg/L) NA-RTG Results* (mg/L) 
Analysis 1 Analysis 2 Analysis 3 Analysis 1 Analysis 2 Analysis 3 
1 8.40 16.92 16.10 4.30 4.79 3.40 
2 0.89 1.67 1.10 0.63 0.21 0.15 
3 0.87 1.81 2.20 9.10 0.49 0.45 
4 0.97 1.25 1.90 9.70 0.37 0.27 
5 1.30 2.95 3.20 9.40 0.65 0.44 
6 1.20 0.30 0.00 0.64 0.07 0.00 
7 2.00 0.70 0.00 1.00 0.56 0.00 
8 0.68 0.68 1.70 0.61 0.28 0.27 
* Analysis 1 and 3 were conducted by the reference laboratory whereas analysis 2 was conducted 
using the transferred method. 
 
 
Paired results (412 samples) were used to create a regression equation describing the line 
of best fit between two methods.  The correlation coefficient for comparison of the 
quantitation results with the reference laboratory methods was very good, giving an R
2
 of 
0.961 (Figure ‎6-1). No interferences were observed with any of the case samples. 
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Figure  6-1: Correlation of AED Concentrations Measured with the Transferred Method 
Versus the Concentrations Measured by the Reference Laboratory for 412 Confirmed AEDs. 
 
Regression equations, Pearson correlations, medians, means and standard deviations were 
calculated for each drug. A summary of the statistical data is presented in Table ‎6-5and 
Table ‎6-6. Median, Mean and Standard deviation for all AEDs were very similar for both 
methods. There was no significant difference between the AEDs values measured by the 
transferred method and the reference laboratory (median: 6.53 mg/L, mean 9.56 ± 9.19 
mg/L vs median: 6.65 mg/L, 9.16 ± 9.22 mg/L, respectively, 95% confidence interval, CI: 
0.0169, 0.3729). 
Table  6-5: Regression Equation
 
and Pearson Correlation for AEDs Tested by the Transferred 
Method and the Reference Laboratory. 
Drug n Regression Equation 
Pearson 
Correlation 
CBZ 15 Validated method concentration = 0.700 + 1.068 Reference lab concentration 0.980 
GBP 72 Validated method concentration = 0.125 + 0.868 Reference lab concentration 0.992 
PGR 33 Validated method concentration =-0.076 + 0.933 Reference lab concentration 0.986 
LEV 24 Validated method concentration = 2.828 + 0.997 Reference lab concentration 0.982 
ZNS 28 Validated method concentration =-0.175 + 1.010 Reference lab concentration 0.989 
RFM 35 Validated method concentration = 2.288 + 0.817 Reference lab concentration 0.977 
LAC 49 Validated method concentration = 0.932 + 0.939 Reference lab concentration 0.970 
LTG 41 Validated method concentration = 0.570 + 0.981 Reference lab concentration 0.988 
PBT 28 Validated method concentration =-0.937 + 0.986 Reference lab concentration 0.983 
TPR 40 Validated method concentration = 0.027 + 1.210 Reference lab concentration 0.987 
PHT 12 Validated method concentration =-0.375 + 1.051 Reference lab concentration 0.979 
TIG 9 Validated method concentration =-0.003 + 1.322 Reference lab concentration 0.994 
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Table  6-6: Median, Mean and Standard Deviation for 18 AEDs Tested by the Transferred 
Method and the Reference Laboratory. 
Drug* 
Transferred Method  Reference Lab 
n 
Median 
(mg/L) 
Mean 
(mg/L) 
SD 
(mg/L) 
n 
Median 
(mg/L) 
Mean 
(mg/L) 
SD 
(mg/L) 
AEDs 412 6.53 9.56 9.19 412 6.65 9.16 9.22 
CBZ 65 7.5 8.7 5.1 10 8.50 7.14 1.48 
CBZO 43 2.41 3.9 5.17 5 1.8 2.8 3.6 
GBP 88 3.8 4.9 4.6 73 4.00 4.79 3.67 
LAC 61 6.7 7.49 4.51 49 6.90 7.21 4.62 
LEV 113 28.1 34.1 24.4 25 14.68 17.32 10.05 
LIC/S-LE 20 21.71 21.96 9.77 0 n/a n/a n/a 
LTG 87 6.0 7.1 6.0 42 4.40 5.62 4.41 
OXC 19 0.18 0.24 0.40 0 n/a n/a n/a 
PBT 68 15.0 19.9 16.8 30 17.00 18.44 12.20 
PGR 44 2.5 4.2 4.7 38 2.60 4.44 4.49 
PHT 72 6.5 7.9 6.4 15 11.75 8.47 4.09 
RFM 40 13.5 16.96 10.18 38 14.00 16.08 10.33 
STP 6 6.52 8.33 4.19 5 5.15 6.55 3.68 
TIG 10 0.03 0.05 0.05 10 0.03 0.04 0.04 
TPR 75 6.9 7.4 5.7 41 4.50 5.28 4.08 
VIG 8 5.5 7.5 6.4 2 n/a n/a n/a 
VPA 75 83.1 82.8 32.4 1 n/a n/a n/a 
ZNS 55 18.4 20.4 14.1 28 16.00 3.18 16.81 
*No positive results for eslicarbazepine acetate and p-HPPH. RTG and NA-RTG excluded 
from the results due to a stability issue. 
 
Even though both methods showed a high correlation for each AED (> 96%); the results do 
not reflect the agreement between them. Bland and Altman plotting in the current study 
showed that the mean difference between the transferred method and the reference 
laboratory was 0.21±1.83 mg/L indicating that the transferred method measured slightly 
higher concentrations than the reference lab methods and that the scatter increases when 
the concentration is greater than 10 mg/L. The lower and upper levels of agreement were -
3.38 and 3.81. Out of 412 samples, only 27 samples were outliers (~7% of the total number 
of compared tests). Mean bias (±SD) and limits of agreement for each AED (95% CI) are 
summarized in Table ‎6-7. (See Appendix 6-1 for correlation and Bland-Altman Graphs for 
each drug). 
Chapter 6  188 
 
C
h
ap
ter 4
 
 
1
8
8
 
 
Figure  6-2: Bland-Altman Plot of the Validated Method Concentrations and the Reference 
Laboratory Concentrations. 
 
Table  6-7: Mean Bias, Standard Deviation and Limits of Agreement at 95% Confidence 
Interval for AEDs. 
Drug n 
Mean Bias ± SD 
(mg/L) 
95% Confidence Interval 
(Limits of Agreement) 
AEDs 412 0.21 ± 1.83 -3.38 - 3.81 
CBZ 15 1.18 ± 1.40 -1.57 - 3.94 
GBP 72 -0.51 ± 0.64 -1.76 - 0.74 
PGR 33 0.37 ±  0.77 -1.88 - 1.13 
LEV 24 2.76 ±  2.28 -1.61 - 7.32 
ZNS 28 0.04 ± 2.56 -4.98 - 5.05 
RFM 35 0.51 ± 2.73 -5.86 - 4.85 
LAC 49 0.50 ± 1.12 -1.7 - 2.69 
LTG 41 0.35 ± 0.68 -0.99 - 1.69 
PBT 28 -1.20 ± 2.27 -5.65 - 3.25 
TPR 40 1.13 ± 1.53 -1.15 - 3.42 
PHT 12 0.05 ± 0.91 -1.73 - 1.84 
TIG 9 0.00 ± 0.03 -0.06 -  0.06 
 
6.3.2 AED Prevalence and Concentration Range 
The number of AEDs detected with concentrations below, within and above the therapeutic 
ranges is detailed in Table ‎6-8. Interestingly, 216 samples were detected with AED 
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concentrations higher than the therapeutic ranges (22.3% of the total 970 detected). S-
licarbazepine, levetiracetam, rufinamide, carbamazepine epoxide, and valproic acid 
accounted for most of these in 45, 34, 32, 27 and 20 samples respectively. Considering that 
only 9 samples were requested to be tested for carbamazepine epoxide, this means that 
more than 20 samples have non controlled high concentrations. Similarly, S-licarbazepine 
concentrations were high in 45 samples and none of these were requested for therapeutic 
drug monitoring. On the other hand 196 samples were below the therapeutic concentrations 
(20.2%). Phenytoin, zonisamide, gabapentin and phenobarbital account for most of these 
with 39, 31, 27 and 21 samples respectively. Overall more than 42% of samples were not 
within the published therapeutic ranges and were not requested to be tested. 
Table  6-8: AED Concentration Ranges, Number of AEDs Below, Within and Above the 
Therapeutic Range. 
Drug 
Therapeutic 
Concentration 
(mg/L) 
Sample 
Concentration 
Range (mg/L) 
No. of 
Samples 
below 
Therapeutic 
range 
No.  of 
Samples 
Within 
Therapeutic 
range 
No.  of 
Samples 
above 
Therapeutic 
range 
CBZ 1.7-15 0.4-20.16 1 60 4 
CBZO 0.5-2.0 0.04-23.86 0 16 27 
GBP 5.0-9.0 0.2-24.58 27 53 8 
LAC 2.5-14.0 0.5-24.98 8 48 5 
LEV 10.0-40.0 0.97-122.11 7 72 34 
LIC/S-LE 6.0-25.0 3.16-39.71 17 25 45 
LTG 2.3-5.6 0.5-44.2 0 16 5 
OXC 0.05-1.2 0.02-1.95 0 18 1 
PBT 10.0-40.0 2.68-107.11 21 41 6 
PGR 1.0-5.0 0.3-18.79 4 28 12 
PHT 7.0-20.0 0.38-32.62 39 32 1 
RFM 2-7 2.79-40.8 0 8 32 
RTG 0.51-1.85 0.3-16.92 0 9 1 
NA-RTG 0.015-0.2 0.21-4.79 1 6 3 
STP 4-22 4.0-14.8 0 6 0 
TIG 0.03-1 0.006-0.131 5 5 0 
TPR 2.4-27 0.44-32.10 19 55 1 
VIG 18-77 1.07-19.64 7 1 0 
VPA 50-100 13.23-200.7 9 46 20 
ZNS 20-28 2.0-76.12 31 13 11 
Total number of samples 196 558 216 
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Out of the 467 samples, only 6 samples were requested to be tested for more than one drug. 
However, sample reanalysis revealed that 43% of these samples had only one AED, 
whereas 57% of the samples had at least 2 AEDs (Figure ‎6-3). Half of the samples had 
either 2 AEDs (30%) or 3 AEDs (20%). Interestingly, 33 serum samples had 4, 5 and 6 
AEDs in 5%, 2% and 0.2% of the cases respectively. Plasma samples had a maximum of 3 
AEDs per sample whereas blood samples had only one AED except for one sample which 
had 2 AEDs (Table ‎6-9). 
 
Figure  6-3: Percentage of AEDs Detected Per Sample. 
 
Table  6-9: Number of AEDs Detected Per Sample for Each Matrix. 
AEDs No. Blood Plasma Serum 
1 6 3 189 
2  1 1 139 
3  0 3 92 
>4  0 0 33 
Total 7 7 453 
 
AEDs detected in samples with 5-6 AEDs are presented in Table ‎6-10. Lamotrigine, 
levetiracetam and phenytoin dominated in 6, 6 and 7 of the 8 samples respectively, 
followed by phenobarbital (4 samples), lacosamide, valproic acid and zonisamide (3 
samples each), vigabatrin, topiramate and rufinamide (2 samples each), gabapentin, 
pregabalin, carbamazepine and its metabolite carbamazepine epoxide (1 sample each). 
The concentrations of most AEDs in these 8 samples are within the therapeutic ranges 
except for lamotrigine in sample 1 and 5; its concentration was higher than its therapeutic 
range (> 5.6 mg/L) with concentrations of 13.95 and 8.28 mg/L respectively. Phenytoin 
concentrations were significantly lower than its therapeutic level (< 7 mg/L) in 5 out of 7 
43% 
30% 
20% 
5% 
2% 0.2% 
One AED Per Sample (198 samples)
Two AEDs Per Sample (141 samples)
Three AEDs Per Sample (95 samples)
Four AEDs Per Sample (25 samples)
Five AEDs Per Sample (7 samples)
Six AEDs Per Sample (1 sample)
Chapter 6  191 
 
C
h
ap
ter 4
 
 
1
9
1
 
samples. The zonisamide concentration was lower than its therapeutic level in sample 3 
(7.88 mg/L). However, all of these samples were requested to be tested for only 1 AED by 
clinicians except for sample 8 which was requested to be tested for 2 AEDs.  
Table  6-10: AED Concentrations in 8 Serum Samples with 5-6 Positive AEDs. 
Sample No. 1 2 3 4 5 6 7 8 
AED No. 6 5 5 5 5 5 5 5 
AED 1  LTG LTG LTG LTG LTG LTG* PHT* PBT 
(mg/L) 13.95 5.64 6.69 5.15 8.28 5.17 9.78 4.12 
AED 2 PHT PHT PHT PHT PHT PHT PBT LEV 
(mg/L) 2.60 12.43 1.77 2.28 1.04 0.87 26.66 12.67 
AED 3 PBT PGR* RFM* LEV LEV PBT LEV VPA* 
(mg/L) 6.00 0.70 10.29 31.06 42.96 19.43 37.52 86.95 
AED 4 LEV TPR VPA RFM* TPR LEV VPA VIG* 
(mg/L) 66.70 6.04 67.49 16.30 7.38 30.02 58.67 15.30 
AED 5 LAC* ZNS ZNS LAC CBZ* LAC GBP ZNS 
(mg/L) 8.84 35.61 7.88 6.44 9.17 7.62 4.55 42.85 
AED 6 VIG 
              
(mg/L) 19.64 
Metabolites 
        
CBZO* 
      
(mg/L) 2.41 
*Shaded cells refer to the AED requested to be tested by clinicians. 
 
Similarly, Table ‎6-11 shows 25 serum samples with 4 positive AEDs per sample (139 
AED tests). The AED 1 column represents the concentrations of AEDs that were requested 
by clinicians. Once again,  all these samples were requested to be tested for only one drug 
except sample number 14 which was tested for 2 AEDs; levetiracetam and valproic acid.  
Out of 25 samples, only 5 samples have AED therapeutic concentrations whereas 20 
samples have at least one AED below or above the recommended therapeutic range. Out of 
139 tests, 33 tests were not within recommended concentrations (23.7%). Although TDM 
guidance does not require blood monitoring for new AED generations, TDM for old 
generations such as carbamazepine, phenytoin, phenobarbital, lamotrigine and valproic 
acid is still a requirement due to their adverse effects (See 1.8, Chapter 1). This table 
shows some old AEDs with concentrations below or higher than their levels required for 
epilepsy maintenance but their analysis was not requested for any of these samples. 
Samples 29 and 32 were positive for S-licarbazepine but as discussed earlier it was not 
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possible to decide whether this was resulting from oxcarbazepine or eslicarbazepine 
acetate treatment.   
Table  6-11: AEDs Concentrations in 25 Serum Samples with 4 Positive AEDs. 
Sample 
No. 
AED 1 
(mg/L)* 
AED 2 
(mg/L) 
AED 3 
 (mg/L) 
AED 4 
(mg/L) 
Metabolite 
(mg/L) 
9 LAC 7.12 ZNS 16.19 TPR 1.57 PHT 16.34 
  
10 LAC 4.70 LEV 28.48 PHT 4.15 VPA 35.59 
  
11 LAC 7.78 ZNS 15.12 PBT 41.67 PHT 4.79 
  
12 LAC 5.27 TPR 0.51 PHT 6.49 VPA 53.37 
  
13 LAC 2.77 LTG 5.40 TPR 0.99 CBZ 6.45 CBZO 6.10 
14** LEV 24.80 LTG 3.10 PBT 6.10 VPA 67.70 
  
15 LEV 24.49 LTG 0.52 VIG 1.45 PHT 6.86 
  
16 LTG 14.13 LEV 3.66 PHT 1.05 VPA 87.18 
  
17 RFM 33.88 LEV 46.36 TPR 10.35 OXC 0.17 SLE 24.46 
18 RFM 30.80 LEV 29.70 LTG 14.96 VPA 97.91 
  
19 RFM 5.10 LEV 28.26 LTG 7.68 TPR 8.01 
  
20 RFM 30.25 LEV 65.55 TPR 10.36 VPA 
129.3
4   
21 RFM 7.04 LEV 22.93 LTG 12.78 VPA 57.03 
  
22 PBT 5.51 LEV 12.40 TPR 2.66 CBZ 18.59 CBZO 9.74 
23 PBT 0.60 LEV 22.26 LTG 1.83 CBZ 12.74 CBZO 5.05 
24 PGR 3.04 LTG 8.10 LAC 8.88 PHT 2.13 
  
25 PGR 7.82 ZNS 17.42 LAC 6.08 PHT 19.12 
  
26 PGR 1.66 LEV 15.70 ZNS 19.28 PBT 18.68 
  
27 RTG 1.67 LTG 9.99 LAC 9.94 PBT 5.17 NRTG 0.21 
28 STP 6.40 ZNS 21.9 RFM 40.80 PBT 24.9 
  
29 TIG 0.006 LEV 46.88 PBT 9.37 OXC 0.00 SLE 13.88 
30 TIG 0.055 LTG 11.83 GBP 24.58 TPR 11.03 
  
31 TPR 9.80 VIG <5(1) GBP 4.70 LTG 1.30 
  
32 TPR 3.30 GBP 2.50 VPA 133.4 OXC 0.21 SLE 14.8 
33 VPA 91.40 LEV 33.7 PBT 8.00 VPA 91.4 
  
 * AED1 column refers to AEDs requested to be tested. 
**Sample 14 was requested to be tested for 2 AEDs, LEV and VPA. 
- Shaded Cells refer to samples with concentrations below or above the therapeutic range. 
 
Table ‎6-12 summarizes AEDs concentrations in plasma and postmortem blood. AEDs in 
plasma samples were all within the therapeutic ranges. Post mortem blood cases were 
requested to be tested for one AED and were confirmed with the transferred method except 
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for sample 1 which had 2 AEDs (STP: 1.90 mg/L and VPA: 28.43 mg/L). However, VPA 
is within therapeutic range. More details on AED concentrations in serum samples with 3, 
2 and 1 AEDs are presented in Table ‎6-13, Table ‎6-14 and Table ‎6-15. 
Table  6-12: AEDs Concentrations in 7 Postmortem Blood and 7 Plasma Samples. 
Matrix 
Sample 
No. 
No. of 
AED 
AED 1 
(mg/L)* 
AED 2 
(mg/L) 
AED 3 
(mg/L) 
Metabolite 
(mg/L) 
Plasma 1 3 RTG 4.2 GBP 8.51 PBT 14.13 NRTG 0.6 
Plasma 2 3 PGR 1.5 LEV 18.5 TPR 5.42 
  
Plasma 3 3 PGR 6.7 ZNS 41.7 LTG 9.44 
  
Plasma 4 2 LAC 8.56 LEV 73.1 
    
Plasma 5 1 PGR 2.1 
    
SLE 7.9 
Plasma 6 1 PGR 1.9 
      
Plasma 7 1 PGR 5.1 
      
Postmortem 
blood 
1 2 STP 1.9 VPA 28.4 
    
Postmortem 
blood 
2 1 GBP 8.4 
      
Postmortem 
blood 
3 1 LEV 17.5 
      
Postmortem 
blood 
4 1 LTG 6.2 
      
Postmortem 
blood 
5 1 PHT 3.3 
      
Postmortem 
blood 
6 1 PHT 13.2 
      
Postmortem 
blood 
7 1 PHT 15.2 
      
* AED1 column refers to AEDs requested to be tested. 
- Shaded Cells refer to samples with concentrations below or above the therapeutic range. 
 
As no case history was available, it was difficult to interpret the variation in concentrations 
or investigate the reason behind the high number of AEDs in some samples. It may be as a 
result of emergency treatment (hospital samples) or due to a change in the treatment 
regime which requires decreasing the concentration of the old drugs and increasing the 
concentration of the new drugs gradually in order to avoid any seizure triggers or any 
withdrawn symptoms that some drugs might have. Alternatively, it might be due to 
patients abusing these drugs or being medicated for something other than epilepsy with 
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different therapeutic level requirements such as neuropathic pain, migraine, bipolar 
disorder and other psychiatric disease (28).  
In general, clinical and forensic laboratories analyse AEDs only when requested by 
clinicians or pathologists and usually the drugs are specified, although 20% of epileptic 
patients are using a polytherapy of AEDs (149). For example, 22 cases have been tested for 
only one drug, although the sample had another three drugs detected by the validated 
method. The analysis cost and time in addition to the ability to afford state of art 
techniques can be obstacles, which may affect the number of tests requested. Therefore, the 
development of the simultaneous analysis of AEDs using a small sample volume and a 
simple extraction procedure may improve the TDM of these drugs and can play an 
important role in enhancing the quality of life for epileptic people. With increased 
awareness of poly-AED use, the incidence of SUDEP could be reduced. As mentioned 
previously, different risk factors account for this phenomenon such as the seizures 
frequency, the number of AEDs taken concomitantly (65, 66) and the variability of AED 
ingestion over time (67). Finally, by monitoring all the medications taken by patients and 
observing any changes in concentrations, which may result from drug interactions, 
pharmacogenetic variations or from other AEDs being taken concomitantly by patient 
either with or without prescription, greater clinical care can be given to these patients. 
6.4 Conclusion 
A simple, accurate and cost-effective LC/MS/MS method was transferred for the 
simultaneous quantification of 15 AEDs and 2 metabolites. The method was extended to 
include another 5 compounds, 3 AEDs and 2 metabolites, so the total number of detected 
and quantitated AEDs by the transferred method was 22 including metabolites. The 
method was validated in postmortem blood, serum and plasma which made it suitable for 
both routine forensic toxicology and TDM. It was successfully verified using 467 authentic 
case samples with a correlation higher than 96%. Bland-Altman plots showed good 
agreement between both methods with a mean difference of 0.21 ± 1.83 mg/L and limits of 
agreement were -3.38 - 3.81, 95% CI. 
The AED analysis successfully quantified 1-6 AEDs per sample although most of these 
samples were requested to be tested for only 1 AED. Simultaneous analysis presents an 
important tool for TDM where AEDs are taken concomitantly and concentration variations 
could significantly affect the quality of life for people with epilepsy related conditions. 
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Table  6-13: AED Concentrations in 92 Serum Samples with 3 Positive AEDs. 
Sample 
No. 
AED 1 (mg/L)* AED 2 (mg/L) AED 3 (mg/L) Metabolite (mg/L) 
34 CBZ 5.66 GBP 3.04 PBT 2.81 CBZO 1.15 
35 CBZ 10.57 LEV 32.96 VPA 101.03 CBZO 23.86 
36 CBZ 10.58 TPR 7.70 VPA 94.14 CBZO 17.26 
37 CBZ 13.60 LEV 37.68 VPA 72.50 CBZO 23.19 
38 CBZ 5.03 LEV 1.59 VPA 73.45 CBZO 2.93 
39** GBP 1.63 LEV 33.19 LTG 12.43 
  
40** GBP 3.00 PBT 10.45 TPR 2.48 
  
41 GBP 12.96 VIG 1.86 CBZ 13.87 CBZO 3.37 
42 GBP 2.54 PHT 4.52 VPA 22.08 
  
43 GBP 3.02 PHT 7.23 CBZ 6.47 CBZO 2.08 
44 GBP 6.27 LEV 15.92 VPA 91.00 
  
45 GBP 7.21 LTG 1.22 RTG 0 NRTG 0.37 
46 LAC 5.76 PHT 12.77 VPA 58.32 
  
47 LAC 4.26 PBT 16.75 OXC 0.22 SLE 16.66 
48 LAC 10.39 LEV 28.12 VPA 78.49 
  
49 LAC 5.80 LEV 24.45 PHT 6.99 
  
50 LAC 4.71 ZNS 13.44 LTG 4.29 
  
51 LAC 7.99 LEV 74.52 VPA 177.56 
  
52 LAC 6.76 ZNS 16.04 LTG 2.65 
  
53 LAC 7.46 LEV 40.25 LTG 12.30 
  
54 LAC 6.65 PHT 5.69 VPA 46.17 
  
55 LAC 6.76 PHT 0.68 OXC 1.95 SLE 20.49 
56 LAC 2.59 LTG 7.56 TPR 6.15 
  
57 LAC 6.92 LTG 3.78 PBT 6.57 
  
58 LAC 4.79 PHT 9.62 VPA 101.51 
  
59 LAC 3.22 LEV 17.71 PHT 18.67 
  
60 LAC 6.83 LEV 22.49 VPA 109.91 
  
61 LAC 6.53 LTG 8.12 CBZ 9.68 CBZO 3.45 
62 LAC 7.07 TPR 9.14 VPA 58.63 
  
63 LAC 6.60 LEV 11.48 PHT 17.17 
  
64 LAC 5.94 LEV 9.35 PHT 9.93 
  
65 LAC 3.19 PHT 3.84 CBZ 11.18 CBZO 3.87 
66 LAC 13.61 LTG 9.57 TPR 15.03 
  
67 LEV 9.1 LAC 0.9 PHT 3.2 
  
68 LEV 41.70 LAC 2.16 PHT 5.00 
  
69 LTG 11.88 PBT 15.16 VPA 107.49 
  
70 LTG 4.94 PGR 1.17 LEV 50.32 
  
71 LTG 6.96 TPR 6.45 VPA 40.55 
  
72 PBT 6.73 LTG 2.42 TPR 2.97 
  
73 PBT 42.29 PHT 7.05 VPA 13.23 
  
74 PBT 49.81 OXC 0.19 VPA 122.80 SLE 15.47 
75 PBT 33.04 GBP 21.51 PHT 18.91 
  
76 PBT 37.11 PHT 7.11 VPA 86.54 
  
77 PBT 14.52 PGR 1.10 PHT 4.68 
  
78 PBT 9.83 GBP 2.84 TPR 4.61 
  
79 PGR <0.5(0.29) LEV 40.44 LTG 44.20 
  
80 PGR 17.44 LEV 95.56 ZNS 25.44 
  
81 PGR <0.5(0.46) ZNS 17.83 PHT 14.55 
  
82 PGR 18.79 LEV 70.60 ZNS 15.43 
  
* AED1 column refers to AEDs requested to be tested. 
**Samples 39 and 40 were requested to be tested for 2 AEDs, GBP&LTG and GBP &TPR respectively. 
- Shaded Cells refer to samples with concentrations below or above the therapeutic range. 
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Table  6-13: AED Concentrations in 92 Serum Samples with 3 Positive AEDs (continued…). 
Sample 
No. 
AED 1 (mg/L)* AED 2 (mg/L) AED 3 (mg/L) Metabolite (mg/L) 
83 PGR 3.70 TPR 10.01 VPA 31.12 
  
84 PGR 6.13 VIG 1.07 LAC 10.00 
  
85 PGR 5.91 LEV 22.78 TPR 32.10 
  
86 PGR 4.15 LEV 63.21 PHT 1.67 
  
87 PGR 1.20 VIG 5.50 LEV 49.31 
  
88 PGR 2.51 GBP 0.79 LEV 25.55 
  
89 PGR 1.92 LEV 48.11 ZNS 23.25 
  
90 PGR 12.53 LEV 78.85 ZNS 24.47 
  
91 PGR 8.88 TPR 16.50 VPA 46.46 
  
92 PGR 4.62 LTG 8.19 TPR 2.08 
  
93 PGR 3.53 LEV 79.47 LTG 22.13 
  
94 PGR 1.15 VPA 90.25 CBZ 14.11 CBZO 18.63 
95 RFM 5.96 ZNS 29.85 OXC 0.16 SLE 24.23 
96 RFM 5.33 LEV 21.37 VPA 71.43 
  
97 RFM 12.32 GBP 4.47 LTG 7.62 
  
98 RFM 15.62 PBT 10.73 TPR 6.01 
  
99 RFM 13.48 TPR 10.54 VPA 89.27 
  
100 RFM 13.53 LEV 50.07 RTG 1.92 NRTG 0.21 
101 RFM 25.58 PBT 39.12 VPA 113.48 
  
102 RFM 33.00 LEV 16.34 VPA 75.61 
  
103 RFM 19.39 TPR 10.13 VPA 91.61 
  
104 RFM 13.23 LTG 10.77 VPA 94.04 
  
105 RFM 11.09 LEV 33.55 ZNS 25.55 
  
106 RFM 13.35 LEV 23.75 OXC 0.27 SLE 39.71 
107 RFM 5.89 LEV 11.11 PHT 9.98 
  
108 RFM 20.47 TPR 4.43 VPA 83.14 
  
109 RTG 16.92 LEV 49.16 PHT 17.58 NRTG 4.79 
110 RTG 1.81 LEV 23.66 LTG 6.39 NRTG 0.49 
111 RTG 0.30 LEV 104.58 ZNS 12.06 NRTG 0.07 
112 RTG 0.70 LTG 6.32 OXC 0.00 SLE 21.71 
       
NRTG 0.56 
113 RTG 0.68 LEV 30.52 LAC 2.34 NRTG 0.28 
114 STP 4.0 ZNS 2.0 VPA 106.9 
  
115 TIG 0.010 TPR 2.21 VPA 62.67 
  
116 TIG 0.031 VPA 86.47 CBZ 11.63 CBZO 5.90 
117 TIG 0.067 LEV 0.97 VPA 83.17 
  
118 TIG 0.107 LEV 24.47 CBZ 1.92 CBZO 0.00 
119 TPR 12.4 OXC 0.24 VPA 113.0 SLE 22.5 
120 TPR 14.9 PBT 7.5 VPA 94.7 
  
121 TPR 1.3 LEV 19.3 PHT 12.2 
  
122 TPR 11.02 OXC 0.25 VPA 105.67 SLE 22.39 
123 TPR 1.16 LEV 10.12 PHT 4.88 
  
124 VIG 7 PBT 6.9 CBZO 6.0 CBZO 3.1 
125 ZNS 11.26 PBT 28.05 VPA 76.17 
  
* AED1 column refers to AEDs requested to be tested. 
**Samples 39 and 40 were requested to be tested for 2 AEDs, GBP&LTG and GBP &TPR 
respectively. 
- Shaded Cells refer to samples with concentrations below or above the therapeutic range. 
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Table  6-14: AED Concentrations in 139 Serum Samples with 2 Positive AEDs. 
Sample No. AED 1 (mg/L)* AED 2 (mg/L) Metabolite (mg/L) 
126 CBZ 12.09 PBT 4.36 CBZO 2.49 
127 CBZ 9.12 TPR 1.65 CBZO 5.64 
128 CBZ 4.07 PHT 9.40 CBZO 0.96 
129 CBZ 6.45 PBT 3.19 CBZO 0.39 
130 CBZ 9.83 LEV 14.22 CBZO 3.52 
136 GBP 3.86 CBZ 18.36 CBZO 7.54 
137 GBP 3.11 CBZ 6.93 CBZO 1.39 
139 GBP 4.70 CBZ 5.10 CBZO 0.30 
144 GBP 5.40 CBZ 4.74 CBZO 1.17 
131 GBP 0.48 PHT 1.99     
132 GBP 2.20 VPA 51.31     
133 GBP 2.15 VPA 75.16     
134 GBP 4.67 PHT 7.91     
135 GBP 8.86 PHT 7.53     
138 GBP 1.66 TPR 7.25     
140 GBP 6.24 CBZ 4.60     
141 GBP 4.84 LTG 1.73     
142 GBP 1.93 PBT 14.42     
143 GBP 6.64 LEV 4.43     
148 LAC 0.51 OXC 0.00 SLE 16.76 
152 LAC 8.93 OXC 0.31 SLE 34.81 
160 LAC 5.45 OXC 0.04 SLE 6.85 
145 LAC 13.83 ZNS 34.26     
146 LAC 8.97 LEV 53.23     
147 LAC 6.16 LEV 21.96     
149 LAC 6.60 LEV 32.09     
150 LAC 7.70 LTG 6.51     
151 LAC 4.85 VPA 101.56     
153 LAC 16.13 LEV 29.49     
154 LAC 1.68 PHT 11.94     
155 LAC 13.42 ZNS 23.97     
156 LAC 11.37 ZNS 8.59     
157 LAC 17.69 LEV 122.11     
158 LAC 16.26 LEV 25.33     
159 LAC 3.56 VPA 60.55     
161 LAC 6.49 VPA 29.22     
162 LAC 5.57 TPR 9.49     
163 LAC 24.98 LEV 53.60     
164 LAC 8.46 LTG 8.62     
165 LAC 11.17 LEV 65.49     
166 LEV 12.50 CBZ 10.90 CBZO 3.75 
169 LEV 29.50 CBZ 12.60 CBZO 7.11 
170 LEV 120.42 CBZ 4.91 CBZO 3.02 
167 LEV 15.25 PHT 32.62     
168 LEV 0.09 PBT 9.92     
171 LEV 17.71 PBT 26.30     
172 LEV 10.56 PBT 19.98     
173 LTG 11.79 VPA 97.95     
174 LTG 0.97 VPA 44.69     
175 LTG 11.89 VPA 80.02     
* AED1 column refers to AEDs requested to be tested. 
**Samples 183 and189 were requested to be tested for 2 AEDs. 
- Shaded cells refer to samples with concentrations below or above the therapeutic range. 
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Table  6-14: AED Concentrations in 139 Serum Samples with 2 Positive AEDs (Continued…). 
Sample No. AED 1 (mg/L)* AED 2 (mg/L) Metabolite (mg/L) 
176 LTG 14.69 LEV 77.32     
177 LTG 10.03 LEV 50.35     
178 LTG 7.72 LEV 23.02     
179 LTG 6.01 CBZ 6.51 CBZO 1.60 
187 LTG 2.91 CBZ 7.66 CBZO 2.06 
180 LTG 3.82 PHT 1.81     
181 LTG 5.02 PHT 1.03     
182 LTG 16.45 GBP 12.02     
183** LTG 8.92 TPR 11.84     
184 LTG 5.89 TPR >0.5     
185 LTG 1.29 VPA 56.28     
186 LTG 1.77 GBP 1.57     
188 LTG 15.71 VPA 123.82     
189** LTG 1.88 ZNS 18.92     
190 LTG 1.95 PHT 0.95     
191 PBT 31.91 PHT 15.41     
192 PBT 24.61 PHT 5.02     
193 PBT 11.92 PHT 6.34     
194 PBT 19.15 PHT 1.08     
195 PBT 29.09 PHT 18.71     
196 PBT 23.69 PHT 5.26     
197 PBT 9.78 GBP 3.68     
198 PBT 33.70 LEV 60.09     
199 PBT 46.31 VPA 116.45     
200 PBT 3.45 LEV 34.21     
201 PBT 16.23 PHT 7.85     
202 PBT 11.78 PHT 5.90     
203 PGR 1.14 TPR 9.73     
204 PGR 1.64 LAC 15.72     
205 PGR 4.40 LEV 20.10     
206 PGR 8.29 ZNS 30.60     
207 PGR 1.38 VPA 58.74     
208 PGR 2.46 LTG 7.84     
209 PGR 14.59 GBP 20.11     
210 PGR 0.00 PHT 1.00     
211 PGR 1.52 TPR 9.70     
212 PGR 4.82 ZNS 0.26     
213 PGR 3.46 PHT 16.15     
214 PGR 0.00 TPR 9.86     
215 PGR 2.85 LTG 2.87     
216 PHT 1.42 LEV 12.90     
217 PHT 6.28 LEV 14.25     
218 RFM 11.68 LTG 10.18     
219 RFM 8.03 VPA 99.80     
220 RFM 20.20 LEV 62.04     
221 RFM 12.12 OXC 0.18 SLE 38.08 
226 RFM 38.25 OXC 0.13 SLE 21.00 
222 RFM 26.14 LTG 1.67     
223 RFM 15.98 PBT 13.98     
224 RFM 26.93 VPA 76.58     
* AED1 column refers to AEDs requested to be tested. 
**Samples 183 and189 were requested to be tested for 2 AEDs. 
- Shaded cells refer to samples with concentrations below or above the therapeutic range. 
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Table  6-14: AED Concentrations in 139 Serum Samples with 2 Positive AEDs (Continued…). 
Sample No. AED 1 (mg/L)* AED 2 (mg/L) Metabolite (mg/L) 
225 RFM 5.92 LEV 18.45     
227 RFM 9.59 LTG 3.16     
228 RFM 14.12 LEV 30.95     
229 RTG 1.25 VPA 51.76 NRTG 0.37 
230 RFM 9.35 PBT 18.24     
231 RFM 35.62 TPR 19.18     
232 RFM 7.48 LTG 14.01     
233 RTG 2.95 PGR 1.56 NRTG 0.65 
234 STP 9.9 VPA 118.2     
235 STP 14.8 VPA 200.7     
236 STP 6.5 VPA 120.9     
237 TIG 0.015 CBZ 16.86 CBZO 4.80 
238 TIG 0.000 PHT 15.76     
239 TPR 7.4 LAC 0.8     
240 TPR 9.05 VPA 83.07     
241 TPR 9.29 LEV 87.28     
242 TPR 3.10 PHT 0.55     
243 TPR 14.84 PHT 0.42     
244 TPR 8.83 LEV 64.20     
245 TPR 6.10 PBT 20.17     
246 TPR 2.25 LEV 15.44     
247 TPR 12.43 LEV 43.04     
248 TPR 16.36 PBT 39.77     
249 TPR 5.12 LTG 4.19     
250 TPR 16.49 LEV 58.46     
251 TPR 9.43 LEV 63.64     
252 TPR 5.61 LTG 3.08     
253 TPR 1.5 CBZ 7.1 CBZO 1.2 
254 TPR 10.0 LEV 15.1     
255 TPR 19.6 OXC 0.41     
256 TPR 4.4 PBT 4.9     
257 VPA 123.90 LEV 32.23     
258 VPA 65.46 TPR 2.84     
259 ZNS 17.3 OXC 0.22 SLE 34.3 
260 ZNS 40.6 LEV 10.0     
261 ZNS 40.8 LTG 11.2     
262 ZNS 19.45 LEV 31.59     
263 ZNS 8.81 PHT 18.51     
264 ZNS 15.76 LEV 27.94     
* AED1 column refers to AEDs requested to be tested. 
**Samples 183 and189 were requested to be tested for 2 AEDs. 
- Shaded cells refer to samples with concentrations below or above the therapeutic range. 
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Table  6-15: AED Concentrations in 189 Serum Samples with One Positive AED. 
Sample No. AED 1 (mg/L)* Metabolite (mg/L) Sample No. AED 1 (mg/L)* 
265 CBZ 9.60 CBZO 0.66 314 GBP 0.23 
266 CBZ 5.61 CBZO 0.23 315 GBP 2.62 
267 CBZ 20.16 CBZO 14.32 316 GBP 1.00 
268 CBZ 0.40 CBZO 0.00 317 GBP 2.03 
269 CBZ 4.66 CBZO 0.36 318 GBP 1.31 
270 CBZ 8.14 CBZO 0.59 319 GBP 3.48 
271 CBZ 4.40 CBZO 0.54 320 GBP 2.51 
272 CBZ 13.48 CBZO 2.90 321 GBP 9.30 
273 CBZ 8.27 CBZO 1.47 322 GBP 11.49 
274 CBZ 3.28 CBZO 0.09 323 GBP 0.67 
275 CBZ 6.23 CBZO 0.16 324 GBP 5.84 
276 CBZ 5.81 CBZO 0.07 325 GBP 0.81 
277 CBZ 4.19 CBZO 0.34 326 GBP 8.81 
278 CBZ 4.91 CBZO 0.04 327 GBP 3.34 
279 CBZ 11.07 CBZO 6.06 328 GBP 0.41 
280 CBZ 7.02 CBZO 2.00 329 GBP 4.71 
281 CBZ 12.49 CBZO 2.29 330 GBP 6.06 
282 CBZ 6.02 CBZO 0.72 331 GBP 6.38 
283 CBZ 6.37 CBZO 0.81 332 GBP 4.52 
284 CBZ 7.48 CBZO 2.21 333 GBP 5.13 
285 CBZ 11.21 CBZO 3.20 334 GBP 6.07 
286 CBZ 12.66 CBZO 5.12 335 GBP 2.10 
287 CBZ 3.83 CBZO 1.18 336 GBP 11.74 
288 CBZ 3.16 CBZO 0.32 337 GBP 5.31 
289 CBZ 4.34 CBZO 0.40 338 GBP 4.26 
290 CBZ 13.56 CBZO 4.39 339 GBP 2.75 
291 CBZ 4.27 CBZO 1.01 340 GBP 5.28 
292 CBZ 8.98 CBZO 2.44 341 GBP 1.81 
293 CBZ 14.71 CBZO 3.61 342 GBP 1.45 
294 CBZ 6.91 CBZO 3.03 343 GBP 3.14 
295 CBZ 14.39 CBZO 5.62 344 GBP 5.74 
296 GBP 2.12   345 GBP 1.93 
297 GBP 1.58     346 GBP 6.96 
298 GBP 5.82     347 LAC 8.69 
299 GBP 17.39     348 LEV 12.8 
300 GBP 5.56     349 LEV 14.4 
301 GBP 4.00     350 LEV 42.7 
302 GBP 1.69     351 LEV 25.18 
303 GBP 1.32     352 LEV 24.30 
304 GBP 5.28     353 LEV 19.22 
305 GBP 2.01     354 LEV 11.47 
306 GBP 4.34     355 LEV 13.02 
307 GBP 0.80     356 LEV 27.98 
308 GBP 9.75     357 LEV 29.30 
309 GBP 3.93     358 LEV 11.47 
310 GBP 1.43     359 LEV 12.68 
311 GBP 3.79     360 LEV 12.75 
312 GBP 1.93     361 LEV 41.40 
313 GBP 2.82     362 LTG 8.81 
* AED1 column refers to AEDs requested to be tested. 
 - Shaded cells refer to samples with concentrations below or above the therapeutic range. 
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Table  6-15: AED Concentrations in 189 Serum Samples with One Positive AED (Continued..). 
Sample No. AED 1 (mg/L)* Sample No. AED 1 (mg/L)* 
363 LTG 1.37 412 TIG 0.000 
364 LTG 4.35 413 TIG 0.131 
365 LTG 6.95 414 TPR 12.7 
366 LTG 2.13 415 TPR 2.3 
367 LTG 7.64 416 TPR 0.8 
368 LTG 3.09 417 TPR 1.6 
369 LTG 3.33 418 TPR 1.01 
370 LTG 5.15 419 TPR 0.44 
371 LTG 3.20 420 TPR 5.48 
372 LTG 5.48 421 TPR 3.40 
373 LTG 6.46 422 TPR 0.95 
374 LTG 1.48 423 TPR 6.17 
375 LTG 6.52 424 TPR 0.64 
376 LTG 1.70 425 TPR 1.61 
377 LTG 2.63 426 TPR 8.81 
378 LTG 1.45 427 VPA 57.12 
379 LTG 4.75 428 VPA 101.33 
380 LTG 5.39 429 VPA 52.66 
381 LTG 2.86 430 VPA 74.41 
382 PBT 25.23 431 VPA 66.15 
383 PBT 2.68 432 ZNS 20.8 
384 PBT 24.80 433 ZNS 12.8 
385 PBT 12.00 434 ZNS 8.21 
386 PBT 24.03 435 ZNS 8.92 
387 PBT 14.82 436 ZNS 8.27 
388 PBT 22.81 437 ZNS 12.63 
389 PBT 10.16 438 ZNS 3.75 
390 PBT 54.83 439 ZNS 19.49 
391 PBT 12.42 440 ZNS 23.77 
392 PBT 0.00 441 ZNS 9.24 
393 PBT 14.74 442 ZNS 36.89 
394 PBT 32.53 443 ZNS 6.14 
395 PBT 107.11 444 ZNS 46.69 
396 PGR 1.37 445 ZNS 35.73 
397 PGR 6.25 446 ZNS 27.10 
398 PGR 0.00 447 ZNS 26.05 
399 PHT 13.11 448 ZNS 48.81 
400 PHT 16.29 449 ZNS 10.81 
401 PHT 8.72 450 ZNS 20.58 
402 PHT 9.61 451 ZNS 5.12 
403 PHT 6.34 452 ZNS 76.12 
404 PHT 11.83 453 ZNS 4.84 
405 PHT 6.54       
406 PHT 1.60       
407 PHT 10.74       
408 RFM 17.13       
409 RFM 13.06       
410 RFM 21.34       
411 RFM 2.79       
* AED1 column refers to AEDs requested to be tested. 
 - Shaded cells refer to samples with concentrations below or above the therapeutic range. 
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7 Gabapentin and Pregabalin Prevalence Among 
Prisoners in Scotland: An Insight Into Their 
Abuse Potential. 
7.1 Introduction 
In Scotland, drug and addiction services such as the Scottish Drug Forum in Glasgow and 
Crew in Edinburgh have raised concerns regarding gabapentin and pregabalin being 
misused on the street and among prisoners.  A recent survey including 129 participants 
showed a 22 % prevalence of GBP and PGR among drug abusers in Edinburgh (109). This 
study gave an indication of the prevalence of these drugs. However, participants at the 
addiction clinics were often unregistered and would turn up without appointments, so it 
was not possible to determine an accurate response rate to this survey. Also, participants 
may not have stated all drugs that they had been using and therefore provide misleading 
data. 
In order to evaluate the prevalence and abuse potential of AEDs among prisoners in 
Scotland, a study was carried out in collaboration with the Scottish Prison Service (SPS) 
after obtaining the required ethical approval from West of Scotland Research Ethics 
Service (WoSRES). Eight prisons in Scotland participated in this study and urine samples 
from admitted and released prisoners over a one month period were collected. The urine 
samples were analysed using a LC/MS/MS-QQQ method which was developed and 
validated for the simultaneous quantification of 21 AEDs in urine.  
Although urine samples can be used only for qualitative analysis, and the presence of drugs 
is only indicative of previous exposure, urine has several advantages over other matrices 
such as blood and hair. Many drugs and their metabolites are present in higher 
concentrations in the urine than in the blood. Some classes of drugs also remain in the 
urine for days or longer following their use. Urine can be noninvasively collected, and does 
not require skilled personnel to perform this task (289).  
This is the first prevalence study to be carried out on a large scale in Scotland to assess the 
prevalence and abuse potential of gabapentinoids and other AEDs using urine analysis to 
confirm the drug consumption.  
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7.2 Ethical Approval 
The study was approved by the West of Scotland Research Ethics Service (WoSRES), 
(reference: 12/WS/0312) (Appendix 7-1). The project was given ethical approval for urine 
and hair sample collection. However, due to the high work load at the prison sites, SPS 
advised that the hair sampling would cause much interruption for the prison health officers 
and prisoners were unlikely to cooperate to donate their hair samples. This was also the 
case with urine samples initially. In order to solve this issue, they kindly suggested 
participating in their annual drug of abuse prevalence study in November of each year 
where they collect urine samples routinely from all admitted and released prisoners. Hence, 
hair sample analysis was stopped at this point and the project focused on urine sample 
analysis. 
7.3 Methodology 
7.3.1 Study Design 
Out of the 16 prisons in Scotland, 8 prisons participated in this study; Addiwell, Perth, 
Barlinnie, Polmont, Low Moss, Corton Vale, Edinburgh, and Greenock (Figure ‎7-1).  
 
Figure ‎7-1: Regional Distribution and Number of Collected Samples From 
Participating Prisons. 
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All‎ these‎ establishments‎ are‎ ‘closed’‎ prisons‎ with‎ facilities‎ in‎ place‎ to‎ prevent‎ escape.‎
Community access is available to suitably risk assessed offenders from Barlinnie, Corton 
Vale, Greenock and Polmont (290). 
The prisons were chosen based on the number of prisoners with the exception of Greenock 
prison which requested to participate in the study in spite of its small population. 
Participants were all prisoners, male and female, released from and admitted to the selected 
prisons over a one month period (November 2013).  
Urine samples were initially collected by the SPS to evaluate the prevalence of other illicit 
drugs.‎All‎specimens‎and‎data‎were‎encoded‎with‎a‎serial‎number‎to‎protect‎the‎prisoner’s‎
confidentiality. After the samples had been tested by the SPS, they were transferred to the 
department of Forensic Medicine and Science and stored at -20 °C until analysis. 
7.3.2 Calibrators, Internal Standards and Quality Control 
Preparation 
All calibrators, internal standards and quality controls were prepared in similar way to 
those prepared for blood, serum and plasma (see 5.2.3 and 5.2.4 Chapter 5 for details). 
7.3.3 Urine Sample Preparation  
On the day of analysis, the samples were left to thaw at room temperature. A 100 µL 
aliquot of the urine sample was transferred to a 2 mL snap top polypropylene 
microcentrifuge tube, 100 µL of internal standard solution and 300 µL methanol were 
added, vortex mixed for 30 seconds and centrifuged for 10 minutes at 10000 rpm. An 
aliquot of 200 µL of the supernatant was transferred to a LC vial and diluted with 500 µL 
of deionized water. 5 µL of the diluted supernatant was injected into the LC/MS/MS. 
Since the focus of this study was gabapentin and pregabalin prevalence among prisoners, 
no urine hydrolysis was applied as more than 81% of gabapentin and pregabalin is excreted 
unchanged in urine (see 1.6.3 for AEDs metabolism and excretion). 
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7.3.4 Instrumentation  
This was the same as described in 3.2.3. 
7.3.5 Qualitative Method Validation 
The method was previously validated for whole blood using the same instrument (see 
Chapter 3). Due to matrix change which might have an effect on the precision, accuracy, 
recovery and matrix effect, a revalidation was required for urine. 
Before screening the urine samples, the method was qualitatively validated, initially for 21 
AEDs, to determine cut offs. NA-RTG could not be analysed because it was out of stock. 
According to standard practices for method validation in forensic toxicology (SWGTOX, 
May 2013), qualitative method validation parameters are: 
a) Selectivity  
b) Carryover  
c) Matrix effect 
d) Limits of detections  
Selectivity was assessed using negative case samples. Specificity was assessed by spiking 
drug-free matrix with each AED individually. Interferences were examined visually.  
Assay LODs were determined for urine using 3 different sources of blank urine samples 
spiked with decreasing concentrations of AEDs and analyzed in duplicate for three 
separate runs.  
Carryover was tested by injecting three blank controls after two injections of the upper 
limit of quantification in the calibration curve. It was evaluated by dividing the blank peak 
area at the expected retention time by the mean peak area of the ULOQ and multiplying by 
100. No carryover is considered if the value is lower than 10%.  
Recovery and Matrix effect were evaluated using the post-extraction addition approach for 
all 21 AEDs in urine (see 2.2.12.4 for details) (248). 
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7.3.6 Quantitative Method Validation of Pregabalin and 
Gabapentin 
Due to the considerable number of gabapentin and pregabalin positive samples detected 
during the qualitative analysis; a linearity, precision and accuracy check for these two 
drugs was carried out before re-analysing the positive samples quantitatively. Linearity 
was assessed by analysing five separate calibration curves prepared by spiking blank blood 
with gabapentin and pregabalin at 8 concentrations ranging from 0.5-50 mg/L. A linear 
regression equation weighted 1/X was applied.  
7.4 Results and Discussion 
7.4.1 Qualitative Method Validation 
7.4.1.1 Selectivity 
No endogenous or exogenous interference was observed and none of the AEDs or their 
internal standards showed any interference at the retention time of the other drugs included 
in the method. The generated results from urine were comparable to the whole blood, 
serum and plasma selectivity study in the previous methods (see 3.3.1 and 5.3.3). 
7.4.1.2  LODs, LLOQs and LOQs 
Instrument LODs were not re-evaluated as they were previously determined (see 3.2.5). 
Compared to whole blood, serum and plasma, the LODs, LLOQs and LOQs for all drugs 
in urine were very similar to those of the other matrices in spite of the different 
composition and content of each matrix (see 3.3.2 and 5.3.4). 
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Table  7-1: Assay LOD, LLOQ and LOQ of 21 AEDs in Urine. 
AEDs LOD LLOQ LOQ 
CBZ 0.25 0.5 0.5 
CBZO 0.05 0.25 0.5 
ESL 0.25 0.5 0.5 
GBP 0.1 0.25 0.5 
LAC 0.05 0.25 0.5 
LEV 0.1 0.5 5.0 
S-LC 0.1 0.25 0.5 
LTG 0.25 0.5 0.5 
OXC 0.05 0.1 0.05 
PBT 1.0 2.5 2.5 
PGR 0.5 1.0 0.5 
PHT 0.5 1.0 1.0 
p-HPPH 0.5 1.0 1.0 
RFM 0.1 0.25 0.5 
RTG 0.025 0.05 0.05 
STP 0.25 0.5 0.5 
TIG 0.01 0.025 0.05 
TPR 0.25 0.5 0.5 
VIG 0.5 1.0 5.0 
VPA 2.5 5.0 5.0 
ZNS 0.5 1.0 1.0 
 
7.4.1.3 Recovery and Matrix Effect 
The matrix factor and recovery results of 2 QCs (low and high) using 6 different sources of 
matrix are detailed in Table ‎7-2. Matrix factor values were acceptable for all the drugs 
(within ± 1.25) and ranged between 0.81 and 1.13. Recovery was greater than 80% for all 
the AEDs. The recovery and matrix effect results in urine were comparable to the values 
obtained in whole blood, serum and plasma except for retigabine. Retigabine exhibited an 
acceptable matrix suppression effect (MF=0.81- 0.86) in all 4 matrices and good recovery 
(>80) in urine, serum and plasma but less so in whole blood which was around 71 % (see 
5.3.7).   
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Table  7-2: Recovery and Matrix Factor Values for 21 AEDs Using Low and High QCs and 6 
Different Urine Sources (n=6 per QC per Matrix). 
AEDs 
QC1 QC2 
Recovery(%) Matrix effect Recovery(%) Matrix effect 
CBZ 107 1.02±0.05 106 1.02±0.12 
CBZO 91 1.04±0.05 98 1.02±0.11 
ESL 89 0.82±0.29 95 0.84±0.30 
LAC 93 1.04±0.04 97 1.00±0.10 
LEV 92 1.01±0.05 95 1.00±0.10 
LIC/SLE 87 1.01±0.06 89 1.00±0.11 
LTG 109 1.03±0.03 102 1.01±0.07 
GBP 104 1.13±0.07 105 1.06±0.09 
PBT 83 0.87±0.08 86 0.87±0.08 
PGR 98 1.03±0.04 98 1.00±0.14 
OXC 105 0.89±0.30 110 0.81±0.16 
PHT 88 0.99±0.05 90 1.02±0.15 
p-HPPH  85 1.00±0.07 81 1.02±0.08 
RFM 96 1.00±0.08 93 1.02±0.09 
RTG 87 0.90±1.84 81 0.81±1.16 
TIG 80 1.00±0.04 85 1.04±0.05 
TPR 102 1.00±0.03 105 1.05±0.09 
VIG 76 0.90±0.23 84 0.90±0.19 
VPA 103 1.03±0.06 108 1.02±0.14 
ZNS 92 1.03±0.06 92 1.04±0.12 
 
7.4.1.4 Carryover 
No carry over was observed for all 21 AEDs in urine. Carryover percentage after the first 
blank injection was 0% for all drugs except levetiracetam, valproic acid and levetiracetam 
which was 0.06%, 0.03% and 0.35% respectively. However, these percentage are 
acceptable (< 10%) and very low compared to the high concentrations used as an ULOQ 
(300 mg/L). Summary of the carryover results is detailed in Table ‎7-3. 
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Table  7-3: Carryover Results of 21 AEDs After Double Injections of Extracted ULOQ in Urine. 
AED 
Peak Area 
Carryover 
(%)* Mean ULOQ 
(n=2) 
Blank 1 Blank 2 Blank 3 
CBZ 1458085 0 0 0 0.00 
CBZO 226910 0 0 0 0.00 
ESL 1584816 0 0 0 0.00 
GBP 355521 0 0 0 0.00 
LAC 861567 0 0 0 0.00 
LEV 180120 111 0 0 0.06 
LIC/SLE 1459655 0 0 0 0.00 
LTG 22188 0 0 0 0.00 
OXC 12086 0 0 0 0.00 
PBT 66953 0 0 0 0.00 
PGR 178962 0 0 0 0.00 
PHT 5679 0 0 0 0.00 
HPPH 4033 0 0 0 0.00 
RTG 115958 0 0 0 0.00 
RFM 3787 0 0 0 0.00 
STP 21644 0 0 0 0.00 
TIG 32889 0 0 0 0.00 
TPR 30365 0 0 0 0.00 
VIG 110506 28 18 0 0.03 
VPA 226775 799 62 0 0.35 
ZNS 7935 0 0 0 0.00 
* Carryover percentage was calculated by dividing blank 1 peak area by ULOQ 
Mean peak area and multiplying by 100. 
 
 
7.4.2 Quantitative Method Validation of Pregabalin and 
Gabapentin 
The calibration curves were linear with a R² greater than 0.998. Accuracy and precision 
were assessed by analysing replicates of spiked controls at 2 different concentrations (7 
and 45 mg/L). Intra-day precision and bias were calculated from 3 replicates per QC in one 
batch. Inter-day precision and bias were determined over 5 different runs. The accuracy 
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values were within the acceptable range of ±15% of the nominal concentrations. The intra- 
and inter-day accuracy ranged from 93.8 - 104.4% for gabapentin and 96.2 - 105.3% for 
pregabalin. Both intra and inter-day precision values were acceptable and less than the 
15%. The intra- and inter day precision values were less than 10.4% for gabapentin and 
less than 7.4% for pregabalin (Table ‎7-4).  
Table  7-4: Accuracy and Precision Results of Gabapentin and Pregabalin in Urine. 
AEDs 
Precision Accuracy 
Intra-day (%) 
n=3 
Inter-day (%) 
n=15 
Intra-day (%) 
n=3 
Inter-day (%) 
n=15 
 
7 mg/L 45 mg/L 7 mg/L 45 mg/L 7 mg/L 45 mg/L 7 mg/L 45 mg/L 
GBP 2.0 1.7 10.4 5.9 93.8 104.4 93.8 104.4 
PGR 5.3 2.7 6.9 7.4 96.2 105.3 96.2 105.3 
 
 
7.4.3 Demographic Data 
A total of 904 urine samples were collected from the 8 prisons over a one month period 
(November 2013). Samples collected were from prisoners who were just admitted to or 
released from prison in November 2013. Due to the high workloads at the prisons, the only 
information provided with the samples was the sample numbers and whether they were 
admission or liberation samples. Hence, accurate demographic data regarding gender and 
age was not applicable in this study. The available data is shown in Table ‎7-5. 
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Table  7-5: Demographic Data on Selected Prisons (291, 292). 
Prison Capacity Population
a
  Sex
b 
Age Total   A
c 
L
d 
Facility Area served 
Addiwell 700 705 M >21 63 33 30 Local Lanarkshire, West Lothian 
Barlinnie 1021 1256 M >21 172 106 66 Local  West of Scotland 
Corton Vale 309 221 F >16 101 90 11 National  Whole of Scotland 
Edinburgh 870 819 M&F >21 85 25 60 Local Edinburgh, Lothian, Borders, Kirkcaldy, Fife 
Greenock
 e 255 244 M&F >21 27 11 16 Local West of Scotland 
Low Moss 784 739 M >21 118 100 18 Local North Strathclyde 
Perth 633 679 M >21 187 123 64 Local  Angus, Dundee, Perth, Kinross, Fife 
Polmont 760 503 M 16-21 151 102 49 National  Whole of Scotland 
Total 5332 5166   904 590 314   
a: Prison Population number and Facility type were last updated on 21-November-2014 by SPS.  
b: M=Male, F=Female. c: A=Admission. d: L=Liberation. 
e: Greenock is a male prison but it held a number of female prisoners at the time of the study due to Corton Vale establishment renovation. 
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7.4.4 Admission vs Liberation 
As shown in Table ‎7-6, the total AEDs prevalence for admission and liberation is similar 
(20% and 16% respectively). Out of 164 positive samples, 115 were admission samples 
(68%) compared to 49 liberation samples (32%). However, AEDs prevalence at Edinburgh 
prison was mainly liberation samples (Figure ‎7-2). This may have been due to the high 
number of liberation samples received over this month; 60 samples out of the total 85 
samples collected were liberation samples. These results can be an indication of GBP and 
PGR abuse among prisoners at Edinburgh prison.  
Table  7-6: Admission, Liberation AEDs Prevalence on Selected Prisons. 
Prison 
Positive 
Samples 
Prevalence 
(%) 
Admission Liberation 
Positive  (%) Positive (%) 
Addiwell 16 25 12 44 4 13 
Barlinnie 16 9 11 10 5 8 
Corton Vale 28 28 25 28 3 27 
Edinburgh 21 25 3 12 18 30 
Greenock 1 4 1 9 0 0 
Low Moss 23 22 21 21 2 11 
Perth 51 27 38 31 13 20 
Polmont 8 5 4 4 4 8 
Total 164 18 115 20 49 16 
 
 
Figure  7-2: AEDs Prevalence Among Admitted and Released Prisoners. 
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7.4.5 AEDs Prevalence per Prison 
The results of the analysis found 164 of the 904 samples to be positive for at least one 
AED (18%). Five of the prisons had prevalence higher than 20% (Table ‎7-6).  
Corton Vale is Scotland's only all-female prison and had the highest AEDs prevalence at 
28%, followed by Perth (27%), Addiwell (25%), Edinburgh (25%) and Low Moss (22%). 
Barlinnie is Scotland's largest establishment and holds all categories of prisoners. It is 
known to be overcrowded with prisoners sharing cells meant for individual use. It is the 
largest dispenser of heroin substitute, methadone in Western Europe with drug use in over 
80% of its population (18). However, AEDs prevalence was only 9% at this prison. 
Polmont is Scotland's national holding facility for young offenders aged between 16 - 21 
years. It showed a very low prevalence of AEDs (5%) among this age group. This can 
either be seen as a sign of their low popularity among adolescents or an indication of their 
low prescription rate among this group of people.  
Finally, Greenock is a small establishment which accommodates a small number of 
prisoners for a range of management and operational reasons. It participated with 27 
samples of which one was positive for GBP. More details of all AEDs detected at each 
prison are shown in Table ‎7-7. 
Table  7-7: Number of Each AED Detected at Each Prison. 
Prison 
GBP PGR LEV LTG VPA VIG 
A* L* A L A L A L A L A L 
Addiwell 11 3 1 1 - - - - - - - - 
Barlinnie 10 3 1 2 - - - - - - - - 
Corton Vale 20 0 3 3 - - 1 - 1 - - - 
Edinburgh 3 9 - 6 - 1 - - - - - 2 
Greenok 1 - - - - - - - - - - - 
Low Moss 1 16 4 - 1 - - - 1 - - - 
Perth 30 8 3 5 - - 2 - 1 - - - 
Polmont 3 - - 3 1 1 - - - - - - 
 
79 39 12 20 2 2 3 0 3 0 0 2 
*A: Admission, L: Liberation 
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7.4.6 AEDs Prevalence by Drug 
The high prevalence of AEDs is mainly due to GBP and PGR on their own or in 
combination (Figure ‎7-3). GBP was identified in 118 samples out of the 164 positive 
samples (68%) and PGR in 32 samples (13%). Other AEDs detected were levetiracetam 
(LEV) and vigabatrin (VIG); 4 samples each.  Lamotrigine (LTG) and valproic acid (VPA) 
were positive in 3 samples each. Carbamazepine (CBZ) and topiramate (TPR) were found 
in 2 and 1 samples respectively. 
 
Figure  7-3: AEDs Prevalence per Drug. 
 
Out of the 164 samples, only 15 samples were positive for 2 AEDs (9%).  Interestingly, 12 
of these specimens contained both GBP and PGR; 8 admission and 4 liberation samples 
(8%). Other drug combinations found were GBP with LTG (1 sample), GBP with TPR (1 
sample) and LEV with VPA (1 sample). 
Since neuropathic pain treatment guidelines recommend combination therapy using drugs 
with different mechanisms of action, it seems unlikely that practitioners would routinely 
prescribe both gabapentinoids together (293, 294). The presence of both drugs may instead 
represent a change in therapy from one agent to the other. The half-lives of gabapentin (t½ 
= 5.9 h) (295) and pregabalin (t½ = 4.6–6.8 h) (296) are relatively short.  However, 
because sudden termination may trigger withdrawal symptoms, changing therapy would 
typically require reducing the dose of the initial drug while escalating the dose of the 
replacement one over at least 5-7 days. In such cases, patients could test positive for both 
drugs. Alternatively, presence of both drugs might indicate medication dependence or 
abuse. PGR and GBP concentrations in these 12 samples are presented in Table ‎7-8. 
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Sample 10 had high concentrations of GBP and PGR (82, 141 mg/L respectively) which 
might be a case of abuse.  
Table  7-8: GBP and PGR Concentrations in Samples Containing Both Drugs.  
Sample No. Sample Type GBP (mg/L) PGR (mg/L) 
1 A 2.2 25.1 
2 L 3.0 1.1 
3 L 8.1 14.2 
4 A 10.5 128.7 
5 L 14.1 2.2 
6 L 18.1 2.7 
7 A 36.4 438.2 
8 A 42.7 0.8 
9 A 66.9 0.6 
10 A 81.7 141.1 
11 A 93.7 2.6 
12 A 170.8 15.2 
 
7.4.7 GBP and PGR Concentration Frequencies  
As shown in Figure ‎7-4 and Figure ‎7-5, urine concentrations of GBP and PGR varied 
across a broad concentration range. The concentrations ranged from 0.4-1100 mg/L (mean: 
61.6 ± 129 mg/L, median: 15 mg/L) for GBP and from 0.4-440 mg/L (mean: 59.9±114 
mg/L, median: 7.3 mg/L) for PGR.  
 
Figure  7-4: GBP Concentration Ranges in 118 Positive Samples. 
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Figure  7-5: PGR Concentration Ranges in 32 Positive Samples. 
 
The median concentrations of GBP were two fold greater than pregabalin. This is generally 
consistent with the relative potency of these drugs. The recommended dose of GBP is 900–
1800 mg/day and its therapeutic range varies between 2.2 to 6.1 mg/L, whereas the 
recommended dose of PGR is 150–600 mg/day with therapeutic range 1.3 to 4.9 mg/L 
(137). Both drugs are not metabolized, not bonded to plasma protein and are eliminated 
unchanged by the kidneys; 81% for GBP and 92% for PGR (137). Urine concentrations 
were reported to range from 2.5 to 35345 mg/L for GBP and 2.5 to 6892 mg/L for PGR 
among pain clinic patients but it was unknown whether all  patients were prescribed these 
two drugs or not (297). In this study, 20 GBP samples (17%) and 10 PGR samples (31%) 
had urine concentrations 5-50 fold higher than the median values of both drugs. Since no 
medication history was available for interpretation of results, it was difficult to determine 
whether these high concentrations were due to prescribed doses of medication or misuse 
among the prison population. 
7.4.8  Illicit Drugs Prevalence in Positive AEDs Samples 
The urine samples were initially screened by the SPS for drugs of abuse using urine 
dipstick analysis. Drugs tested by SPS were amphetamines, barbiturates, benzodiazepines, 
buprenorphine, cannabis, cocaine, methadone, methamphetamines and opiates. AEDs 
positive samples were compared with SPS results in order to investigate other illicit drugs 
associated with AEDs. Information provided by SPS was sample number, screening results 
and whether the drug was prescribed or not. All non-prescribed drugs were considered 
abused by SPS. 
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Unfortunately, only 117 out of the 164 AEDs samples were matched with the SPS database 
due to the variation between their numbering system and the current study numbering 
system. 81 % of the matched samples were positive for at least one illicit drug. It was 
obvious that the number of illicit drugs detected among admitted prisoners (n=93) was 
higher than the liberated ones (n=24) as illustrated in Figure ‎7-6. 
 
Figure  7-6: Number of Drugs Detected in Samples Among Admitted and Released Prisoners. 
 
The most frequently detected drugs along with AEDs were benzodiazepines (67%), opiates 
(57%) and cannabis (47%) including prescribed and non-prescribed samples as shown in 
Figure ‎7-7. The majority of these samples contained non-prescribed drugs. For instance, 
benzodiazepines were non-prescribed in 78 samples (61%) and opiates were also misused 
in 63 samples (54%) whereas all 55 cannabis samples were non-prescribed (47%).  
Methadone was positive in 51 samples (44%) of which 31 samples were abuse cases 
(26%). Cocaine and buprenorphine were also detected in 18 and 17% of the samples 
respectively as abuse use, whereas amphetamines, methamphetamines and barbiturates 
were only found in 4% of the AEDs samples and were all abuse cases. Details of drugs 
detected in samples are presented in Appendix 7-2. 
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Figure  7-7: Prescribed and Non-prescribed Illicit Drugs Associated With AEDs. 
 
7.5 Study Limitation 
The major limitation of the study is the lack of information provided along with each 
sample regarding age, sex and medical history which does not allow differentiation 
between prescribed and abused AEDs. In order to obtain further information to distinguish 
between prescribed and abuse cases, the prison GP leads were contacted. Unfortunately 
due to time restrictions and high workloads, only one prison lead responded. In the 
response received, it was mentioned that AEDs prevalence in this study is not surprising 
and that they are aware of the drug abuse issue among prisoners.  
The difficulty in obtaining further information from medical records is largely due to the 
prescription system used within the prisons. The prescribing system is not computerised 
and paper files are used to record‎ prisoners’‎ medical‎ history.‎ Finding the relevant 
information was therefore seen as time consuming. Additionally, the records may not be 
complete as prisoners may not state all the drugs that they have been using before their 
admission and give misleading data. 
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7.6 Conclusion 
The aim of this study was to evaluate the prevalence and abuse potential of (AEDs) among 
prison populations. Eight prisons in Scotland participated in this study and urine samples 
from admitted and released prisoners over a one month period were collected. Urine 
samples were collected and analysed using a LC/MS/MS-QQQ method which was 
developed and validated for the simultaneous quantification of 21 AEDs in urine. In spite 
of the lack of the medical history, the study results were comparable to the survey 
conducted in Edinburgh but on a larger scale (8). The study shows a high prevalence of 
AEDs (18%) largely due to GBP and PGR on their own or in combination with other drugs 
of abuse. Gabapentin was identified in 118 samples (13%) and pregabalin in 32 samples 
(4%). Interestingly, 12 samples contained both drugs (7%). The concentrations ranged 
from 0.4-1100 mg/L (median: 15 mg/L) for gabapentin and from 0.4 - 440 mg/L (median: 
7.3 mg/L) for pregabalin. Four samples were found to be higher than 400 mg/L. These 
concentrations are at least 20 times above the median concentrations and it is likely that 
those individuals took higher doses than recommended. Other AEDs detected were 
levetiracetam (4 samples), vigabatrin (4 samples), lamotrigine (3 samples), valproic acid (3 
samples), carbamazepine (2 samples) and topiramate (1 sample). The majority of AEDs 
positive samples (81 %) also contained at least one illicit or non-prescribed drug. 
Benzodiazepines, opiates and cannabis were the most frequently found illicit substances 
with a percentage of 61, 54 and 47 % respectively. Other illicit drugs found in positive 
AEDS samples were methadone (26%), cocaine (18%), buprenorphine (17%), 
amphetamines (4%), methamphetamines (4%) and barbiturates (4%). This study shows a 
high prevalence of AEDs largely due to gabapentin and pregabalin on their own or in 
combination with other drugs of abuse.  Clinicians and prison GP leads should be aware of 
the high prevalence of gabapentinoids and their abuse along with other drugs of abuse. 
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8 Simultaneous Analysis of 16 AEDs in Head Hair 
Using LC/MS/MS 
8.1 Introduction 
Drug analysis in hair has multiple applications in clinical and forensic toxicology. In 
forensic cases, hair represents the best alternative choice for analysis when other biological 
samples are not available, for example, due to sample degradation or late reporting of an 
incident(176), or when the history of drug use is required, for example, in therapeutic drug 
monitoring cases where drug taking behaviour may affect the quality of a patient's life and 
may be the reason for unexplained deaths like SUDEP (67). Only a few papers have been 
published regarding conventional AED analysis in hair.  These have covered the drugs 
carbamazepine, valproic acid, phenobarbital, phenobarbitone, phenytoin and lamotrigine 
(167, 172, 174, 298). One paper was found regarding oxcarbazepine (171), lamotrigine 
(166) and most recently a paper was published regarding pregabalin in hair in 2013 (170). 
The aim of this project was to optimize the best extraction conditions for 16 AEDs 
including carbamazepine and its metabolite carbamazepine-10,11-epoxide, eslicarbazepine 
acetate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, 
phenytoin and its metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin, topiramate, 
tigabine, valproic acid, vigabatrin  and zonisamide. Six different digestion conditions and 
three clean up procedures were compared. The method was then qualitatively validated 
using the most efficient extraction for all AEDs together. Finally, two case samples from 
two donors who were known to be prescribed 4 AEDs; carbamazepine, gabapentin, 
lamotrigine for sample 1 and valproic acid for sample 2, were tested using the validated 
method. No more samples were available at the time of the project due to sampling issues 
at the prison sites (see 7.2) and ethical approval being rejected to collect hair samples from 
known epileptic patients.  
8.2 Materials and Methods 
Method development was carried out using hair samples obtained from persons known not 
to have used any drugs being investigated in this study. The hair samples were prepared 
and spiked with the appropriate standards as described in the following sections. 
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8.2.1 Materials  
These were the same as those described in 2.2.1. 
8.2.2 Preparation of Hair Standards 
8.2.2.1 Wash and Cut Procedure 
In order to remove grease and cosmetic preparations, the hair samples were washed using 
deionized water twice, then dichloromethane (DCM) twice. At each wash stage, the 
appropriate solvent was added to completely immerse the hair samples and sonicated for 3 
minutes at room temperature. The solvent was then decanted off and the wash step 
repeated.  After the last hair wash with DCM, samples were dried overnight in an oven at 
40°C. After the samples were washed and dried, hair was finely cut into 1-2 mm pieces 
using scissors and stored at room temperature for later use. 
8.2.2.2 Hair Spiking Procedure 
The cut hair was spiked with a mixed standard of 16 AEDs prepared in methanol.  To 
prepare a target concentration of 1 ng/mg, 500µL of the standard at a concentration of 1 
mg/L was added to 500 mg of hair sample in a glass vial. A 1 ml volume of methanol was 
added to ensure that all the hair was immersed. The vial was sealed and sonicated for 1 
hour at 40 °C. It was then opened and the hair was allowed to dry at room temperature. 
This spiked hair was used for extraction optimization. Internal standards were GBP-D10, 
TUB and CBZ-DiOH at a concentration of 10 mg/L in methanol and added to each sample 
vial to attain a concentration of 1 ng/mg. All hair samples were stored at room temperature. 
Although the use of spiked hair is not ideal, since most of the drug will be on the surface of 
the hair and not incorporated into the hair, it can give an indication of the effect the 
extraction conditions will have on the drugs.  However, to truly assess extraction recovery 
of an incorporated drug from hair, authentic samples should be used.  Sufficient samples 
were not available to assess this. 
8.2.2.3 Preparation of Calibrators and Quality Control 
Stock solutions for 16 AEDs were prepared in methanol at 1 mg/mL for each drug 
individually. The solutions were further diluted to obtain two mixed working solutions at 
100 ng/mL and 10 ng/mL used to spike the hair. Seven hair samples (20 mg each) were 
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spiked at increasing concentrations from 0.05 to 2 ng/mg as given in Table ‎8-1.  Volumes 
were completed to 1 mL with methanol. This calibration was used to calculate AED 
concentrations detected during the qualitative analysis. 
Table  8-1: Preparation Procedure of Hair Calibration Curve (Sample Size: 20 mg). 
Calibrator 
(ng/mg) 
Volume of Stock 1 
 (10 ng/mL), (µL) 
Volume of Stock 2  
(100 ng/mL), (µL) 
MeOH 
(µL) 
0.05 100  900 
0.1 200  800 
0.2 400  600 
0.4 
 
80 920 
0.8 
 
160 840 
1.6 
 
320 680 
2 
 
400 600 
 
Two quality controls (QCs) were prepared at concentrations of 0.5 and 1 ng/mg as follows 
(Table ‎8-2). For the 1 ng/mL concentration, 500 µL of QC stock standard at a 
concentration of 1 mg/L was added to 500 mg of hair in a glass vial. For the 0.5 ng/mL 
concentration, 250 µL of 1 mg/L was added to 500 mg of hair. A 1 ml volume of MeOH 
was added to ensure that all hair was immersed. The vial was sealed and sonicated for 1 
hour at 40°C. The vial was then opened and the hair was allowed to dry at room 
temperature. 
Table  8-2: Preparation Procedure of Hair Quality Controls (Sample Size: 20mg). 
QCs (ng/mg) Sample size (mg) Volume of Stock 3 (1mg/L), (µL) MeOH (µL) 
0.5 500 100 900 
1 500 200 800 
 
8.2.3 Instrumentation 
This is the same as that described in 2.4.3. 
8.2.4 Hair Extraction Optimization 
Six different digestion methods were compared for 16 AEDs. These methods were 
previously reported or modified from the literature and applied on AEDs or on other 
groups of drugs (169-172, 299). Methods compared were: 
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a) Neutral digestion using MeOH on its own. 
b) Basic digestion using basic methanol (MeOH: 25% NH4OH) or alkaline digestion 
(0.1M NaOH and 1M NaOH) followed by liquid-liquid extraction (LLE). 
c) Acidic digestion using acidic methanol (MeOH: trifloroacetic acid (TFA)) or 0.1M 
HCl followed by LLE.  
For each extraction, spiked hair samples (20 mg each at 1 ng/mg concentration) were 
prepared in triplicate and injected in duplicate (n = 6). Samples were immersed in 1 ml 
solvent and sonicated for 2 hours at 60 ºC except 1M NaOH which was sonicated for only 
30 minutes at 60 ºC. Samples after methanolic extraction were spiked with 100 µL internal 
standard 10 mg/L, evaporated and injected directly after reconstitution with 20% methanol 
in water, whereas strong acidic and alkaline digestions which may dissolve the LC column 
silica had to undergo liquid-liquid extraction with DCM before being injected into the 
LC/MS/MS. After LLE, samples were evaporated, reconstituted with 200 µL of 20% 
methanol and transferred to a LC vial. A 15 µL aliquot of the reconstituted solution was 
injected and analysed by LC/MS/MS. Extraction efficiency of these methods was 
evaluated by comparing the recoveries.  
In order to calculate the recovery, six non-extracted standards at the same concentration (1 
ng/mg) were prepared‎at‎the‎same‎time.‎‎A‎volume‎of‎20‎μL‎of‎1‎mg/mL‎standard‎solution‎
and 100 µL internal standard 10 mg/L were evaporated, reconstituted with 200 µL of 20 % 
methanol in water. Recovery was calculated using the following equation: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
Extracted standard peak area /IS peak area ratio
Non_extracted standard peak area/IS peak ratio
   ∗ 100 
Detailed procedures of each digestion and extraction are as follows. 
8.2.4.1 Methanolic Extraction 
Three spiked hair samples (20 mg each) were extracted with 1 ml methanol for 2 hours 
under sonication at 60 °C. The supernatant was then transferred to a 7 ml glass vial. The 
hair was washed twice with 0.5 ml methanol and both fractions were added to the first 
extract. A 100 µL of the 10 mg/L internal standard solution was added. The supernatant 
was evaporated to dryness under a stream of N2 and the residue reconstituted in 200 µl of 
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20 % methanol (in water) and transferred to a LC vial. A 15 µL aliquot of the reconstituted 
solution was injected and analysed by LC/MS/MS. 
8.2.4.2 Basic Methanolic Extraction [MeOH: 25% NH4OH (20:1)] 
Three spiked hair samples (20 mg each) were extracted with 1 ml of MeOH: 25% NH4OH 
(20:1) for 2 hours under sonication at 60 °C. The supernatant was then transferred to a 7 ml 
glass vial. The hair was washed twice with 0.5 ml MeOH: 25% NH4OH (20:1) and both 
fractions were added to the first extract. A 100 µL of the 10 mg/L internal standard 
solution was added. The supernatant was evaporated to dryness under a stream of N2 and 
the residue reconstituted in 200 µL of 20% methanol and transferred to a LC vial. A 15 µL 
aliquot of the reconstituted solution was injected and analysed by LC/MS/MS. 
8.2.4.3 Acidic Methanolic Extraction [MeOH: TFA (50:1)] 
Three spiked hair samples (20 mg each) were extracted with 1 ml of MeOH: TFA (50:1) 
for 2 hours under sonication at 60 °C. The supernatant was then transferred to a 7mL glass 
vial. The hair was washed twice with 0.5 mL MeOH: TFA (50:1) and both fractions were 
added to the first extract. A 100 µL of the 10 mg/L internal standard solution was added. 
The supernatant was evaporated to dryness under a stream of N2 and the residue 
reconstituted in 200 µL of 20% methanol and transferred to a LC vial. A 15 µL aliquot of 
the reconstituted solution was injected and analysed by LC/MS/MS. 
8.2.4.4 0.1 M HCl Digestion Followed by LLE with DCM 
Three spiked hair samples (20 mg each) were digested with 1 mL of 0.1 M HCl for 2 hours 
under sonication at 60 °C. The supernatant was then transferred to a 7ml glass vial. 1mL of 
0.1 M NaOH was added followed by 3 mL of 0.1 M phosphate buffer (pH 6). This solution 
was extracted with 5 mL of DCM by vortex mixing for 1 minute followed by 10 minutes 
centrifuging at 3000 rpm. The lower organic layer was evaporated to dryness after adding 
100 µL of the 10 mg/L internal standard solution and reconstituted in 200 µL of 20% 
methanol and transferred to a LC vial. A 15 µL aliquot of the reconstituted solution was 
injected and analysed by LC/MS/MS. 
8.2.4.5 0.1 M NaOH Digestion Followed by LLE with DCM 
Three spiked hair samples (20 mg each) were digested with 1 mL of 0.1 M NaOH for 2 
hours under sonication at 60 °C. The supernatant was then transferred to a 7 mL glass vial. 
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1 mL of 0.1M HCl was added followed by 3 mL of 0.1 M phosphate buffer (pH 6). This 
solution was extracted with 5 mL of DCM by vortex mixing for 1 minute followed by 10 
minutes centrifuging at 3000 rpm. The lower organic layer was evaporated to dryness after 
adding 100 µL of the 10 mg/L internal standard solution and reconstituted in 200 µL of 20 
% methanol and transferred to a LC vial. A 15 µL aliquot of the reconstituted solution was 
injected and analysed by LC/MS/MS. 
8.2.4.6 1 M NaOH Digestion Followed by LLE with DCM 
Three spiked hair samples (20 mg each) were immersed in 1 mL of 1M NaOH for 30 
minutes under sonication at 60 °C. The hair was filtered-off and washed twice with 0.5 mL 
of 1 M NaOH and both fractions were added to the first extract. This solution was 
extracted with 2 mL of dichloromethane by vortex mixing for 1 minute followed by 10 
minutes centrifuging at 3000 rpm. The lower organic layer was evaporated to dryness after 
adding 100 µL of the 10 mg/L internal standard solution and reconstituted in 200 µL of 
20%  methanol and transferred to a LC vial. A 15 µL aliquot of the reconstituted solution 
was injected and analysed by LC/MS/MS. 
8.2.5 Clean Up Optimization 
A cleaning step was required to remove the digested hair before the sample could be 
injected into the LC/MS/MS. In order to get cleaner samples, two cleaning procedures 
were evaluated; LLE and sample filtration. Three different solvents; DCM, ethyl acetate 
and 9:1ethyl acetate with isopropanol (IPA), were assessed for liquid-liquid extraction to 
compare the effect of the different solvents on recovery.  
Sample filtration is a very common technique for sample clean up in LC/MS/MS. The 
following filters have different types of membranes (300):  
a) Hydrophilic membranes with water affinity such as GHP, PES, Nylon, or PVDF 
membranes for filtering aqueous samples. 
b) Hydrophobic membranes with affinity to aggressive organic solvents such as 
PTFE, making them ideal for gases and organic solvents. 
c) Universal membranes such as hydrophilic polypropylene (GHP) membrane which 
is compatible with both aqueous and organic applications.  
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Most of these membranes with the Acrodisc® syringe filter are low in biomolecule 
binding, less than 1%. Acrodisc® filter structure is presented in Figure ‎8-1. Due to the 
variety of chemical structures of AEDs in this study, a universal GHP (0.45 µm, 13 mm) 
filter was used. 
 
Figure  8-1: Filtration Technique Used in Hair Sample Clean-Up (300). 
 
Analyte peak area/internal standard peak area ratio was used and recoveries were 
calculated as detailed previously in 8.2.4. All clean-up methods were applied on the 
methanolic extract as outlined below.  
8.2.5.1 Methanolic Extraction Followed by Sample Filtration 
Three spiked hair samples (20 mg each) were extracted with 1 mL methanol for 2 hours 
under sonication at 60 °C. The supernatant was then transferred to a 7 mL glass vial. The 
hair was washed twice with 0.5 mL methanol and both fractions were added to the first 
extract. A 100 µL of the 10 mg/L internal standard solution was added. The supernatant 
was evaporated to dryness under a stream of N2 and the residue reconstituted in 200 µL of 
20% methanol. The reconstitution then was filtered using Acrodisc® 13 mm syringe filters 
with 0.45 µm GHP membrane before transferring to a LC vial. A 15 µL aliquot of the 
reconstituted solution was injected and analysed by LC/MS/MS. 
8.2.5.2 Methanolic Extraction Followed by LLE with DCM 
Three spiked hair samples (20 mg each) were extracted with 1 mL methanol for 2 hours 
under sonication at 60 °C. The supernatant was then transferred to a 7 mL glass vial. The 
hair was washed twice with 0.5 mL methanol and both fractions were added to the first 
extract. The supernatant was evaporated to dryness under a stream of N2 and the residue 
was reconstituted with 2 mL of 0.1 M phosphate buffer (pH 6). This solution was extracted 
with 2 mL of DCM by vortex mixing for 1 minute followed by 10 minutes centrifuging at 
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3000 rpm. The lower organic layer was evaporated to dryness after adding 100 µL of the 
10mg/L internal standard solution and reconstituted in 200 µL of 20 % methanol and 
transferred to a LC vial. A 15 µL aliquot of the reconstituted solution was injected and 
analysed by LC/MS/MS. 
8.2.5.3 Methanolic Extraction Followed by LLE with Ethyl Acetate 
Three spiked hair samples (20 mg each) were extracted with 1 mL methanol for 2 hours 
under sonication at 60 °C. The supernatant was then transferred to a 7 mL glass vial. The 
hair was washed twice with 0.5 mL methanol and both fractions were added to the first 
extract. The supernatant was evaporated to dryness under a stream of N2 and the residue 
was reconstituted with 2 mL of 0.1 M phosphate buffer (pH 6). This solution was extracted 
with 2 mL of ethyl acetate by vortex mixing for 1 minute followed by 10 minutes 
centrifuging at 3000 rpm. The upper organic layer was evaporated to dryness after adding 
100 µL of the 10 mg/L internal standard solution and reconstituted in 200 µL of 20 % 
methanol and transferred to a LC vial. A 15 µL aliquot of the reconstituted solution was 
injected and analysed by LC/MS/MS. 
8.2.5.4 Methanolic Extraction Followed by LLE with Ethyl Acetate/IPA (9:1) 
Three spiked hair samples (20 mg each) were extracted with 1 mL methanol for 2 hours 
under sonication at 60 °C. The supernatant was then transferred to a 7 mL glass vial. The 
hair was washed twice with 0.5 mL methanol and both fractions were added to the first 
extract. The supernatant was evaporated to dryness under a stream of N2 and the residue 
was reconstituted with 2 mL of 0.1 M phosphate buffer (pH 6). This solution was extracted 
with 2 mL of ethyl acetate: IPA (9:1) by vortex mixing for 1 minute followed by 10 
minutes centrifuging at 3000 rpm. The upper organic layer was evaporated to dryness after 
adding 100 µL of the internal standard solution and transferred to a LC vial. A 15 µL 
aliquot of the reconstituted solution was injected and analysed by LC/MS/MS. 
8.2.6 Investigation Into Extraction Conditions 
The effects of incubation duration and temperature on the extraction yield were 
investigated. The effect of the use of GHP filters on recovery was also assessed. 
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8.2.6.1 Incubation Duration and Temperature 
Samples were incubated using a water bath sonicator. Four conditions were evaluated to 
investigate the incubation duration and temperature effect on recovery as illustrated in 
Table ‎8-3. These conditions were assessed using 3 different digestion procedures; 
methanol on its own, basic methanol with 25% NH4OH and acidic methanol with TFA. 
Table  8-3: Incubation Duration and Temperature Conditions. 
Group 
Incubation 
Temperature 
Incubation 
Duration 
Following Step 
A 40 ºC 2 Hr  Sample filtered directly and injected. 
B 60 ºC 2 Hr Sample filtered directly and injected. 
C 40 ºC 1 Hr Sample left overnight before filtration 
D 60 ºC 1 Hr Sample left overnight before filtration 
 
Six spiked hair samples (20 mg each) were prepared for each group method. A volume of 1 
mL digestion solvent (MeOH, MeOH:TFA or MeOH:25% NH4OH) was added then 
incubated as illustrated in Table ‎8-3. After incubation, group A and B supernatants were 
transferred to a 7 mL glass vial. The hair was washed twice with 0.5 mL methanol and 
both fractions were added to the first extract. A 100 µL internal standard solution 10 mg/L 
was added. The supernatant was evaporated to dryness under a stream of N2 and the 
residue reconstituted in 200 µL of 20 % methanol. The reconstitution was filtered using a 
Acrodisc® 13 mm syringe filter with 0.45 µm GHP membrane before transferring to a LC 
vial. A 15 µL aliquot of the reconstituted solution was injected and analysed by 
LC/MS/MS. Groups C and D were left overnight before their supernatants were transferred 
to 7 mL glass vials and these then followed the same procedure as groups A and B. 
Analyte peak area/internal standard peak area ratios and recoveries were calculated as 
detailed previously in 8.2.4. 
8.2.6.2 Sample Filtration Effect on Recovery 
In order to evaluate the filtration effect on recovery two sets of six hair samples were 
prepared. Set 1 was prepared as detailed in ‎8.2.4.1 without filtration. Set 2 was prepared 
and filtered as outlined in ‎8.2.5.1. A set of non-extracted standards was prepared and 
recoveries were calculated as outlined before in 8.2.4. 
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8.2.7 Qualitative Method Validation 
The method was qualitatively validated according to the standard practices for method 
validation in forensic toxicology (SWGTOX, May 2013) for hair (13). (See 7.3.5) 
Selectivity was investigated by analysing drug-free hair samples from 10 different 
individuals. No positive detection of any analyte of interest should be found. Specificity 
was assessed by spiking drug-free matrix with each AED individually.  
Recovery and Matrix effect were evaluated in hair samples from 10 individuals using the 
post-extraction addition approach for all 16 AEDs in hair using three sets of samples (see 
2.2.12.4). Set 1 was non-extracted standards prepared in mobile phase and injected directly 
without any treatment. Set 2 was prepared by spiking 6 blank hair samples (20 mg each) 
with standards and internal standard solutions at the beginning before digestion. Set 3 was 
prepared by spiking 6 blank hair samples (20 mg each) with standards and internal 
standard solutions after digestion/extraction but before evaporation and filtration. Both sets 
2 and 3 had to undergo the filtration step due to the dirty samples resulting from the hair 
digestion. After analysing the samples, the peak area was used to calculate the recovery 
and matrix effect as detailed previously in 2.2.14.2. 
Carryover was tested by injecting three blank controls after two injections of a high 
concentration (ULOQ = 2 ng/mg). It was evaluated by dividing the blank peak area at the 
expected retention time by the mean peak area of the high ULOQ and multiplying by 100. 
No carryover is considered if the value is lower than 10%. Carryover percentage was 
calculated by dividing blank 1 peak area by ULOQ mean peak area and multiplying by 
100. 
8.2.8 Case Samples 
As mentioned previously in order for any analytical method to be fully validated, authentic 
samples have to be analysed. However, only two samples were available at the time of this 
project from two different donors due to the difficulties in obtaining authentic hair samples 
(see 7.2).  
Sample 1 was a shaved black beard sample kindly donated from a 60 year old male who 
was on regular lamotrigine, gabapentin and carbamazepine prescription (chronic use). The 
prescribed doses were not provided. 
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Sample 2 was a brown head hair sample donated from a 39 year old male who was known 
to be prescribed valproic acid as a chronic treatment. The prescribed dose was not 
provided. 
Case hair samples were initially analysed qualitatively, then an extracted calibration curve 
was prepared in hair for positively detected AEDs; carbamazepine and its metabolite 
carbamazepine 10, 11 epoxide, gabapentin, lamotrigine and valproic acid which were 
known to be prescribed for the tested samples .  
Linearity, precision and accuracy were carried out before analysing the samples 
quantitatively. Linearity was assessed by spiking blank hair at 7 concentrations ranging 
from 0.05-2 ng/mg. A linear regression equation weighted 1/X was applied.  
Accuracy and precision were assessed by analysing 6 replicates of spiked controls at 2 
different concentrations (0.5 and 1 ng/mg). The method was not fully validated as a 
quantitative analysis due to instrument down time and limited time available. 
8.3 Results and Discussion  
8.3.1 Hair Extraction Optimization 
Recoveries of six different digestion methods were compared and results are presented in 
Figure ‎8-2.  
The methanolic digestions either alone or with weak acid (TFA) or weak base (NH4OH) 
attained acceptable recoveries with almost all 16 AEDs including the amphoteric drugs, 
GBP, PGR and VIG. Recoveries were higher than 65% for all AEDs except VIG, OXC, 
LTG and TIG. LTG and TIG recoveries ranged between 35 - 60% whereas VIG and OXC 
were between 0 and 43%. Although VIG recovery was very low between 20 to 40%, the 
drug was still detectable compared to other digestion procedures where its recovery did not 
exceed 5%. OXC and CBZO have very similar structures (see 2.3.5) and both exhibited 
poor recovery with acidic methanol digestion (< 10 %). Strong acidic and basic digestions 
showed low recoveries (< 60 %) with most AEDs especially the group of amphoteric drugs 
with recovery less than 5%. CBZ and LAC were the only two drugs that gave a good 
recovery (> 55%) with all methods regardless of the pH used, whereas OXC and VIG 
exhibited low recovery with all digestion methods used (5 - 40 %). VPA recovery was 
higher than 60 % for all methods except acidic digestion and 1M NaOH digestion where its 
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recovery was lower than 10%. Similarly, LEV showed a recovery lower than 25 % with all 
strong acidic and basic digestions followed by LLE. Hence, methanolic extraction was the 
method of choice for hair digestion of AEDs samples in the following sections. 
 
 
Figure  8-2: Recovery Comparison of Six Hair Digestion Methods. 
 
8.3.2 Clean Up Optimization 
Recoveries of clean up procedures were compared and results are presented in Figure ‎8-3. 
In general, sample filtration was the only method that achieved a good recovery with all 
AEDs together in one step regardless of their chemical properties (> 50 %). Vigabatrin had 
a low recovery (15 %) which was due to the digestion procedure. This drug did not exhibit 
a higher recovery with any of the methods used earlier.  
Furthermore, all drugs exhibited an acceptable recovery with LLE except the amphoteric 
drugs (GBP, PGR and VIG) and LEV which did not show any improvement by changing 
the LLE solvent. LLE with ethyl acetate on its own or with IPA had slightly higher 
recoveries compared with DCM except for TIG which exhibited a better recovery with 
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DCM (> 40%) compared to ethyl acetate (< 5%). p-HPPH gave a poor recovery with DCM 
extraction (< 7%). 
Consequently, methanolic extraction (neutral, basic and acidic) was chosen for further 
investigation and sample filtration was considered the clean-up procedure of choice in this 
study as a simple clean-up procedure to maintain optimal system performance. 
 
 
Figure  8-3: Recovery Comparison of Four Clean Up Procedures. 
 
8.3.3 Investigation Into Extraction Conditions  
8.3.3.1 Incubation Duration and Temperature 
Recoveries of four digestion conditions were compared and results are presented in 
Figure ‎8-4. For all digestion methods, the highest recoveries for AEDs were attained with 
samples incubated for 1 hour at 60ºC and left overnight, with the exception of VIG and 
VPA. VIG and VPA exhibited higher recoveries when samples were incubated for only 2 
hours at 60ºC. On the other hand, samples incubated at 40ºC for 2 hours or for 1 hour at 
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2 hours only or for 1 hour and leaving samples overnight gave similar recoveries for most 
of the drugs, except for OXC when extracted using acidic conditions. In general, increasing 
both temperature and incubation period improved the extraction recovery. Hence, digestion 
temperature and incubation duration could affect the extraction yield. 
 
 
 
Figure  8-4: Effect of Incubation Duration and Temperature Condition on AED Recovery in 
Hair. 
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8.3.3.2 Sample Filtration Effect on Recovery 
From Figure ‎8-5, it can be seen that the filtration step reduced AED recoveries by 10 - 
30%. However, recovery values were still acceptable for filtered extracts. Furthermore, the 
use of filtration did not affect the drug chromatogram and decreased the baseline noise. 
Despite the slight decrease in recovery, the filters were continued to be used during method 
validation and hair sample analysis due to the resulting dirty hair extracts following 
digestion. Hence, a clean up procedure would help to maintain the instrument performance 
and decrease its down time due to residue build up and blockage of the LC system and 
decrease the matrix effect that would affect the mass spectrometry performance. 
 
Figure  8-5: Sample Filtration Effect on Recovery of 16 AEDs. 
 
8.3.4 Qualitative Method Validation 
8.3.4.1 Selectivity 
No endogenous or exogenous interferences were observed and none of the AEDs or their 
internal standards showed any interference at the retention time of the other drugs included 
in the method as illustrated in Figure ‎8-6 (a-e). 
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Figure  8-6 (a-e): The Chromatograms of 10 Drug-Free Hair Samples Compared to AED Mix Spiked Standard at Concentration of 2 ng/mg. 
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Figure 8-6 (a-e): The Chromatograms of 10 Drug-Free Hair Samples Compared to AED Mix Spiked Standard at Concentration of 2 ng/mg (Continued…). 
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Figure 8-6 (a-e): The Chromatograms of 10 Drug-Free Hair Samples Compared to AED Mix Spiked Standard at Concentration of 2 ng/mg (Continued…). 
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Figure 8-6 (a-e): The Chromatograms of 10 Drug-Free Hair Samples Compared to AED Mix Spiked Standard at Concentration of 2 ng/mg (Continued…). 
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Figure 8-6 (a-e): The Chromatograms of 10 Drug-Free Hair Samples Compared to AED Mix Spiked Standard at Concentration of 2 ng/mg (Continued…). 
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8.3.4.2 Limit of Detection 
LOD, LLOQ and LOQ results are presented in Table ‎8-4. 
Table  8-4: LOD, LLOQ and LOQ of 16 AEDs in Hair. 
AEDs 
LOD 
(ng/mg) 
LLOQ 
(ng/mg) 
LOQ 
(ng/mg) 
CBZ 0.025 0.05 0.05 
CBZO 0.025 0.05 0.05 
ESL 0.025 0.05 n/a 
GBP 0.025 0.05 0.05 
LAC 0.025 0.05 n/a 
LEV 0.025 0.05 n/a 
LTG 0.05 0.1 0.1 
OXC 0.025 0.05 n/a 
PGR 0.025 0.05 n/a 
PHT 0.1 0.2 n/a 
p-HPPH 0.1 0.2 n/a 
TIG 0.1 0.2 n/a 
TPR 0.025 0.05 n/a 
VIG 0.05 0.1 n/a 
VPA 0.01 0.05 0.05 
ZNS 0.1 0.2 n/a 
 
8.3.4.3 Recovery and Matrix Effect 
The matrix factor and recovery results of 2 QCs (low and high) using 10 different sources 
of hair are detailed in Table ‎8-5. Recoveries were higher than 72.9 % for all AEDs except 
valproic acid which had a recovery of 50.8 % at the low concentration.  Despite the high 
recoveries, the matrix factors exhibited low values outside the acceptable range (0.75-1.25) 
for most of the AEDs at the low concentration, except with ESL, LEV, PHT, p-HPPH and 
TPR. Ionization suppression occurred with all AEDs (<1) except OXC and VPA which 
exhibited an ionization enhancement effect (>1). One of the reasons for MF variation may 
be due to the way samples were prepared. Pre and post extracted samples were filtered 
whereas the non-extracted standards were injected directly. It was shown before that the 
filtration step reduced the recovery and since the MF calculated using post extracted 
samples divided by non-extracted samples, the variation may be due to drug loss during the 
filtration step rather than a matrix suppression effect. This explanation is supported by the 
high recovery values obtained when pre and post extracted samples were used for the 
recovery calculation and these were both filtered before extraction. Usually when matrix 
suppression is presented, it is associated with low extraction yield (see 2.3.8.4). 
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Table  8-5: Recovery and Matrix Factor Values for 16 AEDs Using Low and High QCs and 10 
Different Hair Sources (n=6 per QC per Matrix). 
AEDs 
QC1 QC2 
Recovery(%) Matrix Factor Recovery(%) Matrix Factor 
CBZ 87.1 ± 8.4 0.7 ± 0.1 78.2 ± 8.3 0.6 ± 0.1 
CBZO 87.5 ± 6.4 0.7 ± 0.1 81.8 ± 8.2 0.6 ± 0.1 
ESL 85.3 ± 9.6 0.8 ± 0.1 77.9 ± 8.6 0.7 ± 0.1 
GBP 87.4 ± 11.0 0.5 ± 0.1 80.1 ± 9.1 0.5 ± 0.1 
LAC 95.1 ± 16.7 0.5 ± 0.1 80.9 ± 12.6 0.5 ± 0.1 
LEV 92.3 ± 9.8 0.8 ± 0.1 88.5 ± 19.7 0.7 ± 0.1 
LTG 72.9 ± 19.0 0.4 ± 0.1 75.5 ± 8.9 0.5 ± 0.1 
OXC 82.4 ± 7.5 1.7 ± 0.6 79.7 ± 8.9 1.6 ± 0.6 
PGR 90.0 ± 11.1 0.6 ± 0.1 80.4 ± 10.3 0.6 ± 0.1 
PHT 76.0 ± 5.1 0.8 ± 0.1 91.1 ± 34.3 0.6 ± 0.2 
p-HPPH 86.0 ± 11.5 0.9 ± 0.2 81.2 ± 10.1 0.6 ± 0.1 
TIG 104.3 ± 49.8 0.2 ± 0.1 71.4 ± 23.7 0.3 ± 0.1 
TPR 82.7 ±11.5 0.9 ± 0.2 81.2 ± 10.1 0.6 ± 0.1 
VIG 87.0 ± 7.0 0.3 ± 0.1 77.9 ± 12.4 0.3 ± 0.1 
VPA 50.8 ± 16.7 1.2 ± 0.3 75.9 ± 9.7 1.5 ± 0.9 
ZNS 76.0 ± 9.7 0.9 ± 0.2 82.5 ± 7.0 0.7 ± 0.1 
8.3.4.4 Carryover 
No carry over was observed for all 16 AEDs in hair. The percentage of carryover after the 
first blank injection was 0% for all drugs except carbmazepine epoxide, eslicarbazepine 
acetate, gabapentin, oxcarbazepine and vigabatrin which was 0.21%, 0.79%, 0.18%, 0.08% 
and 0.31% respectively. However, these percentages are acceptable (<10%) and very low 
compared to the high concentrations used (2 ng/mg). A summary of the carryover results is 
detailed in Table ‎8-6. 
Table  8-6: Carryover Results of 16 AEDs After Double Injections of ULOQ (2 ng/mg) in Hair. 
AED 
Peak Area Carryover 
(%) QC3 (n=2) Blank 1 Blank 2 Blank 3 
CBZ 413565 0 0 0 0.00 
CBZO 39204 84 33 0 0.21 
ESL 336109 2671 2094 0 0.79 
GBP 70966 124 62 0 0.18 
LAC 131218 0 0 0 0.00 
LEV 28589 0 0 0 0.00 
LTG 10269 0 0 0 0.00 
OXC 21483 16 0 0 0.08 
PGR 36642 112 125 0 0.00 
PHT 559 0 0 0 0.00 
HPPH 497 0 0 0 0.00 
TIG 6870 0 0 0 0.00 
TPR 5231 0 0 0 0.00 
VIG 17414 53 86 0 0.31 
VPA 8960 0 0 0 0.00 
ZNS 952 0 0 0 0.00 
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8.3.5 Case Samples 
Carbamazepine, gabapentin and lamotrigine were detected in sample 1 and valproic acid 
was detected in sample 2 as expected. Chromatograms of AEDs detected in both samples 
are presented in Figure ‎8-7. 
 
Figure  8-7: Chromatograms of AEDs Detected in Both Samples Compared to Non-Extracted 
Standard at 1 ng/mg. 
 
In order to quantitate the AED concentrations, linearity, precision and accuracy checks 
were carried out. The calibration curves were linear with a R² greater than 0.998. Accuracy 
and precision results are presented in Table ‎8-7. Accuracy was within 18% of the nominal 
concentration and ranged between 82.6 to 115.8%. Precision was less than 15% for all 
AEDs except for the LTG low QC which had a precision of 17.5%. 
Table  8-7: Accuracy and Precision Results of 4 AEDs and 1 Metabolite in Hair. 
AEDs Precision% (n=6)  Accuracy%  (n=6) 
  0.5 ng/mg 1 ng/mg 0.5 ng/mg 2 ng/mg 
CBZ 9.3 9.9 105.1 82.6 
CBZO 15.8 5.5 109.6 106.5 
GBP 6 2 105.5 106.4 
LTG 17.5 13.6 103.8 87.6 
VPA 4.9 14.2 115.8 82.7 
 
AED samples were extracted using the two different digestion conditions that gave the 
highest recoveries with spiked hair samples in order to confirm the results obtained 
previously. The two conditions chosen were digestion for 2 hours only followed by direct 
filtration and for 1 hour and left overnight before filtration.  Both digestions were at 60 ºC. 
Samples were digested and analysed in triplicate as described in 8.2.5.1. 
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AED calculated concentrations are presented in Figure ‎8-8. The results were comparable 
using both spiked and real hair samples. Carbamazepine, carbamazepine epoxide and 
gabapentin concentrations increased from 11.3, 4.0 and 2.0 ng/mg to 12.4, 6.2 and 2.9 
ng/mg respectively when samples were left over night. Lamotrigine concentrations did not 
show any variation with a concentration of approximately 2.8 ng/mg. Finally, valproic acid 
has a higher recovery when samples were filtered and injected directly after 2 hours 
digestion (0.77 ng/mg) compared to samples left overnight (0.37 ng/mg). 
 
Figure  8-8: Mean Concentrations of 4 AEDs Detected in 2 Hair Samples Using two 
Digestions Conditions. 
 
8.4 Conclusion 
This is the first study to investigate the extraction optimization of 16 AEDs in hair of 
which 6 had been tested in hair previously; only carbamazepine, valproic acid, phenytoin, 
lamotrigine, oxcarbazepine and pregabalin were reported previously in the literature.  
Six different digestion procedures using different neutral, basic and acidic solvents were 
compared. Methanolic digestion gave acceptable results with all AEDs including 
amphoteric drugs; gabapentin, pregabalin and vigabatrin. Amphoteric drug recovery was 
very low with strong acidic and basic digestion followed by liquid-liquid extraction as a 
cleaning-up procedure which may be due to the LLE step. Their recovery did not improve 
when LLE solvents were changed from DCM to ethyl acetate and IPA. Hence, sample 
filtration was considered the method of choice. Although the filtration step causes a 10-
30% decrease in recovery, a sample cleaning-up procedure was an essential step to 
maintain good analysis and instrument performance. 
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Digestion incubation and temperature also had a significant effect on the sample extraction 
yield. Increasing both of these resulted in increasing AED recovery; however, caution 
should be taken when extraction of thermally labile drugs is carried out. Real case samples 
were used to compare the digestion effect and duration on drug recovery and the results 
were comparable for those obtained using spiked hair samples. 
Finally, the method was qualitatively validated and 2 case samples from known AED users 
were successfully analysed. The samples were positive for the prescribed AEDs; 
carbamazepine and its metabolite carbamazepine epoxide, gabapentin, lamotrigine and 
valproic acid. However, no dose information was provided, hence the data could not be 
compared to what has been published in the literature. 
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9 Conclusion and Future Work 
9.1 Conclusion 
Antiepileptic drugs and their potential role in forensic cases have been investigated in this 
research. A significant growth in their reported abuse was noticed since 2011. Their 
multiple mechanisms of action on the CNS extended their indications to include a variety 
of psychological disorders and alcohol and substance misuse programmes although their 
efficacy in most of these indications is still under investigation. Their off-label prescription 
played a key role in their abuse potential. As well as their abuse with other illicit drugs and 
alcohol to increase euphoric effects, these drugs are being misused as pain killers. 
The prevalence and abuse potential of AEDs among prison populations were evaluated. 
The study showed a high prevalence of AEDs (18%) largely due to GBP (13%) and PGR 
(4%) on their own or in combination with other drugs of abuse. However, the lack of 
information provided along with each sample did not allow differentiating between 
prescribed and abused AEDs. 
A simple and accurate analytical method was successfully developed and validated for the 
simultaneous analysis of commonly encountered AEDs in different biological matrices.  
AEDs were extracted from whole blood, plasma, serum, urine and hair using a simple and 
cheap extraction procedure and a small sample volume (20 mg for hair and 100 µL for the 
other matrices) and analysed using LC/MS/MS QQQ. A wide concentration range to 
include therapeutic and toxic concentrations was used. 
Firstly, the method was developed and quantitatively validated for the simultaneous 
analysis of 15 AEDs and 2 major metabolites in post mortem whole blood and was to be 
suitable for routine clinical and forensic toxicological analysis. The complex mixture of 
AEDs used in this method required a general method in order to attain high recoveries with 
all drugs of interest. Strata X cartridges are recommended for general SPE extraction; 
however, they did not achieve the optimum results for AEDs. Even though protein 
precipitation does not produce a particularly clean extract, the purity of the samples was 
sufficient to be injected into LC/MS/MS when a large reconstitution volume was used (1.5 
mL).  In addition, it is simple, fast, time saving and little solvent is required. Furthermore, 
increasing the centrifuge speed and duration improved the recovery. It is important also as 
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part of any method development to evaluate the effect of reconstitution volume and 
composition due to its significant effect on linearity, LOQ and calibration model. 
Despite the complex composition of postmortem blood samples which lead to the use of a 
large sample volume in order to have a homogenous sample, the method was successfully 
validated using a small sample volume (100 µL). 
Simultaneous methods can be a great advantage for routine laboratory work. Despite the 
high cost of this method at the development stage, on a long-term basis the method would 
save on analyst time, consumable cost and effort. Rather than using many different 
methods to test for these substances individually the same procedure can be used. It may 
also reveal the presence of other drugs that have not been mentioned in the medical history 
either prescribed or misused. Furthermore, simultaneous analysis presents an important 
tool for TDM where AEDs are taken concomitantly and the concentration variations could 
significantly affect the quality of life for people with epilepsy related conditions. 
The method was transferred to another laboratory and extended to include 22 AEDs. It was 
validated for serum and plasma in addition to whole blood. The main factors required to be 
taken into consideration when transferring the LC/MS/MS method from one instrument to 
another or from one laboratory to another were assessed as well. In order to transfer an 
LC/MS/MS method, collision energy and fragmentor voltage have to be assessed to attain 
the highest sensitivity. Mobile phase and column conditions can be easily transferred.  
The first stability study to specifically investigate the stability of 16 AEDs in postmortem 
blood was carried out. Drug stability is very important in forensic cases where analysis 
may be delayed due to the time needed for the autopsy, chain of custody, sending samples 
for analysis and generating results and sometimes sample reanalysis if requested by court 
or police. During this long process, samples may be exposed to various storage conditions 
which can affect the concentration of drugs and other chemicals and lead to false negative 
or positive results. Hence, well designed stability studies under different conditions are 
required to interpret the toxicological findings correctly. Since some drugs are more 
sensitive to storage conditions, it is important during any stability study to report the 
temperature at which the study was carried out especially at room temperature. It was 
noticed that the stability of some drugs significantly decreased when room temperature 
increased from 18°C to 25°C (retigabine, eslicarbazepine acetate and oxcarbazepine). 
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Finally, hair as a biological matrix represents a valuable alternative when other biological 
samples are not available or when a history of drug use is required. The extraction of 16 
AEDs in hair was optimized. Methanolic extraction was the method of choice for all AEDs 
including amphoteric drugs. Amphoteric drug recovery was very low with all strong acidic 
and basic digestions followed by liquid-liquid extraction as cleaning-up procedure. 
Digestion incubation and temperature as well has a significant effect on sample extraction 
yield. Increasing both of these resulted in enhancing AEDs recovery; however, caution 
should be taken into account when extraction of thermally labile drugs is carried out. 
Finally, the method was qualitatively validated and 2 case samples from known AED users 
were successfully analysed.  
9.1 Future Work 
Awareness regarding these drugs and their probability to be abused among GPs and other 
health organisations should be raised. Some guidance for prescribing should be established 
and more care should be considered when they are prescribed especially for people with 
pervious abuse history. 
A larger scale study to include addiction and pain management clinics in addition to 
prisons is recommended to assess AEDs abuse prevalence among substance abusers and 
pain killer misusers. It would be an advantage to obtain more accurate data regarding sex, 
age and medical history to generate more accurate statistics. 
It was noticeable in this research that AED concentrations, especially gabapentin and 
pregabalin, in some samples were above the reported therapeutic limits in the literature. 
Hence, a study to establish the toxic limits of gabapentin and pregabalin concentrations in 
blood is recommended which would aid the pathologist in the interpretation of results in 
postmortem cases. Furthermore, a study is required to compare AEDs concentrations in 
postmortem SUDEP cases in order to investigate any relationship between the number 
and/or concentrations of AEDs taken at the time of death and SUDEP as a cause of death. 
Simultaneous analysis for multiple drugs of abuse using LC/MS/MS would be a great 
advantage in forensic toxicology where most postmortem cases usually include many 
drugs being abused together and not all being declared or requested for analysis. 
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Stability of retigabine and its metabolite requires further investigation to include solvents, 
blood stabilizers, and storage condition in order to ensure accurate quantitive analysis that 
reflect the actual concentration in biological fluids. 
Finally, AEDs analysis in hair would require an extended validation with a larger number 
of authentic samples to include all drugs of interest in order to prove the extraction method 
efficiency and be applicable for forensic and therapeutic drug monitoring analysis. 
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Appendix 1-1: An Overview of Data From Reports of AED Abuse. 
RF AED 
Subject 
(y/g) 
Case Dose/day 
Plasma 
Conc. 
(mg/L) 
Symptoms Drug source RA 
(37), 
1996 
GBP 
VPA 
32/M 
GBP, VPA 
and alcohol 
misuse 
91 g 
GBP 
54 g 
VPA 
44.5 
GBP 
107.1 
VPA 
Dizziness, sleepiness, 
depressed, slurred speech, 
suicidal attempt 
Prescription for 
treating epilepsy 
Oral 
(94), 
1997 
GBP 41/F 
GBP 
dependence 
600-1500 
mg 
N/A 
“Laid-back”‎feelings,‎
decreased cocaine craving 
WS: Suicidal thoughts, 
depression 
Her husband's 
gabapentin to 
wean her off 
Crack cocaine  
Oral 
(99), 
2000 
GBP 38/F 
GBP 
prescription 
900 mg N/A 
Euphoria, feeling well, 
inappropriate laughter, 
increased energy 
Prescription for 
treating epilepsy 
and pain 
Oral 
(99), 
2000 
GBP 37/F 
GBP 
prescription 
1800 mg N/A 
Euphoria, feeling well, 
inappropriate laughter 
Prescription for 
treating epilepsy 
Oral 
(95), 
2007 
GBP 67/F 
GBP abuse 
WS 
4200-
7200 mg 
N/A 
WS: trembling, sweating, 
excitation, exophthalmia 
Prescription for 
treating alcohol 
abuse 
Oral 
(98), 
2007 
GBP 33/M 
GBP abuse 
WS 
3600 mg N/A 
WS: tremulous, confusion, 
agitation, tachycardia, 
hyper-reflex, diaphoretic, 
disoriented 
Prescription for 
cannabis and 
alcohol abuse 
treatment 
Oral 
(98), 
2007 
GBP 63/M 
GBP abuse 
WS 
4900 mg N/A 
Fatigue, increasing 
sedation, confusion 
Prescription as 
analgesic 
Oral 
(122), 
2009 
GBP 44/M 
Driving 
under GBP 
effects 
N/A <0.2 
Unfocused, slow, 
aggressive 
Self-medicating 
with GBP and 
quetiapine for 
bipolar 
Oral 
(122), 
2009 
GBP 24/F 
Driving 
under GBP 
effects 
300 mg 15.5 
Impaired with thick, 
slurred speech, slow 
reactions, sleepiness 
Prescription with 
quetiapine 
Oral 
(122), 
2009 
GBP 51/M 
Driving 
under GBP 
effects 
N/A 2.5 
Slow, deliberate 
movements, lethargy 
N/A Oral 
RF: reference, RA: Route of administration, F: female, M: male, N/A: information not applicable, PHT: phenytoin, VPA: 
sodium valproate, CBZ: carbamazepine, GBP: gabapentin, PGR: pregabalin, VIG: vigabatrin, TIG: tiagabine, ZNS: 
zonisamide, LAC: lacosamide, OXC: oxcarbazepine, TPR: topiramate, LTG: lamotrigine, BNZ: benzodiazepines, AW: 
alcohol withdrawal, WS: withdrawal symptoms. 
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Appendix 1-1: An Overview of Data From Reports of AED Abuse (continued…). 
RF AED 
Subject 
(y/g) 
Case Dose/day 
Plasma 
Conc. 
(mg/L) 
Symptoms Drug source RA 
(102), 
2010 
GBP 53/F 
GBP 
withdrawal 
syndrome 
700 mg N/A 
WS: confusion, agitation, 
anxiety, headache, 
nervousness. 
Prescription as 
analgesic for  
liver cirrhosis, 
resulting from 
alcohol abuse 
Oral 
(122) 
2009 
GBP 24/M 
Driving 
under GBP 
effects 
N/A 4.4 
Subdued,  lethargy, scattered 
thoughts, confusion 
Prescription for 
psychiatric 
disorder 
Oral 
(105), 
2010 
PGR 47/M 
PGR abuse 
with 
alcohol 
and 
cannabis 
7500 mg 29 
Euphoria 
WS: sweating, unrest, 
hypertension, tremor, craving 
for PGR 
A friend who 
was prescribed 
PGR for pain 
Oral 
(103), 
2010 
PGR 28/F 
PGR and 
alcohol 
abuse 
N/A N/A 
Psychotic reaction, became 
high 
N/A Oral 
(103), 
2010 
PGR 18/M 
PGR and 
alcohol 
abuse 
875 mg N/A 
Became high but in high dose 
developed generalized 
seizures 
N/A Oral 
(103), 
2010 
PGR 35/M 
PGR and 
substance 
abuse 
525 mg N/A 
Euphoria, described as 
“amphetamine‎trip” 
Prescription for 
anxiety 
Oral 
(103), 
2010 
PGR 23/M 
Non-
specific 
substance 
abuse 
300 mg N/A Became high N/A Oral 
(103), 
2010 
PGR 26/M 
PGR and 
substance 
abuse 
2400 mg N/A 
Hospitalisation for 
detoxification 
Prescription for 
anxiety 
Oral 
(103), 
2010 
PGR 26/F 
PGR and 
substance 
abuse 
1200 mg N/A 
Slow tapering of dose 
required 
Prescription for 
anxiety 
Oral 
RF: reference, RA: Route of administration, F: female, M: male, N/A: information not applicable, PHT: phenytoin, VPA: 
sodium valproate, CBZ: carbamazepine, GBP: gabapentin, PGR: pregabalin, VIG: vigabatrin, TIG: tiagabine, ZNS: 
zonisamide, LAC: lacosamide, OXC: oxcarbazepine, TPR: topiramate, LTG: lamotrigine, BNZ: benzodiazepines, AW: 
alcohol withdrawal, WS: withdrawal symptoms. 
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Appendix 1-1: An Overview of Data From Reports of AED Abuse (continued…). 
RF AED 
Subject 
(y/g) 
Case Dose/day 
Plasma 
Conc. 
(mg/L) 
Symptoms Drug source RA 
(103), 
2010 
PGR 43/F 
PGR and 
BNZ abuse 
1000 mg N/A 
Euphoria,  described as 
“amphetamine‎trip”,‎
hyperactivity, decreased 
consciousness 
N/A Oral 
(103), 
2010 
PGR 38/M 
PGR and 
substance 
abuse 
3000 mg N/A 
Suicide thoughts when 
decreasing dose 
Prescription 
for anxiety 
Oral 
(103), 
2010 
PGR 51/M 
PGR and 
substance 
abuse 
N/A N/A Amnesia, suicide thoughts N/A Oral 
(103), 
2010 
PGR 29/M 
PGR and 
substance 
abuse 
N/A N/A N/A N/A Oral 
(103), 
2010 
PGR 32/M 
PGR and 
substance 
abuse 
N/A N/A 
Multiple hospital 
admission for PGR and 
zolpidem abuse 
Patient sold his 
PGR tablets 
Injection 
(103), 
2010 
PGR M 
PGR and 
substance 
abuse 
1050 mg N/A Nice BNZ effects 
Prescription 
for anxiety 
Oral 
(103), 
2010 
PGR 19/M 
PGR and 
substance 
abuse 
300 mg N/A 
Became high, effects 
similar to diazepam 
Prescription 
for anxiety 
Nasally 
(103), 
2010 
PGR 29/M 
PGR and 
substance 
abuse 
N/A N/A Behavioural disturbance 
Patient sold her 
tablets on 
black market 
Oral 
(112), 
2001 
TPR 30/F 
Topiramate 
abuse 
450 mg N/A 
Decreased cognition, 
dulled thinking, blunted 
mental reactions, blurred 
vision, paresthesias, 
sleepiness, gastrointestinal 
disturbances 
Prescription 
for treating 
mania 
Oral 
(113), 
2004 
TPR 17/F 
Topiramate 
abuse 
800 mg N/A 
Incoherence, confusion, 
disorientation, speech 
impairments 
From  friends Oral 
RF: reference, RA: Route of administration, F: female, M: male, N/A: information not applicable, PHT: phenytoin, VPA: 
sodium valproate, CBZ: carbamazepine, GBP: gabapentin, PGR: pregabalin, VIG: vigabatrin, TIG: tiagabine, ZNS: 
zonisamide, LAC: lacosamide, OXC: oxcarbazepine, TPR: topiramate, LTG: lamotrigine, BNZ: benzodiazepines, AW: 
alcohol withdrawal, WS: withdrawal symptoms. 
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Appendix 1-1: An Overview of Data From Reports of AED Abuse (continued…). 
RF AED 
Subject 
(y/g) 
Case Dose/day 
Plasma 
Conc. 
(mg/L) 
Symptoms 
Drug 
source 
RA 
(92), 1993 CBZ 24/F 
Beer and 
CBZ abuse 
1000-
1800 mg 
CBZ 
16.5 
Euphoric feeling, light-
headedness, dizziness 
Prescription 
for BNZ 
and alcohol 
abuse 
treatment 
(300 
mg/day) 
Oral 
(103), 
2010 
PGR 42/F 
PGR and 
substance 
abuse 
4200 mg N/A 
Psychosis requiring 
hospitalization 
N/A Oral 
(92), 1993 CBZ 38/M Abuse 1200 mg 18.1 
Euphoric feeling, light-
headedness, dizziness, 
ataxia, diplopia. WS 
appeared after  drug 
discontinuation 
Alcohol 
dependence 
treatment 
Oral 
(93), 1997 CBZ 22/F 
Alcohol 
and CBZ 
dependence 
N/A N/A 
Temazepam and alcohol-
like euphoria 
Purchased 
from the 
street 
Oral 
(110), 
1993 
PHT 40/M 
Crack 
cocaine 
abuse with 
PHT 
60 
capsules 
52 
Difficulty walking, 
slurred speech, tremor, 
double vision and fatigue 
Friends- 
street 
practice 
Smoked 
(110), 
1993 
PHT 42/M 
Crack 
cocaine 
abuse with 
PHT 
N/A 22 
Double vision, unsteady 
gait, prominent 
nystagmus, ataxia (the 
symptoms appeared 
within the therapeutic 
range). 
Prescribed 
for him as 
an epileptic 
patient 
Smoked 
(110), 
1993 
PHT 34/M 
Crack 
cocaine 
abuse with 
PHT 
N/A 50 
Nystagmus, ataxia, 
lethargy, slurred speech 
Prescribed 
for him as 
an epileptic 
patient 
Smoked 
(110), 
1993 
PHT 
36/M  
48/M 
Crack 
cocaine 
abuse with 
PHT 
N/A 7-8 No symptoms found 
Street 
practice 
Smoked 
(111),1995 PHT 36/M 
Crack 
cocaine 
abuse with 
PHT 
N/A 28 Unsteady gait, nausea, 
From a 
friend with 
epilepsy 
Smoked 
(79), 2004 PHT 19/M 
Alcohol, 
marijuana 
and alcohol 
abuse 
N/A 45 
Slurred speech, 
somnolence, agitation, 
combative, ataxia 
From street Smoked 
RF: reference, RA: Route of administration, F: female, M: male, N/A: information not applicable, PHT: phenytoin, VPA: 
sodium valproate, CBZ: carbamazepine, GBP: gabapentin, PGR: pregabalin, VIG: vigabatrin, TIG: tiagabine, ZNS: 
zonisamide, LAC: lacosamide, OXC: oxcarbazepine, TPR: topiramate, LTG: lamotrigine, BNZ: benzodiazepines, AW: 
alcohol withdrawal, WS: withdrawal symptoms. 
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Appendix 2-2: Tuning Results of 15 AEDs and 5 Internal Standards Using the Optimizer 
Software. 
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        Appendix 6-1: Bland-Altman Plot of the Validated Method Concentrations and the Reference Lab Concentrations for Each AED. 
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         Appendix 6-1: Bland-Altman Plot of the Validated Method Concentrations and the Reference Lab Concentrations for Each AED (Continued…). 
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        Appendix 6-1: Bland-Altman Plot of the Validated Method Concentrations and the Reference Lab Concentrations for Each AED (Continued…). 
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        Appendix 6-1: Bland-Altman Plot of the Validated Method Concentrations and the Reference Lab Concentrations for Each AED (Continued…). 
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        Appendix 6-1: Bland-Altman Plot of the Validated Method Concentrations and the Reference Lab Concentrations for Each AED (Continued…). 
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        Appendix 6-1: Bland-Altman Plot of the Validated Method Concentrations and the Reference Lab Concentrations for Each AED (Continued…). 
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Appendix 7-1: Ethical Approval and Amendment Letters from the West of Scotland Research 
Ethics Service (WoSRES) to Collect Urine Samples from Prisoners. 
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Appendix 7-2: Details of Illicit Drugs Detected in Positive AEDs Urine Sample. 
Sample 
No. 
Prison 
Sample
a
 
Type 
GBP PGR 
 Other 
AEDs 
AMP
b 
OPI
c 
BNZ
d 
CAN
e 
COC
f 
MAMP
g 
BARB
h 
BUP
i 
MTD
j Prescribed 
Medication  
1 Low Moss A +                         
2 Low Moss A + +     + + +   +     +   
3 Low Moss A +           +             
4 Low Moss A +         + + +           
5 Low Moss A     CBZ     + +             
6 Low Moss A     
VPA 
LEV 
    + +             
7 Low Moss A +         + +         +   
8 Low Moss A   +   + + + + + + + + +   
9 Low Moss A +       + +         +     
10 Low Moss A +       + +               
11 Low Moss A +       + + +             
12 Low Moss A     CBZ   + + + +     +     
13 Low Moss A + +     + + +     +       
14 Low Moss A +         + +   +         
15 Low Moss A +         +               
16 Low Moss A +       +                 
17 Low Moss A +       + +               
18 Low Moss A +       + +   +       +   
19 Low Moss A + +     + +   +       +   
20 Low Moss L +   TPR                     
21 Addiwell A +       + +               
22 Addiwell A +         +               
a
A: Admission and L: Liberation, 
b
AMP: Amphetamines, 
c
OPI: Opiates, 
d
BNZ: Benzodiazepines, 
  e
CAN: Cannabis,
  f
COC: Cocaine,
  g
MAMP: Methamphetamine,
  h
BARB: Barbiturates,
  
I
BUP: Buprenorphine,
  j
MTD: Methadone.
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Appendix 7-2: Details of Illicit Drugs Detected in Positive AEDs Urine Sample (Continued…). 
Sample 
No. 
Prison 
Sample 
Type 
GBP PGR 
 Other 
AEDs 
AMP OPI BNZ CAN COC MAMP BARB BUP MTD 
Prescribed 
Medication  
23 Addiwell A +                         
24 Addiwell A +         + +       +   Suboxone 
25 Addiwell A +         + + +     +     
26 Addiwell A +       +   +       +     
27 Addiwell A +       + +         +   Suboxone 
28 Addiwell A +       + + +       + +   
29 Addiwell A +       + + +       + +   
30 Addiwell A +         + +             
31 Addiwell A + +         +             
32 Addiwell L +                     + Methadone 
33 Addiwell L +         +               
34 Addiwell L   +                       
35 Addiwell L +                   +     
36 Corton Vale L   +                   + Methadone 
37 Corton Vale L   +                   + Methadone 
38 Corton Vale L + +     +             + Methadone 
39 Corton Vale A +         +               
40 Corton Vale A +       + + +             
41 Corton Vale A +       + +   +       +   
42 Corton Vale A +     + + + +         + Methadone 
43 Corton Vale A +       + +         + + 
Dihydrocodeine, 
Diazapam, 
Methadone  
a
A: Admission and L: Liberation, 
b
AMP: Amphetamines, 
c
OPI: Opiates, 
d
BNZ: Benzodiazepines, 
  e
CAN: Cannabis,
  f
COC: Cocaine,
  g
MAMP: Methamphetamine,
  h
BARB: Barbiturates,
  
I
BUP: Buprenorphine,
  j
MTD: Methadone.
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Appendix 7-2: Details of Illicit Drugs Detected in Positive AEDs Urine Sample (Continued…). 
Sample 
No. 
Prison 
Sample 
Type 
GBP PGR 
 Other 
AEDs 
AMP OPI BNZ CAN COC MAMP BARB BUP MTD 
Prescribed 
Medication  
44 Corton Vale A +         + +         + Methadone 
45 Corton Vale A     VPA   + + +       + +   
46 Corton Vale A   +     + + +         + Methadone 
47 Corton Vale A +       + + +         + Methadone 
48 Corton Vale A   +     + +           + Methadone 
49 Corton Vale A     LTG     +         +   Diazapam 
50 Corton Vale A +         +               
51 Corton Vale A +       +   +     +   + 
Zoplicone, 
Methadone 
52 Corton Vale A +       + + +             
53 Corton Vale A +                         
54 Corton Vale A +       + + + +           
55 Corton Vale A +       + + + +     +   Diazapam 
56 Corton Vale A +       + + +       +     
57 Corton Vale A + +       +           + 
Methadone, 
Diazepam 
58 Corton Vale A +       + + + +       + Methadone 
59 Corton Vale A +       + +         +   Diazepam 
60 Corton Vale A +       + +   +       +   
61 Corton Vale A +       +               Dihydrocodeine 
62 Corton Vale A +       + + +         +   
63 Barlinnie  L +       +               Co-codamol 
64 Barlinnie  L +                     + Methadone 
65 Barlinnie  L +                     + Methadone 
a
A: Admission and L: Liberation, 
b
AMP: Amphetamines, 
c
OPI: Opiates, 
d
BNZ: Benzodiazepines, 
  e
CAN: Cannabis,
  f
COC: Cocaine,
  g
MAMP: Methamphetamine,
  h
BARB: Barbiturates,
  
I
BUP: Buprenorphine,
  j
MTD: Methadone.
  
  
A
p
p
en
d
ices 
 
3
0
9
 
 
Appendix 7-2: Details of Illicit Drugs Detected in Positive AEDs Urine Sample (Continued…). 
Sample 
No. 
Prison 
Sample 
Type 
GBP PGR 
 Other 
AEDs 
AMP OPI BNZ CAN COC MAMP BARB BUP MTD 
Prescribed 
Medication  
66 Barlinnie  L +                     + Methadone 
67 Barlinnie  L   +                       
68 Barlinnie  L +         +           + 
Methadone, 
Diazapam 
69 Barlinnie  A +       + + + +       + 
Co-codamol, 
Methadone 
70 Barlinnie  A +                   +     
71 Barlinnie  A +       + +   +     +     
72 Barlinnie  A +       + + + +       + 
Methadone, 
Diazepam 
73 Barlinnie  A +       + +           + Methadone 
74 Barlinnie  A +       + + + +       + Methadone 
75 Barlinnie  A +         +               
76 Polmont L   +     + + +       +   Suboxone 
77 Polmont L   +                       
78 Polmont L   +         +             
79 Polmont A +           +             
80 Polmont A +         + +             
81 Polmont L     LEV                     
82 Polmont A +         + +             
83 Polmont A     LEV                     
a
A: Admission and L: Liberation, 
b
AMP: Amphetamines, 
c
OPI: Opiates, 
d
BNZ: Benzodiazepines, 
  e
CAN: Cannabis,
  f
COC: Cocaine,
  g
MAMP: Methamphetamine,
  h
BARB: Barbiturates,
  
I
BUP: Buprenorphine,
  j
MTD: Methadone.
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Appendix 7-2: Details of Illicit Drugs Detected in Positive AEDs Urine Sample (Continued…). 
Sample 
No. 
Prison 
Sample 
Type 
GBP PGR 
 Other 
AEDs 
AMP OPI BNZ CAN COC MAMP BARB BUP MTD 
Prescribed 
Medication  
84 Perth A +     + + + + +   + +     
85 Perth A     VIG     + + +           
86 Perth A +                         
87 Perth A   +                       
88 Perth A +         + +         +   
89 Perth A     LTG   +   +       + +   
90 Perth A + +     + +           +   
91 Perth A + +     + +               
92 Perth A +       + + +         +   
93 Perth A +       +   +             
94 Perth A +       + + +       +     
95 Perth A +       + + +             
96 Perth A +       + +           +   
97 Perth A +       + +               
98 Perth A +       +             +   
99 Perth A +       + + +             
100 Perth A +       + +           +   
101 Perth A +       + +   +     + +   
102 Perth A +       + + +         +   
103 Perth A     VIG                     
104 Perth A +       + + +         +   
a
A: Admission and L: Liberation, 
b
AMP: Amphetamines, 
c
OPI: Opiates, 
d
BNZ: Benzodiazepines, 
  e
CAN: Cannabis,
  f
COC: Cocaine,
  g
MAMP: Methamphetamine,
  h
BARB: Barbiturates,
  
I
BUP: Buprenorphine,
  j
MTD: Methadone.
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Appendix 7-2: Details of Illicit Drugs Detected in Positive AEDs Urine Sample (Continued…). 
Sample 
No. 
Prison 
Sample 
Type 
GBP PGR 
 Other 
AEDs 
AMP OPI BNZ CAN COC MAMP BARB BUP MTD 
Prescribed 
Medication  
105 Perth A +       + +           +   
106 Perth A +   LTG   + +           +   
107 Perth A +       + + +     +   +   
108 Perth A +       + + + + +     +   
109 Perth A +       + + +             
110 Perth A +       + + +             
111 Perth A     VPA + + +     +   +     
112 Perth L   +     +             +   
113 Perth L +                         
114 Perth L +                     +   
115 Perth L +                     +   
116 Perth L   +                   +   
117 Perth L +     + +   + +       +   
a
A: Admission and L: Liberation, 
b
AMP: Amphetamines, 
c
OPI: Opiates, 
d
BNZ: Benzodiazepines, 
  e
CAN: Cannabis,
  f
COC: Cocaine,
  g
MAMP: Methamphetamine,
  h
BARB: Barbiturates,
  
I
BUP: Buprenorphine,
  j
MTD: Methadone.
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Appendix 9: Papers and Awards in Support of This Thesis. 
 
Publications 
 Shaza Deeb, Denise A. McKeown, Hazel J. Torrance, Fiona M. Wylie, Barry K. 
Logan,‎ Karen‎ S.‎ Scott.‎ “Simultaneous Analysis of 22 Antiepileptic Drugs in 
Postmortem Blood, Serum and Plasma Using LC-MS-MS with a Focus on Their 
Role in Forensic Cases”. Journal of Analytical Toxicology-Special edition, 2014, 
38 (8): 485-494. 
Oral presentation 
 Shaza Deeb, Fiona M. Wylie, Karen S. Scott. “Gabapentin‎ and‎ Pregabalin‎
prevalence among prisoners in Scotland - an‎insight‎into‎their‎abuse‎potential”.  
- Presented at The United Kingdom and Ireland Association of Forensic 
Toxicologists (UKIAFT) meeting, Aberdeen, UK (August 2014). 
- Presented at the Scottish Prison Service, Edinburgh, UK (April 2015)  
 Karen S. Scott, Shaza Deeb.‎ “Determination‎ of‎ 22‎ antiepileptic‎ drugs‎ in‎
postmortem blood, serum and plasma using LC/MS/MS with a focus on their role 
in‎forensic‎cases”.‎  Presented at the Eastern Analytical Symposium & Exposition, 
Somerset, United States (November 2014).  
 Shaza Deeb, Fiona M. Wylie, Barry K. Logan, Karen‎S.‎Scott.‎“Determination‎of‎
22 antiepileptic drugs in postmortem blood, serum and plasma using LC/MS/MS 
with a focus on their role in forensic‎cases”.‎ Presented at NMS Lab as part of their 
continuing education course, Philadelphia, United States (April 2014).  
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Posters 
 Shaza Deeb, Denise A. McKeown, Hazel J. Torrance, Fiona M. Wylie, Karen S. 
Scott. “Extraction‎ optimization‎ of‎ 15‎ antiepileptic drugs and two selected 
metabolites in postmortem whole‎ blood‎ using‎ LC/MS/MS”. Presented at and in 
Proceedings of Novel Psychoactive Substance (NPS) Conference, Swansea, UK 
(September 2013). 
 Shaza Deeb, Denise A. McKeown, Hazel J. Torrance, Fiona M. Wyli,; Barry K. 
Logan,; Karen S. Scott. “Simultaneous‎analysis‎of‎17‎antiepileptic‎drugs‎in‎whole‎
blood‎using‎LC/MS/MS‎with‎a‎focus‎on‎their‎role‎in‎forensic‎cases”. 
- Presented at and in proceedings of SOFT conference, Orlando, FL, USA, 
(October 2013).  
- Presented at AAFS conference, Seattle, USA (February 2014). 
 Eleanor M. Berry, Denise A. McKeown, Hazel J. Torrence, Shaza Deeb. 
“Significance‎of‎pregabalin‎and‎gabapentin‎concentrations‎in‎postmortem blood”. 
- Presented at The United Kingdom and Ireland Association of Forensic 
Toxicologists (UKIAFT) meeting, Leicester, UK (August 2014). 
Award: 
 Experimental Design and Impact on Toxicology (EDIT) Award - Society of 
Forensic Toxicologists (SOFT), Annual Business Meeting, Michigan, USA 
(October 2014). 
Shaza Deeb, Denise A. McKeown, Hazel J. Torrance, Fiona M. Wylie, Barry K. 
Logan,‎ Karen‎ S.‎ Scott.‎ “Simultaneous Analysis of 22 Antiepileptic Drugs in 
Postmortem Blood, Serum and Plasma Using LC-MS-MS with a Focus on Their 
Role in Forensic Cases”. Journal of Analytical Toxicology-Special edition, 2014, 
38 (8): 485-494. 
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Extraction optimization of 15 antiepileptic drugs and two selected metabolites in 
postmortem whole blood using LC/MS/MS.  
Shaza Deeb, Denise A. McKeown, Hazel J. Torrance, Fiona M. Wylie, Karen S. Scott 
Background/Introduction: 
In recent years, there has been a growth in reports of antiepileptic drugs (AEDs) being 
misused in a variety of toxicological case types such as drug abuse and drug facilitated 
crime. Some of these AEDs are part of routine forensic analysis e.g. carbamazepine 
however many are not. This study aims at comparing seven different protein precipitation 
methods for the simultaneous extraction of the most commonly encountered AEDs in post 
mortem whole blood namely, lacosamide, eslicarbazepine, retigabine, gabapentin, 
pregabalin, topiramate, tigabine, lamotrigine, zonisamide, valproic acid, levetiracetam, 
vigabatrin, oxcarbazepine, carbamazepine and its metabolite carbamazepine-10, 11-
epoxide, phenytoin and its metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH).  
Objective: 
The aim of this project was to optimize the protein precipitation extraction of 15 AEDs to 
create an efficient routine forensic toxicological method. 
Methods: 
A 100 µl aliquot of whole blood spiked with a mixture of 17 AEDs was extracted using 7 
different solvent mixtures with 2 different centrifuging speeds for 3 different periods. 
Samples were analysed using a triple quadruple LC/MS/MS and a Gemini Phenomenex C 
18 column with 2mM ammonium acetate and methanol as the mobile phase. 
Results/Conclusion: 
The precipitants found to yield highest recoveries with lowest standard variations were 
methanol or acetonitrile. Extraction with methanol centrifuged at 5000 rpm for 10 minutes 
was considered as the method of choice because it is cheaper and simpler (200 µL of the 
extract is diluted with 1.5 mL water and injected directly into the LC/MS/MS). The method 
has been used for routine toxicological analysis of postmortem cases. 
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Determination of 15 antiepileptic drugs and two selected metabolites 
in postmortem whole blood using LC/MS/MS.  
Shaza Deeb, Denise A. McKeown, Hazel J. Torrance, Fiona M. Wylie, Karen S. Scott 
Background/Introduction: 
In recent years, there has been a growth in reports of antiepileptic drugs (AEDs) being 
misused on their own or in combination with other drugs of abuse such as heroin and other 
opioids in a variety of toxicological case types such as drug abuse, suicide, overdose and 
drug facilitated crime. Some of these AEDs are part of routine forensic analysis e.g. 
carbamazepine and phenytoin however many are not. A number of laboratory methods 
have been described to quantify AEDs and their metabolites but all of these are for 
therapeutic drug monitoring purposes or for one drug and its metabolites. To our 
knowledge, there are no simultaneous quantification methods for the simultaneous analysis 
of the most commonly encountered AEDs in post mortem whole blood to include 
lacosamide, eslicarbazepine and retigabine in addition to gabapentin, pregabalin, 
topiramate, tigabine, lamotrigine, zonisamide, valproic acid, levetiracetam, vigabatrin, 
oxcarbazepine, carbamazepine and its metabolite carbamazepine-10, 11-epoxide, 
phenytoin and its metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). 
Objective: 
The aim of this project was to develop and validate a method for the determination of 15 
AEDs and two metabolites in whole blood using liquid chromatography triple quadruple 
tandem mass spectrometry (LC/MS/MS) which would be suitable for routine forensic 
toxicological analysis. 
Methods: 
A 100 µl aliquot of the sample was transferred to a 2-mL snap top polypropylene 
microcentrifuge tube, 50 µL of internal standards solution (Gabapentin–D10, Tolbutamide 
and 10, 11 dihydrocarbamazepine) and 250 µL methanol were added, vortexed for 30 
seconds and centrifuged for 10 minutes at 5000 rpm. An aliquot of 200 µL of the 
supernatant was transferred to LC vial and diluted with 1.5 mL of deionized water. A 5 µL 
of the diluted supernatant was injected into an Agilent LC/MS/MS 6420 triple quadruple 
system coupled with an Agilent 1200-series LC system. Electrospray ionization (ESI) was 
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used in dynamic multiple reaction monitoring mode with ion mode switching. The column 
used was a Gemini Phenomenex –C18 (150‎mm‎x‎2.1‎mm,‎5‎μm).‎Gradient‎elution‎was‎
chosen using a mobile phase consisting of 2mM ammonium acetate and methanol at a flow 
rate of 0.3 mL/min. The total run time was 20 minutes with a column temperature 
maintained at 40 °C. 
Results: 
All AEDs were detected and quantified within 20 minutes without endogenous 
interferences. The linear range for each AED was as follows: valproic acid, vigabatrin and 
levetiracetam: 5-300.0 mg/L; carbamazepine, carbamazepine-10, 11-epoxide, 
eslicarbazepine, topiramate, lamotrigine, lacosamide, pregabalin and gabapentin: 0.5-50 
mg/L; zonisamide, phenytoin and its metabolite p-HPPH: 1-50 mg/L. Oxcarbazepine and 
tigabine 0.05-10 mg/L; retigabine: 0.5-10 mg/L.  The correlation coefficient (R2) was 
greater than 0.994 for all AEDs with accuracy and precision exceeding 85% ±15% for all 
analytes. The recovery ranged from 50% to 98%. No carryover was observed in a blank 
injected after the highest standard and the matrix effect was acceptable and ranged from 
90% to 120%. 
Conclusion/Discussion: 
A simple, accurate, and sensitive LC-MS/MS method has been developed for the 
simultaneous quantification of 15 AEDs and 2 metabolites. The method has been used for 
routine toxicological analysis of postmortem cases. 
Key words: Antiepileptic drugs, drug abuse, LC/MS/MS, postmortem blood. 
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Determination of 22 antiepileptic drugs in postmortem blood, serum and 
plasma using LC/MS/MS with focus on their rule in forensic cases.  
Shaza Deeb; Denise A. McKeown; Hazel J. Torrance; Fiona M. Wylie; Barry K. Logan; 
Karen S. Scott. 
In recent years, antiepileptic drugs (AEDs) have been associated with an increased 
likelihood of off-label prescription in non-epilepsy disorders even though most of these 
indications are still under investigation. The widespread use of the new generation of 
AEDs, particularly in patients with psychiatric disorders, often for unlicensed indications, 
increases the risk of self-poisoning, suicide and drug abuse. AEDs are a group of legal 
prescription drugs which are found in abuse cases either alone or with alcohol or other 
common drugs of abuse in order to enhance their effects. Drugs fitting this description 
include gabapentin and pregabalin.   
Sudden unexplained death in epilepsy (SUDEP) is a major cause of death among epileptic 
patients. It is responsible for 18% of epileptic–related deaths. The second most important 
factor after the frequency of seizures is the number of AEDs taken concomitantly. 
Furthermore, many of the AEDs might impair driving if their concentrations are not 
maintained properly; therefore this group of drugs should be tested in cases of suspected 
impaired driving.  
This presentation provides an overview of these drugs and details the development and 
validation of a quantification method for the analysis of the most commonly encountered 
AEDs in post mortem whole blood, serum and plasma which would be suitable for routine 
forensic toxicological analysis and therapeutic drug monitoring at the same time. 
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Gabapentin and Pregabalin Prevalence Among Prisoners in Scotland:  
An Insight Into Their Abuse Potential 
Shaza Deeb*, Fiona M. Wylie, Karen S. Scott 
In recent years, there has been a growth in reports of antiepileptic drugs (AEDs) being 
misused on their own or in combination with other drugs of abuse such as heroin and other 
opioids in a variety of toxicological case types such as drug abuse, suicide, overdose and 
drug facilitated crime. Pregabalin and gabapentin abuse cases have significantly increased 
among drug abusers and prisoners since 2011. Both medicines are indicated for epilepsy, 
neuropathic pain and generalised anxiety disorder. The latter two indications are the more 
common in primary care and prison settings. 
In order to evaluate the prevalence and abuse potential of AEDs among prison populations 
in Scotland, a total of 904 urine samples were collected from 8 prisons in Scotland over a 
one month period (November 2013). These samples were collected initially by the Scottish 
Prison Service to evaluate the prevalence of other illicit drugs. Prisons that participated 
were Perth (187 samples), Barlinnie (172 samples), Polmont (151 samples), Low Moss 
(118 samples), Corton Vale (101 samples), Edinburgh (85 samples), Addiwell (63 
samples), and Greenock (27 samples). After the samples have been tested by the SPS, they 
were stored at -20°C until the analysis time.  
Samples were analysed using a simple and accurate method which has been developed and 
validated for the simultaneous quantification of 22 AEDs (carbamazepine and its metabolite 
carbamazepine-10,11-epoxide, eslicarbazepine acetate and its metabolite S-licarbazepine, 
gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine and its metabolite 10,11-
dihydro-10-hydroxy carbamazepine, pregabalin, phenobarbital, phenytoin and its metabolite 5-(p-
hydroxyphenyl)-5-phenylhydantoin (p-HPPH), retigabine and its metabolite N-acetyl retigabine, 
rufinamide, stiripentol, topiramate, tigabine, valproic acid, vigabatrin  and zonisamide) in urine 
using LC/MS/MS-QQQ (JAT-14-1592.R1).  
Total AEDs prevalence ranged from 4% (Greenock) to 27% (Perth). Gabapentin was 
identified in 118 samples (13%) and pregabalin in 32 samples (4%). Interestingly, 12 
samples contained both drugs (7%). The concentrations ranged from 0.4-1100 mg/L 
(median: 15 mg/L) for gabapentin and from 0.4-440 mg/L (median: 7.3 mg/L) for 
pregabalin. Four samples were found to be higher than 400 mg/L. These concentrations are 
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at least 20 times above the median concentrations and it could at least be suspected that 
those individual took higher doses than recommended. Other AEDs detected were 
levetiracetam (4 samples), vigabatrin (4 samples), lamotrigine (3 samples), valproic acid (3 
samples), carbamazepine (2 samples) and topiramate (1 sample). 
The positive samples were compared with the SPS results in order to see other illicit drugs 
associated with AEDs. 81 % of these samples have at least one illicit drug. 
Benzodiazepine, opiate and cannabis were dominating with a percentage of 61, 54 and 47 
% respectively. All these drugs were not prescribed. Unprescibed Methadone was positive 
in 26% of the samples. Cocaine and buprenorphine were positive in 18 and 17% of the 
samples, whereas amphetamines, methamphetamines and barbiturates only found in 4% of 
the positive AEDs samples. 
 In conclusion, this study shows a high prevalence of AEDs (18 %) majorly due to 
gabapentin and pregabalin on their own or in combination with other drugs of abuse.   
Key words: Gabapentin, pregabalin, antiepileptic drugs, drug abuse, LC/MS/MS, urine. 
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